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ABSTRACT
This thesis describes the development and evaluation of a self-management 
intervention for people admitted to hospital with heart failure due to left ventricular 
systolic dysfunction. The intervention was delivered by a heart failure nurse specialist, 
following optimisation of in-patient medical treatment. It consisted of two sessions 
during the hospital stay, a home visit and follow-up telephone call. The content of the 
intervention and techniques for its delivery were detailed in a manual.
The intervention was evaluated in a single-blind randomised controlled trial. The 
primary outcomes were the number of readmissions to hospital and duration of hospital 
stay in the 90 days after discharge from the index admission. Other outcomes included 
readmissions to hospital and duration of hospital stay in the 12 months after discharge, 
mortality, quality of life and psychological well-being. Process variables included self­
management behaviours and cognitions. One hundred and sixty-five patients were 
recruited to the study and they were followed up for a period of 12 months.
The intervention had a significant effect on aspects of self-management behaviour but 
did not demonstrate a significant effect on readmission to hospital or mortality in the 
total sample. However, a post-hoc sub-group analysis identified a significant impact of 
the intervention in those patients who were newly diagnosed with heart failure. Newly 
diagnosed patients in the intervention group had fewer admissions to hospital for heart 
failure and spent fewer days in hospital for heart failure during the 12 month follow-up 
period than those in the control group. The implications of the findings for future 
research and intervention development are discussed.
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CHAPTER 1 
INTRODUCTION
Heart failure is a common and increasing health problem and, despite advances in 
available medical therapies, prognosis remains poor, both in terms of high mortality 
rates and frequent hospital admissions. There has been an increasing recognition of 
shortcomings in treatment delivery that contribute to poor prognosis and in order to 
rectify these weaknesses, delivery of medical management of heart failure has 
undergone considerable change in recent years.
A significant aspect of this change in many countries has been the introduction of 
disease management programmes. Although different models exist, most programmes 
involve intensive case management with frequent patient follow-up, usually by a heart 
failure nurse specialist. Not only does this approach place a significant demand on 
health care resources but it also neglects the role of patients in managing their illness. 
The current study aimed to address this issue by developing an intervention that would 
enhance patients’ self-management of their heart failure. The chapters that follow 
describe the background to the study, the development of the self-management 
intervention and its evaluation in a randomised controlled trial.
Chapter two provides a description of heart failure and the demands that it places on 
the patient and the healthcare system. The chapter also provides an overview of 
medical management of heart failure and approaches that have been taken to try to 
bring about improvements. Shortcomings in patients’ self-management of their heart 
failure are also described and these raise the need for an intervention to enhance self­
management.
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Chapter three describes how a self-management approach is relevant in heart failure. 
This chapter outlines the theoretical bases of self-management, strategies that can be 
used to enhance self-management and factors that have been found to influence self­
management in heart failure. A systematic review of interventions that included a 
component addressing self-management of heart failure was conducted and the results 
are presented. This review was performed to inform the development of the self­
management intervention in this thesis.
The development of the intervention is described in chapter four and a full description 
of the intervention is set out in the manual in Appendix A.
The randomised controlled trial that was conducted to evaluate the intervention is 
covered in chapters five to ten. These chapters describe the design of the study, the 
participants recruited and the impact of the intervention on primary and secondary 
outcomes. It was recognised that a single type of intervention is unlikely to be suitable 
for all patients and therefore an important part of this study was to examine whether 
particular factors predicted benefit from the intervention and this analysis is included.
The final chapter discusses the findings of the study, its strengths and limitations and 
directions for future research.
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CHAPTER 2 
HEART FAILURE
This chapter provides a description of heart failure, its aetiology and epidemiology. A 
summary of the health outcomes of heart failure is provided, including mortality, 
admission to hospital and the impact of heart failure on quality of life and psychological 
well-being. This chapter also includes details of recommended treatment for heart 
failure and a summary of recognised shortcomings in heart failure management. The 
chapter concludes with a brief overview of disease management programmes that 
have been introduced to try to overcome these shortcomings. The need for approaches 
to heart failure management which do not rely on intensive case management but help 
to enhance patient self-management is addressed.
This chapter aims to provide an overview of current management of heart failure while 
chapters 3 and 4 aim to show how heart failure management at the time the study 
began informed its development.
2.1 Definition and clinical features (Figure 2.1)
Heart failure is a clinical syndrome that can result from any condition that damages the 
ability of the heart to pump blood around the body to meet its requirements. The 
pumping action of the heart is impaired, either in systole, so that the heart can not 
pump hard enough, or in diastole, so that the heart is unable to relax sufficiently to 
allow its chambers to fill with blood. In both cases, blood flow is reduced and an 
insufficient quantity is pumped. This leads to a rise in pressure in the heart’s chambers, 
causing blood returning to the heart to build up in the lungs or veins. Heart failure may 
be predominantly left-sided or right-sided. In left-sided heart failure, the left side of the
18
heart is impaired in its ability to pump blood into the body and so it backs-up behind the 
left ventricle, causing fluid retention in the lungs. In right-sided heart failure, the right 
side of the heart is impaired in its ability to pump venous blood into the pulmonary 
circulation, causing blood to back up in the body.
Figure 2.1 Pumping and filling problems in heart failure (Kranias, 2006)
Normal Systolic Dysfunction Diastolic Dysfunction
Oiastote
(fining)
The ventnctes tilt 
normaWy with blood.
Systots
(pumping)
The ventricles pump 
out about 60% of 
the blood.
The enlarged ventricles 
till with blood.
The ventndes pump 
out less than 40 to 50% 
of the Wood.
The stiff ventricles fill 
with less blood than 
normal.
The ventncles pump 
out about 60% of 
the blood, but the 
amount may be lower 
than normal.
The body’s attempt to compensate for reduced blood flow causes the kidneys to retain 
water and sodium in the body. Excess fluid may leak from blood vessels into body 
tissues leading to swelling (oedema) which usually occurs in the feet, ankles and legs. 
In severe cases, fluid may accumulate in the abdomen (ascites). Fluid build up in the 
lungs (pulmonary oedema) leads to symptoms of breathlessness (dyspnoea) which can 
be particularly problematic when lying down (orthopnoea) and can also lead to waking
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at night (paroxysmal nocturnal dyspnoea). Impaired circulation may lead to fatigue and 
reduced cognitive abilities (Soufer, 1992). Heart failure can also present with a wide 
range of difficult to diagnose and non-specific symptoms. The guidelines of the
European Society of Cardiology (ESC), (Remme & Swedberg, 2002; Task Force for the
Diagnosis and Treatment of Chronic Heart Failure et al., 2005), specify that a diagnosis 
of heart failure requires fulfilment of the following criteria:
1. Symptoms of heart failure (at rest or in exercise)
2. Objective evidence of cardiac dysfunction (at rest)
and (in cases where the diagnosis is in doubt)
3. Response to treatment directed towards heart failure.
The New York Heart Association (NYHA) classification (Dolgin, 1994) is widely used to 
classify severity of heart failure according to how limited patients are due to symptoms 
during physical activity. The classifications are shown in Table 2.1
Table 2.1 New York Heart Association Heart Failure Classification
Class I No limitation: ordinary physical exercise does not cause undue fatigue, 
dyspnoea, or palpitations (by definition treated heart failure)
Class II Slight limitation of physical activity: comfortable at rest but ordinary activity 
results in fatigue, palpitations, or dyspnoea
Class III Marked limitation of physical activity: comfortable at rest but less than ordinary 
activity results in symptoms
Class IV Unable to carry out any physical activity without discomfort: symptoms of 
heart failure are present even at rest with increased discomfort with any physical 
| activity
2.2 Aetiology
The most common causes of heart failure in developed countries are myocardial 
infarction, hypertension, or a combination of both. Other common causes include valve 
disease, alcohol abuse and idiopathic dilated cardiomyopathy, of which some of the
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latter may have a genetic basis. The contribution of diabetes, atrial fibrillation and 
coronary artery disease in the absence of myocardial infarction appear to be important 
but require further clarification (McMurray & Pfeffer, 2005). Heart failure is a syndrome, 
not a disease, therefore it is important to identify the underlying aetiology in order to 
guide treatment. Some causes may be reversible, for example, heart failure due to 
valve disease may be reversed by valve replacement surgery.
2.3 Epidemiology
Between 1-2% of the adult population in developed countries has heart failure. It is 
estimated that almost 900,000 people in the UK have heart failure, of whom 
approximately 54% are male. Prevalence increases with age, from about 1 in 35 in 
those aged 65-74, rising to 1 in 15 in those aged 75 to 84 and 1 in 7 in those aged 85 
and over (Petersen, Rayner, & Wolstenholme, 2002). The epidemiology of heart failure 
among different ethnic groups is not well documented as most epidemiological studies 
have recruited almost exclusively white patients or have not reported ethnicity (Sosin, 
Bhatia, Davis, & Lip, 2004). There is nevertheless some evidence that the risk of heart 
failure may be higher among Afro-Caribbeans and South Asians than among the white 
population in the UK. Chaturvedi (Chaturvedi, 2003) reported a relative risk of heart 
failure in those aged 60-79 of 3.1 for Afro-Caribbeans and 5.2 for South Asians.
Aetiology of heart failure has also been found to differ between ethnic groups. Lip et al 
(Lip, Zarifis, & Beevers, 1997) found that among white patients the most common 
aetiological factors were coronary heart disease and hypertension, among Indo-Asian 
patients they were coronary artery disease and diabetes and among black Afro- 
Caribbean patients they were hypertension and diabetes. Some of these differences 
may be explained by the difference in prevalence of these aetiological factors between 
the ethnic groups.
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It is predicted that the prevalence of heart failure will increase significantly, for example, 
Bonneux, Barendregt, Meeter, Bonsel, & van der Maas (1994) predicted that in the 
Netherlands, heart failure arising from coronary heart disease would rise by 
approximately 70% between 1985 and 2010. In Australia, prevalence of heart failure 
was projected to increase by approximately 50% between 1996 and 2016 (Kelly, 1997). 
Recent population data are not available to assess whether these predictions are on 
course to be realised however a number of factors would support an increasing 
prevalence. Trends in heart failure between 1950 and 1999 found that incidence has 
remained fairly stable since 1970 whereas survival rates have improved (Levy, 
Kenchaiah, Larson et al., 2002), a phenomenon which would result in an increased 
prevalence. The proportion of the elderly in the population is increasing which is likely 
to see an associated rise in prevalence of hypertension and coronary heart disease, 
two of the main risk factors for heart failure (McMurray & Stewart, 2000). Increasing 
rates of obesity and diabetes could also lead to increases in heart failure (Kenchaiah, 
Evans, Levy et al, 2002; Kamalesh & Nair, 2005) and increasing use of treatments 
which extend life will also have the effect of increasing its prevalence (Redfield, 2002).
2.4 Health Outcomes
In spite of advances in treatment, the prognosis of heart failure remains poor with high 
mortality and morbidity.
2.4.1 Mortality
Population studies have found mortality rates of 30-40% within 1 year of diagnosis and 
60-70% within 5 years. Rates are higher in those admitted to hospital for heart failure 
(McMurray & Pfeffer, 2005). The mortality rate for heart failure is worse than that for 
many forms of cancer - one study found that when heart failure was compared with
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cancers of the breast, lung, large bowel and ovary, only lung cancer had a higher 
mortality rate (Stewart, MacIntyre, Hole, Capewell, & McMurray, 2001). There is 
however some evidence that prognosis may be improving. A study of heart failure 
admissions to hospitals in Scotland found that between 1986 and 1995 the 30-day 
mortality rate fell by 26% in men and 17% in women (MacIntyre, Capewell, Stewart et 
al., 2000). McMurray & Stewart (2002) put forward the hypothesis that this may have 
been attributable to new medical treatments. Schaufelberger, Swedberg, Koster, 
Rosen, & Rosengren (2004) also found improvements between 1988 and 2000 in 30- 
day and 1-year mortality among patients in Sweden hospitalised for the first time for 
heart failure. They reported that these improvements coincided with the established 
use of ACE-inhibitor therapy, the introduction of beta-blockers and home-care 
programmes for heart failure, and more effective treatment and prevention of underlying 
diseases but commented that the full benefits of beta-blocker and spironolactone 
treatments would probably not have been achieved during the study period. In 
England, Mehta, Dubrey, McIntyre et al (2006) also reported lower mortality rates than 
were found in a similar study performed approximately a decade earlier (Cowie, Wood, 
Coats et al., 2000).
These changes can make it difficult to compare mortality in intervention studies that 
have been performed in different time periods.
2.4.2 Morbidity
2.4.2.1 Hospital admissions
The high morbidity in heart failure is seen in the large number of hospital admissions. 
Heart failure accounts for approximately 1-2% of healthcare spending (Berry, Murdoch, 
& McMurray, 2001), of which in-patient hospital treatment comprises almost two-thirds 
of the costs (McMurray, Hart, & Rhodes, 1993). Approximately 5% of all medical
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admissions to hospital are for heart failure and it is the single most common reason for 
admission in those aged over 65. Hospital admissions place a significant burden on 
patients and their families as well as on the health service. The British Heart 
Foundation estimated from routine hospital statistics that in 2000/2001 there were 
approximately 86,000 hospital admissions for heart failure to National Health Service 
(NHS) hospitals in the UK, with an estimated cost of £379 million (Petersen et al., 
2002). Hospital admissions for heart failure in England have been projected to increase 
by approximately 50% between 2000 and 2026, mostly due to the aging of the 
population (Gnani & Ellis, 2001).
The risk of repeated hospital admissions is also high. The EuroHeart Failure survey 
programme (Cleland, Swedburg, Foliath et al., 2003) found that of patients who 
survived the index admission, 24% were readmitted within 12 weeks of discharge.
2.4.2.2 Quality of Life
Heart failure has been found to impair quality of life more than many other chronic 
illnesses (Stewart et al, 1989). Stewart et al examined quality of life of 9385 adult out­
patients using the SF-36, a measure of generic health-related quality of life (Ware & 
Sherbourne, 1992). Fifty-four percent of respondents had at least one of nine chronic 
conditions. These were hypertension, diabetes, myocardial infarction, arthritis, chronic 
lung problems, gastrointestinal disorders, back problems, angina and heart failure. 
Patients with heart failure reported worse physical quality of life than all other 
conditions with the exception of those who had had a myocardial infarction. The mental 
quality of life of patients with heart failure was poorer than all except those with chronic 
lung problems and gastrointestinal disorders.
Hobbs et al (2002) also used the SF-36 measure of generic health-related quality of life 
in a population study in the West Midlands region of England. Patients were randomly
sampled from the general population and from 3 diagnostic categories on general 
practice registers. These categories were a diagnosis of heart failure, prescribed 
diuretic medication and patients considered at high risk of heart failure because of 
previous myocardial infarction, angina, hypertension or diabetes. The SF-36 was 
completed by 5961 people of whom 426 had a diagnosis of heart failure. When 
compared with the 3850 people sampled from the general population, patients with 
heart failure had significantly impaired quality of life on all 8 dimensions of the SF-36 -  
physical functioning, role limitations due to physical problems, role limitations due to 
emotional problems, social functioning, mental health, energy, pain and overall 
perception of health. When compared with patients with other common cardiac 
conditions (angina, previous myocardial infarction, atrial fibrillation or hypertension), 
patients with heart failure had poorer quality of life on all dimensions except pain, which 
was greater in those with angina (Figure 2.2).
When compared to patients with arthritis, chronic lung disease or depression, patients 
with heart failure were more severely impaired in physical functioning, role limitation 
due to physical problems and lack of energy than those with arthritis and chronic lung 
disease. They reported less pain than those with arthritis and better mental health and 
less role limitations due to emotional problems than those with depression. The extent 
of impairment in quality of life appeared to be related to NYHA classification with those 
in higher NYHA reporting poorer quality of life (Figure 2.3).
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Figure 2.2 Quality of life in patients with chronic cardiac diseases, including 
heart failure, compared to the general population. (Hobbs et al, 2002)
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Figure 2.3 Quality of life in patients with chronic medical conditions, including 
heart failure, compared to the general population (Hobbs et al, 2002)
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Quality of life is not only an important outcome in its own right but is also related to both 
morbidity and mortality. In the Studies of Left Ventricular Dysfunction (SOLVD) trial, the 
quality of life dimensions of heart failure symptoms, impairment in activities of daily 
living and patients’ assessment of their general health were found to be independent 
predictors of heart failure related hospitalizations and mortality (Konstam, Salem, 
Pouleur et al., 1996).
2.4.2.3 Psychological wellbeing
Depression is common in heart failure although reported prevalence varies. This is 
probably due to differences in the assessment and criteria for classification of 
depression and in the study populations. Most studies use questionnaire assessments 
which identify ‘possible’ or ‘probable’ depression but a diagnostic interview is required 
to confirm the presence of clinical depression. The percentage identified as depressed 
using clinical interview is therefore likely to be smaller than when using questionnaire 
assessment. Reported prevalence of depression in out-patient populations of heart 
failure has ranged from 11% who met the criteria for syndromal depression by 
diagnostic interview schedule (Turvey, Schultz, Arndt, Wallace, & Herzog, 2002), to 
48% who scored in the depressed range on the Beck Depression Inventory (Gottlieb, 
Khatta, Friedmann et al., 2004). A recent UK study used the Structured Clinical 
Interview for Diagnostic and Statistical Manual of mental disorders in a sample of 100 
patients attending a community heart failure chronic disease management programme 
(Haworth, Moniz-Cook, Clark et al, 2005). They found that 29% were diagnosed with a 
depressive disorder.
Prevalence of depression may be higher among in-patient populations. Using a 
questionnaire assessment, Vaccarino, Kasl, Abramson, & Krumholz (2001) found that 
77.5% scored within the depressed range. In a study that used clinical interview, 20%
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met the criteria for a current major depressive episode and 16% met criteria for a 
current minor depressive episode (Freedland, Rich, Scala et al, 2003).
Depression appears in some studies to be more common in younger people and in 
women with heart failure (Freedland et al., 2003), although this finding is not consistent. 
There is also evidence for a relationship between depression and NYHA class, with 
higher rates of depression among those with greater functional limitation (Gottlieb et al., 
2004). This study used a cross-sectional design therefore the causal direction is not 
established so while it is possible that greater functional limitation increases the risk of 
depression, it may also be the case that patients with more depressed mood perceive 
themselves to be more limited.
Depression appears to be associated with a poorer prognosis. Hospital readmission 
has been found to be more frequent in depressed patients and depression has also 
been found to predict mortality (Friedmann, Thomas, Liu et al, 2006; Faris, Purcell, 
Henein, & Coats, 2002). Vaccarino et al (2001) found that after adjustment for 
demographic factors, medical history, baseline functional status and clinical severity, 
an increasing number of depressive symptoms was associated with a significantly 
higher risk of the combined endpoint of functional decline or death. Depression 
appears to predict mortality independently of NYHA and left ventricular ejection fraction 
(LVEF) (Junger, Schellberg, Muller-Tasch et al., 2005). Poorer prognosis may be partly 
explained by poorer medication adherence by people who are depressed (DiMatteo, 
Lepper, & Croghan, 2000).
In contrast to depression, there is little research on anxiety in heart failure. A link 
between anxiety and depression in heart failure has been reported however (Freedland 
& Carney, 2000), in that anxious reactions to dyspnoea were found to be more 
common in depressed than non-depressed patients. Haworth et al, 2005 diagnosed an
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anxiety disorder in 18% of heart failure patients attending a community disease 
management programme, which is higher than that found in healthy older adults 
(Lindesay, Briggs, & Murphy, 1989). Although anxiety is an important outcome in its 
own right, it has not been found to be related to prognosis. In the SOLVD clinical trial of 
the ACE-inhibitor enalapril, no association was found between anxiety and mortality or 
hospitalisation (Konstam et al, 1996), nor did Junger et al (2005) or Friedmann et al 
(2006) find anxiety to predict mortality.
2.5 Management of Heart Failure
The evidence for medical management of heart failure relates mostly to heart failure 
due to left ventricular systolic dysfunction, which is the most common cardiac 
abnormality in heart failure (National Institute for Clinical Excellence, 2003). There is 
considerable debate about the diagnosis of heart failure due to diastolic dysfunction 
(National Institute for Clinical Excellence, 2003) and there is also a lack of consensus 
about its treatment (Vasan & Benjamin, 2001). Accordingly, the study described in this 
thesis was developed for patients with heart failure due to left ventricular systolic 
dysfunction and it is to this type of heart failure that the remainder of the thesis refers.
Guidelines for the management of heart failure have been produced by the American 
Heart Association (Hunt, Abraham, Chin et al., 2005) and European Cardiac Society 
(Task Force for the Diagnosis and Treatment of Chronic Heart Failure et al., 2005). In 
March 2000, the NHS published a national service framework (NSF) for coronary heart 
disease which included a chapter dealing with heart failure (Department of Health,
2000). This specified that “[t]he aims of treating heart failure are to improve quality of 
life by:
• improving symptoms or slowing their deterioration
• reducing mortality
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• reducing the frequency of cardiac events and admissions to hospital
• avoiding adverse effects from treatment
• improving the end-of-life experience for both patients and carers.”
Following on from the NSF, the National Institute for Clinical Excellence (NICE) 
published guidelines for the management of heart failure in July 2003 (National Institute 
for Clinical Excellence., 2003).
When this study began in February 2001, earlier editions of these guidelines were 
available. The most up to date guidelines available at that time were those of the 
Scottish Intercollegiate Guidelines Network (1999). Although the guidelines have been 
updated since the study began, current recommendations are outlined here as 
procedures for providing optimised medical care for heart failure at the study hospital 
would have met with these guidelines. The only exception would have been the time of 
initiation of beta-blocker therapy (see below) which became more frequently prescribed 
earlier in treatment. Recommendations for the treatment of heart failure according to 
current guidelines are set out below:
2.5.1 Pharmacological treatment
Medication forms the basis of the medical treatment for heart failure due to left 
ventricular systolic dysfunction, particularly diuretics, ACE inhibitors, beta-blockers and 
spironolactone. A treatment algorithm for patients with heart failure and reduced left- 
ventricular systolic function is shown in Figure 2.4.
Diuretics are one of the main treatments for heart failure and are prescribed to almost 
all symptomatic patients (Faris, Purcell, Henein, & Coats, 2002; National Institute for 
Clinical Excellence., 2003). They help the kidneys to eliminate excess water and 
sodium thus reducing the workload of the heart by decreasing blood volume.
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Angiotensin-converting enzyme (ACE) inhibitors dilate blood vessels making it easier 
for the heart to pump blood. They reduce retention of salt and water and protect the 
heart’s left ventricle from becoming more enlarged and inefficient. ACE inhibitors have 
been shown to reduce admissions to hospital and mortality and are recommended for 
all patients with systolic heart failure (CONSENSUS Trial Study Group, 1987; Garg & 
Yusuf, 1995; SOLVD Investigators, 1992; National Institute for Clinical Excellence., 
2003).
Beta-blockers are a more recent addition to heart failure therapy. They slow the heart 
and make it beat less strongly and, by a range of only partially understood mechanisms, 
improve left ventricular function and thereby reduce symptoms of shortness of breath 
and fatigue. The addition of a beta-blocker to heart failure therapy has been found to 
further reduce admissions to hospital and mortality. (Packer, Coats, Fowler et al, 2001; 
Beta-Blocker Evaluation of Survival Trial Investigators, 2001; Brophy, Joseph, & 
Rouleau, 2001; Whorlow & Krum, 2000; Packer, Fowler, Roecker et al., 2002). The 
combination of ACE inhibitor and beta-blocker has been described as the cornerstone 
of treatment of left-ventricular systolic dysfunction (McMurray & Pfeffer, 2005) and 
NICE guidelines recommend the initiation of beta-blockers for heart failure due to left 
ventricular systolic dysfunction after diuretic and ACE inhibitor therapy. Initially beta- 
blockers were not recommended for patients who have co-morbid respiratory disorders 
but this situation is changing.
31
Fig 2.4 Algorithm for the pharmacological treatment of symptomatic heart failure 
due to LV systolic dysfunction. (NICE Guideline 2003)
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If patients remain moderately or severely symptomatic after treatment with the 
foregoing medications, the addition of spironolactone is recommended (National
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Institute for Clinical Excellence., 2003; Pitt, Zannad, Remme et al, 1999). This is an 
aldosterone receptor antagonist which is recommended because aldosterone 
encourages the body to release adrenaline and noradrenaline, making the heart beat 
faster and more strongly and raising blood pressure. The RALES study (Pitt et al, 1999) 
showed that addition of low-dose spironolactone to diuretic and ACE inhibitor therapy 
improved survival in patients in advanced heart failure. The order in which this 
medication is added to treatment will however be modified by the clinical picture.
Many patients with heart failure are likely to be prescribed other additional medications, 
which may include treatments for angina, hypertension and atrial fibrillation. Other 
common co-morbid conditions include diabetes, respiratory disease and arthritis (Krum 
& Gilbert, 2003; Zhang, Rathouz, & Chin, 2003) which also require additional 
medications.
It can be seen that the medication regime of patients with heart failure is complicated, 
often including several medications both for heart failure and for co-morbid conditions. 
This is confirmed by the EuroHeart Failure Survey, conducted in 2000-2001, which 
screened discharge summaries of 11304 patients hospitalised for heart failure in 24 
countries, and found that 44.6% of the population used four or more different drugs 
(Komajda, Follath, Swedberg et al., 2003).
2.5.2 Devices and Surgery
Implantable devices that have been found to improve outcomes for some patients with 
heart failure include an implantable cardiac defibrillator and cardiac resynchronisation 
therapy. Patients with heart failure are at risk of sudden death due to ventricular 
arrhythmias but the SCD-HeFT study found that an implantable cardiac defibrillator
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reduced the risk of death by 23% (Bardy, Lee, Mark et al., 2005). In about 25% of 
patients with heart failure, there is dyssynchronous contraction between the walls of the 
left ventricle, caused by abnormal electrical activation. Dyssynchrony may exacerbate 
cardiac dysfunction and further reduce cardiac output. Cardiac resynchronisation 
therapy has been shown to reduce the risk of death or hospital admission in this group 
of patients by 37% (Cleland, Daubert, Erdmann et al., 2005).
Heart transplantation is the treatment of last resort which is suitable for selected 
patients but severely restricted by the limited availability of donor hearts. Controlled 
trials of transplantation have not been performed but recent studies have shown 5-year 
survival of 70-80%. Ventricular assist devices have been used while patients have 
been awaiting transplantation and there is increasing interest in their use as a long­
term treatment (Park, Tector, Piccioni et al., 2005).
In practice, implantable devices and surgery are suitable only for a fairly small number 
of highly selected patients and medication remains the mainstay of medical treatment 
for heart failure.
2.5.3 Other aspects of non-pharmacological management
In addition to taking prescribed medication, a number of non-pharmacological 
measures are also recommended in the guidelines referred to above. Most have not 
undergone randomised controlled trials but are recommended by consensus of experts. 
The guidelines provided by the European Society of Cardiology are described below as 
they are the most detailed on this area of management (Task Force for the Diagnosis 
and Treatment of Chronic Heart Failure, 2001; Task Force for the Diagnosis and 
Treatment of Chronic Heart Failure et al., 2005).
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2.5.3.1 General advice
It is recommended that patients with heart failure and their close relatives should 
receive general advice about topics set out in Table 2.2
Table 2.2 List of subjects to discuss with a heart failure patient and his family
General advice
•  Explain what heart failure is and why symptoms occur
• Causes of heart failure
•  How to recognize symptoms
• What to do if symptoms occur
• Self-weighing
• Rationale of treatments
• Importance of adhering to pharmacological and non-pharmacological prescriptions
• Refrain from smoking
• Prognosis 
Drug counselling
•  Effects
•  Dose and time of administration
• Side effects and adverse effects
•  Signs of intoxication
• What to do in case of skipped doses
•  Self-management 
Rest and exercise
• Rest
•  Exercise and activities related to work
• Daily physical activity
•  Sexual activity
•  Rehabilitation 
Vaccinations
T  ravel
Dietary and social habits
•  Control sodium intake when necessary i.e. some patients with severe heart failure
• Avoid excessive fluids in severe HF
•  Avoid excessive alcohol intake___________________________________________________________
From: European Heart Journal, 2001 ;22:1538, updated 2005 www.escardio.org
2.5.3.2 Weight control
One of the early signs of deteriorating heart failure is rapid weight gain caused by fluid 
retention, therefore patients are advised to weigh themselves on a regular basis. In the 
event of sudden unexpected weight gain of more than 2kg in 3 days it is recommended 
that they alert a health care professional or adjust their diuretic dose accordingly.
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2.5.3.3 Dietary measures
Patients with advanced heart failure are advised to control their sodium intake. No 
studies have been conducted to evaluate specific recommendations for sodium 
restriction but 2g per day is frequently recommended. If this is unpalatable, a 3g diet 
may be a more realistic target which can be achieved by avoiding convenience foods 
and not adding salt to food (Grady, Dracup, Kennedy et al., 2000). Patients with 
advanced heart failure are also advised to restrict their fluid intake. The optimum fluid 
intake is unclear but 1.5 to 2 litres per day is advised. Moderate alcohol intake is 
permitted except in the case of patients whose heart failure is due to alcoholic 
cardiomyopathy, in which case alcohol consumption is contraindicated.
2.5.3.4 Obesity
The ESC recommends that treatment of chronic heart failure should include weight 
reduction if the patient is overweight (body mass index between 25 and 30) or obese 
body mass index >30.
2.5.3.5 Abnormal weight loss
Up to 50% of heart failure patients may have some degree of malnutrition (Carr, 
Stevenson, Walden, & Heber, 1989). Cardiac cachexia (the wasting of body fat and 
lean body mass that accompanies weight loss) is a predictor of reduced survival. 
Patients may reduce their food intake because of feelings of nausea, breathlessness or 
feeling bloated so are advised to take small frequent meals. Increasing muscle mass 
by taking adequate physical activity is also recommended.
2.5.3.6 Smoking
Smoking should be discouraged and use of smoking cessation aids are widely 
encouraged (although this is on the basis of good health grounds rather than evidence 
developed from the heart failure population).
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2.5.3.7 Travelling
Patients should be discouraged from travelling to locations of high altitudes or that are 
very hot or humid. Patients also need to be cautioned about the risks of long air flights 
i.e. dehydration, peripheral oedema and deep vein thrombosis
2.5.3.8 Sexual activity
Recommendations are to reassure those patients who are not severely compromised 
but are concerned about the risk of cardiac decompensation triggered by sexual activity.
2.5.3.9 Advice on immunisations
Immunisation against influenza and pneumococcal infection is also recommended as 
these infections can precipitate worsening of cardiac function and lead to hospital 
admission.
2.5.3.10 Drug counselling
Patients should be given information about the expected effects and side-effects of 
their medications and advice about drugs to avoid when prescribed heart failure 
medication. Self-adjustment of diuretics based on changes in symptoms and fluid 
balance should be encouraged when practical.
2.5.3.11 Rest and exercise
Rest is advised in acute or decompensated heart failure but as the patient’s condition 
improves, active mobilisation should be carried out. If patients are in a stable condition, 
they are encouraged to carry out usual daily physical and leisure activities that do not
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induce symptoms. Exercise training is encouraged in stable patients in NYHA II and III. 
Randomised trials have shown that regular exercise can safely improve peak oxygen 
uptake and strength (McKelvie, Teo, Roberts et al, 2002) and can improve symptoms 
(Corvera-Tindel, Doering, Woo et al, 2004) and quality of life and reduce mortality 
(Belardinelli, Georgiou, Cianci, & Purcaro, 1999).
2.6 Shortcomings in the diagnosis and management of heart 
failure
It is widely recognised that in the past, the diagnosis and management of heart failure 
have been suboptimal (Feenstra, Grobbee, Jonkman, Hoes, & Strieker, 1998; 
McDonald, 2005; Hunt et al., 2002).
2.6.1 Shortcomings in the diagnosis of heart failure
Receipt of the correct diagnosis is essential for the initiation of appropriate treatment. 
Heart failure is recognised as being difficult to diagnose clinically as the principal 
symptoms (breathlessness) and signs (peripheral oedema) are non-specific and 
therefore could be due to other conditions (Task Force for the Diagnosis and Treatment 
of Chronic Heart Failure, 2001). Other signs that are more specific, such as raised 
jugular venous pressure and a third heart sound are less common and more difficult to 
detect. Investigation to confirm the diagnosis is therefore required. European Society of 
Cardiology guidelines recommend that patients with suspected heart failure have an 
electrocardiogram (ECG), chest X-ray, laboratory investigations of haematology and 
biochemistry and an echocardiogram (Task Force for the Diagnosis and Treatment of 
Chronic Heart Failure, 2001). The ECG examines cardiac rhythm, rate and conduction 
and, if normal, suggests that a diagnosis of heart failure is unlikely. The chest X-ray 
can be useful in identifying pulmonary oedema and to exclude pulmonary disease. 
Haematology and biochemistry can identify other conditions that can co-exist with or
38
complicate heart failure such as renal disease and diabetes. A diagnosis of heart 
failure requires objective evidence of cardiac dysfunction at rest and the 
echocardiogram is used for this purpose. Each of these investigations provides 
diagnostic information and also helps to guide treatment (McMurray & Pfeffer, 2005).
The EuroHeart Failure survey programme (Cleland et al., 2003) found that in 2000- 
2001, of patients admitted to hospital with heart failure, over 90% had an ECG, chest 
X-ray and measurement of haemoglobin and electrolytes but only 66% overall, and 
only 56% in the UK, had ever had an echocardiogram. This represents a considerable 
deficiency compared to European Society of Cardiology (ESC) guidelines and 
highlights the requirement for improvement in the diagnosis of heart failure. The 
importance of diagnostic investigations was shown by Polanczyk, Newton, Dec, & Di 
Salvo (2001) who found that, in patients discharged from hospital with a diagnosis of 
heart failure, those patients with unknown ejection fraction or suspected valve disease 
who did not have an echocardiogram were more likely to be readmitted to hospital 
within 90 days.
2.6.2 Shortcomings in the implementation of pharmacological treatment
The MAHLER study evaluated the impact of implementation or non-implementation of 
ESC treatment guidelines from November 2001 to September 2002 in six European 
countries (France, Germany, Italy, The Netherlands, Spain, UK). Cardiovascular and 
heart failure hospitalisation were significantly lower in groups with better adherence to 
guidelines for prescription of ACE inhibitors, beta-blockers and spironolactone 
(Komajda, Lapuerta, Hermans et al., 2005). Polanczyk, Newton, Dec & DiSalvo (2001) 
found that patients who were not treated with ACE inhibitors on discharge from hospital 
were more likely to be readmitted within the following 90 days.
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Data from General Practice in England and Wales showed that in 1998, 91.1% of men 
and 93.5% of women with heart failure were prescribed diuretics but only 53.1% and 
43.6% respectively were prescribed an ACE inhibitor. Beta-blockers are a more recent 
addition to recommended treatment (see above) and in 1998 they were prescribed to 
only 10.6% of men and 11.4% of women with heart failure (Ellis, Gnani, & Majeed,
2001). The EuroHeart Failure Survey (Komajda et al., 2003) found that in 2000-2001, 
86.9% of patients hospitalised for heart failure were prescribed diuretics, 61.8% were 
prescribed ACE inhibitors, 36.9% were prescribed beta-blockers and 20.5% were 
prescribed spironolactone. Only 17.2% received the combination of diuretic, ACE 
inhibitors and beta-blockers.
As well as under-prescription of recommended medications, incorrect prescription has 
also been identified as contributing to unplanned hospital admission. For example, 
Ghali et al 1988 considered inadequately conceived drug therapy to have contributed 
to hospital admission in 17% of cases (Ghali, Kadakia, Cooper, & Ferlinz, 1988). 
Opasich, Febo, Riccardi et al, 1996 followed up 304 patients who had been referred to 
them for assessment for transplant. During the mean follow-up period of 310 days, 161 
patients had a total of 328 nonfatal decompensations. Iatrogenic factors were 
considered to have contributed to 33 (10%) and were mostly associated with 
inadequate medical treatment, particularly withdrawal of ACE inhibitors and/or 
excessive doses of diuretics (Opasich et al., 1996). Vinson, Rich, Sperry, Shah & 
McNamara, 1990) reported that 7/66 (11%) of the readmissions they examined were 
due to dehydration, most probably caused by excessive diuretic use. Iatrogenic factors, 
defined as heart failure precipitated by medications or excessive fluid administration, 
were also considered to have been responsible for 7% of admissions in a study by Rich 
(1996) who examined precipitating factors leading to hospital admission in 401 patients 
70 years of age or older hospitalized with congestive heart failure.
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Tsuyuki, McKelvie, Arnold et al (2001) prospectively explored the immediate 
precipitants associated with exacerbation of CHF in patients enrolled in a 43-week 
multi-centre clinical trial. Use of calcium channel blockers (a medication not 
recommended in heart failure due to systolic dysfunction and contra-indicated in 
addition to beta-blockade) were identified as the cause of exacerbation in 13% of cases 
and inappropriate reductions in CHF therapy in 10% of cases.
These findings highlight both the benefits of optimising prescription of recommended 
medications and the room for improvement in pharmacological management of heart 
failure.
2.6.3 Early discharge and inadequate follow-up
The relationship between premature hospital discharge and risk of unplanned 
readmission has been known for some time. For example, Ashton, Kuykendall, 
Johnson, Wray, & Wu (1995) assessed quality of inpatient care of 2513 male inpatients, 
748 of whom had a diagnosis of heart failure, and the relation to unplanned 
readmission within 14 days of discharge. They reported that in patients with heart 
failure, lower adherence by clinicians to ‘readiness-for-discharge criteria’, which 
included ensuring that patients were clinically stable, was associated with an 
increased risk of readmission. It was considered that 1 in 5 readmissions in patients 
with heart failure were attributable to substandard care.
In contrast, when McDonald, Ledwidge, Cahill et al (2001) optimised in-patient care for 
all patients with heart failure and ensured that they were not discharged until clinically 
stable and on the target dose of ACE inhibitor, no patients in either the optimised 
standard care control group or the intervention group (who received additional
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telephone and clinic follow-up) were readmitted to hospital within one month of 
discharge. This compared to a readmission rate of 20% before instigation of this 
management plan. This study demonstrates the importance of discharging patients 
from hospital only when they are clinically stable and on optimal treatment.
Patients with heart failure can deteriorate rapidly as evidenced by the high rate of 
unplanned readmissions within a short period after discharge from hospital. Haphazard 
follow-up after discharge has been identified as another factor contributing to 
unplanned readmission (Moser & Mann, 2002). Vinson, Rich, Sperry et al (1990) 
considered that inadequate follow-up (as evidenced by failure to involve home care 
and/or prolonged time to next physician appointment) contributed to preventable 
readmissions in 20% of cases. When Tsuchihashi, Tsutsui, Kodama et al (2001) 
followed 230 patients for 1 year after discharge from hospital with a diagnosis of heart 
failure, they found that patients who had ^1 follow-up clinic visit per month were at 
greater risk of readmission (odds ratio 4.9, 95% Cl 2.0-11.8).
Patients who participated in focus groups in the UK for the development of the NICE 
guidelines reported that once discharged from the care of a consultant they could fall 
out of the system and find it difficult to access care easily if they deteriorated (National 
Institute for Clinical Excellence, 2003). The NICE guidelines recommend that 
“frequency of monitoring should depend on the clinical status and stability of the patient. 
Monitoring interval should be short (days to two weeks) if the clinical condition or 
medication has changed, but is required at least six-monthly for stable patients”.
2.6.4 Shortcomings in patient self-management
Living with heart failure requires patients to undertake many different tasks to manage 
their illness, such as taking medication and making dietary changes, amongst others.
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Behaviours such as these, which rely on the patient taking an active role in their illness, 
may be considered part of self-management, which will be described in greater detail in 
the next chapter. Shortcomings in the way patients manage their illness are considered 
to contribute to poor outcomes in heart failure. These shortcomings include non­
adherence to medication and other aspects of the recommended treatment regime and 
failure to identify and act upon early signs of worsening heart failure.
2.6.4.1 Practice of self-management behaviours
2.6.4.1.1 Taking medication
Studies that have measured adherence to medication in heart failure have reported 
rates that vary from 10% to over 90% but most are between 70-85% (van der Wal, 
Jaarsma, & van Veldhuisen, 2005). Studies have used different methods to assess 
medication adherence, including patient self-report, pill counts, prescription refills and 
electronic event monitoring, which records when medication bottles are opened and 
closed. Differing reported rates of adherence may be partly explained by these different 
methods and also by different ways of defining adherence. For example, in an early 
study, Monane, Bohn, Gurwitz, Glynn, & Avorn (1994) assessed how many times a 
sample of 7247 patients refilled prescriptions for digoxin over a 12 month period and 
found that only 10% filled them often enough to have sufficient medication for the 12 
month period. In contrast, Welsh, Heiser, Schooler et al (2002) found that 79% of 
patients attending the emergency department for heart failure reported not having 
deviated from their prescribed regimen. This study used patient interviews to assess 
adherence but a similar rate was found by Bohachick, Burke, Sereika, Murali, & 
Dunbar-Jacob (2002) who assessed adherence to ACE inhibitors over a 3 month 
period using electronic event monitoring and found that 71% of patients took 85-100% 
of the prescribed dose. Nevertheless, 19% of patients took less than 70% of the 
prescribed dose and the rate of adherence was also found to vary by the number of 
daily prescribed doses -  adherence rates of 90%, 84% and 68% were reported for
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medications prescribed once, twice or three to four times a day, respectively. 
Adherence to medication may also decline over time. Butler, Arbogast, Daugherty et al
(2004) compared ACE inhibitor use in the 30 days and 12 months after discharge from 
hospital and found that, of those patients discharged on an ACE inhibitor, 77.1% had 
filled a prescription within 30 days and only 63.3% had a current prescription i.e. filled 
in the prior 30 days, at 12 months.
Although reported rates of medication adherence may vary, these studies indicate that 
it is often sub-optimal and may be influenced by factors such as the daily regime and 
the duration for which a patient has been taking the medication.
2.6.4.1.2 Diet and exercise
Performance of other recommended self-management behaviours may be even lower. 
When Hershberger, Ni, Nauman et al (2001) assessed self-management behaviour of 
patients attending an out-patient management programme, at baseline 80.9% of 
patients reported taking their medication as prescribed all the time but only 47.2% 
reported avoiding salty foods, even though 75.3% reported being aware of the need for 
salt restriction. Other studies have found the percentage of patients restricting their 
sodium intake to vary from 43% to 88% (van der Wal et al., 2005). Few studies have 
examined practise of fluid restriction but those which have suggest that it is fairly 
uncommon. Artinian, Magnan, Sloan, & Lange (2002) reported monitoring of fluid 
intake to be one of the least frequently performed of the self-management behaviours 
they measured. Jaarsma, Abu Saad, Dracup, & Halfens, (2000) reported that only 23% 
of patients adhered to fluid guidelines and Ni, Nauman, Burgess et al (1999) found that 
over one third of patients thought they should drink lots of fluids. Other lifestyle 
changes, particularly regarding physical activity, are also not adopted by many patients. 
The review by van der Wal et al (2005) reported that between 41-58% of patients did 
not follow recommendations regarding activity and rest.
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2.6.4.1.3 Self-monitoring
Heart failure can deteriorate rapidly making it essential to identify early signs of 
problems so that immediate remedial action can be taken. It would appear, however, 
that many patients do not monitor for signs of deterioration and when symptoms 
become worse they often delay before seeking medical help. The review by van der 
Wal et al (2005) identified 8 studies that examined adherence to daily weighing and 
found that rates ranged from 12% to 75% but most were under 50%. Furthermore, 
those patients who do monitor their weight do not necessarily contact a health care 
professional when their weight increases (Jaarsma, Abu Saad, Dracup et al, 2000) or 
when they experience other symptoms of worsening heart failure. In a study of 
181 older adults admitted for heart failure, Friedman (1997) found that 91% reported 
having dyspnoea for an average of 3 days and 35% had oedema for an average of 7 
days before hospital admission. On admission, only 5% reported weight gain as a 
symptom, suggesting that most patients had not been monitoring their weight nor 
recognised weight gain to be an indicator of deterioration. Another study (Evangelista, 
Dracup, & Doering, 2000) found that 28% of patients waited more than 5 days before 
seeking medical attention for symptoms of heart failure. Artinian et al (2002) examined 
heart failure self-care behaviour in 110 patients and found that the least frequently 
performed behaviours related to self-monitoring and to contacting health care 
professionals in response to signs of exacerbation.
2.6.4.2 Implications of shortcomings in self-management
It is apparent from the above examples that a significant proportion of people with heart 
failure do not follow self-management recommendations and a number of studies have 
suggested that these shortcomings contribute to poor outcomes.
Eleven studies published between 1988 and 2002 (van der Wal et al., 2005) 
considered non-adherence to medication or diet to have contributed to worsening heart
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failure in between 15% to 64% of cases. For example, Michalsen, Konig, & Thimme 
(1998) asked 179 patients admitted to hospital for heart failure about their daily fluid 
and salt intake and adherence to prescribed medication. Patients were classified as 
‘non-compliant’ if they reported taking their medication intermittently or not at all, if their 
fluid intake was more than 2.5 litres per day or if they regularly added salt to their food. 
In this study, 43% of patients reported excess sodium intake, 34% reported excess 
fluid intake and 23.5% reported poor adherence to medication. Potential factors 
precipitating the hospital admission were identified in 85.5% of the study sample and 
non-adherence to medication or diet (excessive sodium or fluid intake) was the leading 
precipitating factor for hospital admission, considered to have caused 41.9% of cases.
Delay in seeking medical attention in response to early signs and symptoms of 
worsening heart failure is also considered to contribute to unplanned hospital 
admissions. The studies outlined above showed that many patients wait several days 
before seeking attention in which time remedial action, which may have prevented 
further deterioration, could have been taken. In an examination of 161 patients 
admitted to hospital for heart failure, Vinson, Rich, Sperry et al (1990) considered that 
failure to seek medical attention promptly when symptoms recurred contributed to 20% 
of the hospital readmissions they classified as preventable.
Unfortunately these studies have examined precipitants of worsening heart failure 
retrospectively and the assessment of self-management behaviours was usually poorly 
defined. Prospective examination of the impact of self-management behaviours on 
outcomes therefore remains necessary although difficult to perform. Nevertheless, the 
identification of shortcomings in self-management as a precipitating factor in several 
studies suggests that self-management behaviours appear to be an important target for 
intervention.
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2.6.5 Rectifying shortcomings in management of heart failure -
disease management programmes
The organisation of medical care provision for patients with heart failure has undergone 
considerable change in many countries over recent years. Probably the most widely 
adopted approach has been the introduction of disease management programmes 
which aim to address the shortcomings described above in medical management and 
patient self-management. There is considerable variation in these programmes but 
they typically consist of one or more of, medication review and optimisation of therapy, 
discharge planning i.e. assessing patients’ post discharge needs, coordinating primary 
and secondary care, specialist follow-up and education about heart failure, its 
treatment and identification of early signs of deterioration. The programmes also vary 
across several other parameters, as shown in Table 2.3.
Table 2.3. Variability in disease management programmes
Study variable Variation between studies
Patient selection Many exclusion criteria are fairly consistent across studies, 
such as exclusion of patients with a psychiatric or terminal 
illness, but in addition some studies limit patient selection 
by factors such as age, heart failure severity and risk of 
readmission
Recruitment Most, but not all, programmes are targeted at patients 
admitted to hospital as this group is known to be at high 
risk of readmission and death
Time of intervention delivery Interventions vary in whether they commence during the 
index hospital admission, at the time of discharge or shortly 
after discharge
Place of intervention delivery Interventions are delivered in primary care, outpatient 
clinics, the patient’s home, over the telephone or a 
combination of these
Professional(s) delivering the 
intervention
Most interventions are led by a nurse working under the 
guidance of a cardiologist but a small number are 
multidisciplinary, including one or more of pharmacists, 
dieticians, psychologists, physiotherapists and social 
workers
Intervention duration Interventions vary from a single session to a series of visits 
and telephone calls over a year
Background ‘standard’ care What constitutes ‘standard care’ varies considerably 
between studies, reflecting the differences in care that exist 
between different hospitals and between different health 
care systems. Studies have been conducted in the US, 
Canada, Europe, Australia and New Zealand
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2.6.5.1 Efficacy of disease management programmes
Several reviews of heart failure disease management programmes have been 
performed (Philbin, 1999; Rich, 1999; McAlister, Lawson, Teo, & Armstrong, 2001; 
Windham, Bennett, & Gottlieb, 2003; Gonseth, Guallar-Castillon, Banegas, & 
Rodriguez-Artalejo, 2004; Gustafsson & Arnold, 2004; Gwadry-Sridhar, Flintoft, Lee, 
Lee, & Guyatt, 2004; McAlister, Stewart, Ferrua, & McMurray, 2004; Bruggink-Andre- 
de-la-Porte, Lok, van Wijngaarden et al., 2005; Phillips, Singa, Rubin, & Jaarsma, 2005; 
Roccaforte, Demers, Baldassarre, Teo, & Yusuf, 2005; Whellan, Hasselblad, Peterson, 
O'Connor, & Schulman, 2005; Holland, Battersby, Harvey et al., 2005; Phillips et al., 
2004; Yu, Thompson, & Lee, 2006), and their main findings are summarised in Table 
2.4. Those reviews which combined the studies in meta-analyses concluded that 
disease management programmes have been successful in reducing hospitalisation 
among patients with heart failure. However, the reviews also highlight that there is 
considerable heterogeneity in the findings. For example, in the review by McAlister et 
al., (2004), a significant reduction in all-cause hospitalisation for the combined sample 
was reported (a summary risk ratio of 0.84) but the risk ratios in individual studies 
ranged from 0.15 to 1.26. The programmes were also successful in reducing hospital 
admissions for heart failure (summary risk ratio of 0.73, but again, there was 
considerable heterogeneity in the findings). Few programmes produced reductions in 
mortality.
2.6.5.1.1 Component efficacy
The heterogeneity of study findings raises questions about which components, or 
combinations of components, of these complex interventions are most important to 
achieve improved outcomes. Some of the reviews described above have examined this 
issue but they have not been able to identify the underlying mechanism for improved
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outcomes of disease management programmes (Whellan et al, 2005) nor the most 
effective model of disease management (Gonseth et al, 2004).
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Table 2.4 Summary of reviews of disease management programmes for heart failure.
Review Aim of review Number of studies Findings
Philbin 1999 To evaluate the impact of 
programmes on process of 
care, resource utilisation, 
health care costs and clinical 
outcomes
7 controlled trials published 
1995- 1998
• 6/7 studies reported reductions in hospital readmission 
rates in the intervention group, ranging from 50 -  74%
• 3 studies that examined costs reported a reduction in 
costs in the intervention group
• 4/4 studies reported improvements in functional status
• 1/2 studies reported improved QoL
Rich 1999 To evaluate current status of 
HF disease management
6 randomised controlled trials 
and 10 non-randomised trials 
published 1983 - 1998
Of the randomised trials:
• 5 studies - Reductions in hospital admissions ranged 
from 27% to 73%
• 2 studies - Reductions in hospital days of 25% and 
43%
• 2 studies -  lower hospital costs
• 1 study -  better QoL
McAlister et al 2001 To examine whether 
programmes reduce mortality 
or hospitalisation rates
11 randomised controlled 
trials published 1993 - 1999
In meta-analysis:
• 7 studies -  no significant reduction in mortality 
(pooled RR 0.94, 95% Cl 0.75 -  1.19)
• 11 studies -  significant reduction in readmission 
(pooled RR 0.87, 95% Cl 0.9 -  0.96)
• 7/8 studies reported fewer total hospitalisations in the 
intervention group
• 7/9 studies reported shorter length of stay or reduced 
total hospital days in the intervention group
• 1/5 studies reported better QoL in the intervention 
group
• 7/8 studies reported cost savings in the intervention 
group
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Review Aim of review Number of studies Findings
Windham et al 2003 To define the components of 
successful care management
15 randomised controlled 
trials, 17 non-randomised 
trials published 1971 -2 0 0 2
In the randomised controlled trials :
• 6/14 reported significantly fewer admissions in the 
intervention group
• 0/9 reported lower mortality
• 2/7 reported better QoL in the intervention group
• 2/5 reported fewer emergency visits in the 
intervention group
• 3/9 reported lower costs in the intervention group
Gonseth et al 2004 Review effectiveness of 
disease management 
programmes in reducing 
hospital admissions
27 randomised controlled 
trials and 27 non-randomised 
trials published 1993 - 2003
In meta-analysis of randomised trials:
• 11 studies examined readmission for HF or other 
cardiovascular disease -  significantly reduced risk of 
readmission in intervention group (pooled RR 0.70, 
95% confidence interval (Cl) 0.62 -  0.79)
• 16 studies examined all-cause readmission -  
significantly reduced risk of readmission in intervention 
group (pooled RR 0.88, 95% Cl 0.79 -  0.97)
• 10 studies examined combined outcome of death or 
all-cause readmission -  significantly reduced risk of 
event in intervention group (pooled RR 0.82 95% Cl 
0.72 -  0.94)
Gustafsson et al 2004 To describe and critically 
evaluate HF clinics using 
nurse intervention
18 randomised controlled 
trials published 1993 - 2003
• No clear overall reduction in mortality
• 8/18 studies reported significant reductions in hospital 
readmission rates
Gwadry-Sridhar et al 2004 To evaluate the effectiveness 
of HF programmes on 
hospital readmission rates
8 randomised controlled trials 
published 1993 - 2001
• Pooled RR for readmission was 0.79, 95% Cl 0.68 -  
0.91 favouring the intervention group
• Pooled RR of mortality was not significant (RR 0.98, 
95% Cl 0 .7 2 -1 .3 4 )
• 2/3 studies reported a significant improvement in QoL 
in the intervention group
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Review Aim of review Number of studies Findings
McAlister et al 2004 To examine whether 
programmes improve 
outcomes
29 randomised controlled 
trials published 1993 -  2004
• 2/22 studies reported significant reduction in mortality 
in the intervention group (pooled RR 0.83, 95% Cl 
0.70 -  0.99)
• 3/22 studies reported a significant reduction in all­
cause hospitalisation rate in the intervention group 
(pooled RR 0.84, 95% Cl 0.75 -  0.93)
• 6/19 studies reported a significant reduction in heart 
failure hospitalisation rate in the intervention group 
(pooled RR 0.73, 95% Cl 0.66 -  0.82)
• 11/21 studies reported significantly fewer total 
hospitalisations in the intervention group (pooled RR 
0.70, 85% Cl 0.62 -  0.80)
• There was also a reduction in total HF hospitalisations 
but the number of studies is unclear in the review 
(pooled RR 0.57, 95% Cl 0.49 -  0.67)
• 9/18 studies reported significantly better QoL in the 
intervention group
• 15/18 studies reported that the intervention was cost 
saving
Phillips et al 2004 To evaluate the impact of 
programmes on hospital 
admissions, length of stay, 
mortality, QoL, costs
18 randomised controlled 
trials published 1993 - 2003
In meta-analysis:
• 18 studies - significant reduction in all-cause 
admission (pooled RR 0.75, 95% Cl 0.64 -  0.88)
• 14 studies -  no significant reduction in mortality 
(pooled RR 0.87, 95% Cl 0.73 -  1.03)
• 10 studies -  no significant reduction in mean length of 
stay (Pooled reduction -0.37, 95% Cl -0.15 -  0.60)
• 3/6 studies reported better QoL in the intervention 
group
• Pooled cost savings were significant for US studies 
but not non-US studies
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Review Aim of review Number of studies Findings
Bruggink-Andre de la Porte 
2005
To discuss the applicability of 
HF management 
programmes in countries with 
well structured primary care
21 randomised controlled 
trials published 1995 - 2003
• 5/9 studies reported a significant reduction in the 
combined endpoint of death or all-cause hospital 
readmission
• 2/5 studies reported a significant reduction in the 
combined endpoint of death or HF hospital 
readmission
• 7/18 studies reported a significant reduction in all­
cause readmission rate
• 5/9 studies reported a significant reduction in HF 
readmission rate
• 5/15 studies reported a significant reduction in days 
spent in hospital
• 1/14 studies reported a significant reduction in 
mortality
• 4/13 studies reported significant improvement in QoL
• 2/2 studies reported significant improvement in self- 
care
• 3/14 studies reported significant cost savings
Holland et al 2005 To examine the impact of 
programmes on hospital 
admission and mortality
30 randomised controlled 
trials published 1995 - 2005
In meta-analysis:
• 21 studies - significant reduction in all-cause 
admission (pooled RR 0.87, 95% Cl 0.79 -  0.95)
• 27 studies -  significant reduction in mortality (pooled 
RR 0.79, 95% Cl 0.69 to 0.92)
• 16 studies -  significant reduction in HF admission 
(pooled RR 0.70, 95% Cl 0.61 -  0.81)
• 10 studies -  significant decrease of hospital days of 
1.9 days in favour of intervention group (95% Cl 0.71 -  
3.1)
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Review Aim of review Number of studies Findings
Phillips et al 2005 To study the effectiveness of 
programmes incorporating 
nurse-led clinics in relation 
to the intervention complexity
6 randomised controlled trials 
published 1998 - 2003
In meta-analysis:
• 6 studies -  no significant difference in all-cause 
admission (pooled RR 0.91, 95% Cl 0.72 -1 .1 6 )
• 6 studies -  no significant difference in mortality 
(pooled RR 0.80, 95% Cl 0.57 -  1.06)
• 5 studies -  no significant difference in QoL
• 3 studies -  no significant difference in costs
Roccaforte et al 2005 To summarise evidence of 
effectiveness of disease 
management programmes in 
improving clinical outcomes
33 randomised controlled 
trials published 1993 - 2004
In meta-analysis:
• 28 studies -  significant reduction in mortality (pooled 
RR 0.84, 95% Cl 0.74 -  0.94)
• 32 studies -  significant reduction in all-cause 
hospitalisation rate (pooled RR 0.86, 95% Cl 0.82 -  
0.91)
• 20 studies -  significant reduction in HF hospitalisation 
rate (pooled RR 0.69, 95% Cl 0.63 -.0.77)
• 12 studies -  significant reduction in all-cause hospital 
days (Weighted mean difference -1.49, 95% Cl -2.03 
to -0.95)
• 5 studies -  significant reduction in all-HF hospital days 
(WMD -1.25, 95% Cl -1.99 to -0.50)
Whellan et al 2005 To assess the effectiveness 
of disease management 
programmes in reducing 
hospitalisation and mortality
19 randomised controlled 
trials published 1995 - 2003
• Interventions that included clinic follow-up by a 
cardiologist, home visit or telephone follow-up 
significantly decreased all-cause hospitalisation but 
clinic follow-up with primary care practitioner 
supervision did not decrease hospitalisations.
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Review Aim of review Number of studies Findings
Yu et al 2006 To identify the characteristics 
of disease management 
programmes crucial to 
reducing hospitalisation 
and/or mortality
21 randomised controlled 
trials published 1995 - 2004
• 12 interventions were ‘effective’ i.e. had a significant 
impact on readmission and/or mortality
• 11 studies -  significant reduction in number of hospital 
admissions (RR: 0.56 ± 0.14)
• 4 studies -  significantly reduction in mortality (RR: 
0.42 ± 0.22)
• 8 studies -  significant reduction in combined event 
rate (RR: 0.61 ±0.17)
• Concluded that an effective programme should be 
multifaceted, consist of in-hospital phase of care, 
intensive patient education, self-care supportive 
strategy, optimisation of medication regimen, ongoing 
surveillance and management of clinical deterioration. 
Cardiac nurse and cardiologist should be actively 
involved and a flexible approach should be adopted to 
deliver follow-up care.
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In attempting to address the question of which type of programme is most effective, 
some reviews classified them according to how and where care was provided. 
However, the reviews used different classifications and did not reach the same 
conclusion. For example, McAlister et al (2004) concluded that all-cause hospital 
admission was reduced by multidisciplinary teams and interventions emphasising self- 
care but not those that were telephone based with primary care follow-up. Holland et al
(2005) however, concluded that interventions with a home-based component produced 
the greatest effect on all-cause readmission to hospital while Whellan et al (2005) 
found significant reductions in all cause hospital admissions in interventions that 
consisted of clinic follow-up by a cardiologist, home visit or telephone follow-up.
One shortcoming of the majority of these reviews of disease management programmes 
in heart failure is that they focussed on where the interventions were delivered (e.g. 
clinic or home) and by whom, rather than according to the actual content of the 
programmes. Exceptions are the reviews by Phillips et al (2005) and Yu et al (2006) 
who examined programmes according to their component parts. Phillips et al (2005) 
described eleven different components -  1. discharge planning, 2. pre-discharge 
education, 3. post-discharge education, 4. medication counselling and review, 5. 
optimisation of ACE inhibitors, 6. self-care behaviour, 7. increased communication 
between providers, 8. home visit, 9. telephone follow-up, 10. specialist heart failure 
nurse and 11. heart failure clinics -  and classified interventions according to presence 
or absence of each component. The number of these components contained in the 
interventions reviewed ranged from 7 to 11. The reviewers concluded that better 
outcomes were obtained by programmes that included hospital discharge planning and 
immediate discharge follow-up however the reliability of this finding is limited by the 
small number of studies (n = 6) in the review.
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Yu et al (2006) classified programmes according to six different criteria -  1. structure 
of the care team, 2. inclusion of in-hospital care, with or without discharge planning, 3. 
education, counselling and supportive self-care strategies, 4. optimisation of medical 
therapy, 5. attention to deterioration in signs and symptoms, and 6. follow-up care. 
There was considerable heterogeneity in the programmes and Yu et al compared 
features of the 12 ‘effective’ studies i.e. those which had a significant impact on 
readmission and/or mortality, with the 9 ineffective studies. Yu et al (2006) summarised 
the most common features of effective programmes (see Table 2.4) however there was 
substantial overlap between the composition of the effective and ineffective studies, for 
example, all studies included patient education and the majority of both effective and 
ineffective studies included attention to signs of deterioration.
2.7 Summary
It is clear that management of heart failure by both health care professionals and 
patients themselves has been suboptimal. Developments to improve care through the 
introduction of disease management programmes have shown some benefits but the 
heterogeneity in their content, delivery, control condition and outcomes raises issues 
that require further consideration.
Reviews have not identified an optimal model of care and it is probably unlikely that a 
single model of care will equally benefit all patients. An important research question is 
therefore to examine factors that may predict who will benefit from a particular 
intervention.
The health care environments in which patients are treated vary considerably and 
Bruggink-Andre de la Porte et al (2005) caution that heart failure programmes 
developed in one health care system should not be uncritically implemented in
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countries with a different health care system. The available resources vary between 
health care systems and this also influences what models of care are achievable. Many 
of the interventions that have been implemented to date have been fairly intensive but 
there is no evidence as to their optimal intensity and duration, and a need remains to 
examine whether less intensive models can produce beneficial outcomes. It is 
necessary therefore to develop and evaluate models that can provide cost effective 
benefits for patients in the U.K. National Health Service.
One model that could offer the prospect of achieving benefit without exclusive 
dependence on intensive follow-up by a health care professional is to improve patients’ 
self-management of their heart failure. Shortcomings in self-management have been 
identified as a factor contributing to poor outcomes. Although almost all disease 
management programmes include patient education, it is unclear to what extent they 
have been effective in enhancing patient self-management.
The next chapter will further examine the role of self-management in heart failure. It will 
describe the current understanding of factors associated with heart failure self­
management and review interventions that have included a component aimed at 
improving the way patients manage their heart failure.
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CHAPTER 3 
SELF-MANAGEMENT OF HEART FAILURE
This chapter outlines the theoretical background to self-management and describes 
factors that have been found to influence self-management in heart failure. The chapter 
then includes a systematic review of interventions in heart failure. This systematic 
review examines the extent to which the interventions have adopted a self­
management approach and their effect on self-management behaviours and other 
outcomes.
3.1 Definition and key features of self-management
Living with a chronic illness requires patients to undertake many different tasks to 
manage their illness on a day-to-day basis. This may include monitoring physiological 
markers of changes in the illness, taking medication, changing diet and taking exercise, 
amongst others. The role that patients play in managing their illness is commonly 
referred to as self-management, which Barlow, Wright, Sheasby et al, (2002) define as, 
“the individual’s ability to manage the symptoms, treatment, physical and psychosocial 
consequences and life style changes inherent in living with a chronic condition. 
Efficacious self-management encompasses ability to monitor one’s condition and to 
effect the cognitive, behavioural and emotional responses necessary to maintain a 
satisfactory quality of life. Thus, a dynamic and continuous process of self-regulation is 
established.”
It can be seen from this definition that self-management involves more than adhering to 
the recommended treatment regimen.
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3.2 Theoretical foundations
Self-management of a chronic illness is complex therefore it is not surprising that 
effective self-management can be difficult to achieve (Newman, Steed, & Mulligan, 
2004). It has been shown in other chronic illnesses, such as diabetes, asthma and 
arthritis, that simply providing people with information about what action they should 
take to manage their illness, for example to take medication, change their diet or 
increase their physical activity, is not necessarily sufficient to ensure effective self­
management (Coates & Boore, 1996; Riemsma, Kirwan, Taal, & Rasker, 2002; Gibson 
et al., 2000). The recommended behavioural changes are often not easy to make, or 
patients may choose not to make them, and a number of health psychology theories 
help to elucidate the role of cognitive, emotional and social factors in health behaviour. 
Among these are the Health Belief Model (Becker, 1974; Janz & Becker, 1984), the 
Theory of Planned Behaviour (Ajzen, 1991), Protection Motivation Theory (Rogers, 
1975), the Stress Coping Model (Lazarus & Folkman, 1984), Self-Regulation Theory 
(Leventhal, Nerenz, & Steele, 1984), Social Cognitive Theory (Bandura, 1977), the 
Transtheoretical Model (Prochaska & DiClemente, 1984) and the Model of Action 
Phases (Gollwitzer, 1993). Drawing on these theories can help to facilitate the 
development of interventions designed to enhance self-management. A discussion of 
all of these theories is beyond the scope of this thesis but two of the theories that are 
considered particularly relevant to self-management are outlined below. In addition to 
theories in health psychology, self-management has drawn on cognitive-behavioural 
models of behaviour change such as cognitive restructuring, which is a feature of 
cognitive therapy (Beck, 1976) and problem-solving therapy (D'Zurilla & Goldfried, 
1971).
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3.2.1 Self-regulatory model
Psychological theories of self-regulation propose that human activity is goal-directed 
and that people regulate their behaviour according to their goals (Karoly, 1993). This 
applies equally to behaviours directed to managing an illness hence self-management 
can be seen as a self-regulatory process. Leventhal et al’s model (Leventhal et al., 
1984; Cameron & Leventhal, 2003) proposes how self-regulatory processes operate 
when a person is confronted with a chronic illness. According to the model, the way 
people self-manage is a reflection of how they conceptualise their experience of the 
illness (Horowitz, Rein & Leventhal, 2004).
Leventhal et al propose that people hold a ‘common sense’ model of their illness which 
provides a framework through which they understand and respond to it. This framework, 
or cognitive representation, is influenced by many factors, including a person’s existing 
knowledge about the illness, and information they receive from health care 
professionals, the media, family and friends. The illness also generates an emotional 
response. The coping behaviours (which include self-management behaviours) that 
people select to manage their illness are influenced by both their cognitive 
representations and their emotional state. People evaluate how effective their coping 
behaviours have been in managing the illness and this appraisal can then in turn lead 
to revision of their illness representations and their behaviours. Self-regulation is thus a 
dynamic process which involves ongoing appraisal and modulation of behaviour, 
cognition and emotion.
Leventhal et al have investigated the content of cognitive representations of illness 
and have identified five key dimensions -  identity refers to the symptoms that are 
perceived to be related to the illness, timeline refers to the perception of the likely time 
course of the illness, cause refers to the beliefs people hold about what caused their
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illness, consequences refers to the effect people believe the illness has had on their 
lives and cure/control refers both to how amenable the illness is thought to be to cure 
or control and the extent to which it is under personal control.
3.2.2 Social Cognitive Theory
One of the most influential psychological models in self-management research is the 
social cognitive model (Bandura, 1986), particularly the concept of self-efficacy 
(Bandura, 1997). Self-efficacy is related to the concept of control in the self-regulatory 
model but is more specific, referring to confidence in one’s ability to perform a specific 
behaviour rather than a more general sense of control over one’s illness.
Social cognitive theory proposes that the determinants of behaviour are multifaceted, 
incorporating both personal and socio-structural factors. According to this model, 
behaviour in influenced by the goals people have, their expectations about the outcome 
of their actions (or failure to take action), their confidence that their actions will lead to 
the desired outcome (self-efficacy), and barriers to performance of the behaviour, 
which can be personal, situational or, in the case of health behaviours, may be rooted 
in the health care system.
Self-efficacy plays a pivotal role because whatever a person’s motivation, unless they 
believe that they can achieve the desired outcome through their actions, they will have 
little incentive to perform a behaviour or persevere to overcome difficulties. Self- 
efficacy therefore influences the goals people set for themselves, the outcomes they 
expect to achieve through their efforts and the perseverance they will show in the face 
of obstacles (Bandura, 2000).
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Bandura outlined four factors that influence self-efficacy and therefore can be targeted 
in order to increase self-efficacy and hence encourage behaviour change. One 
important way of increasing self-efficacy is through mastery. Success in performing a 
behaviour builds self-efficacy thereby increasing the likelihood that the behaviour will 
continue and more ambitious goals set. By contrast, failure undermines self-efficacy 
and discourages continued performance of the behaviour. Self-efficacy beliefs can also 
be strengthened through vicarious experience. This is gained through modelling the 
successful behaviour of a person with whom one identifies such as another patient 
living with the same illness. Social persuasion can also strengthen a person’s sense of 
self-efficacy, for example an encouraging health professional could persuade patients 
that they have the capability to perform a given behaviour. Finally self-efficacy beliefs 
can be strengthened by reducing feelings of stress that can lead people to misinterpret 
their physical states and thus misjudge their capabilities.
3.3 Strategies to facilitate behaviour change
These theoretical models provide a basis for understanding cognitions that influence 
self-management behaviour and therefore suggest possible targets for interventions 
that aim to change behaviour. A number of strategies have been identified that are 
considered important in facilitating behaviour change.
3.3.1 Goal selection
Selection of behavioural goals is a prerequisite of self-management. According to 
Creer & Holroyd (1997), goal selection can occur only after preparation, for which 
patients require both information about how their condition can be managed and the 
skills needed to do so. Creer & Holroyd view goal selection as a collaborative activity 
between patients and health professionals. Once goals are established it then
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becomes the responsibility of the patient to utilise the self-management skills that have 
been taught in order to achieve those goals.
3.3.2 Implementation intentions
Selecting a goal is an important step but ensuring that the goal is reached requires 
more than good intentions (Gollwitzer, 1999). Research on the Theory of Planned 
Behaviour, for example, has highlighted the gap between what people say they intend 
to do and actual performance of that behaviour (Armitage & Conner, 2001). Gollwitzer’s 
Model of Action Phases differentiates between goal intentions and implementation 
intentions. While the former specify a desired end state, the latter specify how that 
state will be achieved. By breaking down when, where and how the given behaviour 
will be performed, the goal is more likely to be achieved (Sheeran, 2002).
3.3.3 Self-monitoring
Creer & Holroyd (1997) have asserted that “self-monitoring provides the foundation for 
self-management”. Systematic recording of information, about symptoms for example, 
can serve the purpose of increasing patients’ awareness of what is happening in their 
illness and how it changes over time. It can also help patients to identify conditions that 
affect the outcome being monitored and continual feedback can serve to encourage the 
change process (Bandura, 1997). The self-monitoring process enables patients to 
identify whether they are reaching their goals and is considered an essential feature of 
self-regulatory processes (Karoly, 1993).
3.3.4 Stimulus-control
Stimulus-control is a behavioural learning technique that involves establishing 
appropriate cues to stimulate performance of a new behaviour. By pairing a new 
behaviour with an already established, habitual behaviour, the new behaviour is more
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likely to become established also. For example, one way of assisting people who 
repeatedly forget to take their medication would be to establish more effective cues to 
help them remember. Using daily routines or habits is useful so one approach could be 
to establish a link between taking medication and a routine such as brushing one’s 
teeth or a regular mealtime. The association could be made by keeping medication, or 
a visual reminder such as a medication chart, in a prominent position by the related 
behavioural cue.
Conversely, removing cues to unwanted behaviours can help to reduce them. For 
example, a person trying to give up smoking is encouraged to remove smoking-related 
cues such as ashtrays and cigarette lighter and to break the links between behaviours 
that they usually pair with smoking such as avoiding places where they are tempted to 
smoke.
3.3.5 Problem-solving
Training in problem-solving skills developed from a cognitive-behavioural approach in 
clinical psychology which recognised the importance of these skills in enabling people 
to adapt to the range of problems they may encounter through their lives (D'Zurilla & 
Nezu, 2001). This does not involve solving people’s problems for them by advising 
them what to do, but entails helping people to think through their difficulties and decide 
on a solution that best suits them.
D’Zurilla & Goldfried (1971) set out five key components to the problem-solving 
process. These are:
a. Problem Orientation - the way a problem is perceived by the individual is crucial 
for successful problem solving. Facilitation of a positive problem orientation is 
important so that the individual can see the problem as a challenge which can be
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overcome in contrast to a negative problem orientation in which the problem is 
viewed in a pessimistic way that can inhibit problem-solving attempts
b. Problem definition and formulation -  this involves gaining a clear understanding of 
the nature of the problem and breaking it down into smaller, more manageable 
parts
c. Generation of alternative solutions -  by brainstorming several alternative possible 
ways of dealing with a problem, it should be possible to identify the strategy which 
is likely to be most effective
d. Decision making -  this involves weighing up the pros and cons of each alternative 
generated in the previous step and selecting the one which is considered the most 
appropriate
e. Solution implementation and verification -  the final step involves trying out the 
chosen strategy, evaluating its effectiveness and adapting the strategy or choosing 
a new strategy as appropriate
Although these steps have been presented sequentially, successful problem solving is 
likely to involve movement back and forth between the different stages before the 
process is complete.
3.3.6 Cognitive restructuring
Patients’ beliefs about themselves (e.g. I’m not the type of person who can change) or 
their illness (e.g. heart failure is an acute illness) may impede their self-management 
efforts therefore it is important to address mistaken or unhelpful beliefs. Cognitive 
restructuring, an element of cognitive-behavioural therapy, is a strategy that can be 
used to facilitate the development of more helpful beliefs by challenging aspects of 
patients’ thinking. Common thinking biases have been identified (White, 2001), for 
example, a tendency to catastrophise, i.e. to think about events in the worst possible
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terms, which may lead to patients not taking action to self-manage their illness if they 
think that whatever they do will make no difference. Patients can be encouraged to look 
for alternative ways of thinking that are more conducive to effective self-management.
3.3.7 Social support
Self-management of a chronic illness does not occur in isolation from members of 
patients’ family and social network accordingly support from these significant others is 
potentially an important influence on self-management behaviour (Gallant, 2003). In 
research, this support has been termed ‘social support’ and has been conceptualised 
both structurally, i.e. the size and composition of a person’s social network, and 
functionally, i.e. how a person perceives and evaluates the adequacy of their support 
network. It is the latter which appears to be most closely related to health (McNally & 
Newman, 1999). Social support generally has a positive impact on health outcomes but 
the reverse can also occur (Gallant, 2003). A review by DiMatteo concluded that 
adherence to medical treatment is higher in those from cohesive families but lower in 
those from families that are in conflict (DiMatteo, 2004).
Involving partners or other members of a patient’s network in an intervention may help 
to facilitate self-management by enhancing their understanding of the patient’s illness 
and encouraging them to engage in supportive behaviours.
3.4 Factors influencing self-management in heart failure
The theories outlined above describe some of the constructs that potentially play an 
important role in self-management. The research that has examined potential factors 
associated with self-management of heart failure will now be reviewed. This research 
was not necessarily conducted from a self-management perspective and typically 
focussed on patient ‘compliance’ or ‘adherence’ to medication or to the practice of ‘self­
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care’ behaviours, but given that the behaviours addressed form part of heart failure 
self-management, the studies are included here. The way self-management was 
assessed was not consistent across studies, for example the review by van der Wal et 
al reported that assessment methods included interview, a number of different 
questionnaires, electronic monitoring and chart review, which is likely to influence the 
findings. It should be noted that the studies are mostly cross-sectional and examine 
associations with self-management. None were identified that attempted to change 
potentially modifiable variables in order to improve self-management.
3.4.1 Demographic factors
Studies that sought to identify potential influences on self-management behaviour 
commonly examined demographic characteristics.
Studies that examined the relationship between age and self-management showed 
some consistency, with most studies finding that older age was associated with better 
self-management of at least some of the recommended behaviours. Although 
Rockwell & Riegel (2001) did not find any association between age and self­
management, Chriss, Sheposh, Carlson et al (2004) reported better self-management 
among older patients, and Artinian et al., (2002), Monane, Bohn, Gurwitz et al., (1994) 
and Evangelista Berg & Dracup, (2001) all reported that older patients were more likely 
to follow their medication regimen. When Evangelista, Doering, Dracup et al (2003) 
compared older (>65 years) and younger (<65 years) patients, they found no difference 
in keeping medical appointments, taking medication, smoking cessation or alcohol 
abstinence but older patients were more likely to follow recommended dietary advice 
and take exercise.
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Studies that examined the relationship between gender and self-management in heart 
failure showed inconsistent results (van der Wal et al., 2005). No gender differences 
were found by Rockwell & Riegel (2001), Evangelista, Kagawa-Singer, & Dracup (2001) 
or van der Wal, Jaarsma, Moser et al (2006). However, Chriss et al (2004) found that 
male gender was associated with better self-management whereas Monane et al (1994) 
found that females were more likely to keep to their digoxin regimen. The study by 
Artinian, Magnan, Sloan, & Lange, (2002) did not find any gender differences in overall 
self-management behaviour but men were more likely than women to report obtaining 
an annual flu vaccination.
Neither Evangelista, Berg, & Dracup (2001) nor Artinian et al (2002) found any 
relationship between ethnicity and overall self-management behaviour but on individual 
behaviours, the latter study found that African-American patients were more likely than 
whites to seek medical assistance in response to signs of deterioration whereas white 
patients were more likely to take their medication and get an annual flu vaccination.
The findings relating to education level and self-management are also inconsistent. 
Chriss et al (2004) did not find an association between education and self-management 
whereas in the study by Artinian et al (2002) higher education was associated with 
taking medication as prescribed and less use of convenience foods. Chui, Deer, 
Bennett et al (2003) also found that education predicted medication adherence. 
Although Rockwell & Riegel (2001) found that a higher education level was predictive 
of better self-management, it predicted only 4.6% of the variance. In one study, a lower 
education level was associated with better overall self-management behaviour 
although it seems to be related mainly to fluid restriction (van der Wal et al, 2006).
In the studies that used multivariate analysis, demographic factors accounted for only a 
small percentage of the variance in self-management. For example Rockwell & Riegel
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(2001) found that gender, socioeconomic status, age, education, along with social 
support, co-morbidity and symptom severity explained only 10.3% of the variance in 
self-management. Similarly, Chriss et al, (2004) found that age, gender and education, 
along with comorbidity, social support satisfaction, activity and NYHA class, explained 
just 14.8% of the variance. A slightly higher percentage of variance was explained in 
the study by Evangelista, Berg & Dracup (2001). Age, race, marital status, and years of 
education, along with the variables of mental health, physical health, health satisfaction 
and neuroticism explained 24% of the variance in the overall self-management score.
The findings in self-management of heart failure appear to replicate those in the wider 
literature on adherence to medication which have not shown consistent relationships 
between adherence and demographic factors, with the possible exception of age 
(Horne, 1998). These studies serve to highlight that associations between demographic 
characteristics and self-management are not consistent across all heart failure self­
management behaviours, reinforcing that people may be effective self-managers in 
some areas but not others.
3.4.2 Disease and treatment related factors
The nature of the relationship between disease severity and the performance of self­
management behaviour appears to vary according to which behaviour is being 
examined. For example, perhaps not surprisingly, Ni et al (1999) found that those in 
NYHA class III and IV i.e. those with more severe heart failure, did less exercise than 
those in classes I and II, however, higher NYHA has been associated with better 
adherence to medication (van der Wal et al, 2005). Rockwell & Riegel (2001) found 
that greater symptom severity was associated with better self-management although it 
explained only 2.7% of the variance. In contrast, Evangelista, Berg & Dracup (2001) 
found that self-management was better in those reporting better physical health and
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greater health satisfaction. Artinian et al (2002) found that patients who reported more 
shortness of breath were less likely to weigh themselves but Chriss et al (2004) did not 
find any relationship between NYHA or ability to perform activities of daily living and 
self-management.
Many patients with heart failure have co-morbid conditions and it is possible that these 
could limit their ability to self-manage effectively. For example some patients have 
reported being unable to weigh themselves because of restricted eyesight or not being 
able to stand on the scales independently and not exercising because of disability 
(Jaarsma et al, 2000). Chriss et al (2004) found that co-morbidity was an independent 
predictor of self-management behaviour three months later.
Complexity of the medication regime may be another important factor in how effectively 
people self-manage (Evangelista et al., 2003). Bohachick, Burke, Sereika et al (2002) 
compared rates of adherence to ACE inhibitors between those whose prescriptions 
were for once, twice or three to four times a day and found rates of 90%, 84% and 68% 
respectively. More complex regimens may be more difficult to remember and 
implement correctly. However the number of different medications may not necessarily 
be an issue; Monane et al. (1994) found that people taking a greater number of 
different medications were more likely to follow their digoxin regimen.
The duration for which patients have been living with heart failure may influence how 
effectively they self-manage. Carlson, Riegel & Moser (2001) found that experienced 
patients who had a sudden weight gain were more likely than the newly diagnosed to 
take responsive action by limiting their salt intake and using additional diuretics. Riegel 
et al divided patients into those who had been diagnosed with heart failure for less than 
2 months and those with a longer-standing diagnosis and found that patients who had
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been diagnosed for longer than two months reported better self-management 
behaviour (Riegel, Carlson, Moser et al, 2004).
3.4.3 Knowledge
In common with findings in other chronic illnesses (Coates & Boore, 1996; Taal, Rasker 
& Weigman, 1997; Gibson, Coughlan, Wilson et al, 2000) there is not a strong 
relationship between knowledge and self-management in patients with heart failure. 
The only study that reported a positive relationship between them was by Van der Wal 
et al (2006) who found that a higher knowledge score was associated with fluid 
restriction and weighing behaviour. Other studies did not confirm this finding, for 
example, Michalsen et al found that 55.3% of patients had at least basic knowledge 
about their prescribed drug treatment however knowledge was not significantly 
correlated with patients’ adherence to recommended medication (Michalsen, Konig & 
Thimme, 1998). Of 42 non-adherent patients, 47.6% lacked basic knowledge about at 
least one prescribed drug and among 137 adherent patients, 43.8% lacked basic 
knowledge about at least one prescribed drug i.e. levels of knowledge were similar 
among adherent and non-adherent patients.
Ni et al (1999) also found that knowledge was not sufficient to predict self-management 
behaviour. Although scores were correlated, knowledge did not remain a significant 
predictor of self-management in multivariate analysis. Only 58% of those patients who 
considered daily weight monitoring to be important weighed themselves daily and 14% 
weighed themselves once a month or less. Of those who considered restricting sodium 
intake to be important, only 38-40% reported always avoiding salty foods. When De 
Geest, Scheurweghs, Reynders et al (2003) compared patients with heart failure 
admitted to cardiology and geriatric wards, they found that knowledge of treatment 
recommendations was higher in the former but adherence to some aspects of the
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regimen was higher in the latter, again suggesting that knowledge alone does not 
explain self-management behaviour.
3.4.4 Psychological factors
3.4.4.1 Self-efficacy
Very little research has been conducted into the role of cognitions in heart failure self­
management. One early study was identified that examined the relationship between 
self-efficacy and self-management, both of which found a positive relationship. Ni et al 
(1999) found that lower self-efficacy was associated with poorer adherence to 
recommended self-management behaviours. A more recent study (Schweitzer, Head, 
& Dwyer, 2007) also found that self-efficacy was a significant predictor of performance 
of self-management behaviours.
It is important however that self-efficacy is not misplaced. Carlson, Riegel & Moser 
(2001) found that patients were confident about their ability to evaluate symptom 
importance despite the fact that misperceptions about the importance of specific 
symptoms were common.
3.4.4.2 The role of illness and treatment beliefs in heart failure self-management
Research into cognitive factors in self-management of heart failure is at a very early 
stage with little currently known about the beliefs patients hold about their illness or 
their ability to manage it.
Horowitz, Rein & Leventhal (2004) highlighted that heart failure programmes conducted 
to date have not had the benefit of information about which potentially modifiable 
factors are involved in inadequate self-management. They were interested in patients’
73
knowledge and beliefs about heart failure because, according to the self-regulation 
model (Leventhal et al., 1984) which guided their research, the way patients self- 
manage is a reflection of how they conceptualise their experience of the disease.
In a qualitative study of 19 patients, Horowitz Rein & Leventhal (2004) found that 
patients’ representations of their heart failure lacked depth and breadth in that they did 
not make the connection between the disease and their chronic symptoms and were 
unable to give an explanation of what caused their heart failure or its symptoms. These 
beliefs had implications for patients’ self-management because they did not recognise 
that they could minimise fluid build-up and detect signs of deterioration through self­
management practices. For example, some patients who held an acute model of their 
heart failure thought they needed to take diuretics only when their symptoms became 
severe. This may help to clarify why it is often insufficient to provide patients with 
information about what they need to do to manage their illness e.g. take diuretics, 
without gaining an understanding of the model they hold of their illness which may 
influence how they put the information into practise. Horowitz et al found that lack of a 
coherent representation of the connection between the disease and its symptoms 
meant that signs of deterioration such as weight gain, breathlessness or oedema were 
not necessarily followed by an appropriate response. Few patients self-monitored for 
signs of deterioration, by regular weighing for example, but took action only once their 
symptoms had become severe enough to require emergency medical care. Horowitz et 
al concluded that patients mostly held a model of heart failure as an acute condition 
with episodic exacerbations rather than a chronic condition requiring continuous 
monitoring and self-management.
Just one other study was identified that examined the role of beliefs about the 
treatment regimen in heart failure. When van der Wal et al (2006) examined the
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relationship between patients’ beliefs about their recommended medication and dietary 
regime, they found that patients who perceived benefits from their diet and medication 
were more likely to perform recommended health behaviours.
3.4.4.3 Mood
Depression is recognised as a risk factor for non-adherence to medical treatment. A 
review by DiMatteo, Lepper & Croghan (2000) for example, found that the odds of not 
following medical treatment recommendations were 3 times greater in depressed than 
in non-depressed patients. Only two studies were identified that examined the 
relationship between mood and self-management in heart failure and, not surprisingly, 
found that lower mood is associated with poorer self-management. Van der Wal et al 
(2006) found that patients reporting more depressive symptoms were less likely to 
exercise and Evangelista et al, (2001) found that better mental health and lower 
neuroticism were predictive of better self-management.
3.4.4.4 Lack of social support
The relationship between social support and self-management of heart failure is 
unclear with studies reporting inconsistent findings. Happ, Naylor & Roe-Prior (1997) et 
al found that absence of strong social support was related to poorer adherence and 
patients interviewed by Simpson, Farris, Johnson & Tsuyuki (2000) considered support 
from family and friends to have a positive impact on adherence. Ni et al (1999) found 
poorer self-management among patients who were unmarried. However, Rockwell & 
Riegel (2001), Evangelista et al (2001) and Chriss et al (2004) did not find a 
relationship between social support and self-management behaviour. A study by 
Artinian et al (2002) suggested that social support may have a positive influence on 
some behaviours but a negative impact on others. They found that patients who lived 
with others were more likely to seek medical assistance when symptoms worsened and
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less likely to eat convenience foods than those who lived alone. They were, however, 
less likely to be physically active than those who lived alone.
3.4.5 Summary
These findings indicate that a fairly limited amount of work has investigated factors that 
may influence self-management in heart failure. This is a fairly new area of 
investigation with almost all of the studies having been published during the current 
decade. Most have examined a narrow range of potential influences, concentrating 
mainly on demographic characteristics. The findings are also confounded by the use of 
different measures of self-management/adherence and a focus on different behaviours. 
Furthermore studies have not systematically assessed the relationship between 
potential influences on self-management, the performance of self-management 
behaviours and health outcomes. Most of the studies were cross-sectional so there is 
also a need for longitudinal studies to examine how these factors influence each other 
over time. It is clear that very few studies in heart failure have drawn on the extensive 
literature that exists on self-management of chronic illness.
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3.5 A SYSTEMATIC REVIEW OF INTERVENTIONS TO 
IMPROVE PATIENT SELF-MANAGEMENT OF HEART FAILURE.
3.5.1 Introduction
This next section reports the findings of a systematic review of interventions developed 
to improve care for patients with heart failure to examine how they have addressed the 
issue of patient self-management. The review is limited to papers published to 
February 2001, in order to provide an overview of the field at the time when work on 
the current study commenced and on which the current intervention was informed.
While it has been recognised that people with heart failure have an important role to 
play in managing their illness and that self-management is often sub-optimal, it is not 
clear whether interventions that have tried to improve outcomes for patients with heart 
failure have concentrated solely on improving medical aspects of treatment i.e. disease 
management, or have also included methods aimed at enhancing patient self­
management.
When this study commenced, interventions designed to improve heart failure 
management had been reviewed in three papers, (Philbin, 1999; Rich, 1999; McAlister 
et al., 2001). The reviews identified only a small number of studies, the largest being 16 
studies in Rich, of which only 6 were randomised trials. This appears to reflect the 
relatively undeveloped status of the field at that time. The later review, by McAlister et 
al, identified 11 randomised trials. Although most of the interventions included patient 
education, the reviews gave only a brief summary of the interventions and did not 
report or examine the content of the education component in any detail. The extent to 
which studies aimed to enhance the role of the patient in managing their heart failure
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was not reviewed nor did the reviews examine whether any changes in self­
management resulted in changes in health outcomes. A more detailed examination of 
the way studies addressed these issues was therefore required to inform the 
intervention planned in this study.
3.5.2 Aims
The aims of this systematic review were to examine the effectiveness of interventions 
in heart failure and the extent to which they promoted self-management. In particular, it 
examined which self-management components the interventions addressed, what 
strategies they adopted in order to encourage behaviour change and how effective they 
were in promoting self-management. It also examined whether changes in self­
management resulted in changes in health outcomes.
3.5.3 Methods
3.5.3.1 Search
Electronic database searches of Medline 1966-February 2001, Embase 1980- 
February 2001 and Psyclnfo 1972-February 2001 were conducted. Search terms used 
were (heart failure or cardiac failure or cardiomyopathy) and (patient education or self­
management or non-pharmacological or adherence or behavio* or health promotion or 
nurse or multi-disciplinary) and (program* or intervention or therapy). Studies were 
included if i) they reported a prospective evaluation of an intervention to improve heart 
failure management which included an educational and/or self-management 
component i.e. they aimed to improve the patients’ self-management of their heart 
failure, not only the medical management ii) the study population included adults (£18 
years) with heart failure, iii) they were published in English, iv) the design was either 
pre-test - post-test or a controlled trial, v) effects were tested statistically.
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The titles of all papers identified in the search were screened. Where the study 
appeared to evaluate an intervention, the abstracts were obtained and reviewed. Full 
articles were examined for studies that met the inclusion criteria.
3.5.4 Results
The search identified 21 studies published between 1992 and 2000 (Table 3.1). The 
majority (n=14) were conducted in the USA. Only one of the studies was conducted in 
the UK (Varma, McElnay, Hughes et al, 1999). In comparing the studies included in this 
systematic review with earlier reviews, there was overlap in the studies included, with 
ten of the sixteen studies included in the review by Rich, five of the seven in the review 
by Philbin and nine of the eleven in the review by McAlister et al. Exclusion of some of 
the studies that had been included in earlier reviews usually occurred because they did 
not include an education component or were not prospective evaluations of 
interventions.
3.5.4.1 Study design
Fifteen of the studies (71%) were controlled trials, the remainder were single group pre­
post studies.
Only one study (Gattis, Hasselblad, Whellan & O’Connor, 1999) reported that 
cardiologists involved in the treatment of study patients were blind to study group 
allocation.
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3.5.4.2 Sample demographics
Study samples ranged in size from 20 to 504. Several of the studies were small with 
ten studies having fewer than 100 participants. Mean age ranged from 52, in a sample 
of patients referred for transplant, to 80 in a study with an inclusion criterion of age £65. 
Sex distribution ranged from 33% to 98% male. Given the age and sex distribution of 
the general heart failure population, a number of the studies would appear to comprise 
samples that are not representative of the patient population. Most studies did not 
report socioeconomic data.
3.5.4.3 Disease Variables
3.5.4.3.1 Inclusion and exclusion criteria
Most studies (16/21, 76%) recruited from patient populations who had been admitted to 
hospital with a diagnosis of heart failure i.e. those at a high risk of readmission and 
death. Studies typically excluded those who had cognitive impairment, psychiatric 
illness, were living in residential care or outside the hospital catchment area, did not 
speak the language of the country where the study was conducted, had a terminal 
illness or were awaiting cardiac surgery. Recruitment rates, including the numbers who 
were excluded and those who refused, were often not reported, making it difficult to 
draw conclusions about the representativeness of the interventions in relation to the 
general population with heart failure. In the first large randomised controlled trial (Rich 
et al., 1995) for example, only 21.6% of patients who fulfilled the criteria for diagnosis 
of congestive heart failure were randomised into the study.
3.5A.3.2 Diagnosis of Heart Failure
Several studies did not specify the criteria on which the diagnosis of heart failure was 
based nor if the study was limited to those with left ventricular systolic dysfunction.
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Diagnostic criteria that were reported did not always include objective confirmation of 
heart failure, for example by echocardiography.
3.5.4.3.3 Disease severity
Disease severity was reported differently across studies, making comparison difficult. 
Extent of left ventricular systolic dysfunction as evidenced by left ventricular ejection 
fraction (LVEF) was reported in seven studies and the mean ranged from 21% to 44%.
Eight studies reported severity of functional impairment by New York Heart Association 
(NYHA) classification but failure of most studies to report the time of the assessment 
limits the usefulness of this information. It would be expected that most patients would 
be in class III or IV at the time of an admission to hospital but class I or II by the time 
they are well enough to be discharged. To compare severity of functional impairment 
across study populations, uniformity in time of NYHA assessment would be required.
3.5A.3.4 Co-morbidity
In the population of patients with heart failure, who are mostly elderly, presence of co- 
morbid illness is common (Krum & Gilbert, 2003) and this is likely to contribute to the 
probability of readmission to hospital (Braunstein, Anderson, Gerstenblith et al, 2003) 
as well as increasing self-management demands. Eight studies did not report the 
prevalence of co-morbid illnesses and others varied in the number of illnesses they 
reported on. Of the 13 studies that reported co-morbidity, eight studies reported rates 
of hypertension, which ranged from 29% (Jaarsma et al., 1999) to 76% (Rich et al., 
1995). In the 6 studies that reported atrial fibrillation (AF) rates ranged from 18% 
(Fonarow, Stevenson, Walden et al, 1997) to 41% (Ekman, Andersson, Ehnfors et al,
1998). All the studies reported rates of diabetes, which ranged from 15% (Shah, Der,
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Ruggerio, Heidenreich, & Masssie, 1998) to 34% (Stewart, Marley, & Horowitz, 1999). 
Rates of lung disease in 6 studies which reported it ranged from 20% (Smith, Fabbri, 
Pai, Ferry, & Heywood, 1997) to 36% (Stewart, Pearson, & Horowitz, 1998; Stewart, 
Marley & Horowitz, 1999). A number of other illnesses, for example arthritis, are likely 
to have been common in this population but were not reported. The impact of co- 
morbid illnesses on study outcomes was not examined specifically in any of the studies 
but comorbid illnesses are likely to have played a role in the number of hospital 
admissions for reasons other than heart failure.
3.5.4.4 Standard care
The nature of standard medical care that patients received, aside from the intervention 
under study, is an important consideration. If standard care is suboptimal, an 
intervention has the potential to make a greater impact. For example, if patients in the 
intervention group, but not the standard care control group, receive treatment 
according to recommended guidelines it would not be surprising if outcomes are better 
in the intervention group. Factors that have been identified as contributing to early 
readmission to hospital include discharge when not yet clinically stable and under­
prescription of recommended heart failure medication. It is important therefore to 
consider whether interventions simply optimise medical care in the intervention arm of 
the study but not the controls. Differences in standard care in different health care 
settings means that the optimised intervention arm in one study may be receiving care 
comparable to the control group in a study conducted in another health care setting 
with better standard care.
In the studies under review, standard care was not always described and varied 
considerably in those studies where it was reported. For example, in a Swedish study 
(Ekman et al, 1998) follow-up post discharge was generally by GP. In contrast, in an
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Australian study (Stewart et al, 1999), standard care included in-patient and 
community-based contact with a cardiac rehabilitation nurse, dietician, social worker, 
pharmacist and community nurse where appropriate plus an appointment with the 
primary-care physician, the cardiology outpatient clinic, or both, within 2 weeks of 
discharge and regular outpatient review by the cardiologist throughout the follow-up 
period.
None of the studies reported on whether medical care was optimised for all study 
patients but one indicator is the proportion of patients who had been prescribed 
recommended heart failure medication. Thirteen studies reported details of medication 
prescribed at baseline however the measurement time was not always clearly specified. 
In those studies that reported medication at discharge from hospital, the proportion of 
patients who were prescribed ACE inhibitors ranged from 53% (Riegel et al, 2000) to 
81% (Stewart et al 1998) and diuretic prescription ranged from 84% (Rich et al, 1995) 
to 99% (Stewart et al, 1998), indicating heterogeneity in the delivery of recommended 
medical treatment between studies.
Differential prescription rates between study groups would suggest that at least part of 
any intervention effects could be attributable to optimisation of medical treatment rather 
than other components of the intervention. Only two studies (Cline, Israelsson, 
Willenheimer, Broms, & Erhardt, 1998; Gattis, Hasselblad, Whellan, & O'Connor, 1999) 
reported differences in medication prescription between intervention and control groups, 
both of which were found at follow-up. As other studies did not report medication 
prescription at follow-up, it is not known to what extent optimisation of treatment 
differed between intervention and control groups.
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The amount and content of any education provided as part of standard care was not 
always reported, making it difficult to tell whether control groups were provided with 
even basic information about their treatment and how to manage their illness. In the 
eight studies that did report details, standard care information provision varied. For 
example, Schneider, Hornberger, Booker, Davis, & Kralicek, (1993) reported that usual 
education provided to the control group by the staff nurses was thought to vary 
between patients and to be haphazard at times. In contrast, Linne, Liedholm, & 
Israelsson (1999) compared two education programmes in which the control condition 
received standardised general information about heart failure and its management 
along with instruction on weight monitoring and individual limits for short-term weight 
change. This may have been equivalent to the information given to intervention groups 
in other studies.
3.5.4.5 Interventions
Most of the interventions aimed to improve delivery of medical care through a 
combination of one or more of medication review, enhanced discharge planning and 
enhanced follow-up (Table 3.2). Interventions were included in this systematic review 
only if they incorporated an education or self-management component, however the 
sections that follow will show that most of the included studies adopted a traditional 
information giving model rather than what would usually be considered self­
management. For this reason, they are referred to as ‘patient education’ rather than 
‘self-management’.
3.5.4.5.1 Improving delivery of medical care
Almost all of the studies incorporated a component that aimed to improve patients’ 
medication regimen. For example, several included medication review and 
simplification, which in one study (Schneider, Hornberger, Booker et al., 1993) included
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adaptation of the medication schedule to fit in with the patient’s everyday routine. Four 
interventions included input from a pharmacist.
Five interventions included enhanced discharge planning. This incorporated, for 
example, identification of anticipated problems with the treatment regimen, physical 
functioning or home environment, putting the appropriate services in place and 
ensuring that there was adequate communication between hospital and primary care 
services. The variability in standard care highlighted above must be taken into account 
when considering the impact of such intervention components.
Thirteen interventions (62%) included enhanced follow-up by a health care professional. 
This involved home visits, clinic out-patient visits and telephone calls, but studies 
varied considerably in the combination used and in the number of contacts, as well as 
the period over which the intervention was delivered. Interventions ranged from a 
single home visit (Stewart et al., 1998) to three home visits within a week of discharge 
then at regular intervals plus telephone follow-up (Rich et al., 1995) to easy access to a 
nurse-led clinic as required (Cline et al., 1998).
3.5.4.5.2 Patient Education -  Self-Management behaviours targeted
Patient education typically included information about heart failure and its treatment, 
including information about medication and instruction in what patients need to do to 
manage their illness. Study reports did not always provide detailed descriptions of the 
education components so some self-management behaviours may have been omitted. 
Sixteen different self-management behaviours were identified from the papers (Table 
3.3). All studies addressed at least one self-management behaviour but there was 
considerable variation between studies. The most commonly addressed behaviours
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were medication adherence (n = 17, 81%) and self-monitoring through daily weighing 
and symptom monitoring (n = 16, 76%). Nine studies (43%) addressed sodium 
restriction and a further 4 studies (19%) incorporated dietary advice which, although it 
was not mentioned specifically, may have included sodium restriction. Exercise is 
increasingly recognised as an important part of heart failure self-management but only 
5 (24%) of the interventions published up to February 2001 included exercise.
3.5.4.5.3 Patient education -  emotional aspects of self-management targeted
Four (19%) studies addressed emotional aspects of heart failure self-management. A 
study in which only 7 patients were in the therapy arm evaluated an intervention that 
included cognitive therapy, exercise training and a dietary intervention (Kostis, Rosen, 
Cosgrove, Shindler, & Wilson, 1994) and Luskin et al (Luskin, Newell, & Haskel, 1999) 
carried out a pilot study of stress management training. A multidisciplinary disease 
management programme included an out-patient support group (Riegel, Carlson, 
Glaser, & Hoagland, 2000) and a mail-delivered programme included components 
dealing with depression and stress (Serxner, Miyaji, & Jeffords, 1998). A fifth study 
(Jaarsma et al., 1999) referred to the provision of support for psychosocial problems 
but it is unclear if this comprised any more than discussion of problems with a nurse.
3.5.4.5.4 Behaviour Change -  Theoretical Framework
All the interventions included in this systematic review incorporated components that 
addressed aspects of self-management. Apart from the cognitive therapy and stress 
management interventions referred to above, most did not make reference to any 
theoretical basis to their interventions. Exceptions were two studies (Jaarsma et al, 
1999; Schneider et al, 1993) that designed interventions based on Orem’s nursing 
theory of self-care (Orem, 1995). This describes three sets of limitations to self-care -
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limitations of knowledge, decision making and skills. Another study (West, Miller, 
Parker et al, 1997) referred to social learning theory but did not describe how it 
informed the intervention content. Riegel et al (2000) implemented a multidisciplinary 
programme, describing the team philosophy as self-care, which was conceptualised as 
involving four different stages but it is not clear how these were identified or if they 
were theoretically based. Serxner Miyaji & Jeffords (1998) asserted the importance of 
patients’ self-efficacy in managing their illness and also measured it but they did not 
report how they addressed self-efficacy in their intervention.
The implicit model underlying most of the studies would appear to have been that 
informing patients of the recommended self-management behaviours would be 
sufficient to bring about behaviour change. Some studies that did appear to recognise 
that the issue is more complex did not necessarily make use of the literature on health 
behaviour change.
3.5.4.5.5 Behaviour change techniques used
Most of the interventions included in this systematic review did not utilise established 
behaviour change techniques. Only five (24%) studies made any reference to what 
strategies were used to promote behaviour change, reinforcing the implication that 
most relied on information being sufficient. Studies that did make at least some 
reference to behavioural strategies were nevertheless often unclear, and did not refer 
to a recognised theory but rather used vague terms such as ‘behavioural interventions’ 
(West et al., 1997) and ‘remedial counselling’ (Stewart et al, 1998; Stewart et al., 1999) 
without providing any detail of what these entailed. Although Bushnell (1992) did not 
report a theoretical framework, the intervention did initiate patient performance of self­
management behaviours in hospital which, by encouraging performance mastery,
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could potentially increase patients’ self-efficacy to maintain the behaviours post 
discharge. In another study (Ekman et al., 1998) behavioural goals were set, for 
example weighing three times a week, but it is not clear if these were chosen by the 
nurse or the patient. In the intervention reported by Schneider et al (1993) the nurse 
posed problems and discussed possible actions and probable results with the patient. 
Several of the interventions included medication and weight charts which may have 
acted as aide memoirs to encourage adherence.
3.5.4.5.6 Mode of delivery
One intervention was wholly mail-delivered (Serxner et al 1998). Eleven interventions 
(52%) were delivered by a nurse specialist (Bushnell, 1992; Schneider et al, 1993; 
Weinberger et al, 1996; Fonorow et al, 1997; Smith et al, 1997; W est et al, 1997; Cline 
et al, 1998, Ekman et al, 1998; Shah et al, 1998; Jaarsma et al, 1999; Stewart et al,
1999) and two by a pharmacist (Gattis et al, 1999; Varma et al, 1999) while two were 
delivered by both a nurse and pharmacist (Stewart et al, 1998, Linne et al, 1999). Of 
the other studies, only the interventions by Kostis et al (1994) and Luskin et al (1999) 
did not include a nurse in the team. Four interventions were delivered by a multi­
disciplinary team (Rich et al, 1993; Kostis et al, 1994, Rich et al 1995; Riegel et al,
2000). The small number of studies that made reference to behaviour change 
techniques did not report any form of training in behaviour change techniques for the 
staff delivering the intervention. These skills do not form part of usual training for most 
health professionals.
The place of delivery of the interventions included one or more of in hospital, home 
visits, out-patient clinics and by telephone. Almost all studies that recruited patients 
during a hospital admission commenced the intervention during the hospital stay. Other
sessions took place either at home visits or clinic appointments but not both, and 
telephone contact was used to follow up and supplement these sessions.
3.5.4.5.7 Intervention intensity
The interventions varied considerably in intensity, from a single 20 minute session 
(Schneider et al, 1993) to approximately 7 home visits over a 6-month period (Riegel et 
al, 2000), while Cline et al (1998) offered access to a nurse clinic for the duration of the 
12-month study period.
In studies that combined patient education with other components, the intensity of 
patient education was difficult to assess as studies often did not provide detailed 
information. Some studies, such as Rich et al (1995), reported that education was 
reinforced at each meeting but others did not make this explicit.
3.5.4.6 Study duration
The duration of follow-up also varied between studies. Luskin et al (1999) assessed 
study outcomes one week post intervention, however this was unusual. Studies mostly 
assessed outcomes at 3, 6 or 12 months after baseline. It is important that in some 
studies the assessment will have been conducted several months after the intervention 
finished whereas in others the intervention may have been continuing throughout the 
follow-up period. For example, Varm a et al (1999) assessed outcomes 12 months after 
a brief intervention whereas in the study by Cline et al (1998), which also reported 12 
month outcomes, clinic access was available to the intervention group throughout this 
period.
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3.5.4.7 Outcomes
The most frequently measured outcomes in the studies included in this systematic 
review were reduction in unplanned admissions to hospital and mortality. Although 
these outcomes are shown in the tables for both pre-post studies and controlled trials, 
the findings of studies with pre-post designs are less informative as they can not 
provide a clear indication of how much the intervention improves upon standard care. 
Some studies, such as W est et al (1997), compared hospitalisations during the study 
period to an equivalent duration before the study began, however factors other than the 
intervention under examination, for example differences in the populations, could have 
influenced the findings.
3.5.4.7.1 Hospital Admissions
Hospital admissions were reported in two ways in the studies reviewed. Some reported 
all cause hospitalisation and others reported hospitalisation for heart failure. Some 
studies reported both.
Sixteen studies reported hospitalisations for any cause of which 11 were controlled 
trials. Of the controlled trials, 4 reported significantly fewer hospitalisations in the 
intervention group than in controls. Only one study (Weinberger, Oddone & Henderson, 
1996) reported significantly more hospitalisations in the intervention group. This study 
also included patients with diabetes and C O PD  and reported the significance level only 
for the whole sample, however the number of readmissions, days of rehospitalisation 
and proportion of patients readmitted for heart failure were all higher in the intervention 
than in the control group. The poorer outcomes in this study may have arisen because 
it was a generic intervention that provided increased access to primary care in contrast 
to others that were heart failure specific, often involving specialist follow-up.
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Admissions for heart failure were reported in 10 studies of which 7 were controlled 
trials and one further study (Jaarsma et al, 1999) reported cardiac hospitalisations. Five 
studies reported statistically fewer admissions for heart failure in the intervention group 
than in the control group and no study reported more admissions in the intervention 
group.
Of the 9 controlled trials which compared length of hospital stay between intervention 
and control groups, Rich et al (1995), Stewart et al (1998) and Stewart et al (1999) 
reported significantly fewer total days spent in hospital in the intervention group. Only 2 
studies reported duration of hospital stay for cardiac or heart failure admissions, neither 
of which found a significant difference between intervention and control groups. No 
study reported an intervention group spending significantly longer in hospital than 
controls.
3.5.4.7.2 Mortality
Sixteen studies reported mortality rates. Three month mortality reported by Rich et al, 
(1995) was 11% for the total sample and, although slightly higher in the controls than 
the intervention group, was not a statistically significant difference. Six-month mortality 
was reported in 9 studies and ranged from 4%  (Gattis et al., 1999) to 34%  in a small 
early study (Bushnell, 1992). Twelve-month mortality was reported in 2 studies in which 
it varied from 17% (Varma, McElnay, Hughes, Passmore, & Varma, 1999b) to 29%  
(Cline et al., 1998). No study reported a statistically significant difference in mortality 
between the intervention and control groups but there were usually more deaths in the 
control groups, except in the case of Jaarsma et al (1999) in which 26%  of the 
intervention group and 17% of controls died within 9 months of discharge from hospital.
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3.5.4.7.3 Admission-free survival
Analysing the outcomes of hospital admissions and mortality separately is problematic 
because inevitably, longer survival allows for the possibility of more hospital 
admissions. The combined outcome of admission-free survival is therefore more 
accurate in assessing the impact of an intervention. Just 6 studies reported the 
numbers of patients who survived the study period without being readmitted to hospital. 
Of these, Rich et al (1995) and Stewart et al (1998,1999) reported statistically 
significant differences between the groups with more intervention group patients 
surviving without readmission.
3.5.4.7.4 Comparison of hospitalisation and mortality across studies
An important factor to consider when comparing the efficacy of interventions across 
studies is not only whether a study reported better outcomes in the intervention group 
than in the control group, but also how the studies compared with each other on 
occurrence of events such as death or readmission to hospital. It is possible that an 
intervention performed well in comparison to its control group but not in comparison to 
interventions in other studies with non-significant outcomes. For example, Stewart et al 
(1999), reported significantly lower 6-month mortality in the intervention group (18%) 
than the control group (28% ). In contrast, the study by Riegel et al (2000) did not report 
a significant effect of the intervention on mortality, however the overall 6-month 
mortality rate for the study was 9 .2%  i.e. approximately half the rate of the intervention 
group in Stewart et al (1999). Stewart et al also reported a significant difference in the 
number of hospital admissions between the intervention group (0.68 per patient) and 
the control group (1.18 per patient) in the 6-month follow-up period. Although Riegel et 
al did not find a significant difference between the intervention (0.63 admissions per 
patient) and control groups (0.60 per patient), outcomes for both were comparable to 
those of the intervention group in Stewart et al’s study. Such findings could possibly
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arise from differences in the quality of standard care between studies or differences in 
the study populations. The study by Stewart et al had a higher percentage of male 
patients and all patients had at least one previous admission to hospital however it is 
not possible to assess whether this explains the difference in outcomes. The standard 
care received by the control groups appears from the study reports to have been more 
structured and possibly more specialised in the study by Stewart et al so it is perhaps 
surprising that the control group in this study had poorer outcomes. The two studies 
reported NYHA at different timepoints so it is not possible to tell if one patient sample 
was more ill than the other at entry into the studies or whether this could explain the 
finding. Comparison across other studies included in this review was not possible 
because of the variability in the outcomes reported and duration of the follow-up period.
3.5.4.7.5 Psychological well-being and Quality of Life
Factors such as depression and anxiety could have an impact on other health 
outcomes and also affect patients’ ability to manage their heart failure but few studies 
assessed the impact of their interventions on patients’ psychological well-being. 
Depression and anxiety were assessed by Kostis et al (1994) who compared an 
intervention that incorporated exercise training, dietary intervention, cognitive therapy 
and stress management with a group receiving digoxin and a placebo control. This 
study reported significant improvement in anxiety and depression in the therapy group 
and deterioration in the other groups over the 12-week study period but the study was 
so small (a total sample size of 20 randomised to one of three groups) that the value of 
these findings is limited. In another small pre-post study (n = 14) evaluating a stress 
management programme, Luskin et al (1999) reported a significant improvement in 
perceived stress but not depression, anxiety, self-esteem or quality of life.
It is possible that an intervention which asks patients to increase self-monitoring of their 
illness and to make lifestyle changes could have the unintended effect of impairing their
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quality of life. It is important therefore to look not just at clinical outcomes but also at 
the impact from the patient’s perspective. Eight studies evaluated quality of life. Rich et 
al (1995) gave the Chronic Heart Failure Questionnaire (Guyatt, Nogradi, Halcrow et al., 
1989) to a subset of 126 patients. Over the 90-day study period, quality of life improved 
in both groups but there was significantly more improvement in the intervention group 
(p=.001) and they showed consistent improvement in all four subscales of the measure 
-  dyspnoea, fatigue, emotional function and environmental mastery. Both W est et al 
(1997) and Stewart et al (1999) found significant improvement in the physical 
composite scores of the S F-36 (W are & Sherbourne, 1992), and although scores on 
the mental composite scores also improved, these were not statistically significant. In 
the latter study, effects on the physical component were not maintained at the 6 month 
follow-up. Smith et al (1997) found that quality of life measured with the Minnesota 
Living with Health Failure questionnaire (M LHF) (Rector, Kubo & Cohn, 1987) 
improved over the 6 month intervention period. Also using the MLHF, Stewart et al 
(1999) found that the intervention group reported better quality of life than controls at 3- 
month but not 6-month follow-up and Varm a et al 1999 reported better scores in the 
intervention group at the 9-month but not 3, 6 or 12-month follow-ups. Cline et al (1998) 
did not find any difference between intervention and control patients in quality of life at 
baseline or at 12-month follow-up.
These studies indicate that the interventions did not have a detrimental impact on 
quality of life and in most cases had a beneficial effect, although the benefits appear to 
be short-lived.
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3.5.4.7.6 Self-Management Behaviours
Only five studies (24% ) measured and/or reported practice of self-management 
behaviours as part of their intervention evaluation.
Three studies reported adherence to medication but different methods of assessment 
were used and the results were variable. Rich et al (1995), using a pill count 30 days 
post discharge, found a significantly higher rate of adherence to medication in the 
intervention group (82.5% ) than in controls (64.9% ). Varma et al (1999) also assessed 
medication adherence. Self-reported adherence did not differ significantly between 
intervention and control group patients at any assessment during the 12 month follow- 
up. Drug records from community pharmacists were available for a sub-sample of 23 
patients of which more intervention group patients were adherent with all medications 
(p=.039). Serxner et al (1998) found that patients who received a mail-delivered 
education programme were less likely than controls to report forgetting medication. 
Forgetting did not decrease in the intervention group post-intervention, but it increased 
in the controls.
Dietary behaviour was reported by two studies. Serxner et al (1998) found that patients 
in the intervention group were more likely than controls to report making positive 
dietary changes. A small study by W est et al (1997) using a single group pre-post 
design reported a 38%  reduction in sodium intake over the 6-month study period.
Jaarsma et al (1999; 2000) was the only study in which self-management behaviour 
was measured in any detail. This study assessed self-management behaviour on a 19- 
item scale and found that at baseline, patients in both groups practiced an average of 9 
behaviours on the scale. They were most likely to report adhering to medicine (88%).
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Fewer weighed daily (57% ), restricted sodium (50%), contacted their doctor about leg 
oedema (42% ) or breathlessness (45% ), took exercise (54%) or noticed diuresis (22%). 
Both groups practiced a higher number at 1-month follow-up although this was greater 
in the intervention group. Practice decreased over time but was still significantly better 
in the intervention group at 3-month follow-up but not by 9-months. The increase over 
time was still significant in the intervention group, but not the control group at 9-month 
follow-up. Unfortunately Jaarsma et al (2000) did not report change for each behaviour 
so it is not possible to tell if the intervention was more successful in changing some 
behaviours than others.
So few studies examined performance of and changes in self-management behaviours 
that it is not possible to compare across studies or draw any conclusions about which 
type of intervention may produce the greatest enhancement in practice of self­
management behaviours. It is encouraging nevertheless that the few studies which 
measured behaviours reported positive findings.
3.5.4.7.7 The relationship between intervention composition and outcomes 
The heterogeneity in the effectiveness of the interventions in this systematic review 
makes it important to examine what components of the interventions or aspects of their 
delivery may have contributed to their effectiveness. It is of course possible that a 
component or group of components may influence some outcomes but not others.
All interventions included an education component but these were usually not 
described in detail therefore it is not possible to assess whether one type of education 
programme was more successful than others. Furthermore, as few studies evaluated 
behaviour, it is difficult to assess what role education may have played in changing 
behaviour and what impact any behaviour change may have had on study outcomes.
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Of the 5 studies that assessed self-management behaviours, only two examined the 
relationship between these behaviours and other outcomes. Rich et al (1995) found 
that medication adherence was not predictive of readmission in univariate or 
multivariate analysis but there was a trend towards fewer multiple admissions in 
patients with >90%  adherence. Jaarsm a et al found that heart failure self-management 
behaviour correlated slightly with psychosocial adjustment at 3 and 9 months after 
discharge and with overall wellbeing score at 9 months. Self-care behaviour showed 
only a limited relationship with hospital readmissions. In the control group, self-care 
behaviour at 1 month after discharge was related to the number of readmission days 
for cardiac reasons at 3 months in that higher self-care behaviour scores were related 
to fewer readmission days. There were no significant relationships between behaviour 
and admissions at other time-points. Jaarsm a et al (1999) also assessed self care 
agency - patients’ self-ratings of their ability to care for themselves - and found that it 
was related to functional capabilities, symptoms and psychosocial adjustment to illness 
at 3 and 9 months and with overall score of wellbeing at 9 months. Three months after 
discharge, higher self-care agency scores in the intervention group was related to 
fewer GP contacts and fewer readmission days in the following 6 months. This 
relationship was not found in the control group.
It is possible that another component of the interventions was key, for example 
discharge planning or medication review, however examination of the studies did not 
reveal a clear pattern. The place of delivery of the intervention i.e. home visit, clinic visit, 
by mail and by telephone was another factor which varied between studies but again 
no clear pattern emerged of greater effectiveness for a single approach.
Intervention intensity did not appear to explain differences between studies. For 
example, in the study by Stewart et al (1998), which consisted of just a single home 
visit, the intervention group had fewer readmissions to hospital and spent fewer days in
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hospital over the 6-month follow-up period than the control group. In contrast, in an 
intervention comprising follow-up at a nurse-monitored out-patient programme, in which 
clinic visits ranged from 1-14 and telephone follow-up averaged 4 per patient, the days 
spent in hospital over the 6-month study period were slightly higher in the intervention 
group, although the difference was not statistically significant (Ekman et al, 1998).
Riegel et al (2000) suggested that differences in outcomes may be related to 
differences in the patient populations. Their study used an unselected population 
whereas others have been more restricted to, for example, patients considered at high 
risk of readmission. When Riegel et al examined their findings by functional class, 
measured on the Specific Activity Scale (Goldman, Hasimoto, Cook & Loscalzo, 1981) 
they found that in those who had been least impaired at baseline (class I), the 
intervention group had more hospitalisations compared with controls whereas in those 
in higher functional classes (i.e. more impaired) the intervention and control groups did 
not differ. The intervention was most successful in reducing hospital days and total 
costs in the group of patients in functional class II i.e. those with minimal functional 
compromise. Other studies did not examine the efficacy of their intervention by 
functional class so comparison of this finding with other studies was not possible.
3.5.5 Discussion of systematic review findings
In 2001, when the current study began, the delivery of care for people with heart failure 
had been undergoing a period of change. Shortcomings in the delivery of medical care 
had been recognised and disease management programmes had been introduced as a 
way of improving care. Most studies that had been published at that time, and which 
were included in this review, were evaluating the effectiveness of these new models of 
care delivery. This review has shown that the way in which this care was delivered
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nevertheless varied considerably across studies, as did intervention efficacy. The most 
commonly assessed outcomes were hospital admission and mortality and findings 
generally favoured the intervention group, although they often did not reach statistical 
significance. Interventions were more often successful in reducing readmissions for 
heart failure than all-cause readmissions but none produced significant reductions in 
mortality.
An important question to emerge in this review was which type of intervention 
produced the greatest benefit. Heterogeneity in patient populations, standard care and 
the content, duration and delivery of interventions made comparison between studies 
and identification of the most effective interventions difficult and no single model of 
intervention emerged as consistently more successful than others. For example, it did 
not seem to be the case that one mode of delivery, such as home visit or clinic 
appointment was better than the other. As few interventions assessed behaviour, it was 
not possible to tell if one approach was better than another at promoting self­
management and whether this had an impact on outcomes.
The work by Stewart et al (1998,1999) indicated that very brief interventions can be 
effective whereas other studies show that more intensive interventions may not be. The 
finding that less intensive interventions can result in significant benefits is important. 
Highly intensive interventions are expensive to implement and may not be feasible in 
all healthcare environments. If it is possible to achieve similar results with less intensive, 
and therefore less costly, interventions, there will be greater potential to make such 
interventions more widely available.
An important matter to emerge from this review was the nature of standard care 
provided to the control group. It is evident that there was considerable heterogeneity 
between studies in several components of standard care and optimal recommended
99
treatment was often not provided. This has implications for evaluating the impact of 
interventions because some may be comparing an intervention group to a control 
group who are receiving sub-optimal medical care whereas others may be making the 
comparison with a control group who are receiving much better medical care. The  
scope for improving outcomes in the latter case is likely to be more limited. There are 
also implications for the design of future interventions because there would seem to be 
no justification for designing interventions that do not first ensure that all participants 
receive medical treatment according to recommended guidelines. The goal should be 
to examine whether interventions can be designed which provide additional benefits 
over and above medical care that meets recommended guidelines.
One of the aims of this review was to evaluate the extent to which interventions 
promoted self-management. Shortcomings in patient self-management had been 
recognised as a contributor to poor health outcomes and the interventions included in 
this systematic review all incorporated an education component aimed at improving 
self-management. The review found some uniformity across studies in the behaviours 
taught in their education programmes. Most interventions stressed the importance of 
adherence to medication and self-monitoring for early signs of worsening heart failure. 
Dietary advice, usually including sodium restriction was also common. Few studies, 
however, addressed the psychological aspects of heart failure that could affect self­
management.
Although the interventions aimed to improve patient performance of several self­
management behaviours, the approach adopted was usually one of patient education 
rather than self-management. Most studies did not make explicit the theory or rationale 
that was behind the design of the educational components of their interventions. In 
general they did not indicate any awareness of the considerable literature on self-
100
management of chronic illness and few interventions reported the use of theoretical 
constructs. Most studies appeared to adopt a traditional educational approach, which 
assumes that it is sufficient to provide information about the recommended treatment 
regimen that patients are expected to follow. It is recognised in other chronic illnesses 
that while knowledge is necessary, it is usually not sufficient to change behaviour (e.g. 
Coates & Boore, 1996; Gibson et al., 2000), thus to enable patients to optimise self­
management, other approaches are required. Nevertheless, few interventions reported 
using strategies to facilitate behaviour change, such as problem-solving strategies, nor 
did they report that healthcare professionals who delivered the interventions had 
received training in these techniques.
Another indication that self-management was not the main focus of these interventions 
was that few studies assessed self-management behaviours and, of those that did, few  
examined the relationship between these behaviours and health outcomes.
This review has shown that at the time of commencement of the current study, the 
promotion of self-management for patients with heart failure was still fairly undeveloped. 
While it is encouraging that the small number of studies that examined self­
management behaviours reported positive findings, in general, the studies published 
up to February 2001 provided limited guidance in the development of self-management 
interventions for this patient population. At the time it remained necessary to develop 
interventions that specifically targeted self-management and evaluate whether it was 
possible to improve patients’ self-management of their heart failure and if this in turn 
helped to improve health outcomes.
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However, a number of important issues have emerged from this review:
behaviours considered important in self-management of heart failure were 
identified
the review identified a need to develop an intervention which could help to 
enhance self-management of heart failure
the review found that an intervention of low intensity could produce significant 
benefits
evaluation of a new intervention should involve comparison to a standard care 
control group who receive medical care according to established guidelines 
a single intervention model will not necessarily be applicable for all patients 
therefore evaluation of the intervention should include examination of which factors 
predict success of the intervention
The way in which these issues were incorporated into the intervention and study design 
are dealt with in more detail in the next two chapters.
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Table 3.1 Description of studies
No Authors, year 
and country
Design Participants Description of Intervention and 
Control
Follow-up
period
Findings
N (start) 
Mean age 
% Male
Patient group
1 Bushnell 1992 
USA
Pre-post 41
71 years 
58% male
Patients admitted to 
medical teaching 
units of large acute 
care hospital with 
primary diagnosis of 
heart failure
Self-care nursing intervention - Two
sessions before discharge included 
education booklet, review and testing of 
patient knowledge. Patient began 
weighing, self-monitoring and making 
dietary changes in hospital
6 months Mortality - 34% died within 6 months
All cause hospitalisations - After 3 months,
16% had two or more readmissions, 26%  had 
one readmission, 58% had no readmissions. 
After 6 months, 25%  had one or more 
admissions (sic)
2 Rich et al 1993 
USA
RCT 98
79 years 
41% male
Admitted to a 
secondary and 
tertiary care 
university teaching 
hospital with HF at 
moderate or high 
risk of readmission. 
Mean N Y H A :
2.7 Int 
3.0 Con
1. Comprehensive multidisciplinary 
treatment strategy - Daily visits during 
hospital admission, 3 home visits in first 
week and then at regular intervals plus 
telephone contact. Included intensive 
education, detailed review of 
medications, simplifying regime where 
possible, early discharge planning, 
enhanced follow-up through home care 
and telephone contacts. 'Emotional 
support' provided in majority of cases but 
nature of this not described.
2. Standard care - all conventional 
treatments as requested by patient's 
attending physician which could include 
social service evaluation, dietary and 
medication teaching, home care, all other 
available hospital services
90 days post 
discharge
All cause hospitalisations - 45.7%  controls 
vs. 33.3% intervention readmittted (n.s.) 
(Readmission rate was lower in moderate risk 
subgroup but not high-risk subgroup.) Average 
4.8 days hospitalised. Intervention 1.4 fewer 
days than controls (n.s.). In moderate risk 
subgroup, intervention spent average 3.5 fewer 
days than controls (n.s.). In high risk subgroup, 
intervention spent 2.1 more days hospitalised 
than controls (n.s.)
103
No Authors, year 
and country
Design Participants Description of Intervention and 
Control
Follow-up
period
Findings
N (start) 
Mean age 
% Male
Patient group
3 Schneider et al
1993
USA
CT 54
72 years 
50%  male
Admitted with a 
diagnosis of HF to 
cardiac nursing unit 
of non-profit mid- 
western medical 
centre
1. Medication discharge planning -
One 20min education session with 
patient and family member prior to 
discharge. Medication schedule to fit 
patient’s routine. Discussion of possible 
problems and suggested solutions. 
Physician contact details given.
2. Usual care -  included usual education 
offered by staff nurses on unit which was 
thought to vary between patients and to 
be haphazard.
31 days All cause hospitalisations - 2 intervention 
(7.7% ) vs 8 control (28.6% ) readmitted (p=.05)
4 Kostis et al
1994
USA
RCT 20
66 years 
70%  male
Patients with HF, 
NYHA II or III, LVEF 
<40%. Source of 
recruitment unclear
1. Intensive lifestyle modification -
Group cognitive behavioural therapy 60- 
90 mins 2x per week for 12 weeks. 
W eekly meetings with dietician. Gradual 
increase in exercise over 3 week period 
to 1 hr, 3 to 5 times per week at heart rate 
of 40 to 60% functional capacity.
2. Digoxin
3. Double-blind drug placebo
12 weeks Mortality - 1 death (17%) in placebo group.
Anxiety and Depression -  Improved 
significantly in Group 1 (p<.05) but not in 
Groups 2 & 3
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No Authors, year 
and country
Design Participants Description of Intervention and 
Control
Follow-up
period
Findings
N (start) 
Mean age 
% Male
Patient group
5 Rich et al 1995 
USA
RCT 282
median 79 
years 
37% male
Admitted to a 
secondary and 
tertiary care 
university teaching 
hospital with HF at 
risk of readmission. 
Mean NYHA 2.4
1 . Multidisciplinary intervention -
Intensive education about HF, individual 
dietary assessment and instruction, 
consultation with social services about 
discharge and care post discharge, 
medication analysis to simplify regime, 
intensive post discharge follow-up, 
individual home visits and telephone 
contact.
2. Usual care - all standard treatments 
and services ordered by their primary 
physicians. In no case was standard or 
generally accepted therapy withheld.
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90 days Mortality -  13 (9.2% ) intervention vs. 17 
(12.1% ) controls died within 90 days. Of these, 
6 intervention and 2 controls had died prior to 
discharge from initial admission
All cause hospitalisations - 41 (28.9% ) 
intervention vs. 59 (42.1%) controls had at 
least one readmission (p=.03). Total of 53  
readmissions in Intervention vs. 94 in controls 
i.e. reduction of 44.4%  (p=.02). Total days 556  
Intervention vs. 865 Control (p=.04) This 
translates to 3.9 per patient in Intervention 
group vs. 6.2 per patient in Control
HF hospitalisations -  24 readmissions in 
Intervention vs. 54 in controls i.e. a reduction 
of 56.2%  (p=.04). At 12 m follow-up, 80 
readmissions in controls vs. 57 in intervention 
(p=.08)
Admission free survival - Survival for 90 days 
without readmission in 91 (64.1% ) intervention 
vs. 75 (53.6% ) controls (p=.09) BUT when 
analysis restricted to survivors of initial 
hospitalisation, 54.3%  controls vs. 66.9%  
intervention survived without readmission 
(p=.04)
Quality of Life -  (sub-sample n =126) - 
improved in both groups but significantly more 
in treatment group (p=.001)
Behaviour - Good compliance, defined as 80%  
taken correctly, was achieved by 82.5%  in 
treatment group vs. 64.9% controls (p=.02)
No Authors, year 
and country
Design Participants Description of Intervention and 
Control
Follow-up
period
Findings
N (start) 
Mean age 
% Male
Patient group
6 Weinberger et 
al 1996 
USA
Study also 
included 
diabetes and 
COPD but only 
results for 
heart failure 
are reported 
here
RCT 504
63 years 
98% male
Patients who had a 
diagnosis of HF (not 
necessarily the 
reason for 
admission) 
hospitalised at one 
of 9 Veteran Affairs 
Medical Centres 
NYHA:
I, 12% 11,37%
111,33% IV, 18%
1 . Increased access to primary care -
Within 3 days before discharge, nurse 
assessed needs, listed medical 
problems, provided education materials, 
gave numbers of primary care nurse and 
physician. Doctor reviewed discharge 
plans, problems, medication regimes. 
Within 2 days post discharge, nurse 
phoned patient to assess difficulties with 
medication, health problems. Doctor and 
nurse reviewed and updated treatment 
plan at first post-discharge appointment.
2. Usual care -  post discharge care 
provided by community physicians or at 
Veterans Affairs clinics, as arranged by 
in-patient physician
6 months All cause hospitalisations - 52.2%  
Intervention vs. 41.5%  Control patients 
readmitted. Intervention had 0.27 readmissions 
per month vs. Control 0.15 per month. 
Intervention 11.7 days vs. Control 6.8 days 
(significance level not reported)
Quality of Life - scores were low at baseline 
and remained low throughout study period, 
n.s.d. between groups at either follow-up 
assessment period. BUT were not reported 
separately for HF
7 Fonarow et al
1997
USA
Pre-post 214
52 years 
81% male
Patients referred to 
cardiomyopathy 
centre for 
assessment for 
transplant.
NYHA III, 44%
IV, 56%
Comprehensive management 
programme plus education -w eekly  
clinic follow-up until stable, systematic 
approach to drug therapy, education 
about diet, exercise, self-monitoring, 
emphasis on abstinence from alcohol 
and smoking. Follow-up by HF 
cardiologists in conjunction with referring 
physician
Mortality - 9 (4% ) died within 6 mths
All cause hospitalizations - 26%  of patients 
readmitted in 6 month follow-up period 
compared with 92%  in the 6 mths prior to 
referral
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No Authors, year 
and country
Design Participants Description of Intervention and 
Control
Follow-up
period
Findings
N (start) 
Mean age 
% Male
Patient group
8 Smith et al
1997
USA
Pre-post 21
61 years 
100% male
New patients 
referred to 
cardiomyopathy 
clinic,with 
symptomatic CHF
1. Cardiomyopathy clinic - Frequency 
of clinic visits was determined by severity 
of CHF and need for medication titration, 
patients could be seen without 
appointment if they had exacerbation or 
ran out of medications. Nurse practitioner 
was available by telephone to answer 
any concerns
Post (after 6 
months 
intervention 
period)
Mortality - 5%
All cause hospitalisation -  number of 
hospitalisations reduced from 13 prior to 
intervention to <2 during study period (p=.017)
Quality of Life -  improved over time (p=.001)
9 W est et al
1997
USA
Pre-post 53
66 years 
71 % male
Patients 
hospitalised at 
Kaiser-Permanente 
medical centre in 
previous 12 months 
with primary or 
secondary 
diagnosis of HF or 
out-patients 
referred for HF 
treatment.
NYHA:
1 22%
II 38%
III 28%
IV 12%
MULTIFIT system - Initial visit then 
weekly telephone contact for 6 weeks. 
Frequency of telephone contact 
thereafter depended on clinical status.
-  3 objectives:
promote optimal dose of ACE 
inhibitors
promote daily sodium intake <2g 
surveillance for signs, symptoms and 
laboratory evidence of worsening 
HF, and appropriate and efficient 
triage of patients demonstrating 
clinical instability. Clinical 
abnormalities prompted referral for 
urgent evaluation by primary 
physician
Average 
138 ± 4 4  
days
Mortality - 1(2%) died
All cause hospitalisations - 9 hospitalisations. 
Compared with the 12 mths before enrolment, 
total hospitalisation rates declined 74%, from 
1.61 to 0.42/year (p=.0001)
HF hospitalisations - 3 hospitalisations. 
Compared with the 12 mths before enrollment, 
hospitalisation rates for HF declined 87%, from 
1.12 to 0.15/year (p=.0001). Length of stay 4.3 
± 3.2 days
Behaviour - Sodium intake reduced by 38%
(p<.0001)
Quality of Life -  (n = 35) physical but not 
mental composite score improved at 6 mths
(p=.01)
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No Authors, year 
and country
Design Participants Description of Intervention and 
Control
Follow-up
period
Findings
N (start) 
Mean age 
% Male
Patient group
10 Cline et al
1998
Sweden
RCT 190
76 years 
53% male
Admitted to 
University hospital, 
primarily for HF 
NYHA: III, 62%  
Mean 2.6
1. Education and easy access clinic - 2
x 30min in-patient sessions plus 1 x 60 
min session for patient and family 2 
weeks post discharge.
Education, adherence emphasised, 
guidelines for self-mgt of diuretics, dairy 
of weight, swelling, symptoms, easy 
access clinic, nurse available by phone 
and at short notice. One prescheduled 
visit at 8 months post discharge. Nurse 
could schedule doctor visits when 
considered appropriate. Out-patient 
cardiology appt one and four months post 
discharge.
2. Usual care - out-patient follow-up by 
either cardiologists in private practice or 
primary care physicians as considered 
appropriate by discharging physician.
12 months Mortality -  30% Intervention vs. 28% Controls
(p=.06)
All cause hospitalisations -  39% Intervention 
vs 54%  Controls readmitted (p=.08). Mean 
hospitalisations per patient 0.7 Intervention vs 
1.1 Control (p=.08). Mean days hospitalised 4.2 
Intervention vs 8.2 Control (p=.07)
Admission free survival -  30% intervention vs 
28%  Control (n.s.)
Time to first event/readmission -  Mean days 
to first readmission 141 Intervention vs. 106 
Controls (p<-05)
Quality of Life - No significant differences
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No Authors, year 
and country
Design Participants Description of Intervention and 
Control
Follow-up
period
Findings
N (start) 
Mean age 
% Male
Patient group
11 Ekman et al
1998
Sweden
RCT 158
80 years 
33% male
Admitted to medical 
wards of secondary 
care regional 
hospital with a 
discharge diagnosis 
of HF and/or 
cardiomyopathy. 
Those in need of 
specialist care 
treated in 
cardiology dept. 
Mean NYHA 3.2
1. Structured-care nurse-monitored 
out-patient programme - Intervention 
group contacted a week after discharge 
and offered a visit to clinic. 29% never 
visited the nurse. Number of visits ranged 
from 1 to 14. Telephone follow-up - 
median number of contacts 4 per patient. 
Patient’s primary care provider and home 
health staff were continually informed 
about patient's situation by HF clinic 
nurse
2. Usual care - Current clinical practice 
which in general meant follow-up by GP 
and visit to ER if symptoms worsened.
6 months Mortality -  24% Intervention [BUT16% of those 
who attended] vs 19% Controls (n.s.)
All cause hospitalisation -  61% Intervention 
[63% of those who attended] vs. 57% Controls 
readmitted (n.s.). Mean days hospitalised 26  
Intervention [20 for those who attended] vs 18 
Control (n.s.)
Heart Failure hospitalisation -  46%
Intervention [50% of those who attended] vs. 
49%  Controls readmitted for heart failure (n.s.)
Admission free survival -  32% Intervention 
[36% of those who attended] vs. 39% Controls 
(n.s.)
12 Serxner et al
1998
USA
RCT 109
71 years 
48% male
Patients admitted to 
hospital ‘large 
healthcare system’ 
with a primary 
discharge diagnosis 
of HF
1. Patient Education -  education 
materials mailed every 3 weeks x 4. 
Materials on CHF, medication, risk 
factors, behavioural health issues, coping 
with change, depression, stress
2. Usual care - normal and customary 
education in hospital but no special 
information once patients were 
discharged
6 months Heart Failure hospitalisation -  27%
Intervention vs 50% Controls readmitted 
(p<.01). Number of readmissions 21 
Intervention (1.4 per patient) vs. 43 Control 
(1.59 per patient) (p not reported)
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No Authors, year 
and country
Design Participants Description of Intervention and 
Control
Follow-up
period
Findings
N (start) 
Mean age 
% Male
Patient group
13 Shah et al
1998
USA
Pre-post 27
62 years 
100% male
Patients recently 
discharged from 
hospital after 
admission with CHF  
and out-patients 
referred to HF clinic 
at Veterans Affairs 
Medical Centre with 
clinical evidence of 
HF for at least 6 
mths.
NYHA: II, 37% lll/IV  
63%
Interactive Home Monitoring -
Education materials mailed weekly for 8 
weeks covering information on CHF, 
medication, diet. Given BP monitor, 
weighing scale. Sent reminders re 
medication, weighing, BP and heart rate 
measurement. Telephoned once a week 
to ascertain clinical status. Given 24 hr 
access to nurse.
12 months 
(mean 8.5m)
Mortality - 4  (15%) died
AH cause hospitalisation -  Reduced from 0.8 
to 0.4 per patient per year (n.s.). Days 
hospitalised reduced from 9.5 to 7.8 per patient 
per year (p<.05)
Heart Failure hospitalisation -  Reduced from 
0.8 to 0.7 per patient per year (n.s.)
14 Stewart et al
1998
Australia
RCT 97
75 years 
48%  male
Patients admitted to 
a tertiary referral 
hospital with 
congestive HF and 
impaired systolic 
function, intolerence 
to exercise and 
history of 1 or more 
admissions for 
acute HF.
NYHA at discharge 
ll:lll:IV
Intv 24:23:2 
Control 24:20:2
1. Home-based intervention - Before 
discharge, nurse counselling about 
compliance and reporting clinical 
deterioration. One week post discharge, 
home visit and assessment by nurse and 
pharmacist -  those with poor medication 
knowledge or compliance received 
remedial counselling, daily reminder 
routine, weekly pill containers, monitoring 
by caregiver, medication information and 
reminder card, referral to community 
pharmacist. Patients requiring medical 
review were referred to GP.
2. Usual care - review by GP or 
cardiologist within 2 weeks of discharge. 
(27%  of controls were also receiving 
domiciliary care or community nurse 
visits)
6 months Mortality -  12% Intervention vs. 25% Controls 
(n.s.)
All cause hospitalisation -  49% Intervention 
vs. 65% Control readmitted (n.s.). Number of 
readmissions 36 Intervention vs. 63 Control (p 
=.03). Days hospitalised 261 Intervention vs. 
452 Control (p=.05)
Heart failure hospitalisation -  Zero
Intervention vs. 5 Control had 3 or more 
admissions for heart failure (p=.02)
Admission free survival -  0.8 Intervention vs. 
0.4 Control unplanned readmission or death per 
patient (p= 03)
Time to first event -  Intervention tended to be 
readmitted earlier (n.s.)
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No Authors, year 
and country
Design Participants Description of Intervention and 
Control
Follow-up
period
Findings
N (start) 
Mean age 
% Male
Patient group
15 Gattis et al
1999
USA
RCT 181
Median age 
71 .5 (1 )63 .0  
(C)
68% male
All patients 
undergoing 
evaluation in 
cardiology clinic of 
university medical 
centre with 
diagnosis of HF 
NYHA on 
enrolment
I 12.7%
II 54.1%
III 29.8%
IV 3.3%
1. Clinical pharmacist addition to heart 
failure team -  optimisation of heart 
failure medication in collaboration with 
physician, discussion and explanation of 
medication with patient then telephone 
follow-up after 2, 12 and 24 weeks. 
Patients could contact pharmacist to ask 
questions or if problems arose. If patients 
indicated continuing or worsening 
symptoms, pharmacist recommended 
they contact physician and pharmacist 
also contacted physician.
2. Usual Care
Patient assessment and education were 
provided by attending physician and/or 
physician assistant or nurse practitioner
Median 6 
months
Mortality -  3% Intervention vs. 5% Control 
(n.s.)
All cause hospitalisation -  excluding non­
emergency or elective procedures, 19% 
Intervention vs. 33% Control readmitted (p not 
reported)
Heart failure hospitalisation -  1%
Intervention vs. 12% Control readmitted for HF 
(p=.005). 9% Intervention vs. 25% Controls had 
cardiovascular admissions (p=.004)
Admission free survival - 68% Intervention 
vs. 60% Control survived without admission 
(n.s.), excluding non-emergency or elective 
procedures, 78% vs. 62%  respectively.
I l l
No Authors, year 
and country
Design Participants Description of Intervention and 
Control
Follow-up
period
Findings
N (start) 
Mean age 
% Male
Patient group
16 Jaarsma et al 
1999
Netherlands
RCT 179
73 years 
58% male
Patients admitted to 
cardiology unit of 
university hospital. 
NYHA during 
admission III 17% 
lll-IV 21% IV 61%
1. Supportive Education - In hospital, 
nurse assessed needs, provided 
education and support. Telephone call 1 
week after discharge assessed potential 
problems. Home visit reinforced and 
continued education as needed by 
patient’s situation. After the home visit, 
patients were advised to call their 
cardiologist, GP or emergency heart 
centre in case of difficulties.
2. Usual care - Standard care, some 
may have received information about 
medication and lifestyle, depending on 
HCP they encountered.
9 months Mortality -  26%  Intervention vs. 17% Controls 
(p not reported)
All cause hospitalisation -  37% Intervention 
vs. 50%  Control (p=.06). Days hospitalised 768 
(mean 9) Intervention vs. 861 (mean 9) Control 
(n.s.)
Cardiac hospitalisation -  29% Intervention vs. 
39% Control admitted (p=.096). Mean days 
hospitalised 5.1 Intervention vs. 7.1 Control 
(n.s.)
Behaviour - Appraisal of Self-care Agency 
Scale - n.s.d. between groups. Heart Failure 
Behaviour Scale - intervention group reported 
greater adherence to self-care behaviours at 1 
month (p = .001) and 3 months (p = .005) but 
not 9 months (p= .106). Over time, both groups 
improved at 1 month (p<.001) but this 
decreased thereafter, however intervention 
score remained higher at 9 mths than baseline.
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No Authors, year 
and country
Design Participants Description of Intervention and 
Control
Follow-up
period
Findings
N (start) 
Mean age 
% Male
Patient group
17 Linne et al
1999
Sweden
RCT 130
70 years 
64% male
Patients discharged 
from HF unit of 
university hospital 
NYHA
I 8%
II 66%
III 22%
IV 0%
4% not determined
1. Systematic education - Approx 2 
weeks post randomisation, 1 hr group 
education re symptoms, self-adjustment 
of diuretics, information on drug 
treatment. One week later, pharmacist 
provided information on drugs, side 
effects. CD-ROM dealt with symptoms, 
signs and causes of impairment, drug 
info and side effects
2. Usual care - At discharge, all patients 
receive conventional information about 
their disease, symptoms and medication 
by a doctor. Medication list and individual 
limits allowed for change in body weight 
are provided. All patients receive 
standardised information booklet, 
containing information on HF and its 
management, individually set limits for 
short-term change in body weight, to be 
followed by frequent checks of weight at 
home. All patients (intervention and 
control) have at least one visit to a HF 
nurse except for those who do not need 
close follow-up. After one or more visits, 
most patients are discharged to GP or 
cardiologists
6.5 months M o rta lity - 5% Intervention vs. 5% Control
Knowledge -  Intervention group scored higher 
than controls on knowledge questionnaire at 6 
months (p=.0051)
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and country
Design Participants Description of Intervention and 
Control
Follow-up
period
Findings
N (start) 
Mean age 
% Male
Patient group
18 Luskin et al
1999
USA
Pre-post 14
75 years 
50% male
Patients enrolled in
university hospital
cardiac
rehabilitation
exercise
programme
Stress Management -  75 mins per week 
for 8 weeks out-patient group stress 
management training by psychotherapist.
1 week post 
intervention
Quality of Life -  No significant difference
19 Stewart et al
1999
Australia
RCT 200
76 years 
62% male
Patients admitted to 
tertiary referral 
centre under care of 
cardiologist with at 
least one previous 
admission for acute 
heart failure.
NYHA: at discharge 
(%): ll:lll:IV 
intervention 
42:46:12 
control 48:43:9
1 . Multidisciplianry home-based 
intervention -  Single home visit plus 
telephone calls at 3 and 6 months. 
Additional home visit if patient had 2 or 
more unplanned readmissions within 6 
months of index admission. After 
comprehensive home assessment, 
patient and family received counselling, 
strategies to improve adherence, 
exercise plan, monitoring, flexible diuretic 
regimen. Report sent to GP, cardiologist. 
Increased pharmacist contact, home 
support services for some.
2. Usual care - existing norms for 
discharge planning - inpatient and 
community-based contact with a cardiac 
rehabilitation nurse, dietician, social 
worker, pharmacist and community nurse 
where appropriate. All patients had appt 
with GP, cardiology out-patient clinic or 
both within 2 weeks of discharge and 
regular out-patient review undertaken 
throughout the follow-up period.
6 months Mortality -  18% Intervention vs. 28% Control 
(p=.098)
All cause hospitalisation -  Number of 
readmissions 68 (.14 per month) Intervention 
vs. 118 (.34 per month) Control (p=.03). Days 
hospitalised 460 Intervention vs. 1174 Control 
(P =02)
Heart failure hospitalisation -  50%
Intervention vs. 49%  Control admissions were 
for heart failure
Admission free survival -  51% Intervention 
vs. 38% Controls remained event free (p=.04). 
Beneficial effects remained at 9 months 
(p=.037)
Quality of Life - At 3 months, MLHF + SF36  
physical improved more in intervention group (p 
= .04 + p = .02 respectively, no significant 
difference in SF36 mental health. No 
differences on any scale at 6 months
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Design Participants Description of Intervention and 
Control
Follow-up
period
Findings
N (start) 
Mean age 
% Male
Patient group
20 Varma et al 
1999 
Northern 
Ireland
RCT 83
76 years 
41% male
Inpatients and out­
patients from 3 
hospitals with 
diagnosis of HF 
NYHA mean 2.2
1. Structured pharmaceutical care -
Educated by research pharmacist in 
structured fashion about CHF, prescribed 
drugs and management of CHF 
symptoms. Physicians and community 
pharmacists contacted about project.
2. Standard care, in-patient care not 
described but both groups were 
assessed 3-monthly at out-patient clinic
12 months Mortality -  17% died in each group
Heart failure hospitalisations -  33%
Intervention vs. 66%  Control readmitted
(p=.006)
Quality of Life - SF-36 - in general Intervention 
tended to score better but only significant on 
subscale Physical Function at 9 mths (p=.009) 
and 12 mths (p=.03) BUT it had also been 
higher at baseline (p=.04). Intervention also 
scored better on Mental Health subscale at 9 
mths and 12 mths (both p=.014). Intervention 
scored better on subscales Vitality (p=.04) and 
Social functioning (p=.015), only at 12 mths. 
MLHF - Intervention significantly better at 9 
months but not baseline, 3, 6, 12mths.
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% Male
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21 Riegel et al 
2000  
USA
Quasi­
experiment
al
240
Intervention 
significantly 
older - 
74.44 v 
70.77  
(p<.05)
45% male
‘Unselected 
population’ admitted 
with HF to 5 
hospitals 
NYHA on 
admission
I 0%
II 11%
III 51.9%
IV 37.1%
1. Multidisciplinary disease 
management - to promote self­
management using educational 
materials, in-hospital counselling by 
pharmacists and dieticians, discharge 
assessment by social work, outpatient 
support groups, physician collaboration, 
home visits by HF nurses, telephonic 
case management. All interactions 
focused on promoting self-care abilities. 
Improvements in physician practice 
patterns were targeted through 
educational efforts. Approx 7 home visits 
and 6 telephone calls per patient.
2. Usual care - managed by primary care 
physician or cardiologist without 
assistance of case manager. Staff nurses 
taught patients about HF during 
hospitalisation using AHA or 
pharmaceutical company brochures. 
Dietician and social worker were 
consulted in problematic situations.
Some patients referred for routine home 
care.
Post (after 6 
months 
intervention 
period)
Mortality -  11% Intervention vs. 8% Control (p 
not reported)
All cause hospitalisation -  Number of 
hospitalisations per patient .63 Intervention vs . 
60 Control (n.s.). Days hospitalised 2.66 per 
patient Intervention vs. 3.03 Control (n.s.).
Heart failure hospitalisation - .32
hospitalisations per patient Intervention vs. .23 
Control (n.s.). 1.31 days per patient Intervention 
vs. 1.08 Control (n.s.)
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Table 3.2 Intervention components
No Authors
and
country
Year Brief description 
of intervention
Components Duration of 
intervention
Patient contacts
In hospital Home visit Out-patient Telephone
1 Bushnell
USA
1992 Self-care nursing 
intervention
Education 
Patient begin self­
management in 
hospital
Complete by 
time of 
discharge
2 sessions
2 Rich
USA
1993 Comprehensive 
multidisciplinary 
treatment strategy
Education 
Review and 
simplification of 
medication regime 
Discharge planning 
Enhanced follow- 
up
ongoing Daily visits 3 within first 
week post 
discharge then 
at regular 
intervals
Follow-up 
telephone 
calls made but 
frequency not 
reported
3 Schneider
USA
1993 Medication 
discharge planning
Education 
Medication review 
with schedule 
adapted to 
patient’s routine
Single, 20
minute
session
1 session
4 Kostis
USA
1994 Intensive lifestyle 
modification
Group CBT
Exercise
Diet
12 weeks CBT 60-90min 
2x pw 
Weekly 
meetings with 
dietician 
Gradual 
increase in 
exercise over 
3 weeks to 1 hr 
3x pw
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No Authors
and
country
Year Brief description 
of intervention
Components Duration of 
intervention
Patient contacts
In hospital Home visit Out-patient Telephone
5 Rich
USA
1995 Multidisciplinary
intervention
Education
Dietary
assessment and 
instruction 
Social services 
discharge 
consultation 
Medication review 
and simplifying 
Intensive follow-up
ongoing Daily visits 3 within first 
week post 
discharge then 
at regular 
intervals
Follow-up 
telephone 
calls made but 
frequency not 
reported
6 Weinberger
USA
1996 Increased access 
to primary care
Discharge 
planning, including 
discussion 
between primary 
and secondary 
care physicians 
Education 
Medication review
Ongoing One visit from 
primary care 
nurse within 3 
days before 
discharge, one 
visit from 
primary care 
physician 
within 2 days 
of discharge
None Primary care 
clinic
appointment 
within 1 week 
of discharge 
[Frequency of 
visits
thereafter not 
reported]
First within 2 
days post 
discharge. 
Over course of 
study patient 
received 
average 7.5 
calls
7 Fonarow
USA
1997 Comprehensive 
management 
programme plus 
education
Systematic 
approach to drug 
therapy 
Education 
Intensive follow-up
Weekly until 
stable
8 Smith
USA
1997 Cardiomyopathy
clinic
Education 
Regular out-patient 
follow-up
ongoing Frequency of 
clinic visits 
determined by 
severity and 
need for 
medication 
titration
Patients could 
telephone 
nurse about 
any concerns
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No Authors
and
country
Year Brief description 
of intervention
Components Duration of 
intervention
Patient contacts
In hospital Home visit Out-patient Telephone
9 West
USA
1997 MULT I FIT system Optimise ACEi 
Promote restricted 
sodium intake 
Self-monitoring
Ongoing One
(but reporting 
unclear)
Weekly for 6 
weeks then as 
needed
10 Cline
Sweden
1998 Education and 
easy access clinic
Education
Easy access clinic
follow-up
2x 30 minute
education
sessions
1x 60min 
education 
session for 
patient and 
family.
Easy access 
to nurse clinic 
as required 
Prescheduled 
nurse visit at 
8mths 
Cardiology 
appt at one 
and four mths 
Nurse could 
schedule visit 
to doctor if 
required
11 Ekman
Sweden
1998 Structured-care
nurse-monitored
out-patient
programme
Guidelines for 
nurse 
Education 
Goals set 
Out-patient follow- 
up
Ongoing Offered clinic 
appointment. 
29% of 
patients did 
not visit clinic. 
Number of 
visits ranged 
from 1 - 1 4
Median 4 
contacts per 
patient
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No Authors
and
country
Year Brief description 
of intervention
Components Duration of 
intervention
Patient contacts
In hospital Home visit Out-patient Telephone
12 Serxner
USA
1998 Patient Education Education 12 weeks 4 sets of
patient
education
materials
mailed at 3
weekly
intervals
13 Shah
USA
1998 Interactive Home 
Monitoring
Education 
Home monitoring
8 weeks Education 
materials 
mailed weekly
Telephoned 
weekly to 
ascertain 
clinical status. 
Patient had 
24hr access to 
nurse
14 Stewart
Australia
1998 Home-based
intervention
Education 
Home visit by 
nurse and 
pharmacist 
Referral to 
community 
pharmacist
1 week post 
discharge
One session One visit one 
week post 
discharge
15 Gattis
USA
1999 Clinical pharmacist 
addition to heart 
failure team
Education
Optimising
medication
24 weeks Single
education and 
review from 
pharmacist
2, 12, 24 
weeks
16 Jaarsma
Netherlands
1999 Supportive
Education
Education 
Needs assessment
About 4 
sessions
One visit 
within 10 days 
of discharge
One within 3 
days of 
discharge
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No Authors
and
country
Year Brief description 
of intervention
Components Duration of 
intervention
Patient contacts
In hospital Home visit Out-patient Telephone
17 Linne
Sweden
1999 Systematic
education
Education 3 weeks 1 hour group 
education 
approximately
2 weeks post 
enrolment. 
Individual 
session 1 
week later
18 Luskin 1999 Stress
management
Stress
management
8 weeks 75mins pw x 8 
weeks
19 Stewart
Australia
1999 Multidisciplinary
home-based
intervention
Comprehensive 
home assessment 
Education 
Flexible diuretic 
regimen 
Increased 
pharmacist contact 
Home support 
services for some
6 months One home 
visit 7-14 days 
post
discharge. 
Additional visit 
if patient had 2 
or more 
unplanned 
readmissions 
within 6 
months
3 mths, 6 mths
20 Varma
Northern
Ireland
1999 Structured
pharmaceutical
care
Education Seems to 
have been a 
single session 
but not clear 
where
21 Riegel
USA
2000 1. Multidisciplinary
disease
management
Education 
Discharge planning 
Support group 
Home visit 
Telephonic case 
management
6 months Number of
sessions
unclear
Approx 7 visits Approx 6 calls
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Table 3.3 Behaviours addressed
No Study Behaviours addressed
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1 Bushnell 1992 X X X X X
2 Rich 1993 X X X
3 Schneider 1993 X
4 Kostis 1994 X X X X X X X X
5 Rich 1995 X X X X
6 Weinberqer 1996 Not clear
7 Fonarow 1997 X X X X X X
8 Smith 1999 X X X X
9 West 1997 X X X X X X X X
10 Cline 1998 X X X X
11 Ekman 1998 X X X X
12 Serxner 1998 X X X X
13 Shah 1998 X X X X
14 Stewart 1998 X X
15 Gattis 1999 X
16 Jaarsma 1999 X X X X X X X X
17 Linne 1999 X X X
18 Luskin 1999 X
19 Stewart 1999 X X X X X
20 Varma 1999 X X X X
21 Riegel 2000 X X X X X
Total 9 14 17 10 6 3 2 5 7 1 2 2 1 4 1
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CHAPTER 4
DEVELOPMENT OF A SELF-MANAGEMENT 
INTERVENTION FOR PATIENTS ADMITTED TO 
HOSPITAL WITH HEART FAILURE
This chapter describes the development of the self-management intervention. The 
development involved a review of the literature, described in the previous chapters, 
consultation with health professionals, training of a nurse to deliver the intervention and 
a pilot phase.
4.1 Development team
Development of the intervention was a collaboration between the Cardiovascular 
Medicine department of the Whittington Hospital NHS Trust and University College 
London Centre for Behavioural and Social Sciences in Medicine. The development 
team consisted of two health psychologists, a consultant cardiologist and a heart failure 
nurse specialist. The team met on several occasions during the development stage to 
discuss,
a) patients to be included in the study
b) the nature of care provided to the control group
c) content and delivery of the intervention
Patient input was obtained during the pilot phase of the intervention.
4.2 Objectives
Chapter 2 provided an overview of the poor health outcomes experienced by people 
with heart failure, which include high mortality, repeated unplanned hospital admissions 
and poor quality of life. The objective of the study was to develop an intervention that 
could improve these outcomes.
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When this study began, most of the interventions that had been implemented in heart 
failure were disease m anagement programmes and many involved intensive case 
management. This type of m anagement makes considerable demands on health care 
resources and therefore may be limited in the extent to which it can be implemented 
throughout the health care system. As the number of patients with heart failure 
increases, a service that offers intensive case management to all patients is likely to 
reach a point where it becomes more and more difficult to sustain. In this study, an 
important objective was to develop a brief intervention that could be delivered within 
the resources available to most hospitals.
Intensive case managem ent also overlooks the role that patients play in managing their 
illness and has the potential to make patients more dependent upon the hospital and 
health care professionals. An important objective in designing the intervention in this 
study was to encourage patient self-management.
4.3 Study population
Patients admitted to hospital with heart failure were considered to be the most 
appropriate group to target because they are known to be at high risk of early 
readmission to hospital and death and they consume immense NHS resources (see 
Chapter 2). Cleland, Swedberg, Solal et al, (2000) asserted that a hospital admission is 
a critical event because diagnosis and management are likely to be revised. They 
reported that up to 80%  of first-diagnoses of heart failure occur at the time of 
hospitalisation and one-third of patients with heart failure will be hospitalised within any 
given year. Accessing such patients at this time would seem to be important not only 
because of the high frequency of later hospitalisation but it was also considered that a 
hospital admission may be a trigger for patients newly diagnosed with heart failure to 
initiate self-management behaviours and for patients with existing heart failure to
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review their self-management behaviours and possibly be more open to making 
changes.
The literature reviewed in Chapter 3 indicated that demographic factors were unlikely to 
influence self-management therefore the intervention in this thesis was designed to be 
applied to all heart failure patients regardless of age, gender and other demographic 
factors. There was a suggestion from one study (Riegel et al, 2000) that patients may 
show a differential response to a multidisciplinary self-management programme 
according to their functional status. This was a post-hoc analysis and one that was not 
performed in other studies, therefore while it would be of interest to examine how 
patients in different functional classes respond, the current intervention was to be 
designed to target as broad a selection of the hospital in-patient heart failure population 
as possible.
4.4 Intervention development
A number of different elements contributed to the development of the intervention. 
These included the literature on heart failure and self-management, clinical guidelines 
for the treatment of heart failure, the literature on self-management in other chronic 
illnesses, the conceptual basis of self-management interventions as well as a number 
of practical considerations.
4.4.1 Content of the intervention
The content of the intervention i.e. the components to be targeted, were based on the 
literature on heart failure and self-management and the clinical guidelines for the 
treatment of heart failure.
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The literature reviewed in Chapter 2 highlighted shortcomings in patients’ self­
management of heart failure and indicated that these shortcomings were associated 
with a greater risk of admission to hospital. These studies support the need for an 
intervention that can facilitate adoption and maintenance of self-management 
behaviours.
The literature reviewed in Chapters 2 and 3 provided some consensus about the self­
management behaviours that should be targeted, with most interventions addressing 
adherence to medication and self-monitoring. Another important source of input 
regarding the areas to be covered in the self-management intervention was the heart 
failure guidelines (Task Force of the Working Group on Heart Failure of the European 
Society of Cardiology 1997; Scottish Intercollegiate Guidelines Network 1999) which 
outline several behaviours that are recommended for patients to adopt (see section 
2.5.3). A poor understanding of heart failure and its treatment also emerged in the 
literature as a possible cause of poor self-management.
The literature review and clinical guidelines thus identified a number of factors that 
were related to health outcomes in heart failure and which were considered important 
to include in the intervention. These were:
4.4.1.1 Understanding of heart failure, its signs, symptoms and treatment
Some studies had indicated that patients had a poor understanding of their treatment 
regime. Concern was also expressed in the intervention development team that 
patients are not always given a clear explanation of their diagnosis and many interpret 
the information that there is a build up of fluid in their lungs as indicative of lung, not 
heart, disease. Misconceptions about heart failure have also since been reported by 
Horowitz, Rein & Leventhal, (2004). It was therefore considered important that patients’ 
understanding of heart failure and its treatment should be explored and clarified where
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appropriate. A clear understanding of heart failure is considered necessary for patients 
to place their symptoms and behaviours into context i.e. patients need to understand 
how heart failure leads to fluid build-up and how their behaviours such as medication 
and salt and fluid intake influence fluid balance.
4.4.1.2 Adherence to medication
Non-adherence to medication had been identified as a factor precipitating readmission 
to hospital and therefore was considered an important aspect to address in the 
intervention. As non-adherence to medication can be intentional (e.g. discontinuing 
medication once one is feeling better) or unintentional (e.g. forgetting to take 
medication) (Verm eire, Hearnshaw, van Royen & Denekens, 2001), it was considered 
important that the intervention should aim to address both causes.
4.4.1.3 Fluid balance
Maintaining a stable fluid balance is an important part of heart failure self-management. 
In addition to taking medication, avoiding fluid build up through excessive salt or fluid 
intake were considered important topics for inclusion in the intervention.
4.4.1.4 Self-monitoring for early signs of deterioration
Self-monitoring has been described as the foundation of self-management (Creer 
2000). It not only provides the information on which patients base self-management 
decisions but also shows if self-management objectives have been achieved.
Heart failure can deteriorate rapidly and research has shown that patients often delay 
in seeking medical intervention. This delay means that patients have often deteriorated 
to such an extent that they require long hospital stays to restore clinical stability. Self­
monitoring to identify early signs of deterioration has the potential to help to prevent 
further decline by enabling action to be taken at an early stage when re-stabilisation is
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easier. Self-monitoring of signs of fluid retention through weight monitoring and 
checking for oedem a were therefore considered important components of the 
intervention.
4.4.1.5 Lifestyle changes
Lifestyle factors that are considered important in heart failure include smoking 
cessation, minimal alcohol intake and regular physical activity. Although smoking 
cessation would be encouraged, it was not seen as a specific target of the intervention 
as it was considered likely to require more intensive specialist intervention that could 
not be accommodated in a brief self-management intervention as planned for this study. 
Patients with current alcohol addiction were excluded from the study however those 
who drank more than recommended limits but stated that they intended to cut down 
were included. Physical activity has been shown to be beneficial in heart failure 
(McKelvie, Teo, McCartney et al, 1995) but patients may restrict their activity because 
of breathlessness, a belief that they are unable to take exercise or fear of exacerbating 
symptoms. Encouragement to remain physically active or to increase activity as 
appropriate was considered an important matter for inclusion in the intervention.
4.4.1.6 Mood
While the potential influence of mood on self-management was acknowledged, mood 
was not considered a primary target of this intervention. This decision was taken 
because the intervention was designed to be brief and was therefore limited in the 
scope of components it could include. Hence the decision was made to focus on 
behaviours and cognitions as opposed to mood. It was also considered that strategies 
to directly address emotions would have required additional time plus additional skills 
from the intervention facilitator. An intervention specifically directed to address mood in 
heart failure would have been very different from the one in this thesis. Mood was 
rather considered as a dimension that potentially can be influenced by improvements in
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patients’ ability to self-manage their heart failure, achieved through changes in 
behaviour and cognitions and their perception of increased abilities to manage their 
condition.
4.4.2 Facilitating change
As reported in the sections above, the components to be targeted in the intervention 
comprised behaviours and cognitions. Although many heart failure interventions have 
targeted these and other self-management behaviours, they have adopted an 
information-giving approach which assumes that increased knowledge will lead to 
behaviour change. However, research in heart failure has shown that there is not a 
strong association between knowledge of the recommended heart failure self­
management behaviours and their performance. It is also important that previous 
intervention studies have rarely measured behaviour or behaviour change therefore the 
impact of the intervention on behaviour and the impact of behaviour on outcomes in 
these studies is not known. With regards to an examination of cognition in relation to 
heart failure, the literature review indentified only one study that examined cognitive 
factors in relation to heart failure managem ent (Ni et al, 1999). Consequently, although 
the literature in heart failure provided guidance about which aspects of self­
management needed to be targeted, it provided little guidance about the best approach 
to adopt in order to enhance self-management as interventions have relied on provision 
of information rather than being informed by theories of behaviour and behaviour 
change (see section 3.5).
An important consideration in developing the intervention was thus to choose the 
methods which were most likely to facilitate change in these behaviours and cognitions. 
This was informed by the literature on self-management and health psychology theory. 
The literature on health psychology theories, as outlined in chapter 3, proposes that
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important determinants of self-management behaviour are the beliefs that people hold 
about their illness and its treatment (the self-regulatory model), and their self-efficacy in 
their ability to perform the behaviours (social cognitive theory). Although only a small 
amount of research has examined these factors in heart failure (see section 3.4), the 
findings offer some evidence for their importance.
The literature from self-m anagem ent in other chronic illnesses provides additional 
guidance on how to enhance self-management. A full review of the considerable 
literature on self-m anagem ent in chronic illness is beyond the scope of this thesis but 
reviews in other illnesses have been examined. A consistent finding from the reviews 
was that interventions which provided patients solely with information were ineffective 
(Coates et al., 1996; Taal, Rasker & W iegman, 1997; Gibson et al., 2000a). However, 
interventions that incorporated behavioural techniques were more successful. In 
asthma, a Cochrane review (Gibson, Coughlan, Wilson et al, 2000b) identified three 
components that seem ed to be important in reducing asthma exacerbations. These 
were self-monitoring for early signs of problems, regular review by clinicians and use of 
written action plans for managing symptoms. Literature on self-management of 
diabetes has indicated that theoretically-based interventions, particularly those based 
on social learning theory, tend to be more effective than educational approaches 
(Griffin, Kinmouth, Skinner & Kelly, 1998). Self-efficacy has also been identified as an 
important influence on outcomes in arthritis (Taal et al, 1997).
In summary, the literature from other chronic illnesses demonstrates that an 
intervention which simply provides patients with information about their illness and its 
management is unlikely to improve their self-management whereas inclusion of other 
components such as self-monitoring and strategies to facilitate behaviour change 
appear to be important.
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Based on the literature summarised above, the key concepts that embrace both 
behavioural and cognitive aspects of behaviour change and thus would form the basis 
of this self-m anagem ent intervention were considered to be:
• The inclusion of clear behavioural goals and self-monitoring
• The concept of self-efficacy
• the potential role of illness and treatment beliefs as factors that may influence the 
adoption of self-m anagem ent behaviours
These are considered further in the following sections.
4.4.2.1 Behavioural goals and self-monitoring
The behavioural goals of the intervention were based on the behaviours highlighted in 
section 4.5.1 above i.e. adherence to medication, fluid balance, lifestyle changes and 
self-monitoring for early signs of deterioration.
In the case of self-monitoring, the intervention included skills training in how to self­
monitor effectively for signs of deterioration and an action plan for the magnitude of 
change which should trigger contact with the health care service so that remedial 
action could be taken. The use of similar types of action plan in asthma have been 
found to improve outcomes (Gibson et al, 2000b).
In the case of medication adherence, it was considered appropriate to help facilitate 
participants to take all their medication as prescribed. The intervention thus involved 
identification of factors that could act as barriers to taking medication and aimed to help 
participants overcome these (see sections 4.5.2.2 and 4.5.2.3 below ).
In the case of fluid intake, the heart failure guidelines provide an approximate fluid 
intake that is recommended and the intervention used this as a guide. Participants
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however decided on how to manage their fluid intake throughout the day. Similarly with 
salt intake, the heart failure guidelines suggest a maximum daily salt intake, so the 
intervention was designed to assist participants to identify their current salt intake and 
whether reduction was recommended and encourage them to decide on how to reduce 
their salt intake if necessary.
Physical activity levels were likely to vary considerably between participants therefore 
the goal of the intervention was for participants to maintain or increase physical activity 
levels as appropriate. The intervention was designed to help patients plan how they 
would incorporate physical activity into their day.
Many self-m anagem ent interventions include formal goal-setting and contracting 
sessions in which participants set goals for the changes they intend to make, and write 
contracts for the performance of those behaviours (e.g. Lorig et al, 1999). Over a 
period of several weeks, participants can increase these goals and set goals for new 
behaviours. Given the time-limited nature of the intervention in this study, this process 
was not considered feasible. Furthermore, this process is more suitable for some 
behaviours than others. For example, it is suitable for encouraging increasing physical 
activity over time. However, taking medication as prescribed is essential to prevent 
heart failure deterioration and as such, it would be inappropriate for a self-management 
intervention to facilitate goal-setting for anything other than complete adherence. As 
such, taking medication as prescribed was a predefined goal of the intervention. Rather 
than choosing one or two behavioural goals, patients were encouraged to perform all 
the behaviours included in this intervention. As the intervention was designed to be 
brief, it incorporated only a small number of behaviours, all of which are recommended 
according to heart failure m anagem ent guidelines (see section 2.5.3). Patients were 
however actively involved in planning and deciding how to integrate the behaviours into 
their daily lives therefore they were involved in deciding how the goals were
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implemented. For example, participants would decide if they were going to try to 
reduce the salt in their diet and if so, how they would do it e.g. by cutting out/down on 
certain foods, stopping adding salt to cooking and/or to the food on their plate and so 
on. Similarly, in the case of exercise, participants were actively involved in deciding 
what and how much activity they would do and how they would integrate it into their 
daily life.
4.4.2.2 Self-efficacy
The literature in self-m anagem ent and in behaviour change more generally has shown 
the importance of enhancing self-efficacy to facilitate change. Key to enhancing self- 
efficacy is mastery experiences (see section 3.2.2), as success in performing a 
behaviour increases the likelihood that it will continue, whereas failure undermines self- 
efficacy and discourages the behaviour. An important aspect of the intervention was 
therefore to promote mastery by helping participants to overcome any factors that 
could act as barriers to performing the behaviour.
The problem-solving approach of D ’Zurilla & Goldfried (1971) (see section 3.3.5) was 
considered suitable for this purpose. Hence for each behavioural goal of the 
intervention, participants would make the decision on how best to perform the 
behaviour by identifying any problems to implementing it and choosing a strategy that 
they considered would be most effective for overcoming any difficulties. After 
implementing this strategy they would review its effectiveness and adapt it or try a new 
strategy as appropriate.
It was anticipated that some of the problems that participants would identify in adopting 
and maintaining self-m anagem ent behaviours would involve difficulty in understanding 
and remembering when and how to perform them. Such factors could give rise to 
unintentional non-adherence. Therefore medication and self-monitoring charts were
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offered and participants were provided with a booklet as an aide memoir (Appendix B). 
The intervention facilitator could also suggest some possible strategies based on 
stimulus control (see section 3.3.4) to help participants to remember, such as 
establishing a link between taking medication and a routine such as brushing one’s 
teeth. Participants could then decide whether or not they considered this a useful 
general strategy to adopt and how they would adapt this to their lifestyle and 
circumstances.
4.4.2.3 Illness and treatment beliefs
Although the literature which has examined patients’ beliefs about heart failure is very 
limited, it suggests that patients hold a poor understanding of the illness and its 
treatment. Furthermore, studies of the self-regulatory model (see section 3.2.1) indicate 
that patients’ beliefs influence how they manage their illness. Accordingly it was 
considered important that patients’ beliefs about their illness and treatment should be 
elicited as part of the intervention. Misconceptions could then be corrected and 
unhelpful beliefs could be challenged. Strategies for challenging beliefs are drawn from 
cognitive restructuring techniques (see section 3.3.6).
4.4.3 Practical and clinical issues
Several practical and clinical considerations were taken into account when designing 
the intervention.
4.4.3.1 Structure and duration of the intervention
As mentioned above, an important aim was to develop a brief and therefore potentially 
cost effective intervention. It was decided that a minimum of three sessions was 
necessary. The first session would involve introduction of the self-management tasks. 
After a period in which patients would have the opportunity to put the self-management
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intervention into practice, the second session would review any problems encountered 
and examine ways to overcome them. A third session would then provide the 
opportunity to review progress.
Given that heart failure can deteriorate rapidly, it was considered important to initiate 
the intervention in hospital so that patients could practice some of the behaviours 
during their hospital stay and would be ready to continue them in their own home. It 
was therefore planned to schedule the first session prior to discharge from hospital. 
The heart failure nurse specialist on the development team considered that a single 
meeting prior to discharge would be insufficient to develop a relationship with the 
patient so a brief introductory session was added to this part of the intervention. Follow- 
up in the early period post discharge was considered necessary to review progress and 
address any problems that arose in the immediate post discharge period. A home visit 
one week after discharge was chosen as this enabled early review and could be useful 
for identifying problems that arose in the home environment. It was decided that the 
final session which reviewed progress after the home visit should be by telephone thus 
helping to optimise efficiency of healthcare resources.
4.4.3.2 Mode of delivery
As patients were to be seen first during their hospital stay and later in their own home, 
the intervention was designed to be delivered to patients individually rather than as a 
group programme.
4.4.3.3 Who should deliver the intervention?
In deciding who should deliver the intervention it was taken into account that the 
intervention would include disease-specific information as well as self-management 
techniques. While a psychologist may be considered to be the health professional best 
qualified to deliver the aspects of a self-management intervention that deal with beliefs
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and behaviour change, a nurse would be more appropriate for other aspects of the 
intervention. Furthermore, the generalisability of the intervention to other environments 
would be more limited if it required a psychologist. The requirement was to design a 
brief intervention which for practical purposes could be delivered by a single health 
professional. Other health professionals and lay people have been trained to deliver 
self-management interventions (Newman, Mulligan & Steed, 2001), therefore it was 
decided that the most appropriate option was to train a heart failure nurse specialist in 
self-management techniques. This would also have the benefit that integration of such 
an intervention into routine heart failure care would be fairly straightforward.
4.4.3.4 Clinical care
Ideally from the perspective of evaluating the self-management intervention, clinical 
care would have been completely separate from the intervention so that the only 
difference between the care received by the intervention and control groups would 
have been the self-m anagem ent intervention. However in practice this was not possible. 
As the heart failure nurse was to visit patients at home following discharge from 
hospital it was considered ethically necessary to include a clinical examination during 
the visit and to take action as clinically appropriate.
Also, patients were being asked to self-monitor for early signs of deteriorating heart 
failure therefore it was important for them to have rapid access to a health care 
professional who could offer appropriate clinical input. It was therefore decided to 
advise patients to contact the heart failure nurse if they identified indicators of 
deterioration.
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4.5 Manual (Appendix A)
Self-management interventions are usually complex and the many interventions that 
have been developed in several chronic illnesses vary considerably. This can make 
comparison of interventions difficult as the ways in which they differ are not always 
clear from journal reports. Journal word restrictions mean that interventions can not be 
fully reported but it is important that the intervention is described in detail elsewhere so 
that it can be replicated. For this reason it was considered important to describe the 
intervention in detail in a facilitator’s manual. The manual was not designed to be used 
on its own but as a supplement to the training sessions which are described below.
The manual for this intervention was divided into two sections
a) the skills that the nurse would need to use to facilitate behaviour change
including the m anner of interaction with patients, problem-solving strategies and
eliciting and challenging unhelpful beliefs
b) the procedures for each session of the intervention..This section of the manual
set out in detail what was to be covered in each session. It set out the
objectives of each session and the behaviours that were to be addressed. It 
also offered suggestions on the types of open questions that could be used to 
elicit information about the difficulties patients were having in adopting self­
m anagement behaviours and about their beliefs about the illness and its 
treatment.
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4.6 Nurse training
4.6.1 Difference between usual nursing practise and delivering a self­
management intervention
An important difference between usual nursing practice and a self-management 
intervention is the general relationship with the patient. In the former, the nurse often 
provides information i.e. advises the patient what to do, whereas the latter requires a 
more open, enquiring approach to try to elicit and understand how the patients think 
and feel about their heart failure. The relationship is more like a partnership than the 
teacher-pupil relationship of the traditional educational model. In their traditional caring 
role nurses may try to solve problems for patients but in a self-management 
intervention, the role of the nurse is to act as a facilitator to help patients find their own 
solutions. It is important for the nurse to resist the temptation to suggest what may 
seem obvious solutions.
Whitehead (2001) commented that nurses “are often unaware of the extremely 
complex human phenom ena associated with modifying health-related behaviours...”. 
The traditional educational approach that is usually adopted in nursing practice 
assumes that knowledge of appropriate health behaviour will be sufficient to bring 
about behaviour change. It was therefore important that the nurse should recognise the 
limitations of a traditional educational approach and gain an understanding of the role 
of psychosocial factors in behaviour change.
Delivering a self-m anagem ent intervention also entails specialist skills that are not 
taught as part of routine nursing training. The nurse therefore required training in skills 
to facilitate behaviour change such as problem-solving techniques and how to elicit and 
challenge patients’ beliefs.
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4.6.2 Aim and content of training sessions
The aim of the training sessions was to teach the nurse the skills required to deliver the 
self-management intervention. Training sessions took place before starting the 
intervention, then, periodically over the course of the implementation period, sessions 
were held to review and refresh the nurse’s skills. In all, approximately 15 hours of 
training was given. Training was conducted by two health psychologists, including the 
author.
The nurse was given a background to self-management theory and factors influencing 
behaviour change. A series of role plays was used to teach the skills required to deliver 
the intervention. These included asking open questions to elicit patients’ beliefs and 
understanding about their illness and treatment, the use of problem-solving techniques 
and how to challenge beliefs. In the role plays, the nurse practiced delivering the 
intervention to one of the health psychologists who took the role of the patient. The 
other health psychologist observed and provided feedback. One of these sessions was 
video recorded and feedback provided.
The nurse had the opportunity to practice using these skills with patients during the 
pilot phase of the study. She reported on her experiences with each patient in the pilot 
phase and training sessions provided an opportunity to examine any difficulties that 
were encountered and to review the acquisition of self-management facilitation skills.
Following the pilot phase, the nurse began delivering the intervention using the 
intervention manual. Training sessions were held approximately 3 monthly during the 
course of the intervention. These involved the nurse feeding back her experiences of 
working with different patients and the difficulties she had encountered as well as 
examples of situations she felt had been dealt with effectively. One important feature of
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the training was for the trainers to model the techniques that were being taught in the 
training sessions. For example when the nurse brought a problem to the session, it was 
dealt with by using problem-solving techniques.
4.7 Pilot phase
The intervention was piloted with 10 patients. The patients gave positive feedback 
about the intervention and were pleased with the nurse’s input. They did not offer any 
suggestions about how the intervention should be changed. The nurse did not suggest 
any changes to the content of the intervention based on the pilot phase. Outcomes for 
patients who participated in the pilot phase are not included in the results sections of 
the study.
4.8 Standard care control group
The focus of many of the interventions that have been developed in heart failure is on 
more intensive healthcare professional input to achieve optimal medical care i.e. care 
according to published medical guidelines. This study did not wish to confound 
optimising of medical care with self-m anagem ent therefore it was considered crucial in 
this study that the intervention group should be compared to a control group who 
received optimal medical care. In addition, given that optimising medical care has been 
demonstrated to lead to improved outcomes, it was also considered unethical to do 
otherwise. Therefore all study patients received standard information about their 
diagnosis, that they received care according to recommended guidelines while in 
hospital and regular cardiology follow-up after discharge. The only aspect of care which 
was designed to differ between the intervention and control group was the self­
management intervention.
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As part of its heart failure service, the hospital aimed to optimise its standard care for 
all patients admitted with heart failure. Hospital admissions records were examined 
every week day and all patients with symptoms on admission that could have indicated 
heart failure were reviewed by the cardiology clinical research fellow from the study 
team. Patients who had signs and symptoms of heart failure received an 
echocardiographic examination to confirm the diagnosis. Patients who were admitted 
to cardiology wards were under the sole care of the cardiology team and those who 
were admitted to medical wards received shared care, meaning that they were 
managed on a day-to-day basis by their physicians with frequent input from the 
cardiology clinical research fellow and the consultant cardiologist where necessary. 
Weekly meetings were held with the consultant cardiologist on the study team to 
discuss the m anagement of all patients. Medical treatment followed a standard protocol 
(Appendix C). Patients were not discharged from hospital until their medication and 
clinical condition i.e. weight, symptoms and renal function had remained stable for two 
days. All patients received out-patient follow-up by a cardiologist within 6-8 weeks post 
discharge and thereafter as necessary. To ensure that intervention and control group 
patients received the same medical care, the cardiologists who provided follow-up care 
and conducted the clinical assessments were not advised of study group allocation. 
Patients in the control group had no contact with the heart failure nurse. All patients 
received the hospital’s standard heart failure leaflet, which included information about 
heart failure and its treatment (Appendix D). A summary of the components of both the 
intervention and control groups are shown in Table 4.1.
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Table 4.1 A summary of the components of the intervention and control conditions
Standard care control group Intervention group
1. Medical treatment according to protocol 1. Medical treatment according to protocol
2. Hospital information leaflet which included:
- a definition of heart failure
- information about its signs and symptoms
- information about medication and surgery
- advice on lifestyle change -  to lose weight 
if necessary, avoid salt, change fluid intake, 
not smoke, keep active and moderate 
alcohol intake
2. Hospital information leaflet which included:
- a definition of heart failure
- information about its signs and symptoms
- information about medication and surgery
- advice on lifestyle change -  to lose weight if 
necessary, avoid salt, change fluid intake, not 
smoke, keep active and moderate alcohol 
intake
3. Intervention based on self-management 
principles to facilitate:
- adherence to medication
- self-monitoring for early signs of deterioration
- fluid management
- reduced salt intake
- physical activity
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CHAPTER 5 
METHODS
5.1 Aim
The aim of this study was to design a brief self-management intervention for patients
admitted to hospital with heart failure and to evaluate its effectiveness in a randomised
controlled trial.
5.2 Hypotheses
It was hypothesised that
1. Patients in the intervention group would report better performance of self­
m anagement behaviours i.e. adherence to medication, self-monitoring for early 
signs of deterioration, salt and fluid management and physical activity.
2. Patients in the intervention group would experience lower rates of readmission 
to hospital than the standard care control group in the 90 days and 12 months 
following discharge from the index admission and lower 12-month mortality.
3. Patients in the intervention group would report better quality of life and mood 
than the standard care control group at 6-8 weeks and 12 months following 
discharge from the index admission.
4. The effect of the intervention on health outcomes would be mediated by 
changes in self-m anagem ent behaviour, self-efficacy and illness and 
medication beliefs.
5.3 Ethical approval
Ethical approval for the study was sought from and granted by the Ethics Committee of 
the Whittington Hospital.
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5.4 Design
The self-management intervention was evaluated in a randomised controlled trial. A 
between-subjects repeated measures design was used.
5.5 Setting
The study was conducted in the Whittington Hospital, a District General Hospital in 
North London.
5.6 Participants
Patients aged >18 years (with no upper age limit) who were admitted to the Whittington 
Hospital NHS Trust, with a primary or secondary diagnosis of heart failure due to left 
ventricular systolic dysfunction were eligible for the study.
Heart failure was diagnosed using the European Society of Cardiology definition 
(Rem m e & Swedberg, 2001) i.e.
• symptoms of heart failure (breathlessness, fatigue, ankle oedema) at rest or in 
exercise and
• objective evidence of cardiac dysfunction at rest [usually echocardiogram] and
• in cases where the diagnosis is in doubt, response to treatment directed 
towards heart failure.
Patients who were admitted with symptoms of heart failure (breathlessness, fatigue, 
ankle oedema) and had ECG evidence of uncontrolled atrial fibrillation (ventricular 
response>100 bpm), and responded to treatment directed towards heart failure, were 
also eligible because in these circumstances echocardiographic assessment of left 
ventricular function is unreliable.
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Patients were excluded from the study if they
• did not speak sufficient English to understand the intervention and assessments
• had a severe psychiatric disorder, cognitive impairment (learning disability, 
dementia or Abbreviated Mini Mental (Hodkinson, 1972) score of less than 7 out 
of 10) or physical disability which would have made completion of the 
assessments and/or participation in the intervention difficult or impossible
• had severe alcohol or drug abuse
• had suffered an ST elevation myocardial infarction within 3 months of admission 
to hospital
• had another life-threatening illness such as end stage malignant disease
• lived outside the hospital catchment area where a home visit would be 
unfeasible.
• were being discharged to, or followed up by, another hospital
• were being discharged to long-term residential care
5.7 Study outcomes
The primary study outcomes were the number of unplanned hospital readmissions and 
the days spent in hospital in the 90 days post discharge from the index admission 
(including admission to hospitals other than the study hospital). In this context, 
unplanned readmission refers to admissions other than for elective procedures. 
Secondary outcomes were mortality in the 90 days post discharge from the index 
admission, the number and duration of hospital admissions and mortality in the 12 
months post discharge, mood and quality of life.
Process or mediator variables are those through which the intervention may be 
expected to influence outcomes i.e. behaviours and cognitions. The process variables
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assessed included self-management behaviours and beliefs about self-efficacy, the 
illness and medication.
5.8 Power calculation
The outcome used for the power calculation was the duration of hospital admissions. 
The aim of the study was to reduce this outcome by 30%, based on what had been 
achieved by earlier studies (e.g. Rich et al, 1995). Using 1999 data from the study 
hospital, the mean duration of hospital stay for patients with a primary diagnosis of 
heart failure was 13.3 days, median 9.6 days, S D 11.3 days. To detect a 30%  reduction 
in duration of hospital stay, with 80%  power, alpha = 0.05, required a total sample size 
of 198.
5.9 Measures
The study measures were chosen on the following basis:
• To demonstrate that the intervention and control groups were similar in 
demographic background, disease severity and the medical treatment they 
received.
•  To examine the effect of the intervention on mediator or process variables
• To examine the effect of the intervention on outcome variables
• To examine the role of potential moderator variables on the intervention i.e. 
variables which may influence the strength of the effect of the intervention on 
the outcome variable. These could include demographic variables such as 
education level and disease variables such as disease severity or duration.
A simple model of the proposed causal relations in the intervention is shown in Figure
5.1. It is acknowledged that there will be other inter-relations between the variables that
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are not shown in this model. Also, some variables may directly affect the outcome, 
irrespective of any influence they may have on the intervention but these direct 
relationships are not shown (for example, co-morbidity may have a direct effect on 
outcomes as well as having a potential moderating effect on the intervention). In 
addition, it is recognised that a variable such as mood may act as a mediator and may 
change as a result of the intervention, but because mood was not directly targeted in 
the intervention, it is shown only as an outcome variable in this model.
A summary of the data collected and assessment times are shown in Table 5.1. Patient 
questionnaires are shown in Appendix E.
5.9.1. Demographic characteristics
Data were collected on patients’ age, gender, ethnicity, body mass index, marital status, 
education, employment status and living conditions.
5.9.2 Clinical variables
5.9.2.1 Medical history
A cardiology research fellow recorded details of the patients’ medical history. This 
included a history of cardiac and other co-morbid illness and also the history of their 
heart failure i.e. the aetiology of heart failure (whether ischaemic or non-ischaemic), 
whether heart failure was newly diagnosed on this admission to hospital, duration since 
diagnosis and history of hospital admissions.
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Figure 5.1 Proposed causal m odel of the intervention
Intervention Mediator variables
Hospital adm issionS elf-e fficacy
B ehaviourM edication  be lie fs  
Illness beliefs
Psychological w ellbeing
Moderator variables
D em ograph ic  variab les  
D isease  variab les
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5.9.2.2 Co-morbidity
The presence of co-morbid illness was considered likely to influence the study 
outcomes therefore participants were asked if they had been diagnosed with one or 
more of 5 major co-morbidities -  cancer, stroke, arthritis, diabetes, asthma. Each 
illness was allocated a score of one and these were summed to provide a total score.
5.9.2.3 Echocardiographic evidence of left ventricular dysfunction
Echocardiographic data were collected because they provide objective evidence of 
cardiac function. As such, they were important to ensure that the intervention and 
control groups did not differ significantly at baseline. Cardiac function is also a potential 
moderator variable as the severity of cardiac dysfunction could impact on a person’s 
ability to adopt and maintain self-management behaviours. The global left ventricular 
function, as judged by the echocardiographer, and the regional wall motion score were 
recorded as indicators of the level of left ventricular dysfunction.
5.9.3 Physical examination
Severity of heart failure symptoms, including breathlessness and oedema were 
assessed by the cardiologist who then classified patients’ functional status according to 
New York Heart Association classification criteria (Dolgin, 1994). This is a descriptive 
classification of symptoms and disability based on patient report. Symptoms of heart 
failure on admission to hospital were also recorded from hospital notes as part of the 
baseline assessment.
5.9.4 Medication
Information on medication prescription was recorded as an indicator of the extent to 
which the intervention and control groups received similar medical care. The type and 
daily dose of heart failure medications i.e. diuretics, ACE inhibitors and beta-blockers
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were recorded at discharge from hospital for the baseline assessment and at 6-8 week 
and 12 month follow-ups. A list of other medications prescribed was also recorded.
5.9.5 Hospital admission
Both total admissions for worsening heart failure and those for any cause (including 
heart failure) were recorded. It is important to examine these separately as an 
intervention could be successful in reducing admissions for worsening heart failure but 
at the risk of causing other problems. For example, heart failure medication could 
reduce blood pressure to a level that results in a patient having a fall and requiring a 
hospital stay.
All readmissions of study patients to the Whittington Hospital were monitored and 
recorded. The cardiology research fellow (who was blind to group allocation) presented 
information on each admission to a panel of two cardiologists who were not involved in 
the study and were also blind to group allocation. The panel decided on the reason for 
the readmission i.e. whether for worsening heart failure of for other causes. The  
cardiology research fellow also visited the general practitioners of all patients and 
recorded details of admissions to other hospitals.
5.9.6 Mortality
The status of all study patients was recorded at 90 days and 12 months post discharge. If 
patients died during an admission to the Whittington hospital or the hospital had been 
advised about a death, the date of death was recorded from hospital records. Information 
on out of hospital deaths and deaths in other hospitals was obtained from patients’ GPs. 
The patient consent form included consent to access information maintained by the NHS  
and the General Register Office so details of any deaths could be obtained from other 
sections of the NHS and/or the Office of National Statistics as necessary.
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5.9.7 Time to first event
The time in days to first event, either death or admission to hospital was also recorded. 
This outcome augments data on occurrence of an event in that it shows not only 
whether or not patients experienced an event during the follow-up period but also how 
long they survived without a readmission to hospital.
5.9.8 Questionnaire measures
The questionnaires were chosen to measure factors that were likely to change as a 
result of the self-management intervention and also those that could influence 
response to the intervention.
5.9.8.1 Quality of Life
5.9.8.1.1 Generic health related quality of life
Generic health related quality of life was assessed with the Medical Outcomes Study 
Short Form 36 (SF-36) (Ware & Sherbourne, 1992). The SF-36 is a widely used 
measure of health-related quality of life. Eight subscales assess physical function, role 
limitation caused by physical function, pain, general health, energy/vitality, social 
function, role limitation caused by emotional difficulties and mental health. It also 
provides two composite scores for physical and mental quality of life. A U.K. version of 
the SF-36 with population norms is available (Jenkinson, Layte, Wright & Coulter 1996). 
To compare scores with populations norms, scores are transformed to a 0-100 scale 
on which the population mean is 50 and the standard deviation is 10. A higher score 
signifies better quality of life. The SF-36 has been validated for use with heart failure 
patients (Berry & McMurray 1999).
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5.9.8.1.2 Disease-specific quality of life
Disease-specific quality of life was assessed with the Minnesota living with Heart 
Failure Questionnaire (MLHF) (Rector, Kubo & Cohn, 1987). The MLHF is a very 
widely used questionnaire for assessing heart failure related quality of life that has 
been validated and is user friendly (Berry & McMurray 1999). The MLHF is a 21 item 
questionnaire that asks how much heart failure had prevented the respondent living as 
they wanted to during the past month. Each item is scored 0 if it does not apply or from 
1 -  5 on a scale signifying from ‘very little’ to ‘very much’. The questionnaire provides a 
total score from 0 - 1 0 5  with a higher score signifying worse quality of life. The 
questionnaire also has a physical subscale comprising 8 of the items and an emotional 
subscale comprising 5 of the items.
5.9.8.2 Psychological wellbeing
Mood has been found to influence participation in self-management interventions (e.g. 
Shaw, Cronan & Christie, 1994) therefore it was considered an important factor to 
measure. Also, patients with heart failure are known to experience impaired mood (see 
section 2.4.2.3) and an intervention which enhanced patients’ confidence in their ability 
to m anage their illness might be expected to also improve mood (e.g. Lorig, Sobel, 
Stewart et al, 1999). Anxiety and depression were assessed with the Hospital Anxiety 
and Depression Scale (HADS) (Zigmond & Snaith 1983). This questionnaire was 
chosen because it was designed to assess anxiety and depression within a clinical 
population and therefore excludes somatic items that could lead to over-diagnosis of 
impaired mood in the physically ill. The HADS is a 14-item questionnaire that provides 
two separate scales for anxiety and depression. Each scale is scored from 0 - 2 1  with 
a higher score signifying greater anxiety or depression. A score of £8 indicates possible 
clinical depression/anxiety and a score of £11 indicates probable clinical 
depression/anxiety. Both the mean score and classification according to presence or 
absence of anxiety or depression were used in the analysis.
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It was of interest to examine not only whether the intervention could reduce negative 
mood but also whether it could enhance feelings of positive mood. To assess mood in 
this way, the Positive and Negative Affect Scale (PANAS) was used (Watson, Clark, & 
Tellegen, 1988). The Positive and Negative Affect Schedule consists of tw ol0-item  
scales for positive affect and negative affect. Each scale is scored from 1 0 -5 0  with 
higher scores indicating greater positive affect and greater negative effect. The PANAS 
has proven reliability and validity in a UK population (Crawford & Henry, 2004).
5.9.8.3 Health behaviours
Information on patients’ smoking history, weekly alcohol consumption and weekly 
exercise were recorded at the baseline assessment and 6-8 week and 12 month follow- 
ups.
5.9.8.4 Self-management behaviour
At the time of the study development, a number of possible questionnaires to evaluate 
self-management behaviour were considered but no suitable questionnaire was 
identified. One questionnaire that had been published, developed by Riegel, Carlson & 
Glaser (2000), included questions about behaviours that were not part of the self­
management intervention, for example, self-adjustment of diuretic medication, and 
therefore was considered inappropriate. Furthermore, it had undergone only 
preliminary reliability analyses and the developers of the scale did not advocate it for 
use for research purposes at that time. A measure by Bennett, Milgrom, Champion & 
Huster (1997) was concerned with beliefs about compliance rather than the practice of 
the relevant behaviours. Therefore a brief questionnaire was compiled for the study to 
assess the practice of self-management behaviours. This was based on the Revised 
Summary of Diabetes Self-Care Activities Scale (Toobert, Hampson & Glasgow, 2000).
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The questionnaire asked respondents how many days out of the past seven they had 
performed each behaviour that formed part of the self-management intervention.
Physical activity was measured using a scale developed by Lorig, Stewart, Ritter et al 
1996. This asks how much time was spent in 6 different physical activities over the 
course of the previous week, with answers on a 5-point ordinal scale from none, less 
than 30 minutes, 30-60 minutes, 1-3 hours and more than 3 hours. These are then 
converted to the number of minutes spent - 0, 15, 45, 120 and 180 respectively. A 
limitation of this conversion is that it could over- or under-estimate the actual time spent.
5.9.8.5 Beliefs
5.9.8.5.1 Beliefs about medication
The beliefs people hold about their medicines have been found to be associated with 
medication adherence (Horne & W einm an, 1999). Beliefs were assessed with the 
Beliefs about Medication Questionnaire (BMQ) (Horne, Weinman & Hankins, 1998). 
This questionnaire contains 10 items which items are scored on a 5-point Likert scale. 
It consists of two subscales that measure concerns about medication and beliefs about 
the necessity of taking medication.
5 .9.8.5.2 Self-efficacy beliefs -  heart failure specific
Self-efficacy is recognised as an important variable in self-management interventions. 
When the study was designed, there was no available questionnaire to assess heart 
failure self-efficacy beliefs. Ni et al (1999) had used only two items which were not 
behaviour specific and although the Kansas City Cardiomyopathy Questionnaire 
(Green, Porter, Bresnahan & Spertus, 2000) claims to measure this variable, the 
relevant items would appear to relate to knowledge rather than self-efficacy. Therefore  
a scale was developed for the study. Items were chosen that related to the behaviours
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covered in the self-management intervention. The scale had seven items, measured on 
a 5-point Likert scale, a higher score indicating greater self-efficacy.
5 .9.8.5.3 Self-efficacy beliefs -  general
It is possible that people’s beliefs about their general ability to cope with life’s
challenges may influence how they respond to a self-management intervention. These 
are known as general self-efficacy beliefs and were assessed with the Generalised 
Self-efficacy Scale (GSES) (Schwarzer 1993). This is a 10-item scale, scored on a 4- 
point scale from ‘not at all true’ to ‘exactly true’. The scores of the 10 items are
summed to provide a total score with higher scores indicating greater self-efficacy.
5.9.8.5.4 Illness beliefs
The beliefs people have about their illness have been shown to influence their health 
behaviour (e.g. Glasgow, Hampson, Strycker & Ruggiero, 1997) and therefore were 
assessed as part of the study. Illness beliefs were measured using the Illness 
perceptions Questionnaire (IPQ) (W einman, Petrie, Moss-Morris & Horne, 1996) which 
is derived from the self-regulatory model of illness (Leventhal, Nerenz & Steele, 1984). 
The IPQ assesses beliefs about illness in 5 domains: (i) identity -  the symptoms the 
person perceives to be related to the illness, (ii) cause -  beliefs about what caused the 
illness (iii) timeline -  perception of the likely time course, (iv) consequences -  
perception of the effect of the illness, (v) cure/control -  beliefs about how amenable the 
illness is to cure and/or control. The identity sub-scale of the IPQ contains 12 core 
symptoms and these were supplemented with 7 other symptoms known to occur in 
heart failure. A total score is obtained by calculating the sum of the symptoms that 
respondents report experiencing. The timeline, consequences and cure/control 
subscales consist of 3, 7 and 6 items respectively, each scored on a 5-point Likert 
scale and summed to obtain a total score for the subscale. The analysis in this thesis 
concentrated on the dimensions of identity, consequences, cure/control and timeline.
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5.9.8.7 Patient satisfaction and value of the intervention
Acceptability of the intervention to the patient was assessed in two ways. The Client 
Satisfaction Questionnaire (Attkisson & Zwick, 1982) was used to compare the 
intervention and control groups on levels of satisfaction with care. This is an 8-item  
scale, scored on a 4-point scale. A total score is obtained by calculating the sum of 
scores on the 8 items. Patients in the intervention groups also completed a 
questionnaire asking about how helpful they found the intervention. This was a 5-item  
measure, scored on a 5-point scale from ‘not at all’ to ‘very much’ which was designed 
for the study based on the components of the intervention. The scale also asked 
patients about their use of the intervention booklet, weight and medication charts.
5.10 Procedures
A flow-chart of the study procedures is shown in Figure 5.2
5.10.1 Recruitment
Potential study patients were identified through frequent checks of hospital admissions 
and inpatient echocardiograms and by physician referral to the heart failure team. All 
patients admitted with a possible diagnosis of heart failure were reviewed by a 
cardiology research fellow. Once clinically stable on optimal therapy and due to be 
discharged, the cardiology research fellow informed patients about the study and gave 
them the written information sheet (Appendix F). Patients were given at least an hour to 
read the information sheet, discuss it with their spouse or family members if they 
wished and consider whether they wanted to participate. The cardiology research 
fellow answered any questions that the patient and spouse or family members had 
about the study. Written consent was obtained.
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Figure 5.2 Study procedures
Home visit
Intervention Control
Randomised
Exclusions
Telephone
follow-up
Recruited to study
HF Diagnosis 
confirmed
Two meetings with 
nurse before 
hospital discharge
Baseline clinical and
questionnaire
assessment
6-8 week clinical and 
questionnaire assessment
90 day mortality and 
admissions data 
collection
12 month clinical and 
questionnaire 
assessment plus 
mortality and admissions 
data collection
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5.10.2 Baseline assessment
Before randomisation, the cardiology research fellow completed a clinical data 
collection form. This included both data which was collected from patient self-report e.g. 
current symptoms, and data collected from hospital records e.g. echocardiographic 
examination. All participants then completed baseline questionnaire assessments with 
the health psychology research fellow. Some clinical data were also recorded at the 
time of hospital discharge e.g. discharge medication.
5.10.3 Randomisation
After completion of the baseline measures, patients were randomised to the 
intervention or standard care control group using pre-randomised sealed opaque 
envelopes.
5.10.4 Procedures for Intervention and Standard Care Control
5.10.4.1 Standard Care Control Group
Patients randomised to the control group received the hospital’s standard medical care 
for heart failure as described in section 4.8. To ensure that intervention and control 
group patients received the same medical care, the cardiologists who provided follow- 
up care and conducted the clinical assessments were not advised of study group 
allocation. Patients in the control group had no contact with the heart failure nurse
5.10.4.2 Intervention group
In addition to the care received by the standard care control group, patients in the 
intervention group were also seen by the heart failure nurse specialist. The self­
management intervention described in the previous chapter was delivered in two 
sessions prior to discharge from hospital, plus a single home visit within one week of 
discharge followed by a telephone call one week later. Patients were encouraged to
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contact the nurse if they identified signs of worsening heart failure. If patients in the 
intervention group were readmitted to hospital, the nurse visited them once before 
discharge. In addition to the self-management aspects of the intervention, at the home 
visit the nurse also reviewed the patient’s clinical status and took any necessary action 
in accordance with a standard protocol. Any concerns were discussed with a 
cardiologist and additional clinic visits or admission to hospital could be arranged 
where necessary. The nurse’s discussion of a patient with a cardiologist did not lead to 
‘unblinding’ because the nurse also saw other patients who were not recruited to the 
study therefore the cardiologists would not have known whether or not the patient 
being discussed was a study patient.
5.10.5 Follow-up assessments
5.10.5.1 6-8 weeks post discharge
Questionnaire and clinical data as shown in Table 5.1 were collected at 6-8 weeks post 
discharge. The assessment was organised to coincide with patients’ routine out-patient 
cardiology visits. The questionnaire assessments were completed with the health 
psychology research fellow before patients had any investigative tests or were seen by 
the cardiologist.
5.10.5.2 90 days post discharge
Data on hospital admissions and mortality were collected at this time-point. The health 
psychology research fellow made frequent checks of hospital admissions and kept an 
on-going record of hospital admissions and deaths as they became known. The 
hospital’s computer record of patient admissions was checked for all study patients to 
ensure that all events which occurred at the study hospital had been captured. The  
cardiology research fellow contacted the GPs of all study patients to obtain details of 
admissions to other hospitals and/or out of hospital deaths.
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5.10.5.3 12 months
Hospitalisation, mortality, questionnaire and clinical data as shown in Table 5.1 were 
collected at 12 months post discharge. The questionnaire and clinical assessment was 
organised to coincide with patients’ routine out-patient cardiology visits. The 
questionnaire assessments were completed with the health psychology research fellow 
before patients had any investigative tests or were seen by the cardiologist.
The method of collecting data on admissions and deaths that had been used to obtain 
the 90-day data was continued. The health psychology research fellow made frequent 
checks of hospital admissions and kept an on-going record of hospital admissions and 
deaths as they became known. The hospital’s computer record of patient admissions 
was checked for all study patients to ensure that all events which occurred at the study 
hospital had been captured. The cardiology research fellow contacted the GPs of all 
study patients to obtain details of admissions to other hospitals and/or out of hospital 
deaths. In addition, all patients who attended their 12 month follow-up visit were asked 
if they had been admitted to any other hospitals in the previous year.
5.11 Statistical analysis
Statistical analysis was performed using SPSS version 12.0.1 for Windows.
5.11.1 Data cleaning
The data were checked by examining the ranges of all variables to ensure that they fell 
within the ranges specified by the questionnaires or within usual ranges for that 
variable. Any that fell outside these ranges were checked and amended where 
necessary.
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Where data were missing randomly, items were replaced with the group mean value of 
that item (Tabachnick & Fidell, 1996). If whole scales or subscales were missing, data 
on that (sub)scale for that participant were omitted from the analysis. The number of 
participants in each analysis is reported in the results section.
5.11.2 Distribution of variables
Distribution of the variables was examined to check for normality of distribution. This 
was examined both visually, by plotting histograms, and statistically using the 
Kolmogorov-Smirnov test. W hen deciding whether to perform parametric or non- 
parametric tests, the advice of Tabachnick & Fidell (1996) was taken into account. 
They state that for two-tailed tests of analysis of variance (ANOVA) and analysis of 
covariance (ANCOVA), where the groups are fairly equal in size and there are no 
outliers, if there are at least 20 degrees of freedom for error, the test is considered 
robust to violations of normality.
Data collected on readmissions to hospital and mortality i.e. the number and duration of 
hospital admissions and the time between discharge from the index admission and 
either death or readmission (time to first event) were not expected to be normally 
distributed and appropriate non-parametric tests were used (see below).
5.11.2.1 Outliers
In analysis of variance analyses (ANOVA and ANCOVA) and logistic regression 
analyses, scores on independent variables were examined for outliers so that those 
greater than 3 standard deviations from the mean could be excluded.
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5.11.3 Comparison of intervention and control groups on baseline 
characteristics
The intervention and control groups were compared on baseline characteristics using 
Student’s t-tests for continuous normally distributed data, chi-squared for categorical 
data and Mann-Whitney U tests for ordinal data and non-normally distributed 
continuous data.
5.11.4 Comparison of intervention and control group on study 
outcomes
Chi-squared tests were used to compare the intervention and control groups on 
mortality and whether or not they had experienced a readmission to hospital. 
Readmissions for all causes and readmissions for worsening heart failure were 
distinguished. The number of readmissions to hospital and the number of days spent in 
hospital had a non-normal distribution and therefore Mann-Whitney U-tests were used 
to compare the intervention and control groups on these variables. The groups were 
also compared on rate of death, death or all-cause admission and death or heart failure 
readmission on a time to first event basis using Kaplan-Meier survival curves followed 
by the log-rank test which is used to test whether the survival distributions differ.
Differences between the groups at follow-up on other outcomes were examined by 
analysis of covariance (ANCO VA), with the baseline score entered as a covariate. 
ANCOVA, conducted at each follow-up, was chosen to examine intervention efficacy 
because it is a more sensitive test than repeated measures analysis of variance 
(ANOVA) (Tabachnick & Fidell, 1996). Separate ANCOVAs, as opposed to a single 
repeated measures ANOVA over all three time-points, also maximises participant 
numbers in the analysis. Post-hoc Bonferroni adjusted repeated measures ANOVAs 
were then performed to examine differences between baseline and follow-up within 
each group. While ANCOVAs are appropriate for examining group differences at each
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time-point they do not show maintenance of change between follow-up assessments 
therefore Bonferroni repeated measures ANOVAs were also performed. These show 
time, group and interaction effects over the three assessment periods.
5.11.5 Prediction of study outcomes
To examine predictors of the occurrence of death or hospital admission and possible 
mediators of intervention outcomes, logistic regressions were performed. Logistic 
regression analyses the probability of a person having a particular outcome, given the 
pattern of their responses to the predictor variables. This statistical analysis does not 
require the predictors to be normally distributed, linearly related or of equal variance 
within each group, and the predictors can be continuous, discrete or dichotomous 
(Tabachnick & Fidell 1996). A minimum ratio of 10 cases per independent variable is 
recommended for logistic regression (Harrell, Lee, Califf et al 1984) where ‘cases’ 
refers to the number of observations of the less frequently occurring outcome.
To identify which independent variables were likely to be the best predictors, 
preliminary univariate analyses were performed and those variables that were 
significantly related to the outcome variable were entered into the regressions. The 
univariate analysis involved performing logistic regression analyses but entering only a 
single independent variable. A level of p £.05 was used as a criterion for entry into the 
multivariate regression however, if the number of statistically significant independent 
variables identified using this entry criterion was too large to allow the recommended 
ratio of 10 cases per independent variable, the maximum recommended number of 
independent variables was chosen based on the highest Wald statistic values. The  
independent variables were entered into the regression in blocks in the following order: 
1.study group, 2 .demographic variables, 3. co-morbid illnesses, 4. echocardiographic
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variables, 5. symptoms, 6. patients’ beliefs about their illness, medication and self- 
efficacy, self-management behaviour, 7. mood.
To examine whether changes in self-efficacy and beliefs mediated any effect of the 
intervention on behaviour, the methods for mediator analysis recommended by Baron 
and Kenny (1986), using a series of regression analyses, were followed. For a 
mediator effect to arise, a) the independent variable must have a significant effect on 
the proposed mediator variable, b) the independent variable must have a significant 
effect on the dependent variable, and c) when the mediator and independent variable 
are both entered into the regression, the proposed mediator variable must have a 
significant effect on the dependent variable. For a mediator effect to be found, the 
effect of the independent variable on the dependent variable must be less in c) than in 
b).
This analysis was also undertaken to examine whether any effect of the intervention on 
the primary outcomes were mediated by behaviour.
To examine whether any variables moderated the effect of the intervention, a number 
of sub-group analyses were performed. The subgroups were selected on the basis of 
factors that had been found in the literature to have an impact on self-management in 
heart failure (this is dealt with in greater detail in section 10.4). An alternative approach 
would have been to test for all possible moderator variables however it was considered 
that this would involve too many statistical tests, increasing the risk of making a Type I 
error.
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Table 5.1. Assessment measures and times
Assessments Baseline 6-8
weeks
90 days 12
months
Demographic variables
Age, sex, marital status, living conditions, ethnicity, 
education, height, weight, employment status
V
Disease variables
Aetiology of Heart failure, Previous cardiac history , 
Co-morbidity
V
Symptoms and Signs of Heart Failure, NYHA V V V
Investigations
Echocardiogram, Chest x-ray, V
12 Lead ECG, Haematology, Biochemistry V V V
Medication
Type and daily dose V V V
Health Behaviours
Smoking, Exercise, Alcohol V V V
Self-management behaviours
Adherence to medication, self-monitoring and diet
\ V
Resource utilisation
Number of hospitalisations for HF and for all causes 
Number of days hospitalised for HF and for all causes
V
V
V
V
Number of nurse contacts (intervention group on ly) V
Mortality
Death from any cause V V
Psychologuical well-being 
Mood
Anxiety -  Hospital Anxiety and Depression Scale 
(HADS),
Depression -  HADS,
Positive and Negative Affect Scale (PANAS)
V V V
Quality of Life
Generic Health-related Quality of Life -  SF-36 
Disease specific -  Minnesota Living with Heart 
Failure Questionnaire
V V V
Process variables
Self-efficacy 
general 
HF specific 
Illness Perceptions -  IPQ 
Beliefs about Medication Questionnaire
V
V
V
V
V
V
V
V
V
V
Patient satisfaction
Client Satisfaction Questionnaire V V
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CHAPTER 6 
RESULTS -  BASELINE CHARACTERISTICS
6.1 Sample characteristics
Four hundred and sixty-seven patients with a diagnosis of heart failure who survived 
the index admission were identified, of which 263 (56%) were excluded (Figure 6.1). Of 
the 204 eligible patients, 38 (19% ) refused participation and one hundred and sixty-six 
patients were recruited to the study. Eighty-five patients were randomised to the 
intervention group and 81 to the control group but after randomisation, the diagnosis of 
one control group patient was revised, rendering her ineligible for the study. The patient 
was treated as a protocol violation and her data were excluded from all analyses, 
leaving 80 patients in the control group.
6.1.1 Exclusions
Two hundred and sixty-three patients were ineligible for the study. The main reasons 
for exclusion were cognitive impairment (n = 58, 22%) and non-English speaking (n = 
56, 21%).
6.1.2 Demographic characteristics
The characteristics of the sample are shown in Table 6.1. The intervention and control 
groups did not differ significantly on any demographic variable. The study sample was 
not different from the general heart failure population in terms of age and gender, with 
a median age of 74, and almost 60% male. Education level was low with most having 
left school aged 14; two-thirds of patients had no formal qualifications. Nearly 60%  of 
patients were living in social housing, an indication of the low socio-economic status of 
the study sample, which reflects the hospital catchment area.
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Figure 6.1 Recruitment
Confirmed 
diagnosis of 
Heart Failure 
n = 467
Exclusions
Cognitive impairment
Psychiatric illness
Non-English speaking 56
Other life-threatening illness
Recent Ml 25
Transfer/follow-up at another hospital
Living in residential care
Severe alcohol/drug abuse
Refused, n = 38Awaiting surgery
Outside catchment area
Disability preventing participation 
Participation in another study
Total 263
Randomised n = 166
Intervention Control n = 81
n = 85 1 protocol violationoCOnc
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Table 6.1. Demographic characteristics
Variable Total
n = 165
Intervention
n = 85
Control
n = 80
Statistical significance
Age, median (range) 74 (21-94) 74 (31-94) 75.5(21-93) Mann-Whitney U = 3170.5, z= -.749, p = .45
Male, n (%) 96 (58.2) 50 (58.8) 46 (57.5) X2 (df=1) =.03, p = .86
Ethnicity, n (%)
Afro-Caribbean 16(9.7) 7 (8.2) 9(11.3)
X2 (df=4) = 1.800, p = .77
Asian 5 (3.0) 3 (3.6) 2 (2.5)
White British/Irish 120 (72.7) 63 (74.1) 57 (71.3)
White other 20 (12.1) 9(10.6) 11 (13.8)
Other 4(2.4) 3 (3.5) 1 (1-3)
Marital status, n (%)
Married/Cohabiting 59 (35.8) 33 (38.8) 26 (32.6)
X2 (df=1) =.717, p = .40
Single/Divorced/Widowed 106 (64.2) 52 (61.2) 54 (67.5)
Living, n (%)
Alone 77 (46.7) 43 (50.6) 34 (42.5)
X2(df=2) = 1.112, p = .57
With others 76 (46.1) 36 (42.4) 40 (50.0)
Sheltered accommodation 12 (7.3) 6 (7.1) 6 (7.5)
Housing, n (%)
Owner occupier 49 (29.7) 21 (24.7) 28 (35.0)
X2(df=2) = 2.104, p = .35
Social housing 92 (55.8) 51 (60.0) 41 (51.3)
Other/unknown 24(14.5) 13(15.3) 11 (13.8)
Years in full-time education, 10 9 10 Mann-Whitney U =2722, z = -1.661, p = .10
median (range) (0 -2 2 ) (0 -1 9 ) (4 -  22)
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6.1.3 Clinical variables
The clinical characteristics of the sample are shown in Table 6.2 and comorbid 
illnesses in Table 6.3. There were no significant differences between the intervention 
and control groups on any of these variables. The majority of patients had moderate or 
severe heart failure as evidenced by echocardiogram. Existence of comorbid illness 
was common, with 70.4%  of the sample having at least one other significant 
comorbidity. The most frequently occurring were arthritis and diabetes, reported by 
44.7%  and 27.7%  of patients respectively.
Almost all patients had been started on diuretics (97.6%) and ACE inhibitors (94.5% ) 
prior to discharge indicating that the hospital’s heart failure guidelines were being 
successfully implemented and optimised medical therapy applied in most cases. 
Pharmacological treatment did not differ significantly between intervention and control 
group patients.
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Table 6.2. Clinical variables at baseline
Variable Total
n = 165
Intervention
n = 85
Control
n = 80
Statistical significance
Heart Failure history
HF = primary admitting diagnosis, n (%)
New HF, n (%)
Days in hospital on index admission, median 
(range)
142 (86.1) 
90 (54.5) 
16(4-116)
76 (89.4) 
43 (50.6) 
16(5-116)
66 (82.5) 
47 (58.8) 
15.5 (4-86)
X2(1df) = 1.641, p = . 20 
X2 (1 df) = 1.107, p = .29 
Mann Whitney U = 3100, z= -.979, p = .33
NYHA class at recruitment to study, n (%)
/
II
III
IV
13 (7.9)
111 (67.3) 
40 (24.2)
1 (0.6)
7 (8.2) 
58 (68.2) 
19(22.4) 
1 (1.2)
6 (7.5) 
53 (66.3) 
21 (26.3) 
0 (0.0)
Mann Whitney U =3306.5, z = -.369, p = .71
Echocardiogram -
Left ventricular subjective global function, n (%) 
Unclassifiable 
Mild
Moderate
Severe
14 (8.5) 
29(17.6) 
55 (33.3) 
67 (40.6)
8 (9.4) 
14(16.5) 
25 (29.4) 
38 (44.7)
6 (7.5) 
15(18.8) 
30 (37.5) 
29 (36.3)
X2(df=3) = 1.643, p = .65
Medication at discharge from hospital (n= 164) 
n (%) prescribed medication
Diuretics
ACE/ATI 1
B-blockers
Spironolactone
160 (97.6) 
155 (94.5) 
70 (42.7) 
106 (64.6)
82 (97.6) 
80 (95.2) 
34 (40.5) 
58 (70.0)
78 (97.5) 
75 (93.8) 
36 (45.0) 
47 (58.8)
X2 (df=1) =.002, p = .96 
X2(df=1) = .175, p = .68 
X2 (df=1) = .343, p = .56 
X2(df=1) = 2.366, p = .12
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Table 6.3. Self-reported co-morbid illness
Illness (data for n=159) 
n (%)
Total
n = 159
Intervention
n = 82
Control
n = 77
Statistical significance
Diabetes mellitus 44 (27.7) 25 (30.5) 19(24.7) X2(df=1) = .670, p = .41
Cancer 12 (7.5) 6 (7.3) 6 (7.8) X2(df=1) = .013, p = .91
COPD/Asthma 31 (19.5) 16(19.5) 15(19.5) X2 (df=1) = .000, p = 1.00
Stroke 21 (13.2) 11 (13.4) 10(13.0) X2(df=1) = .006, p =.94
Arthritis 71(44.7) 32 (39.0) 39 (50.6) X2(df=1) = 2.171, p =.14
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Table 6.4 Quality of life
Variable Total Intervention Control t P
Generic Health-related Quality of Life (SF-36)1 n = 164 LO
00IIc n = 79 df=162
Composite Scores
Physical, mean (S.D.) 29.3(11.7) 28.3(10.5) 30.4(12.8) -1.139 .26
Mental, mean (S.D.) 44.3 (12.4) 43.9(13.3) 44.7 (11.4) -.437 .66
Subscales
Physical Function 43.7 (28.9) 40.6 (27.2) 46.9 (30.5) -1.385 .17
Role Physical 25.9(34.2) 23.5 (32.6) 28.4 (36.0) -.920 .36
Pain 65.2 (34.3) 63.7 (34.4) 66.8 (34.3) -.587 .56
General Health 48.8(19.8) 48.6 (20.6) 49.1 (19.0) -.189 .85
Vitality 38.7 (23.7) 35.8 (23.4) 41.7(23.7) -1.600 .11
Social Function 57.8 (31.2) 56.5 (31.2) 59.2 (31.4) -.560 .58
Role Emotional 40.8 (42.2) 41.2 (43.5) 40.4 (41.0) .115 .91
Mental Health 67.3 (23.6) 65.6 (25.0) 69.0 (22.0) -.912 .36
Disease-specific Quality of Life (MLHF) n = 165
LO00IIc o00IIc df=163
Total score, mean (SDf 44.9 (22.5) 45.3 (22.7) 44.5 (22.4) .212 .83
Physical subscale3 23.6(11.4) 24.1 (11.0) 23.2 (11.9) .522 .60
Emotional subscale4 7.6 (6.7) 7.5 (7.0) 7.8 (6.5) -.301 .76
1. Scale 0-100, population norm 50, higher score = better quality of life
2. Scale 0-105, higher score = poorer quality of life
3. Scale 0 - 40, higher score = poorer physical quality of life
4. Scale 0 - 25, higher score = poorer emotional of life
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6.1.4 Quality of Life
Baseline scores for Quality of Life are shown in Table 6.4. There were no significant 
differences between the intervention and control group on total scores or subscales of 
the generic and disease-specific measures.
6.1.4.1 SF-36
The mean physical composite score of the S F-36 was two standard deviations below 
the population mean, indicating impaired physical quality of life. The mean score on the 
mental composite score was within one standard deviation below the population mean, 
suggesting that in spite of having impaired physical quality of life, patients in this 
sample were able to maintain a reasonable mental quality of life. There was no 
statistically significant difference between the intervention and control groups on SF-36  
subscales or composite scores (Table 6.4).
6.1.4.2 Minnesota Living with Heart Failure Questionnaire
The intervention and control groups did not differ significantly on the MLHFQ (Table 
6.4).
6.1.5 Mood
Scores on the Hospital Anxiety and Depression Scale are shown in Table 6.5. There 
were no significant differences between the intervention and control groups on anxiety 
or depression. Comparison with normative data (Crawford, Henry, Crombie & Taylor, 
2001) found that mean anxiety scores were very similar to the general adult UK  
population (a mean score of 6.53, compared with 6.14 in the general population) but 
mean depression scores were a little higher (5.54 in this study compared with 3.68 in 
the general population). The percentages reporting mild (a score of 8-10), moderate (a
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score of 11-15) and severe anxiety (a score of 16 or over) in the current study were 
19.5%, 17.1% and 3%  respectively, compared with 20.6% , 10.0%  and 2.6%  
respectively in the normative sample. The percentages reporting mild, moderate or 
severe depression were 19.5% , 11.6%  and 0%  respectively compared with 7.8% , 2.9%  
and 0.7%  respectively in the normative sample (Crawford et al, 2001).
Comparison with normative data for the PANAS (Crawford & Henry 2004) found that 
the mean score on negative mood in this study was very similar to the normative 
sample (16.41 in the current study compared with 16.00 in the general population) 
however study patients reported lower levels of positive mood than the normative 
sample (a mean baseline score of 24 compared with the normative score of 32).
These findings indicate that although patients with severe psychiatric illness had been 
excluded, the psychological wellbeing of study participants was poorer than the general 
UK adult population.
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Table 6.5. Hospital Anxiety and Depression Scale
Variable Total Intervention Control Statistical significance
N 164 84 80
Anxiety1
mean (S.D.))
Mild (8-10), n (%) 
Moderate (11-15), n (%) 
Severe (16-21), n (%)
6.53 (4.37)
32(19.5)
28(17.1)
5 (3.0)
6.51 (4.41)
17(20.2)
15(17.9)
2 (2.4)
6..55 (4.35)
15(18.8)
13(16.3)
3 (3.8)
t (df=162) = -.056, p = .96 
X (df=3) = .381 „  p = .94
Depression1
mean (S.D.)
Mild (8-10), n (%) 
Moderate (11-15), n (%) 
Severe (16-21), n (%)
5.54 (3.72)
32(19.5)
19(11.6)
0 (0.0)
5.64 (3.54)
20 (23.8)
7 (8.3)
0 (0.0)
5.44 (3.92)
12(15.0)
12(15.0)
0 (0.0)
t (df=162) = .352, p = .73 
X (df=2) = 3.229, p = .20
1. Scale 0 -  21, higher score = greater depression/anxiety
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Table 6.6. Positive and Negative Affect Scale
Variable Total Intervention Control Statistical significance
N 163 83 80
Positive Affect1
mean (S.D.)
24.74 (8.59) 23.72 (8.03) 25.79 (9.05) t (df=161) = -1.537, p = .13
Negative Affect1
mean (S.D.)
16.41 (6.41) 15.70 (5.81) 17.14(6.93) t (df=161) = -1.438, p = .15
1. Scale 1 0 -5 0 , higher score = greater positive/negative affect
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6.1.6 Process variables
Process variables are those through which the intervention may be expected to 
influence outcomes i.e. behaviours and cognitions.
6.1.6.1 Health Behaviours
There was no difference in health behaviours between the intervention and control 
groups (Table 6.6). The majority were non-smokers and non-drinkers and sixty-five 
percent of patients were taking at least some exercise, although this could be as little 
as under thirty minutes per week.
Table 6.7. Health behaviours
Variable Total Intervention Control Statistical significance
Smoking, n (%)
Current smoker 
Ex-smoker 
Never smoked
18(10.9) 
90 (54.5) 
57 (34.5)
7 (8.2)
46 (54.1) 
32 (37.6)
11 (13.8) 
44 (55.0) 
25 (31.3)
X* (df=2) = 1.643, p = .44
Units of alcohol
per week, n (%) 
0 
1-21 
>21
93 (56.4) 
54 (32.7) 
18(10.9)
53 (62.4) 
24 (28.2) 
8 (9.4)
40 (50.0) 
30 (37.5) 
10(12.5)
X* (df=2) = 2.557, p = .28
Exercise per
week1,
median (range)
82.5 (0-630) 45 (0-405) 120 (0-630) Mann-Whitney U = 3042.5, 
z = -1.064, p = .29
1. Scale 0 -  1080, higher score = more time spent exercising
6.1.6.2 Self-efficacy
Patients’ self-efficacy beliefs are shown in Table 6.7. The intervention and control 
groups did not differ significantly in either general or heart failure specific self-efficacy 
beliefs.
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Table 6.8 General and disease specific self-efficacy
Variable Total Intervention Control Statistical significance
General self-efficacy1, mean (S.D.) n = 159 n = 81 n = 78 t (df=157) = -.980 p = .33
27.7 (7.4) 27.1 (7.5) 28.3 (7.3)
Heart failure self-efficacy2, mean (S.D.) n = 160 n = 81 n = 79
Manage illness 3.14(1.12) 3.23(1.21) 3.04(1.02) t (df=158) = 1.11 p = .27
Monitor change 3.08(1.23) 3.21 (1.23) 2.95(1.23) t (df=158) = 1.34 p = .18
Contact doctor/nurse 3.41 (1.15) 3.47 (1.13) 3.35 (1.18) t (df=158) = .63 p = .53
Take medication 3.92 (1.06) 3.83(1.09) 4.03(1.01) t (df=158) = -1.19 p = .24
Exercise 2.56(1.33) 2.59(1.31) 2.52(1.36) t (df=158) = .35 p = .73
Low salt diet 3.23 (1.27) 3.33(1.29) 3.13(1.24) t (df=158) = 1.03 p = .31
Fluid intake 3.46(1.19) 3.62(1.03) 3.29(1.32) t (df=158) = 1.74 p = .08
1. Scale 1 0 -4 0 , higher score = greater self-efficacy
2. Scale 1 -  5, higher score = greater self-efficacy
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6.1.6.3 Illness beliefs
Scores on the Illness Perceptions Questionaire are shown in Table 6.8.
The intervention and control groups did not differ significantly in the number of 
symptoms they attributed to heart failure with both reporting a mean of 9 symptoms. 
There was considerable variability in the beliefs of patients in the study about the 
timeline, consequences and controllability of their heart failure. There were no 
statistically significant differences between the intervention and control groups in these 
beliefs.
6.1.6.4 Beliefs about medication
Table 6.9 shows patients’ scores on the Beliefs about Medication questionnaire. These 
scores indicate that, in general, patients believed that their medication was necessary 
and did not have strong concerns about it. There were no significant differences 
between intervention and control groups in medication beliefs.
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Table 6.9. Illness beliefs, mean (S.D.)
Variable Total Intervention Control Statistical significance
Consequences1, n = 157 3.2 (.70) 3.1 (.60) 3.2 (.79) t (df=155) = -.479, p = .63
Cure/control2, n = 157 3.4 (.58) 3.4 (.52) 3.4 (.64) t (df=155) = .000 p = 1.00
Timeline3, n = 157 3.3 (.97) 3.3 (.95) 3.4 (.99) t (df=155) = -.438 p = .66
Identity4, n = 158 9.1 (4.66) 8.8 (4.61) 9.4 (4.71) t (df=156) = -.751 p = .45
1. Scale 1-5, higher score = more serious perceived consequences
2. Scale 1 -5, higher score = greater perceived control
3. Scale 1-5, higher score = longer perceived timeline
4. Scale 0-19, higher score = more symptoms attributed to heart failure
Table 6.10 Beliefs about medication
Variable Total Intervention Control Statistical significance
Concerns1, n = 161 2.59 (.87) 2.60 (.88) 2.58 (.90) t, (df=159) = .179, p = .86
Necessity2, n = 161 4.18 (.65) 4.14 (.65) 4.23 (.65) t (df=159) =-.859, p = .39
1. 5-item Scale 1 -  5 , higher score = more concerned about taking medication
2. 5-item Scale 1 -  5 , higher score = stronger belief in the necessity of medication
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6.2 Comparison of the study sample with other intervention 
studies.
6.2.1 Participation rate
Fifty-six percent of patients with confirmed heart failure were ineligible for the study. Of 
those who were eligible, 19% refused participation. It is difficult to compare these 
figures with other intervention studies as many studies have not reported these data 
while other studies report these data in different ways. For example, some studies 
include the number of patients who were screened for heart failure rather than those 
with a confimed diagnosis, others report only the percentage of eligible patients who 
participated. However, similar participation rates are not uncommon. For example, 
Koelling, Johnson, Cody & Aaronson (2005) used very similar exclusion criteria and 
excluded 58% of patients, although their refusal rate of 11% was somewhat lower than 
the current study. McDonald, Ledwidge, Cahill et al (2001) excluded 43% of patients 
however it should be noted that in that study, which was conducted in Dublin, only 1 
patient had to be excluded because of inability to speak English. The refusal rate of 
21% was slightly higher than in the current study.
6.2.2 Demographic characteristics
In terms of demographic make-up, the study sample is similar to other intervention 
studies. Although some intervention studies have recruited younger heart failure 
patients, a large proportion are comprised of populations with a mean age of over 70 
years. Other intervention studies have typically recruited between 50-70% males so the 
current study is also comparable on this variable. Information on socio-economic status 
is rarely reported in studies of heart failure interventions making comparison with other 
studies difficult on this factor but given the low socio-economic status of the study 
sample it is likely that many other studies comprise less socially disadvantaged 
populations. In common with most other heart failure intervention studies, the majority
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of participants were of white ethnicity, however, 28 (17%) spoke English as a second 
language, a variable that is not reported in other studies.
6.2.3 Disease severity
Many other intervention studies have also recruited patients who had been admitted to 
hospital for heart failure, with similar inclusion and exclusion criteria to the current study. 
Disease severity of the patient population in this study is therefore likely to be broadly 
similar to that of other studies.
6.2.4 Presence of comorbid illness
Prevalence of diabetes in the study sample (27.7%) was broadly similar to other 
studies which report rates ranging from 14% to 59% but with most comprising less than 
35% of patients with diabetes. Rates of chronic pulmonary disease in other intervention 
studies range from 9-35% and the percentage in the current study (19.5%) falls within 
this range. The percentage of patients who have had a stroke, a history of cancer or 
arthritis is rarely reported in other heart failure intervention studies so comparison is not 
possible. These are however important comorbidities which are likely to have an impact 
on outcomes.
6.2.5 Quality of life
The scores on the SF-36, generic health-related quality of life measure were similar to 
those found in other heart failure studies. In a sample of heart failure patients recruited 
to a trial of a hospital-to-home transition programme, Harrison, Browne, Roberts et al 
(2002) obtained baseline scores on the physical composite score of 28.63 in the 
intervention group and 28.35 in the control group. Scores on the mental composite 
score were 50.49 and 49.81 respectively. Jerant, Azari & Nesbitt (2001) measured
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quality of life in patients randomised to three models of hospital discharge care and 
obtained baseline physical composite scores of 30.5, 30.3 and 31.1 and mental 
composite scores of 41.9, 42.1 and 42.9. An observational study which recruited 
patients admitted for heart failure related emergency admissions also reported similar 
quality of life with mean physical and mental composite scores of 33.88 and 42.79 
respectively (Rodriguez-Artalejo, Guallar-Castillon, Pascual et al 2005).
Scores on the Minnesota Living with Heart Failure Questionnaire were also similar to 
samples in other heart failure studies. For example, O’Loughlin, Ledwidge & McDonald 
(2005) reported mean scores for the total scale, physical subscale and emotional 
subscale of 49.3 (±26.1), 23.8 (±12.4) and 10.9 (±7.6) respectively in a sample of 
hospitalised heart failure patients who were recruited to a multidisciplinary 
management programme. This indicates marginally poorer emotional quality of life than 
in the current study but almost identical physical quality of life. Scores very similar to 
the current study were also obtained by Dunagan, Littenberg, Ewald et al (2005) in a 
group of hospitalised heart failure patients recruited to a telephone-based disease 
management intervention. They reported baseline physical and emotional subscale 
scores of 23.0 (±11.3) and 8.2 (±7.3) respectively in their control group and 23.6 (±10.8) 
and 7.5 (±7.5) respectively in their intervention group. Similar scores were obtained by 
Harrison et al (2002), who reported baseline scores for the intervention group on the 
total scale, physical subscale and emotional subscale were 44.82, 25.46 and 6.38 
respectively and for the control group were 44.56, 25.45 and 6.98 respectively. The 
observational study by Rodriguez-Artalejo et al (2005) also reported similar quality of 
life with mean scores for the total scale, physical subscale and emotional scale of 
48.23, 25.67 and 9.91 respectively.
In summary, when compared to other intervention studies, the population recruited to 
the current study were broadly similar in terms of age and gender, heart failure disease
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severity, comorbidity and quality of life. Comparison with other studies of 
socioeconomic status was not possible but the current study sample is likely to be of 
lower socioeconomic status than those of other studies due to the hospital catchment 
area.
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CHAPTER 7 
RESULTS - HOSPITAL READMISSION AND MORTALITY
This chapter reports outcomes for readmission to hospital and mortality in the 90 days 
and 12 months following discharge from the index admission. Hospital admissions 
data are reported both as total admissions for any cause and as admissions due to 
worsening heart failure. Mortality data refer to death from any cause; heart failure is not 
recorded as the cause of death on death certificates therefore no attempt was made to 
differentiate between causes of death.
7.1 Attrition
Nine patients randomised to the intervention group did not complete the intervention i.e. 
they did not meet with the nurse for all planned intervention sessions. Of these nine 
patients, one was transferred to another hospital and three patients became unwell 
before the first part of the intervention in hospital could be completed, the remaining 
five completed the in-hospital part of the intervention but then dropped out of the study 
and did not have any contact with the nurse after discharge from hospital. Two patients 
randomised to the control group subsequently became unwell prior to discharge from 
hospital and were discharged to residential care. Analyses were performed on an 
intention-to-treat basis therefore these patients are included in the results for 
hospitalisation and mortality that follow. All patients in the study were traced, including 
those who dropped out of the intervention or who moved away, thus mortality and 
hospital admissions data were collected for the complete study sample at both 90 day 
and 12 month assessment times.
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7.2 Clinical care
This study was designed to evaluate the impact of a self-management intervention over 
and above the medical care given to both groups. It is therefore necessary to first 
check that both groups received the same levels of care to ensure that any differences 
in outcomes can be attributed to the intervention and not to other differences in clinical 
care. It is not possible to examine directly whether both groups received the same level 
of follow-up care, but the number of cardiology out-patient appointments and the 
percentage of patients prescribed heart failure medications can be used to provide two 
useful indicators.
There was no statistically significant difference between the groups in the number of 
cardiology out-patient visits in the 12 months following discharge from the index 
admission. The intervention group had a median of 3 visits (range 0-10) and the control 
group had a median of 2 visits (range 0-9), Mann-Whitney, Z (163df) = -1.012, p = .31. 
There were no statistically significant differences between the groups in the percentage 
prescribed heart failure medications at each time point (Table 7.1). These findings 
therefore indicate that the amount of care and prescription of medication was similar in 
both groups.
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Table 7.1 Prescribed medication
Medication, n (%) of patients prescribed medication
Assessment
time
Total
n
Intervention 
n, (%)
Control 
n, (%)
Statistical significance
Diuretics Baseline 164 82 (97.6) 78 (97.5) Fisher’s Exact test
p = 1.00
6-8 wks 137 64(94.1) 67 (97.1) Fisher’s Exact test 
p = .44
12 mths 111 52 (88.1) 48 (92.3) Fisher’s Exact test 
p = .54
ACE/ATII Baseline 164 80 (95.2) 75 (93.8) Fisher’s Exact test 
p = .74
6-8 wks 135 59 (90.8) 58 (82.9) X2(1df) = 1.83,
p = .18
12 mths 111 48 (81.4) 48 (92.3) Fisher’s Exact test
p = .10
Beta-blockers Baseline 164 34 (40.5) 36 (45.0) X* (1 df) = .34, 
p = .56
6-8 wks 139 28 (40.6) 34 (48.6) X (1 df) = .90, 
p = .34
12 mths 111 31 (52.5) 31 (59.6) X (1df) = .56, 
p = .45
Spironolactone Baseline 164 59 (70.2) 47 (58.8) X* (1 df) = 2.37,
P = 12
6-8 wks 140 41 (58.6) 37 (52.9) X (1 df) = .46, 
p = .50
12 mths 110 24 (41.4) 25 (48.1) X2 (1 df) = .50, 
p = .48
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7. 3 Ninety day outcomes (Tables 7.2, 7.3, 7.4)
The following sections report the number of patients who were readmitted to hospital, 
the total number of admissions they had and the total number of days they spent in 
hospital. Also reported are the number of deaths and the combined end-point of death 
or hospital readmission. Time to first event is reported for the number of days following 
discharge that patients remained alive and without readmission to hospital (event-free 
survival).
Table 7.2. Unplanned readmissions for any cause within 90 days of discharge
n
Total
165
Intervention
85
Control
80
Statistical significance
Number of patients 
readmitted at least once,
n (%)
51 (30.9) 25 (29.1) 26 (32.5) X 2 (df=1) = .184, p= 0.67
Total number of 
readmissions 
(number per patient)
66 (0.4) 33 (0.4) 33 (0.4) Mann-Whitney U = 3320, 
Z — -.321, p= 0.75
Days in hospital 
(number per patient)
983 (6.0) 492 (5.8) 491 (6.1) Mann-Whitney U = 3342. 
z= -.231, p= 0 .82
Table 7.3. Unplanned readmissions for heart failure within 90 days of discharge
n
Total
165
Intervention
85
Control
80
Statistical significance
Number of patients 
readmitted at least once 
for HF, n (%)
24(14.6) 10(11.8) 14 (17.5) X2 (df=1) =1.091, p = .30
Total number of 
readmissions for HF 
(number per patient)
30 (0.2) 12(0.1) 18(0.2) Mann-Whitney U = 3199, 
z =-1.071, p=.28
Days in hospital for HF 
(number per patient)
512(3.1) 225 (2.6) 287 (3.6) Mann-Whitney U = 3209, 
z = -1.016, p=.31
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7.3.1 Number of patients readmitted to hospital in the 90 days post discharge
The intervention and control groups did not differ significantly in the percentage of 
patients readmitted to hospital in the 90 days following discharge from the index 
admission. A total of 51 patients, 25 (29%) in the intervention group and 26 (33%) in 
the control group, had at least one unplanned readmission to hospital for any cause, x2 
(1df) = .184, p =.67 (Table 7.2). Of these, a total of 24 patients, 10 (12%) in the 
intervention group and 14 (18%) in the control group, were readmitted at least once for 
heart failure, x20df) = 1.091, p = .30 (Table 7.3).
7.3.2 Number of hospital admissions in the 90 days post discharge
The intervention and control groups did not differ significantly in the total number of 
hospital readmissions in the 90 days following discharge from the index admission. A 
total of 66 unplanned readmissions to hospital for any cause occurred during the 90 
day period, 33 in each group, Z(163df) = -.321, p= .75 (Table 7.2). Of these, 30 
admissions were for heart failure, 12 in the intervention group and 18 in the control 
group, Z(163df) = -1.071, p=.28 (Table 7.3).
7.3.3 Number of days spent in hospital in the 90 days post discharge
The intervention and control groups did not differ significantly in the number of days 
spent in hospital in the 90 days following discharge from the index admission. A total of 
983 days were spent in hospital owing to unplanned admission for any cause, 492 (5.8 
per patient) in the intervention group and 491 (6.1 per patient) in the control group, 
Z(163df) = -.231, p= .82 (Table 7.2). Of these, 512 days were spent in hospital for heart 
failure, 225 (2.6 per patient) in the intervention group and 287 (3.6 per patient) in the 
control group, Z(163df) = -1.016, p=.31 (Table 7.3).
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7.3.4. All cause mortality in the 90 days post discharge (Table 7.4)
Mortality did not differ significantly between the intervention and control groups in the 
90 days following discharge from the index admission. A total of 14 patients died in the 
90 days post discharge, 8 (9.4%) in the intervention group and 6 (7.5%) in the control 
group, x2(1df) = .194, p = .66.
Table 7.4. Combined outcome of death or readmission to hospital within 90 days 
of discharge _____________________________________ ______________
n
Total
165
Intervention
85
Control
80
Statistical
significance
Mortality, n (%) 14(8.5) 8 (9.4) 6 (7.5) X2 (df=1) =.194, 
p = .66
Death or all-cause
readmission, n (%)
57 (34.6) 30 (35.3) 27 (33.8) X2(df=1)=.043, 
p = .84
Death or heart 
failure readmission, 
n (%)
33 (20.0) 17(20.0) 16(20.0) X2(df=1)=.000,
p = 1.00
7.3.5 Combined end-point of death or readmission to hospital in the 90 days post 
discharge (Table 7.4)
The intervention and control groups did not differ significantly in the combined end­
point of death or readmission to hospital in the 90 days following discharge from the 
index admission. Fifty-seven patients, 30 (35%) in the intervention group and 27 (34%) 
in the control group died or were readmitted to hospital, x 2 (1 df) = -043, p = .84. Event- 
free survival at 90 days for the study sample was therefore 65.4%. Of those who 
experienced an event, 33 died (of any cause) or were readmitted to hospital for heart 
failure, 17 (20%) in the intervention group and 16 (20%) in the control group, x20df)
=.000, p = 1.00.
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7.3.6 Time to first event
Rates of death, death or readmission for any cause and death or readmission for heart 
failure were examined on a time to first event basis using the log rank test (Table 7.5). 
No statistically significant differences were found between the groups in time to death, 
time to first all-cause event (death from any cause or hospital readmission for any 
cause), or time to first heart failure event (death from any cause or hospital 
readmission for heart failure). Kaplan-Meier curves depicting event-free survival for 
these three outcomes at 90 days are shown in Figures 7.1, 7.2 and 7.3.
Table 7.5. Time to first event within 90 days of hospital discharge
Outcome Log rank test
Time to death Log rank (df=1) = .20, p = .65
Time to death or all­
cause admission
Log rank (df=1) = .01, p = .90
Time to death or heart 
failure admission
Log rank (df=1) = .00, p = .99
191
Figure 7.1 Time to first event -  90 day mortality
Survival within 90 days of discharge
1.0 -
0 .8 -
«  0.6 -
0.4-
0 .2 -
0.0 -
0 2010 30 40 50 60 70 80 90
study allocation group 
mmmmm control
intervention 
+  control-censored 
■ intervention- 
*  censored
Days to death
Figure 7.2 Time to first event -  death or all cause admission within 90 
days
Days to first event within 90 days -  
death or unplanned admission for any cause
study allocation group 
— —  control 
—  intervention 
+  control-censored
■ intervention-
■ censored
1.0 -
0 .8 -
%S$
2  0 .6 -
• 5  0 .4-
o 0 .2 -
0 .0 -
900 20 8010 30 40 50 60 70
Number of days to first event
192
Pr
op
or
tio
n 
ali
ve
 
wi
th
 
no 
ho
sp
ita
l 
ad
m
is
si
on
s 
fo
r
Figure 7.3 Time to first event -  death or heart failure admission within 90 days
Days to first event within 90 days - 
death or unplanned admission for heart failure
1.0-
0.8 -
0 .6 -
U.z
0.4-
0 .2 -
0.0 -
study allocation group
 ■■■— control
intervention  
«f* control-censored
• intervention-
• censored
20 30 40 50
Number of days to first event
193
7.3.7 Summary of 90 day outcomes for hospitalisation and mortality
In the 90 days following discharge from the index hospital admission, there were no 
statistically significant differences between the intervention and control group in the 
number or rate of deaths, the number of patients readmitted to hospital, the number or 
rate of admissions or the number of days spent in hospital, either for all causes or for 
heart failure.
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7.4 Twelve month outcomes (Tables 7.6, 7.7, 7.8)
The following sections report the number of patients who were readmitted to hospital, 
the total number of admissions they had and the total number of days they spent in 
hospital. Also reported are the number of deaths and the combined end-point of death 
or hospital readmission. Time to first event is reported for the number of days following 
discharge that patients remained alive and without readmission to hospital.
Table 7.6. Unplanned readmiss ons for any cause within 12 months of discharge
n
Total
165
Intervention
85
Control
80
Statistical significance
Number of patients 
readmitted at least 
once, n (%)
91 (55.2) 46(54.1) 45 (56.3) x2(df=1) =.076, p=.78
Total number of 
readmissions 
(number per patient)
191 (1.2) 105(1.2) 86(1.1) Mann-Whitney U = 3390, 
z = -.035, p=.97
Days in hospital 
(number per patient)
3674 (22.3) 2224 (26.2) 1450 (18.1) Mann-Whitney U=3353.5, 
z = -.159, p= .87
Table 7.7. Unplanned readmissions for heart failure within 12 months of 
discharge_______ __________ ___________ ______________________
n Total
165
Intervention
85
Control
80
Statistical significance
Number of patients 
readmitted at least 
once for HF, n (%)
47 (28.5) 19(22.4) 28 (35.0) x2(df=1)= 3.236, p=.07
Total number of 
readmissions for HF 
(number per patient)
85 (0.5) 41 (0.5) 44 (0.6) Mann-Whitney U=3002.5, 
z = -1.634, p=.10
Total number of days 
in hospital for HF 
(number per patient)
1544 (9.4) 858 (10.1) 686 (8.6) Mann-Whitney U=3011.5 
z = -1.591, p=.11
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7.4.1 Number of patients readmitted to hospital in the 12 months post 
discharge
The intervention and control groups did not differ significantly in the percentage of 
patients admitted to hospital in the 12 months following discharge from the index 
admission. A total of 91 patients, 46 (54.1%) in the intervention group and 45 (56.3%) 
in the control group, had at least one unplanned readmission to hospital for any cause, 
X2(1df) =.076, p=.78. Of these, a total of 47 patients, 19 (22.4%) in the intervention 
group and 28 (35%) in the control group, were readmitted at least once for heart failure, 
X2 (1 df) = 3.236, p = .07.
7.4.2 Number of hospital admissions in the 12 months post discharge
The intervention and control groups did not differ significantly in the number of 
readmissions to hospital in the 12 months following discharge from the index admission. 
A total of 191 unplanned readmissions to hospital for any cause occurred, 105 (1.24 
per patient) in the intervention group and 86 (1.08 per patient) in the control group, 
Z(163,df) = -.035, p = .97. Of these, 85 admissions were for heart failure, 41 (0.48 per 
patient) in the intervention group and 44 (0.55 per patient) in the control group Z(163,df) 
= -1.634, p = .10.
7.4.3 Number of days spent in hospital in the 12 months post discharge
The intervention and control groups did not differ significantly in the number of days 
spent in hospital in the 12 months following discharge from the index admission. A total 
of 3674 days were spent in hospital owing to unplanned admission for any cause, 2224 
(26.2 per patient) in the intervention group and 1450 (18.1 per patient) in the control 
group Z (163,df) = -.159, p = .87. Of these, 1544 days were spent in hospital for heart 
failure, 858 (10.1 per patient) in the intervention group and 686 (8.5 per patient) in the 
control group, Z(163,df) = -1.591, p = .11.
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7.4.4 All cause mortality in the 12 months post discharge
Mortality in the 12 months post discharge did not differ significantly between the 
intervention and control groups. A total of 29 patients died, 13 (15.3%) in the 
intervention group and 16 (20.0%) in the control group, x 2 (1df) = .630, p = .43.
Table 7.8. Combined outcome of death or readmission to hospital within 12 
months of discharge___________ ________________________________________
n Total
165
Intervention
85
Control
80
Statistical
significance
Mortality, n (%) 29(17.6) 13(15.3) 16(20.0) X2 (df=1) = .630, 
p = .43
Death or all-cause 
admission, n (%)
100 (60.6) 53 (62.4) 47 (58.8) X2 (df=1) = .224, 
p = .64
Death or HF 
admission, n (%)
61 (37.0) 27 (31.8) 34 (42.5) X2(df=1) =2.038, 
p = .15
7.4.5 Combined end-point of death or readmission to hospital in the 12 months 
post discharge
The intervention and control groups did not differ significantly in the combined end­
point of death or readmission to hospital in the 12 months post discharge. One hundred 
patients, 53 (62.4%) in the intervention group and 47 (58.8%) in the control group died 
or were readmitted to hospital, x 2 (1df) = .224, p = .64. Event-free survival at 12 months 
for the whole sample was therefore 39.4%. Of those who had an event, 61 died or were 
readmitted to hospital for heart failure, 27 (31.8%) in the intervention group and 34 
(42.5%) in the control group, x2(1df) = 2.038, p = .15.
7.4.6 Time to first event
Rates of death, death or readmission for any cause and death or readmission for heart 
failure were examined on a time to first event basis using the log rank test (Table 7.9). 
No statistically significant differences were found between the groups in time to death,
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time to first all-cause event (death from any cause or hospital readmission for any 
cause), or time to first heart failure event (death from any cause or hospital 
readmission for heart failure). Kaplan-Meier curves depicting event-free survival for 
these three outcomes at 12 months are shown in Figures 7.4, 7.5 and 7.6.
Table 7.9. Time to first event within 12 months of hospital discharge
Outcome Log rank test
Time to death Log rank (df=1) = .56, p= .45
Time to death or all-cause 
admission
Log rank (df=1) = .12, p= .73
Time to death or heart 
failure admission
Log rank (df=1) = 1.80,p= .18
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Figure 7.6 Time to first event -  death or heart failure admission within 12 months
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7.4.7 Summary of 12 month outcomes for hospitalisation and mortality
In the 12 months following discharge from the index hospital admission, there were no 
statistically significant differences between the intervention and control group in the 
number or rate of deaths, the number of patients readmitted to hospital, the number or 
rate of admissions or the number of days spent in hospital either for all causes or for 
heart failure.
7.5 Findings in participants who completed the study
The results that have been reported in this chapter are based on intention-to-treat 
analysis. The reasons for using intention-to-treat analysis were outlined in chapter 5. 
However, it might be argued that evaluation of an intervention’s efficacy should be 
based only on those who actually completed the intervention. Therefore the analysis
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was repeated excluding those 9 patients in the intervention group and 2 patients in the 
control group who may be considered study dropouts (see section 7.1). The results in 
this analysis did not differ from the findings reported in the sections above.
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CHAPTER 8 
RESULTS - QUALITY OF LIFE AND MOOD
8.1 Quality of Life
Quality of life was assessed with both a generic and a heart-failure-specific measure of 
health-related quality of life. Generic health-related quality of life was assessed with the 
SF-36 (Ware & Sherbourne, 1992; Jenkinson et al, 1996) which was completed by 164 
patients at baseline and by 143 and 109 patients at 6-8 weeks and 12 months 
respectively. One hundred and six patients completed the assessment at all three time 
points. Disease specific quality of life was assessed with the Minnesota Living with 
Heart Failure Questionnaire (MLHF) (Rector et al, 1987). This was completed by all 
165 patients at baseline and by 144 and 110 patients at 6-8 weeks and 12 months 
respectively. One hundred and nine patients completed the assessment at all three 
time points.
Examination of the distribution of the data showed that the physical and mental 
composite scores of the SF-36 were normally distributed at baseline and 6-8 weeks 
(Kolmogorov-Smirnov test, p£.05). Neither were normally distributed at 12 months, 
however skewness and kurtosis fell within acceptable levels to meet parametric 
requirements of normality. The MLHF total score was normally distributed at baseline 
but not at the two follow-up assessments however skewness and kurtosis fell within 
acceptable levels.
Mean and S.D. scores on the 8 subscales of the SF-36 at each time point are shown in 
Table 8.1. Scores on all eight subscales were below the population norm of 50 at all 
three time-points. The intervention and control groups did not differ on these subscales
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except on role emotional at 6-8 weeks at which time the intervention group reported 
better QoL on this subscale, t (df=141) =2.02, p < .05.
Mean and S.D. scores on the physical composite score and mental composite score of 
the SF-36 and the total score of the MLHF for total completers at each time point are 
shown in Table 8.2. There were no significant differences in baseline scores on these 
scales between patients who completed assessments at all timepoints and those who 
did not.
Analyses of covariance (ANCOVA) were performed to compare the groups on the 
composite scores at 6-8 weeks and at 12months, co-varying for baseline scores. 
Bonferroni adjusted repeated measures analysis of variance (ANOVAs) were then 
performed to examine change over time within each group. Results at 6-8 weeks are 
shown in Table 8.3 and results at 12 months are shown in Table 8.4.
There were no statistically significant differences between the groups or changes over 
time within the groups on the physical composite score of the SF-36 at 6-8 weeks or 12 
months. Quality of life on the mental composite score of the SF-36 did not differ 
significantly between the groups at 6-8 weeks (F (1, 139) = 3.19, p = .08) or 12 months 
(F (1, 105) = 3.76, p = .06). There was however a significant improvement from 
baseline to 6-8 weeks in the intervention group (F (1,71) = 9.67, p=.003) but not the 
control group (F (1,69) = .35, p=.56). At the 12 month follow-up, scores on the mental 
composite score remained higher than at baseline in the intervention group (F (1, 55) = 
16.10, p <.001) but there was no change between baseline and 12 months in the 
control group (F (1, 51) = 2.49, p = .12).
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Table 8.1 SF-36 Quality of life subscale scores at baseline, 6-8 weeks and 12 
months
n Intervention Control Between group differences
Vitality Baseline 164 37.13
(11.89)
40.13(12.05) t (df=162) = -1.60, p = .11
6-8 wks 144 42.64
(11.99)
42.73(10.79) t (df=142) = -.05, p = .96
12 months 111 42.74
(11.47)
42.55 (13.73) t (df=109) = .08, p = .94
General
Health
Baseline 165 37.45
(10.35)
37.75 (9.56) t (df=163) = -.19, p = .85
6-8 weeks 144 36.57
(11.04)
36.57(10.11) t (df=142) = .00, p = 1.00
12 months 110 35.76
(11.44)
37.23(12.00) t (df=108) = -.66, p = .51
Mental
Health
Baseline 164 45.29
(14.51)
47.24(12.78) t (df=162) = -.91, p = .36
6-8 weeks 144 49.07
(13.66)
48.58(12.36) t (df=142) = .22, p = .82
12 months 111 49.22
(13.39)
48.50(11.78) t (df=109) = .30, p = .77
Pain Baseline 165 41.78
(15.88)
43.23(15.82) t (df=163) = -.59, p = .56
6-8 weeks 144 43.31
(14.76)
44.61 (14.80) t (df=142) = -.53, p = .60
12 months 111 42.09
(14.55)
43.64(13.51) t (df=109) = -.58, p = .56
Physical
Function
Baseline 165 23.44
(15.13)
26.90(16.98) t (df=163) = -1.39, p = .17
6-8 weeks 143 24.59
(15.30)
25.39(16.76) t (df=141) = -.30, p = .77
12 months 111 23.86
(16.33)
27.61 (16.78) t (df=109) = -1.19, p = .24
Role
Emotional
Baseline 165 36.85
(13.71)
36.61 (12.90) t (df=163) = .12, p = .91
6-8 weeks 143 41.53
(12.31)
37.19(13.39) t (df=141) = 2.02, p < .05
12 months 110 47.32
(11.14)
43.13(12.69) t (df=108) = 1.84, p = .07
Role
Physical
Baseline 165 29.19
(10.89)
30.83 (12.02) t (df=163) = -.92, p = .36
6-8 weeks 144 32.31
(10.95)
31.44(11.11) t (df=142) = .47, p = .64
12 months 111 37.01
(12.54)
36.79(13.52) t (df=109) = .09, p = .93
Social
Function
Baseline 164 33.89
(15.94)
35.29(16.04) t (df=162) = -.56, p = .58
6-8 weeks 144 35.60
(17.01)
36.22(14.92) t (df=142) = -.23, p = .82
12 months 111 38.10
(15.36)
35.74(15.92) t (109 df) = .80, p = .43
204
Table 8.2. Quality of life scores at baseline, 6-8 weeks and 12 months, mean (S.D.)
n Intervention Control Between group 
differences
SF-361
Physical
Baseline 164 28.33(10.51) 30.41 (12.78) t (162 df) =-1.14, 
p = .26
6-8 wks 143 28.71 (12.00) 30.11 (12.09) t (141 df) =-.70, 
p = .49
12 mths 109 28.81 (13.89) 31.42(13.49) t (107 df) =-.99, 
p = .32
SF-361
Mental
Baseline 164 43.85(13.31) 44.70(11.43) t (162 df) = -.44, 
p = .66
6-8 weeks 143 48.56(11.95) 46.52(10.32) t (141 df) = 1.09, 
p = .28
12 months 109 51.19(11.15) 47.65(10.81) t (107 df) = 1.69,
p = .10
MLHF*
Total
Baseline 165 45.28 (22.67) 44.54 (22.43) t (163 df) = .21, 
p = .83
6-8 weeks 144 31.30 (24.09) 36.59 (23.10) t (142 df) = -1.35,
p = .18
12 months 110 30.39 (23.86) 33.63 (24.84) t (108 df) = .70, 
p = .49
1. Scale 0 -1 0 0 , population norm 50, higher score = better quality of life
2. Scale 0 -1 0 5 , higher score = poorer quality of life
Table 8.3 Differences between groups in change in quality of life between
baseline and 6-13 weeks
n Baseline 
Mean (S.D.)
6-8 weeks 
Mean (S.D.)
Post-hoc analysis 
of within group 
change from 
baseline
Between group
differences
ANCOVA
SF-361
Physical
Int
n=72
28.12(10.43) 28.71
(12.00)
F (1,71) = .20,
p -  .66
F (1,139) = .04, 
p = .84
Con
n=70
31.23(12.47) 29.99
(12.13)
F (1,69) = .70, 
p = .41
SF-361
Mental
Int
n=72
43.75(12.62) 48.56
(11.95)
F (1,71) = 9.67, 
p = .003
F (1,139) = 3.19,
p = .08
Con
n=70
45.53(11.07) 46.31
(10.24)
F (1,69) = .35, 
p =.56
MLHF*
Total
Int
n=73
44.68 (21.52) 31.30
(24.09)
F (1,72) = 26.62, 
p < .001
F (1,141) = 3.26, 
p = .07
Con
n=71
42.97 (21.05) 36.59
(23.06)
F (1,70) = 5.29,
p = .02
1. Scale 0 -1 0 0 , population norm 50, higher score = better quality of life
2. Scale 0 -1 0 5 , higher score = poorer quality of life
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Table 8.4 Differences between groups in change in quality of life between 
baseline and 12 months
Baseline 
Mean (S.D.)
12 months 
Mean (S.D.)
Post-hoc analysis 
of within group 
change from 
baseline
Between group
differences
ANCOVA
SF-361
Physical
Int
n=56
29.24 (9.59) 28.81 (13.89) F (1 ,55) = .08 
p = .78
F (1, 105) = .44 
p = .51
Con
n=52
30.56(12.23) 31.17(13.49) F (1, 51) = .11 
p =  .74
SF-361
Mental
Int
n=56
43.55(13.44) 51.19(11.15) F (1,55) = 16.10
p < .001
F (1, 105) = 3.76
p = .06
Con
n=52
45.11 (10.67) 47.79(10.87) F (1, 51 df) = 2.49
p=.12
MLHF*
Total
Int
n=56
43.20 (22.74) 30.39 (23.86) F (1,55) = 16.61
p < .001
F (1, 107) = .31 
p = .58
Con
n=54
45.15(21.61) 33.63 (24.84) F (1,53) = 9.09 
p = .004
1. Scale 0 -100 , population norm 50, higher score = better quality of life
2. Scale 0 ■ 105, higher score = poorer quality of life
There was a significant improvement in QoL on the MLHF between baseline and 6-8 
weeks in both the intervention (F (1, 72) = 26.62, p <.001) and control groups (F (1, 70) 
= 5.29, p = .02) but the groups did not differ significantly (F (1,141) = 3.26, p = .07). At 
12 months, QoL was better than at baseline in both the intervention (F (1, 55) = 16.61, 
p <.001) and control groups (F (1, 53) = 9.09, p = .004). The groups did not differ 
significantly at 12 months (F (1, 107) = .31, p = .58)
To examine maintenance of change in QoL over the follow-up period, repeated 
measures ANOVAs were conducted. This analysis could include only those 
participants who had completed the questionnaires at all three time-points. Results are 
shown in Table 8.5. Data were available for 106 participants on the SF-36 and 109 
participants on the MLHF. Changes over the three time points are shown in Table 8.5. 
No statistically significant interaction effects were found.
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Table 8.5. Change over time in quality of life
Baseline 
Mean (S.D.)
6-8 weeks 
Mean (S.D.)
12 months 
Mean (S.D.)
Group x Time 
Interaction
SF-36
Physical
Int
n=55
29.14 (9.65) 29.12(12.08) 28.52(13.84) F(2,103) = .20,
p = .82
Con
n=51
30.64(12.33) 31.00(12.45) 31.35(13.56)
SF-36
Mental
Int
n=55
43.87(13.34) 48.42(12.35) 51.30(11.23) F(2,103) = .52, 
p = .59
Con
n=51
45.43 (10.53) 46.14 (9.92) 47.51 (10.78)
MLHF Int
n=56
43.20 (22.74) 32.14(25.26) 30.39 (23.86) F(2,106) = .48,
p = .62
Con
n=53
44.42 (21.13) 37.70 (23.36) 33.74 (25.07)
8.2 Psychological wellbeing
8.2.1 Anxiety and depression
The Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983) was 
completed by 164 patients at baseline, 141 at the 6-8 week follow-up and 110 at the 12 
month follow-up. One hundred and seven patients completed the scale at all three time 
points. ANCOVA tests were performed on 6-8 week and 12 month outcomes, co- 
varying for baseline scores. Bonferroni adjusted repeated measures analysis of 
variance (ANOVAs) were then performed to examine change over time within each 
group.
The groups did not differ significantly on anxiety or depression at 6-8 weeks or 12 
months (Table 8.6). Neither were there any statistically significant changes within the 
groups from baseline to 6-8 weeks nor from baseline to 12 months (Tables 8.7 and 8.8). 
As no significant differences were found on these tests, further repeated measures 
ANOVAs to examine maintenance over time were not conducted.
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Table 8.6 Mean (S.D.) Anxiety and Depression Scores
n Intervention Control Between group 
differences
HADS 
Anxiety, 
Mean (S.D.)
Baseline 164 6.51 (4.41) 6.55 (4.35) t (df=162) =-.056, 
p = .96
6-8 wks 141 6.23 (4.74) 7.09 (4.57) t (df=139) =-1.089, 
P = -28
12 mths 110 5.80 (4.42) 6.96 (4.55) t (df=108) =-1.355,
p = .18
HADS
Depression, 
Mean (S.D.)
Baseline 164 5.64 (3.54) 5.44 (3.92) t (df=162) = .352, 
p = .73
6-8 weeks 143 6.30 (4.00) 5.72 (3.58) t (df=139) = .906, 
p = .37
12 months 110 5.89 (3.57) 6.09 (3.38) t (df=108) = -.301, 
p = .76
Table 8.7 Differences between groups in change in anxiety and depression 
between baseline and 6 - 8  weeks
Baseline 
Mean (S.D.)
6-8 weeks 
Mean (S.D.)
Post-hoc analysis 
of within group 
change from 
baseline
Between group
differences
ANCOVA
HADS
Anxiety
Int
n=73
6.52 (4.26) 6.23 (4.74) F (1 ,72) = .32 
p = .58
F(1, 138) = 2.49, 
p = .12
Con
n=68
6.29 (4.18) 7.09 (4.57) F (1 ,67) = 3.22
p = .08
HADS
Depression
Int
n=73
5.75 (3.61) 6.30 (4.00) F (1 ,72) = 1.80 
p = .18
F(1, 138) = .07, 
p = .79
Con
n=68
5.01 (3.66) 5.72 (3.58) F (1,67) = 2.93 
p =.09
Table 8.8 Differences between groups in change in anxiety and depression 
between baseline and 12 months ________________
Baseline 
Mean (S.D.)
12 months 
Mean (S.D.)
Post-hoc analysis 
of within group 
change from 
baseline
Between group
differences
ANCOVA
HADS
Anxiety
Int
n=56
6.39 (4.18) 5.80 (4.42) F (1 ,55) = 1.29,
p =.26
F(1, 107) = 2.38, 
p = .13
Con
n=54
6.52 (4.29) 6.96 (4.55) F (1 ,53) = .62, 
p=.44
HADS
Depression
Int
n=56
5.54 (3.45) 5.89 (3.57) F (1 ,55) = .74, 
p=.40
F(1, 107) = .18, 
p = .67
Con
n=54
5.48 (3.99) 6.09 (3.38) F (1 ,53) = 1.79,
P=-19
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8.2.2 Positive and negative affect
The Positive and Negative Affect Scale (PANAS) (Watson, Clark & Tellegen, 1988) 
was completed by 163 patients at baseline, 140 at the 6-8 week follow-up and 104 at 
the 12 month follow-up. One hundred and three patients completed the scale at all 
three time points. Results for total completers at each time point are given in Tables 8.9 
and 8.10. Scores for negative affect at all time points and scores for positive affect at 6- 
8 weeks and 12 months were not normally distributed, however ANCOVA tests were 
performed in preference to Mann-Whitney as outlined above. Because of the difference 
in the size of the sample at each time point, two separate ANCOVAs were computed, 
one for change over the first two time points and one for change over all three time 
points. These analyses were performed for positive affect and negative affect. There 
were no statistically significant time, group or interaction effects for positive or negative 
affect at any time point (Tables 8.11 and 8.12).
Table 8.9 Mean (S.D.) scores for positive affect at baseline, 6-8 weeks and 12 
months
PANAS 
positive affect
n Intervention Control Between group 
differences
Baseline 
Mean (SD)
163 23.72 (8.03) 25.79 (9.05) t (df=161) = -1.54, 
p = .13
6-8 weeks 
Mean (SD)
140 23.97 (7.98) 25.68 (8.02) t (df=138) = -1.24,
p = .21
12 months 
Mean (SD)
104 24.37 (8.79) 26.04 (9.33) t (df=102) = -.94, 
p = .35
Table 8.10 Mean (S.D.) scores for negative affect at baseline, 6-8 weeks and 12 
months ___
PANAS
negative affect
n Intervention Control Between group 
differences
Baseline 
Mean (SD)
163 15.70 (5.81) 17.14(6.93) t (df=161) = -1.44, 
p = .15
6-8 weeks 
Mean (SD)
140 15.33 (5.66) 16.88 (7.38) t (df=138) = -1.40,
p = .16
12 months 
Mean (SD)
104 14.65 (4.95) 16.34 (5.91) t (df=102) = -1.59,
p -  .12
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Table 8.11 Differences between groups in change in positive and negative affect 
between baseline and 6-8 weeks
Baseline 
Mean (S.D.)
6-8 weeks 
Mean (S.D.)
Post-hoc analysis 
of within group 
change from 
baseline
Between group
differences
ANCOVA
PANAS
Positive
affect
Int
n=72
23.73 (8.27) 23.97 (7.97) F (1 ,71) = .09 
p = .77
F(1, 137) = .20,
p = .66
Con
n=68
25.91 (8.84) 25.68 (8.02) F (1 ,67) = .06
p =.81
PANAS
Negative
affect
Int
n=72
15.43 (5.74) 15.33 (5.66) F (1 , 71) = .02 
p = .89
F(1, 137) = .92, 
p = .34
Con
n=68
16.54 (6.32) 16.88 (7.38) F (1 ,67) = .18 
p =.67
Table 8.12 Differences between groups in change in positive and negative affect 
between baseline and 12 months ____
Baseline 
Mean (S.D.)
12 months 
Mean (S.D.)
Post-hoc analysis 
of within group 
change from 
baseline
Between group
differences
ANCOVA
PANAS
Positive
Affect
Int
n=54
24.53 (8.26) 24.37 (8.79) F (1 ,53) = .20, 
p = .89
F(1, 101) = .40, 
p = .53
Con
n=50
25.86 (9.14) 26.04 (9.33) F (1 ,49) = .02, 
p = .89
PANAS
Negative
Affect
Int
n=54
15.83 (6.29) 14.65 (4.95) F (1 ,53) = 3.36, 
p = .07
F(1, 101) = 1.81, 
p = .18
Con
n=50
16.86 (6.40) 16.34 (5.91) F (1 ,49) = .29, 
p =.59
8.3 Chapter summary
The results reported in this chapter show that the intervention did not have a 
statistically significant effect on quality of life or mood.
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CHAPTER 9 
RESULTS - BEHAVIOUR AND COGNITIONS
The intervention aimed to improve outcomes in the intervention group by changing 
participants’ behaviours and cognitions. This chapter reports the findings for these 
process variables at 6-8 weeks and 12 months.
9.1 Health Behaviours
Patients were asked how many minutes exercise they had been taking per week before 
admission to hospital and again at 6-8 weeks and 12 months post discharge. Patients 
were also asked if they smoked and how many units of alcohol they drank per week.
9.1.1 Exercise
Information about duration of exercise per week was completed by 164 patients at 
baseline, 141 at 6-8 weeks and 108 at 12 months. Of these, 140 completed 
assessments at both baseline and 6-8 weeks and 104 completed assessments at all 
three time-points. Results for total completers at each time point are reported in Table 
9.1. It should be borne in mind that although the results are reported in minutes per 
week, the scale is scored in time bands which may tend to overstate the total time 
spent exercising. This is nevertheless consistent across participants. The data deviated 
considerably from a normal distribution and did not meet the recommendations of 
Tabachnick & Fidell (1996) (see section 5.11.2) therefore ANOVA/ANCOVA tests to 
examine change over time were not performed.
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Table 9.1 Duration of exercise, median (range)
Exercise 
minutes p.w.
n Intervention Control Between group differences
Baseline 164 45.0 (0-405) 120.0(0-630) Mann-Whitney U = 3042.5, 
Z — -1.064, p=.29
6-8 weeks 141 120.0 (0-405) 60.0 (0-360) Mann-Whitney U = 2211.0, 
z= -1.141, p=.25
12 months 108 120.0 (0-555) 120.0 (0-540) Mann-Whitney U = 1304.5, 
z= -.951, p=.34
9.1.2 Smoking and alcohol intake
There were no significant differences between the groups in smoking behaviour at any 
of the three assessment times. Although the majority of participants (65.5%) had been 
smokers at some time in their lives, most were non-smokers at the time of recruitment 
into the study i.e. they had not smoked for at least 3 months prior to recruitment. 
Twenty-six patients (16%), thirteen in each group, were smokers at baseline (x2 (df=1) 
= 0.03, p= .87). Of the 22 current smokers who responded at 6-8 weeks, one 
intervention group patient had given up smoking (Fisher’s Exact, p= 1.00). Eighteen 
patients responded at 12 months, of whom 2 control group patients had given up 
smoking (Fisher’s Exact, p= .18).
There were no significant differences between the groups in following recommended 
guidelines on alcohol intake at any of the three assessment times. At baseline, 13 
participants (7.9%), 5 in the intervention and 8 in the control group were drinking above 
the recommended weekly intake of 28 units for men and 21 units for women (x2 (df=1) 
= 0.96, p= .33). One participant in the control group and no participants in the 
intervention group drank above the recommended limit at the 6-8 week (Fisher’s Exact, 
p= .49) and 12 month (Fisher’s Exact, p= .48) follow-up assessments.
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9.2 Self-management behaviour
Self-management behaviour was not assessed at baseline because a proportion of 
study participants would be newly diagnosed with heart failure and therefore would not 
have been advised to perform the self-management behaviours prior to the index 
hospital admission. Self-management behaviour was assessed at the 6-8 week and 12 
month follow-ups.
The self-management behaviour questionnaire of 8 items was developed for this study. 
It would not be expected to have a high internal consistency because self-management 
behaviours are not necessarily highly correlated with each other (Glasgow, Toobert, 
Riddle et al, 1989) and Cronbach’s alpha was found to be .643. However, the 
questionnaire contained three items related to salt intake so these were combined into 
a single item using the mean. The Cronbach’s alpha for the three items was .683. The 
commonly recommended level for alpha is >.70 (DeVellis, 2003) so this score is a little 
low, however some have suggested that a level of .60 is acceptable (Nunnally & 
Bernstein, 1994). The combined single item was considered appropriate because the 
scale then provided one item for each self-management behaviour.
The data for the self-management behaviours deviated considerably from a normal 
distribution. Patients tended to perform the behaviours all, or almost all, of the time or 
hardly ever. Although it would have been possible to compare the groups using Mann- 
Whitney tests, some further analysis (see the analysis of behaviour by subgroup in 
Chapter 10) would not have been possible with data of this distribution therefore 
conversion to dichotomous variables with analysis by Chi-squared tests was 
considered preferable. Data were split according to performance of the behaviour on 6 
or 7 days, which was classified as ‘full’ and 5 days or fewer which was classified as
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‘incomplete’. This split was chosen both on the basis of examination of the spread of 
participants’ responses and also with reference to adherence research which has 
tended to classify adherence as following recommendations at least 75% - 85% of the 
time (Myers & Midence, 1998).
At the 6-8 week assessment, intervention group patients were more likely than controls 
to report eating a low salt diet, sticking to the recommended daily fluid intake, weighing 
themselves, checking their ankles for signs of swelling and following exercise 
recommendations on £6 days (Table 9.2). There was no difference between the groups 
on taking medication; both reported very high medication adherence with over 97% 
reporting having taken their medication as prescribed on £6 days.
By the 12 month assessment, performance of some behaviours had decreased, 
nevertheless a significant difference remained between the intervention and control 
groups in the percentage of patients who were weighing themselves on £6 days 
(36.4% v. 3.8%, x2(df=1) = 17.67, p <.001). Although performance of all other self­
management behaviours remained higher in the intervention group than controls at 12 
months, these differences were not statistically significant (Table 9.2, Figures 9.1, 9.2).
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Table 9.2. Comparison of intervention and control groups on self-management 
behaviours at 6-8 weeks and 12 months, n (%) performing behaviour on >6 days
Behaviour Assessment
time
n
Intervention Control Between group 
differences
Ate low salt diet 6-8 weeks 
n = 140
31 (43.1) 18(26.5) X* (df=1) = 4.23, p = .04
12 months 
n = 108
19(34.5) 11 (20.8) X* (df=1) = 2.56, p = .11
Took medicine as 
prescribed
6-8 weeks 
n = 140
71 (98.6) 66(97.1) (df=1) = .40, p = .53
12 months 
n = 108
53 (96.4) 48 (90.6) X*(df=1) = 1.50, p = .22
Kept within fluid 
guidelines
6-8 weeks 
n = 140
57 (79.2) 40 (58.8) X‘ (df=1) = 6.80, p = .009
12 months 
n = 106
41 (74.5) 30 (58.8) X* (df=1) = 2.96, p = .09
Checked weight 6-8 weeks 
n = 139
48 (67.6) 4 (5.9) X*(df=1) = 56.51, p<.001
12 months 
n = 108
20 (36.4) 2 (3.8) X* (df=1) = 17.67, p <.001
Checked for signs 
of oedema
6-8 weeks 
n = 140
62 (86.1) 40 (58.8) X*(df=1) = 13.17, p <.001
12 months 
n = 108
38 (69.1) 31 (58.5) X*(df=1) = 1.32, p = .25
Exercised 6-8 weeks 
n = 140
29 (40.3) 19(27.9) X* (df=1) = 2.36, p = .12
12 months 
n = 108
19(34.5) 14(26.4) X* (df=1) = .84, p = .36
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Figure 9.1 Self-management behaviour at 6-8 weeks
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Figure 9.2 Self-management behaviour at 12 months
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9.3 Cognitions
9.3.1 Self-efficacy
The heart failure specific self-efficacy questionnaire was completed by 160 patients at 
baseline and 139 and 104 at 6-8 weeks and 12 months respectively. Ninety-eight 
participants completed the questionaire at all three time-points.
As self-efficacy is postulated to be behaviour-specific, each item of of the self-efficacy 
questionnaire was analysed separately to examine differences between the groups at 
each time-point. The results of this analysis are shown in Table 9.3. At the 6-8 week 
follow-up, the intervention group reported significantly higher self-efficacy than controls 
to eat a low salt diet and to follow guidelines on fluid intake. There were no other 
significant differences between the groups on heart failure self-efficacy.
Analyses of covariance (ANCOVA) were performed to compare the groups at 6-8 
weeks and at 12months, co-varying for baseline scores. Bonferroni adjusted repeated 
measures analysis of variance (ANOVAs) were then performed to examine change 
over time within each group. Significant group differences were found at 6-8 weeks 
only on self-efficacy for salt and fluid intake (results not shown). No significant 
differences were found at 12 months. Repeated measures ANOVAs to examine 
maintenance of change over time on self-efficacy for salt and fluid intake did not find 
any significant effects (results not shown).
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Table 9.3 A comparison of the intervention and control groups on heart failure 
specific self-efficacy at baseline and 6-8 weeks and 12 months post discharge 
from hospital
Self-
efficacy to:
Assessment
time
n Intervention Control Between group 
differences
Manage
illness
Baseline 160 3.23(1.21) 3.04(1.02) t (df=158) = 1.11, p = .27
6-8 weeks 139 3.14(0.98) 3.21 (1.09) t (df=137) = -.37, p = .71
12 months 104 3.21 (1.14) 2.98(1.37) t (df=102) = .94, p = .35
Monitor 
signs of 
change
Baseline 160 3.21 (1.23) 2.95(1.23) t(df=158) = 1.34, p = .18
6-8 weeks 139 3.14(1.13) 3.04(1.13) t (df=137) = .51, p = .61
12 months 104 3.31 (.96) 2.94(1.38) t (df=102) = 1.57, p = .12
Contact
doctor/
nurse
Baseline 160 3.47(1.13) 3.35(1.18) t (df=158) = .63, p = .53
6-8 weeks 139 3.38(1.09) 3.40(1.17) t (df=137) = -.09, p = .93
12 months 104 3.63(1.03) 3.19(1.33) t (df=102) = 1.90, p = .06
Take
medication
Baseline 160 3.83(1.09) 4.03(1.01) t (df=158) = -1.19, p = .24
6-8 weeks 139 4.14(0.85) 4.07(1.00) t (df=137) = .43, p =  .67
12 months 104 4.17(0.96) 4.19(0.93) t (df=102) = -.10, p = .92
Exercise Baseline 160 2.59(1.31) 2.52(1.36) t (df=158) = .35, p = .73
6-8 weeks 138 2.66(1.25) 2.44(1.38) t (df=136) = .97, p = .34
12 months 104 2.81 (1.28) 2.65(1.56) t (df=102) = .55, p = .58
Low salt 
diet
Baseline 160 3.33(1.29) 3.13(1.24) t (df=158) = 1.03, p = .31
6-8 weeks 138 3.41 (1.21) 2.96(1.25) t (df=136) = 2.19, p = .03
12 months 104 3.17(1.34) 3.17(1.29) t (df=102) = .00, p = 1.00
Fluid
intake
Baseline 160 3.62(1.03) 3.29(1.32) t (df=158) = 1.74, p = .08
6-8 weeks 139 3.69 (0.97) 3.28 (1.12) t (df=137) = 2.32, p = .02
12 months 104 3.46(1.08) 3.29(1.32) t (df=102) = .73, p = .47
9.3.2 Beliefs about medication
Beliefs about medication were assessed with the Beliefs about Medication 
Questionnaire (BMQ) (Horne et al, 1998). Scores for total completers at each time 
point are given in Table 9.4. There were no significant differences in beliefs about 
medication between the groups at any of the three time points. ANCOVA, co-varying 
for baseline scores, did not show any significant group effects at 6-8 weeks or 12
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months (results not shown). As no significant differences were found on these tests, 
further repeated measures ANOVAs to examine maintenance of change over time 
were not performed.
Table 9.4. Beliefs about medication
n Intervention Control Between group 
differences
Concerns1 Baseline 161 2.60 (.88) 2.58 (.90) t (df=159) =.179,
p = .86
6-8 weeks 138 2.73 (.87) 2.76(1.02) t (df=136) = -.210, 
P = -83
12 months 107 2.56 (.87) 2.72(1.02) t (df=105) = -.860, 
p = .39
Necessity* Baseline 161 4.14 (.65) 4.23 (.65) t (df=159) =-.859, 
p = .39
6-8 weeks 138 4.11 (.62) 4.25 (.59) t(df=136) = -1.365,
p = .18
12 months 108 4.13 (.74) 4.20 (.67) t (df=106) =-.550, 
p = .58
1. Scale 1 - 5 ,  higher score = more concerned about taking medication
2. Scale 1 -  5, higher score = stronger belief in the necessity of medication
9.3.3 Illness Beliefs
Patients’ illness beliefs are shown in Table 9.5. Unfortunately a large number of 
respondents did not complete the questionnaire at the 6-8 week follow-up assessment. 
Belief that heart failure could be cured/controlled reduced between baseline and 12 
months in both groups but there was no significant difference between the groups. The 
groups did not differ significantly in perceived duration of heart failure however 
perceived duration increased over time in the intervention group but did not change 
significantly in the control group. There were no statistically significant changes over 
time or group differences in perceived severity of the consequences of heart failure.
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Table 9.5. Illness beliefs, mean (S.D.)
IPQ subscale Assessment
time
n Intervention Control Between group 
differences
Identity Baseline 158 8.8 (4.6) 9.4 (4.7) t (df=156) =-.751, p=.45
6-8 wks 140 8.4 (4.8) 9.2 (4.2) t (df=131) = -.99, p=.33
12 mths 100 8.7 (4.9) 9.6 (4.9) t (df=98)= -.884, p=.378
Cure/control Baseline 157 3.39 (.52) 3.39 (.64) t (df=155)=.000, p=1.00
6-8 wks 88 3.27 (.43) 3.37 (.58) t (df=86)=-.889, p = .38
12 mths 102 3.16 (.50) 3.24 (.68) t (df=100) = -.698, p=.49
Consequences Baseline 157 3.14 (.60) 3.19 (.79) t (df=155)= -.479, p= .63
6-8 wks 88 3.27 (.59) 3.18 (.60) t (df=86)= .705, p = .48
12 mths 103 3.19 (.67) 3.21 (.83) t (df=101 )= -.103, p= .92
Timeline Baseline 157 3.30 (.95) 3.37 (.99) t (df=155)= -.438, p=.66
6-8 wks 88 3.67 (.94) 3.55 (.85) t (df=86)=.605, p=.55
12 mths 103 3.72 (.93) 3.61 (1.00) t (df=101 )= .546, p = .59
Higher scores 
consequences,
= more symptoms, greater perceived control, 
longer perceived timeline
more severe perceived
Table 9.6. Differences between groups in change in illness beliefs between
baseline and 6-8 weeks, mean (S. 0 )
n Baseline
Mean
(S.D.)
6-8 weeks
Mean
(S.D.)
Post-hoc 
analysis of within 
group change 
from baseline
Between group
differences
ANCOVA
Identity Int
n=65
9.1 (4.4) 8.4 (4.8) F (1,64) = 2.29, 
p = .14
F (1,128) = 1.52,
p = .22
Con
n=66
9.1 (4.7) 9.2 (4.2) F (1,65) = .02,
p = .88
Cure/control Int
n=46
3.36 (.50) 3.28 (.43) F (1,45) = .87, 
p = .36
F (1,83) = .08, 
p = .77
Con
n=40
3.50 (.69) 3.37 (.58) F (1,39) = 2.33, 
p = .14
Consequences Int
n=46
3.19 (.50) 3.28 (.60) F (1,45) = 1.432, 
p = .24
F (1,83) = .69, 
p = .41
Con
n=40
3.17 (.68) 3.18 (.60) F (1,39) = .02, 
p = .89
Timeline Int
n=46
3.37 (.97) 3.70 (.89) F (1,45) = 11.87 
p = .001
F (1,83) = 1.70,
p = .20
Con
n=40
3.44(1.03) 3.55 (.85) F (1,39) = .54, 
p = .47
Higher scores = more symptoms, greater perceived control, more severe perceived 
consequences, longer perceived timeline
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Table 9.7. Differences between groups in change in illness beliefs between
baseline and 12 months
n Baseline
Mean
(S.D.)
12 months
Mean
(S.D.)
Post-hoc 
analysis of 
within group 
change from 
baseline
Between group
differences
ANCOVA
Identity Int
n=50
8.8 (4.4) 8.8 (4.9) F (1,49 df) = .00 
p = .96
F (1,95 df) = .17 
p = .68
Con
n=48
9.4 (5.0) 9.4 (4.9) F (1,47 df) = .00 
p = .95
Cure/control Int
n=52
3.36 (.50) 3.15 (.50) F (1,51 df) = 6.36
p = .02
F (1,97 df) = .07 
p = .79
Con
n=48
3.50 (.58) 3.26 (.69) F (1,47 df) = 8.00 
p = .007
Consequences Int
n=52
3.13 (.61) 3.20 (.68) F (1,51 df) = .68 
p = .41
F (1,98 df) = .26
p = .61
Con
n=49
3.22 (.75) 3.20 (.84) F (1,48 df) = .04 
p = .85
Timeline Int
n=52
3.44 (.98) 3.73 (.93) F (1,51 df) = 4.60 
p = .04
F (1,98 df) = .22 
p = .64
Con
n=49
3.39(1.02) 3.63(1.00) F (1,48 df) = 1.68 
p = .20
Higher scores = more symptoms, greater perceived control, more severe perceived 
consequences, longer perceived timeline
Repeated measures ANOVAs were not conducted in view of the small number of 
participants who completed the IPQ at all 3 timepoints (n = 65).
9.4 Satisfaction with care
Patients in both groups completed the Client Satisfaction Questionnaire at 6-8 week 
and 12 month follow-ups. This is an 8-item scale on which the total score can range 
from 8 to 32. Reported satisfaction with care was very high in both groups with a 
median score of 30 (range 20-32) in the intervention group at 6-8 weeks and a score of 
29 (19-32) at 12 months. Scores in the control group were 29 (20-32) and 30 (16-32) 
respectively. The groups did not differ significantly at either time point.
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9.5 Additional assessment performed only with the 
intervention group
In addition to the assessments that were conducted to enable comparison between the 
study groups, additional data were collected from the intervention group. These were 
conducted to gain patients’ feedback about the intervention, to assess the extent to 
which they utilised the self-management tools provided and whether they contacted the 
nurse in response to signs of deteriorating heart failure.
9.5.1 Intervention group patients’ evaluation of the intervention
In addition to the assessment of patient satisfaction that was completed by all study 
patients, the intervention group was asked to complete an evaluation of the intervention. 
Fifty-five patients in the intervention group (65%) completed evaluations of the 
intervention at the 12 month follow-up. Of these, 39 (71%) reported finding the 
intervention helpful and 38 (69%) felt that they were able to put the advice received into 
practice. For both items this refers to a score of 4 or 5 on a 5-point scale where 1 = ‘not 
at all’ and 5 = ‘very much’.
9.5.2 Patient initiated nurse contact
Fifty-four patients (64%) in the intervention group contacted the heart failure nurse at 
least once. A total of 85 calls were received and the number of contacts per patient 
ranged from 1 to 17 (Figure 9.3). Some patients also made informal contact with the 
nurse, calling into the clinic when they were visiting the hospital for other routine 
appointments. Thirty-one patients made no contact with the nurse. Of these, 22 (71%) 
had at least one event, suggesting that they may have been showing signs of 
deteriorating heart failure but did not take the suggested action.
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Following the calls received by the nurse, 7 patients were admitted to hospital, 45 were 
asked to come to see the nurse at clinic and 5 were booked for an out-patient 
appointment with a cardiologist. Twelve calls resulted in an alteration to medication. 
Sixteen calls did not require any further action; these were generally queries about 
appointments or medication or to report medication changes made by the patient’s G.P.
Figure 9.3 Patient initiated contact with nurse
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9.5.3 Use of intervention materials
Fifty-five intervention group patients (65%) completed assessments about use of 
intervention materials at the 12 month assessment (Figure 9.4). Approximately 15% of 
those who responded did not use the charts at all and approximately one third were still 
using them at 12 months.
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Figure 9.4 Duration of use of weight and medication charts
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CHAPTER 10.
RESULTS -  PREDICTORS OF OUTCOME AND SUBGROUP 
ANALYSES
It had been the intention to examine whether any effects of the intervention on the 
primary outcome were mediated by cognitions and behaviour but as the intervention 
did not have an effect on the primary outcomes, this analysis became redundant. It 
nevertheless remained of interest to examine other factors that may have influenced 
outcome, and relationships between potential mediators and outcomes, since this 
analysis could inform the development of future interventions in heart failure. Another 
important question was whether the intervention, although not effective overall, was 
effective in some subgroups of patients. Accordingly, a number of secondary analyses 
were performed to examine:
• The influence of baseline variables on 12 month hospitalisation and mortality
• The influence of baseline variables on those variables targeted by the intervention
i.e. behaviour and cognitions
• The influence of behaviour at 6-8 weeks on 12 month hospitalisation and mortality
• The effectiveness of the intervention within subgroup(s) of patients
10.1 Baseline predictors of 12 month hospitalisation and 
mortality
One of the areas of interest for this study was to explore whether baseline 
characteristics could be used to identify who would be most likely to benefit from the 
intervention. To examine baseline predictors of the occurrence of death, death or all­
cause admission and death or heart failure admission, logistic regressions were 
performed (see methods Chapter 5, section 5.11.5). Given the relatively small number
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of patients who had had an event at 90 days i.e. ‘cases’ for the purpose of regression 
analysis, the analyses were performed to predict only the 12 month outcomes. As the 
study groups did not differ at baseline or in the outcomes of death or hospital 
admission, group allocation was not entered into the regression analyses.
Table 10.1 shows the baseline variables that were significant predictors of one or more 
of the outcomes in univariate analyses. The risk of mortality was higher in those of 
older age, who spent longer in hospital during the index admission, and reported lower 
generic and HF specific self-efficacy to manage their illness at baseline. Owing to the 
small number of ‘cases’ for this outcome (29 deaths), a maximum of 3 independent 
variables (IVs) could be entered into the multivariate logistic regression. Age and 
patients’ self-efficacy to manage their heart failure remained significant (Table 10.2).
The baseline variables that most consistently predicted hospital admission or the 
combined outcomes of death or readmission were comorbidity, whether the diagnosis 
of heart failure was new or existing and the number of symptoms attributed to heart 
failure, assessed by the IPQ Identity subscale. A greater number of comorbid illnesses 
and a greater number of symptoms attributed to heart failure were both associated with 
an increased risk of an event whereas those with newly diagnosed heart failure were at 
less risk of an event than patients for whom the diagnosis had been longer standing. 
When entered into the multivariate logistic regression analyses (Tables 10.3 -  10.6), 
only comorbidity and a new diagnosis of heart failure remained significant.
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Table 10.1 Univariate predictors of 12 month outcomes using logistic regression
analyses. Wald statisl ic reported.
Predictor variable5 Mortality All cause 
admission
Death or 
all cause 
admission 
(‘All-cause 
event’)
HF
admission
Death or 
HF
admission
(‘HF
event’)
Number of events 29 91 100 47 61
Baseline variables:
Age 6.171* - - - -
Comorbidity - 8.916** 9.213** 7.067** 8.234**
HF aetiology (ischaemic 
/  non-ischaemic)
- - - - 4.103*
New HF - 4.310* 7.324** 10.652*** 15.133***
Duration (days) of index 
admission
6.867** - - - -
NYHA at study 
recruitment
- - - - 5.470*
IPQ Identity - 4.523* 4.548* 6.345* 7.463**
IPQ Cure/control - - - - -
Generic self-efficacy 4.389* - - - -
HF self-efficacy to 
manage illnesst
9.219** - 6.114* - 6.104*
HF self-efficacy to keep 
to fluid guidelines
- - - - 4.143*
6-8 week behaviour:
Weekly exercise 
duration
5.425* 4.203* 5.766* - -
Self-mgt behaviour - 
daily weighing
4.060* - - - -
p<.05, **p£.01, ***p<001
§ Only variables that were statistically significant predictors of at least one outcome variable are 
included in the table
t  Question 1 of the HF self-efficacy scale - How confident are you that you can do all the things 
necessary to manage your heart failure on a regular basis?
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Table 10.2 Baseline predictors of 12 month mortality. 
__________Multivariate logistic regression analysis
n = 165 B S.E. Wald df P Exp(B)
Age .046 .021 4.653 1 .03 1.047
Duration of index hospital 
stay
.015 .012 1.581 1 .21 1.015
HF self-efficacy to 
manage illness
-.528 .209 6.354 1 .01 .590
Constant -3.759 1.741 4.662 1 .03 .023
Nagelkerke R2 .172
Table 10.3 Baseline predictors of death or all cause readmission to hospital
n = 156 B S.E. Wald df P Exp(B)
New HF -.824 .369 4.988 1 .03 .439
Comorbidity .533 .211 6.374 1 .01 1.704
IPQ Identity .032 .040 .625 1 .43 1.032
HF self-efficacy to 
manage illness
-.303 .169 3.198 .07 .739
Constant 1.050 .742 2.005 1 .16 2.858
Nagelkerke R2 .182
Table 10.4 Baseline predictors of death or readmission to hospital for heart 
__________ failure. Multivariate logistic regression analysis ________^___
n = 156 B S.E. Wald df P Exp(B)
New HF -1.219 .392 9.658 1 .002 .296
Comorbidity .458 .210 4.770 1 .03 1.581
IPQ Identity .047 .045 1.105 1 .29 1.049
NYHA at study recruitment .206 .369 .311 1 .58 1.229
Aetiology .606 .380 2.544 1 .11 1.833
HF self-efficacy to manage 
illness
-.266 .185 2.082 .15 .766
HF self-efficacy to keep to 
fluid guidelines
-.212 .172 1.513 .22 .809
Constant -.101 1.268 .006 1 .94 .904
Nagelkerke R2 .282
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Table 10.5 Baseline predictors of all cause readmission to hospital
n = 156 B S.E. Wald df P Exp(B)
New HF -.692 .348 3.954 1 .05 .500
Comorbidity .518 .198 6.844 1 .01 1.678
IPQ Identity .039 .038 1.020 1 .31 1.039
Constant -.272 .469 .378 1 .56 .762
?
Nagelkerke R .132
Table 10.6 Baseline predictors of readmission to hospital for heart failure
n = 156 B S.E. Wald df P Exp(B)
New HF -1.178 .385 9.376 1 .002 .308
Comorbidity .415 .201 4.277 1 .04 1.514
IPQ Identity .060 .044 1.920 1 .16 1.062
Constant -1.396 .533 6.857 1 .009 .247
Nagelkerke R2 .181
10.2 Baseline predictors of cognitions and self-management 
behaviour
An important aim of the self-m anagem ent intervention was to change cognitions and 
behaviour and it was hypothesised that these changes would have a beneficial impact 
on health outcomes i.e. that they would mediate the effect of the intervention on health 
outcomes. It had therefore been the intention to perform mediator analysis to examine 
this relationship but as the intervention did not have an effect on the primary outcomes, 
this analysis was not possible (see section 5.11.5 for the requirements of mediator 
analysis). It nevertheless rem ained of interest to examine whether change in cognitions 
and behaviour could be predicted from baseline variables as this could help to inform 
future interventions. As the intervention had not resulted in changes in cognitions, 
these variables were not examined further. However, the intervention group had 
reported greater performance of self-management behaviours than controls at the 6-8  
week follow-up assessment therefore the influence of baseline variables on 6-8 week
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behaviour and the relationship between behaviour and hospitalisation and mortality 
outcomes were examined.
Univariate logistic regression analyses were performed to examine whether baseline 
variables could predict 6-8 week behaviour and whether 6-8 week behaviour predicted 
12 month health outcomes. The baseline variables that significantly predicted 
behaviours in univariate analysis are shown in Table 10.7. Multivariate logistic 
regressions to predict daily weighing, monitoring for oedema and fluid m anagem ent are 
shown in Tables 10.8, 10.9 and 10.10 respectively. Group allocation remained a 
significant predictor in multivariate analyses of weight monitoring, monitoring oedema  
and keeping to fluid recommendations with intervention group patients more likely to 
perform the behaviours. Besides group allocation, age was also a significant predictor 
of weight monitoring, with older patients less likely to weigh themselves on >6 days. 
Perceived duration of heart failure (IPQ  timeline) was a significant predictor of 
monitoring oedema, with patients who perceived the illness to have a longer timeline 
more likely to monitor on >6 days. No variables remained significant in the multivariate 
analyses for eating a low salt diet and exercise (results not shown). Analysis was not 
performed for adherence to medication as almost the whole sample reported full 
adherence.
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Table 10.7 Univariate log isitic regression analysis of baseline predictors of self- management behaviours. Wald statistic reported
Daily weights Check ankles Salt intake Fluid intake Exercise
Number performing / not 
performing behaviour >6 days
52/87 102/38 49/91 97/43 48/92
Study group allocation 37.305*** 12.184*** 4.165* 6.601**
Demographics
Age 5.646* 4.219*
Symptoms
IPQ identity 5.821* 4.846*
Beliefs
IPQ Consequences 
IPQ Cure/control 
IPQ Timeline 
BMQ Necessity 
BMQ Concerns 
HF self-efficacy:
Manage illness 
Monitor change 
Contact HCP  
Take medication 
Exercise 
Low salt diet 
Fluid recommendations 
General self-efficacy
4.688* (timeline)
4.891* (monitor change) 
5.117* (low salt)
4.258* (BMQ concerns) 
5.386* (low salt)
4.713* (cure/control) 
4.018* (fluid)
5.386* (consequences)
5.163* (manage illness) 
6.292* (monitor change)
9.403** (exercise)
Mood
HADS Anxiety 
HADS Depression 
PANAS Positive 
PANAS Negative
4.878* (anxiety)
5.383* (PANneg)
4.868* (depression)
* p<.05, **p< 01, ***p<.001
Table 10.8 Baseline predictors of weight monitoring at 6-8 weeks -  
__________multivariate logistic regression analysis _____ _^___
n = 139 B S.E. Wald df P Exp(B)
Group allocation 3.911 .661 35.015 1 .000 49.969
Age -.058 .020 8.875 1 .003 .943
Constant 1099 1.303 .712 1 .399 3.002
Nagelkerke R2 .562
Table 10.9 Baseline predictors of monitoring oedema at 6-8 weeks -  
_________ multivariate logistic regression analysis _____ _____
n = 135 B S.E. Wald df P Exp(B)
Group allocation -1.650 .473 12.181 1 .000 .192
Self-efficacy - monitor change .317 .181 3.048 1 .081 1.372
Self-efficacy -  low salt diet .308 .188 2.685 1 .101 1.361
IPQ Timeline .590 .233 6.384 1 .012 1.804
Constant -.182 1.219 .022 1 .882 .834
Nagelkerke R2 .260
Table 10.10 Baseline predictors of keeping to fluid guidelines at 6-8 weeks -  
multivariate logistic regression analysis ______________ ____________
n = 135 B S.E. Wald df P Exp(B)
Group allocation -1.046 .424 6.0691 1 .014 .351
Age .030 .016 3.407 1 .065 1.030
IPQ cure/control -.753 .399 3.553 1 .059 .471
Self-efficacy -  fluid .323 .182 3.170 1 .075 1.382
PANAS negative mood -.055 .034 2.655 1 .103 .947
Constant 2.753 2.174 1.603 1 .206 15.682
Nagelkerke R2 .221
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10.3 The influence of self-management behaviour at 6-8 weeks 
on 12 month hospitalisation and mortality
Table 10.1 shows the 6-8 week behaviours that were significant predictors of one or
more of the 12 month outcomes in univariate analyses. Although exercise duration at
baseline was not associated with outcomes, a longer duration of exercise at 6-8 weeks
was associated with a lower risk of death and all-cause readmission to hospital. W hen
entered into multivariate logistic regression analyses in which age was entered in the
first step, exercise remained a significant predictor of all-cause admission to hospital
but not of mortality or the combined outcome of death or admission to hospital.
However, if comorbidity, a variable likely to influence exercise duration, was entered
into the regression, exercise duration was no longer significant (regression tables not
shown).
Of the self-m anagem ent behaviours, self-monitoring by daily weighing was a predictor 
of mortality but not readmission to hospital. However, when entered into multivariate 
logistic regression analyses in which age was entered in the first step, weight 
monitoring was no longer statistically significant (regression table not shown). Older 
patients were less likely than younger patients to monitor their weight on >6 days. None 
of the other self-m anagem ent behaviours were significant predictors of hospitalisation 
or mortality.
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10.4 Sub-group analysis
The analysis in sections 10.1 and 10.2 examined whether it was possible to predict 12 
month study outcomes from the variables measured at baseline. That analysis provides 
an indication of some of the variables that may need to be targeted in order to bring 
about change. An additional important analysis is to examine whether the intervention, 
although not effective overall, was effective in some sub-groups of patients. This has 
been reported in a previous study, by Riegel et al (2000), who found that their 
intervention was not effective overall but did have a beneficial effect in patients who 
were moderately symptomatic. It was therefore decided to conduct post-hoc analyses 
to exam ine whether the current intervention also had an effect among some sub­
groups of patients who could be identified from baseline variables. The hazards of sub­
group analysis (Lagakos, 2006) are recognised, and findings therefore need to be 
interpreted with caution, nevertheless this analysis has potential value. It is important to 
examine whether different types of patients respond differently to the intervention. Any 
significant findings that emerge, whilst not conclusive, do provide indicators of 
important areas for further examination in future studies.
The studies reviewed in Chapter 3 identified a number of demographic and disease- 
related factors that may have an effect on self-management of heart failure. These  
were age, NYHA, comorbid illness and whether the diagnosis of heart failure was new  
or longer-standing (see sections 3.4.1 and 3.4.2). Accordingly these variables were 
chosen as subgroups in which to examine whether the intervention was effective. To 
conduct this analysis, age and number of comorbid illnesses had to be transformed 
from continuous to categorical variables, which was carried out based on examination 
of the distribution of the data. Comorbidity was divided into three subgroups with 0, 1 
and >2 comorbidities. Age was also divided into three subgroups, aged ^68, 69 -  79  
and >80. Differences between the intervention and control group in each subgroup
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were then examined by conducting separate x2 analysis. Tables 10.11 and 10.12 show  
the differences between intervention and control groups within each subgroup in 90 
day and 12 month outcomes respectively.
An important issue to consider in this analysis is that there are many other potential 
subgroups that could have been examined. Subgroups could arise in demographic and 
clinical variables, behaviours, beliefs, mood and social variables. For example, it would 
have been possible to examine whether the intervention performed differently in men 
and women, in depressed versus non-depressed patients, and so on. However, this 
would require a very large number of statistical tests, increasing the risk of making a 
Type I error.
The subgroup analysis did not find any difference between the intervention and conrol 
groups within the subgroups of age, NYHA or comorbid illnesses. However, in the sub­
group of patients who were newly diagnosed with heart failure, fewer patients in the 
intervention group were readmitted for heart failure or had a HF event i.e. combined 
outcome of death or readmission for heart failure and patients in the intervention group 
spent fewer days in hospital for heart failure than controls in the 12-months following 
discharge (Tables 10.11, 10.12 and 10.13).
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Table 10.11 Differences in 90-day outcomes between intervention and control within sub-groups
90 days
All cause Heart Failure
Subgroup Mortality
Readmitted to 
hospital
Died or 
readmitted to 
hospital
Total days in 
hospital**
Readmitted to 
hospital
Died or 
readmitted to 
hospital
Total days in 
hospital**
Age
<68, n=55 Fisher’s*, p=1.00 x2 =.041, p=.84 X2 -.231, p-.63 Z=-.195, p=.85 X2 =.164, p=.69 X2 -.005, p=.94 Z=-.277, p=.78
6 9 -7 9 , n=56 Fisher’s, p=1.00 X2 -.025, p-.88 X2 -.000, p-1.00 Z=-.099, P-.92 X2 -.078, p=.78 X2 =.049, p=.82 Z=-.235, p-.81
80+,n=54 Fisher’s, p=1.00 X2 -.254, p=.61 X2 -.015, P-.90 Z-.402 , p=.69 X2 =1.037, p=.31 X2 -.020, p=.89 Z=-.989, p=.32
NYHA
I/ll, n=124 Fisher’s, p=1.00 X2 -.540, p=.46 X2 -.024, p-.88 Z=-.398, P-.69 Fisher’s, p=.14 X2 -.230, p=.63 Z=-1.595, p=.11
11 I/I V, n=41 Fisher’s, p=.66 X2 -.201, p=.54 X2 -.605, P-.44 Z-.102 , P-.92 Fisher’s, p=.73 X2 -.595, p=.44 Z—.334, p-,74
New/Existing
New HF, n=90 Fisher’s, p=.44 X2 -.229, p=.63 X2 -.198, p=.66 Z--.311, P-.76 Fisher’s, p=.06 Fisher’s, p=.12 Z=-2.054, p=.04
Existing HF, n=75 Fisher’s, p=.13 X2 =.107, p=.74 X2 -.258, p-.61 Z=-.166, P-.87 Fisher’s, p=1.00 Fisher’s, p=.31 Z=-.104, p=.92
Co-morbidity
0, n = 49 Fisher’s, p=1.00 Fisher’s, p=.26 X2 -.262, p=.61 Z—1.240, p=.22 Fisher’s, p=.15 Fisher’s, p=.44 Z—1.711, p-.09
1, n = 66 Fisher’s, p=1.00 X2 -.000, p=1.00 X2 =.067, p=.80 Z=-.110, P-.91 Fisher’s, p=.48 X2 -.096, p=.76 Z=-1.043, p=.30
2 or more, n = 50 Fisher’s, p=.46 X2 -.297, p=.59 X2 =.703, p-.40 Z=-.804, p=.42 Fisher’s, p=.49 X2 -1.290, p=.26 Z -.806 , P-.42
*Fisher’s Exact Test
** Mann-W hitney U tests performed, z statistic reported
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Table 10.12 Differences in 12 month outcomes between intervention and control within sub-groups
12 months
Subgroup
All cause Heart Failure
Mortality
Readmitted to 
hospital
Died or 
readmitted to 
hospital
Total days in 
hospital**
Readmitted to 
hospital
Died or 
readmitted to 
hospital
Total days in 
hospital**
Age
<68, n=55 
69 -  79, n=56 
80+ ,n=54
Fisher’s*, p=.61 
Fisher’s, p=1.00 
Fisher’s, p=.13
X2 =.022, p=.88 
X2 =.021,p=.88 
X2 =.034, p=.85
X2 =.014, p=.91 
X2 =.044, p=.83 
X2 =.254, p=.61
Z=-.354, p=.72 
Z=-.183, p=.86 
Z=-.292, p=.77
X2 =1.547, p=.21 
X2 =.025, p=.88 
X2 =2.658, p=.10
X2 =.900, p=.34 
x2 =.044, p=.83 
X2 =1.718, p=.19
Z=-.787, p=.43 
Z=-.230, p=.82 
Z=-1.510, p=.13
NYHA
I/ll, n=124 
lll/IV, n=41
X2 =.537, p=.46 
X2 =.067, p=.80
X2 =.046, p=.83 
X2 =.016, p=.90
X2 =.420, p=.52 
X2 =.010, p=.92
Z=-.180, p=.86 
Z=-.242, p=.81
x2 =3.115, p=.08 
X2 =.266, p=.61
X2 =1.303, p=.25 
X? =.605, p=.44
Z=-1.639, p=.10 
Z=-.193, p=.85
New/Existing
New HF, n = 90
Existing HF, 
n=75
Fisher’s, p=.052 
Fisher’s, p=.79
X2 =.037, p=.85 
X2 =.830, p=.36
X2 =.000, p=.99 
X2 =.155, p=.69
Z=-.567, p=.57 
Z=-.574, p=.57
Fisher’s, p=.01
Fisher’s, p=.64
X2 =6.307, p=.01
X2 =.035, p=.85
Z=-2 .545 , p=.01
Z=-.406, p=.69
Co-morbidity
0, n = 49
1, n = 66
2 or more, n = 50
Fisher’s, p=.26 
X2 =.096, p=.76 
Fisher’s, p=1.00
X2 =.000, p=1.00 
X2 =.061, p=.81 
X2 =.244, p=.62
X2 =.246, p=.62 
X2 =.254, p=.61 
X2 =.024, p=.88
Z=-.090, p=.93 
Z=-.718, p=.47 
Z=-.020, p=.98
Fisher’s, p=.15 
X2 =.713, p=.40 
X2 =.384, p=.54
X2 =2.522, p=.11 
X2 =.273, p=.60 
X2 =.074, p=.79
Z=-1.451, p=.15 
Z=-.959, p=.34 
Z=-.281, p=.78
*Fisher’s Exact Test
** Mann-W hitney U tests performed, z statistic reported
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Table 10.13 Mortality and hospital readmission in the 90 days and 12 months following discharge in patients with newly diagnosed 
heart failure
90 days 12 months
Total I C Statistical Total I C Statistical
n 90 43 47 significance 90 43 47
significance
Mortality, n(%) 7 (7.8) 2 (4.7) 5 (10.6) Fisher’s, p=.44 11 (12.2) 2 (4.7) 9 (19.1) Fisher’s, p=.05
Patients who died or had at 
least one all cause
readmission, n (%)
25 (27.8) 11 (25.6) 14 (29.8) X2 (df=1)=.198,
p=.66
46 (51.1) 22 (51.2) 24 (51.1) X2 (df=1)=.000, 
p=.99
Patients with at least one all 
cause readmission, n (%)
23 (25.6) 10(23.3) 13 (27.7) X2 (df=1)=.229. 
p=.63
43 (47.8) 21 (48.8) 22 (46.8) X2 (df=1)=.037, 
p=.85
Total number of all cause 
readmissions(no. pp)
29 (.18) 12 (.28) 17 (.36) Mann-Whitney 
U=963.0, z=-.504,
p=.61
72 (.80) 36 (.84) 36 (.77) Mann-Whitney 
U=977.5, z=- 
.292, p=.77
Total all cause days in hospital 
(no. p.p.)
385 (4.3) 145 (3.4) 240 (5.1) Mann-Whitney 
U=981.0, z=-.311, 
p=.76
1424 (15.82) 765 (17.79) 659(14.02) Mann-Whitney 
U=945.5, z=- 
.567, p=.57
Patients who died or had at 
least one HF readmission, n (%)
12 (13.3) 3 (7.0) 9 (19.1) Fisher’s, p=.06 21 (23.3) 5 (11.6) 16(34.0) X2(df=1)= 
6.307, p=.01
Patients with at least one HF 
readmission, n (%)
8 (8.9) 1 (2.3) 7 (14.9) Fisher’s, p=.12 16(17.8) 3(7) 13(27.7) Fisher’s, p = .01
Total number of HF 
readmissions (no. pp)
9 (.10) 1 (.02) 8 (.17) Mann-Whitney 
U=883.0, 
z=-2.088, p=.04
18(0.20) 3 (0.07) 15(0.32) Mann-Whitney 
U=798.5, 
z=-2.580, p=.01
Total days in hospital for HF 
(no. p.p.)
102
(1.13)
14 (.33) 88 (1.87) Mann-Whitney 
U=885.0, 
z=2.054, p=..04
317(3.52) 37 (0.86) 280 (5.96) Mann-Whitney 
U=800.5, 
z=-2.545, p=.01
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10.4.1 Predictors of outcome in subgroups
An interesting question then arises about what factors may have influenced the 
outcome for this subgroup i.e. if the findings can be explained by those variables that 
were addressed in the intervention - behaviour and cognition. Although mood was not 
directly targeted by the intervention it was also included in this analysis because it has 
been shown to be an important predictor of outcome in other studies and it may be 
expected to change as behaviour and cognitions change. To examine this question, it 
was necessary to examine whether there was a differential effect of the intervention on 
behaviour, cognition and mood according to whether or not heart failure was newly 
diagnosed i.e. an interaction effect. A series of A N C O VA  tests, covarying for baseline, 
were performed for exercise duration, self-efficacy, medication beliefs, illness beliefs, 
anxiety, depression, positive and negative mood, with study group and a new or 
existing diagnosis of heart failure both entered as between-subject factors. This 
analysis did not find any significant interaction effects, indicating that the process 
variables did not change differentially by study group within the subgroups. 
Examination of the number of out-patient appointments and nurse contacts also found 
no differences between patients according to whether the diagnosis was new or 
existing.
As performance of self-m anagem ent behaviours had been transformed into 
dichotomous variables, and had not been assessed at baseline, x 2 tests, rather than 
ANCOVAs were used. This analysis examined whether there was a difference in 
behaviour at 6-8 weeks between the intervention and control groups in newly 
diagnosed patients that was not found in patients with a longer standing diagnosis. No 
significant differences were found.
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CHAPTER 11 
DISCUSSION
11.1 Introduction
The aim of this study was to design a self-m anagem ent intervention for people 
admitted to hospital with heart failure, to describe the intervention in detail in a manual 
and to evaluate the intervention in a randomised controlled trial. This chapter discusses 
the efficacy of the intervention on the primary and secondary outcomes, possible 
explanations for the findings and suggestions for how the intervention could be 
improved. The chapter also discusses directions for future research.
In considering the findings of this study, it is important to first of all place the 
intervention in the context of other interventions that have been implemented in heart 
failure. In terms of its effect on clinical outcomes, this study will inevitably be compared 
with disease management programmes which are the most common current approach 
to improving outcomes in heart failure. It is important that the vast majority of heart 
failure programmes that have been published to date are not self-m anagem ent 
interventions but rather disease managem ent programmes, which aim to reduce 
hospital admissions and mortality through improving the delivery of recommended  
clinical care. As discussed in Chapter 3, the beneficial outcomes of these interventions 
would appear to be explained by the optimisation of medication and/or closer 
monitoring of patients by health professionals to detect and treat early signs of 
worsening heart failure. Although most programmes include education about self­
m anagem ent behaviours, it is not their primary focus and they do not focus on 
techniques to improve self-management. The current study was one of the first to try to 
improve outcomes for patients with heart failure through enhancing self-management.
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As such, it is not strictly comparable with the many disease m anagement programmes 
that have been reported in the heart failure literature.
11.2 Acceptability of the intervention
Over 80%  of those approached agreed to take part in the study, suggesting that a large 
proportion of patients with heart failure would be interested in participating in a self­
m anagem ent programme. Since a proportion of those who refused may have been 
declining participation in the research study rather than the intervention, actual 
acceptability of the intervention may be greater than this figure suggests.
Three different factors provided indications that the intervention was acceptable to 
patients. Firstly, there was a low attrition rate with less than 6%  of those randomised 
dropping out of the intervention sessions. Patients were also asked to provide feedback 
about the intervention and of those who did, most reported finding the intervention 
helpful. This was supported by the finding that a high proportion of intervention patients 
(almost two-thirds) made contact with the heart failure nurse.
The acceptance rate into the study is higher than in many other studies of self­
m anagem ent interventions (e.g. Glasgow, Eakin & Toobert, 1996) which may be due to 
a number of factors. Firstly, recruitment took place on an in-patient ward where patients 
may be more likely to accept an intervention that could be of help. Secondly, 
participants had been admitted to hospital with what was clearly a major life- 
threatening illness. Thirdly, in contrast to many self-management interventions, the 
short duration of the intervention meant that the time and effort required to participate 
was relatively low.
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11.3 Consequences of the self-management intervention on 
follow-up care
The intervention and control groups received similar numbers of follow-up cardiology 
appointments. Although slightly higher in the intervention group, this was not 
statistically significant so while the nurse may have referred intervention group patients 
for cardiology appointments where considered clinically necessary, the difference 
made to the overall number of visits was not large. Prescribed medication also did not 
differ between the groups. These findings indicate that any differences between the 
intervention and control groups in study outcomes can be attributed to the self­
m anagem ent intervention rather than differences in cardiology care.
There had been some concern when designing the study that providing patients with 
telephone access to the nurse would lead to an unm anageable demand on the service. 
In practice, there was a total of 85 calls to the nurse, an average of one per patient in 
the intervention group of which 45 led to patients being asked to visit the nurse at the 
clinic.
11.4 Intervention efficacy - hospitalisation and mortality
It had been hypothesised that patients in the intervention group would experience lower 
rates of readmission to hospital than the standard care control group in the 90 days 
and 12 months following discharge from the index admission and lower 12-month 
mortality. These hypotheses were not supported for the study sample as a whole.
There are a number of possible reasons why an overall impact on outcomes was not 
achieved. It was hypothesised that the intervention would have an effect on 
hospitalisation and possibly mortality (although the study was not powered the find the 
latter effect) by improving self-efficacy to perform self-management behaviours and
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altering beliefs that could act as a barrier to performing these behaviours. These  
mechanisms would lead to better performance of the self-management behaviours 
which would in turn reduce hospitalisation and possibly mortality. The following 
sections will discuss the impact of the intervention on self-m anagem ent behaviour, self- 
efficacy and medication and illness beliefs and their impact on outcomes. They will also 
consider ways in which the intevention could possibly have been altered that may have 
resulted in improved outcomes.
First of all, it is important to examine how the primary outcomes of this study compare 
with other interventions that have been developed for heart failure, but bearing in mind 
the qualification made in the second paragraph of this chapter. Reviews suggest that 
disease managem ent programmes in heart failure have been successful in reducing 
hospital admission, although there is variation in their efficacy (see Chapter 2). At first 
glance it may appear therefore that the findings of the current study compare 
unfavourably with other approaches. However, closer examination reveals that this is 
not necessarily the case.
One possible explanation for the lack of an overall significant difference between the 
intervention and control groups in these outcomes may be the high quality of standard 
care received by the control group, making improvement on standard care more 
difficult. Comparison of outcomes for the standard care control group in this study with 
the outcomes of other studies supports this possibility. Many of the heart failure 
programmes published to date have compared an intervention group who received 
improved medical care with a control group who did not. In the current study, patients 
in both the intervention and control groups were discharged from hospital only when 
they were clinically stable on maximum tolerated heart failure medication and both 
groups also received out-patient follow up by a cardiologist as often as considered 
clinically necessary. W hen comparing study findings it is important therefore to
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examine not only whether studies find statistically significant differences between the 
intervention and control groups but also to compare different studies on the rate of 
events in the control groups. This gives an indication of the effect of differences in 
standard care between studies (although it is recognised that any differences between  
study populations are also important). For example, in a study by Stromberg, 
Martensson, Fridlund et al (2003), which reported statistically significant benefits of a 
nurse-led heart failure clinic, total days in hospital in the first 3 months averaged 6.7  
days in the intervention group and 11 days in the control group, compared with 5.8 
days and 6.1 days respectively within 90 days in the current study. In a more recent 
study of a brief education programme (Koelling et al, 2005), which reported statistically 
significant benefits for the intervention group, approximately half the control group had 
died or been readmitted to hospital within 90 days of discharge, compared with 33.8%  
in the current study, while the rates for the intervention groups was similar in both 
studies. Dunagan et al (2005) reported a lower 12 month readmission rate in their 
intervention group than in controls (66%  vs. 73% , p = .045) however this compares with 
54 .1%  in the intervention group and 56 .3%  in the control group of the current study. In 
the first British study (Blue, Lang, McM urray et al, 2001), the 3-month rate of death or 
readmission for heart failure was approximately 20%  in the intervention group and 33%  
in the control group, compared with 20%  in both groups in the current study. Such 
findings indicate that although there was no significant difference between the 
intervention and control groups in this study, outcomes for the control group were on a 
par with the intervention group of several other studies that have reported beneficial 
effects. By aiming to improve upon high quality standard care, the current study was 
setting itself a more difficult target than most other heart failure intervention studies.
This interpretation gains some support from the comments of Cleland et al (2007) 
regarding the non-significant findings of the COACH study (Jaarsm a et al, 2004), in 
apparent contradiction of many previous findings of disease m anagem ent programmes
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(McAlister et al, 2004). The CO ACH study is a large randomised controlled trial, 
conducted over 18 months, which compared standard care (4 appointments with a 
cardiologist) with a basic programme (standard care plus 9 nurse contacts) and an 
intensive programme (standard care plus 22 nurse contacts) for patients admitted to 
hospital with heart failure. Recently reported findings indicated that there were no 
significant differences in hospitalisation or mortality between the intervention and 
control groups. Cleland, Coletta & Clark (2007) suggested one explanation for this 
finding may be the high standard of usual care, making it difficult to find an effect. A 
study that did find benefits over and above optimised inpatient care was reported by 
McDonald, Ledwidge, Cahill et al (2002). However, the control group in that study did 
not receive regular follow-up by a cardiologist which may explain the difference in effect 
between the studies. The findings of the CO ACH study have not yet been published 
and the findings reported here are taken from a conference presentation therefore a 
more detailed examination of possible explanations for these findings awaits study 
publication.
Approaches to improve outcomes for heart failure patients must ensure that patients 
receive clinical care that meets with recommended guidelines. Therefore the challenge 
is to develop interventions that improve on good clinical care. In spite of improvements 
in outcomes for patients with heart failure over recent years, prognosis remains poor 
and ways to improve on current care are an important objective. The current study can 
be seen in terms of this more challenging goal. The following sections will discuss in 
more detail factors that m ay help to explain the outcomes of hospitalisation and 
mortality in this study.
The limitations of hospitalisation and in particular the duration of hospital admission as 
an outcome measure must however be recognised. Duration of hospital stay is clearly 
influenced by factors outside those which could potentially be influenced by the
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intervention. For example, duration of hospital stay may be influenced not only by 
illness severity but by factors such as hospital procedures and social factors such as 
whether the patient has someone at home who can help to care for them. However, 
these outcomes were chosen because they are the outcomes which are most 
commonly assessed in other heart failure intervention studies and therefore were 
necessary to enable comparison of the intervention in this study with other studies in 
the field.
11.4.1 The role of self-management behaviour
It had been hypothesised that patients in the intervention group would report better 
performance of recommended self-m anagem ent behaviours than patients in the control 
group. This hypothesis was mostly supported in the short-term, in that the intervention 
group reported more frequent performance of several of the self-management 
behaviours. This is an important finding as behaviour change is a key outcome of self­
m anagem ent interventions (New m an et al, 2004). Significant differences between the 
groups were found in eating a diet low in salt, keeping within guidelines for fluid intake, 
self-monitoring by daily weighing and checking ankles for signs of oedem a. Both 
intervention and control groups in this study reported high levels of adherence to 
medication. Whilst shortcomings in self-reported assessment of adherence are 
acknowledged (DiMatteo, 2004 ) if the patients did provide fairly accurate reports, there 
would have been little room for improving medication adherence.
Some of the self-m anagem ent behaviours were performed more often than others, for 
example at 6-8 weeks, 43%  of the intervention group reported keeping to a low salt diet 
whereas 86%  self-monitored for signs of oedema. Variation in practice of different self­
m anagem ent behaviours was also seen in the control group and has also been
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reported elsewhere (van der W al et al, 2006). It is not unexpected that dietary change 
should be more difficult to make and maintain than simply checking ankles for signs of 
oedem a but this variation highlights areas where a heart failure self-management 
intervention may need to adopt additional measures to facilitate change in some 
behaviours.
It is disappointing that the significant impact on behaviour found at the 6-8 week 
assessment did not translate into an overall reduction in events. There are a few  
possible reasons why this did not occur. First of all, it must be recognised that 
performance of the recommended self-management behaviours will not necessarily 
reduce the occurrence of events in all patients. Heart failure is a serious illness and the 
underlying disease process will inevitably influence outcomes and this may occur 
regardless of patients’ actions.
The relationship between self-m anagem ent behaviours and health outcomes is 
complex and other studies have shown that improvements in behaviours do not 
necessarily explain health outcomes following a self-management intervention (Lorig, 
Seleznick, Lubeck et al, 1989). A review of self-management interventions in asthma, 
arthritis and diabetes found that some interventions achieved behaviour change in the 
absence of change in clinical outcomes while others found improvement in clinical 
outcomes in the absence of behaviour change (Newman et al, 2004). Clearly this 
relationship requires further examination.
Although previous research has identified shortcomings in the performance of heart 
failure self-m anagem ent behaviours to be a predictor of poorer outcomes (see Chapter 
2), the strength of the relationship between frequency of performance of the 
recommended self-management behaviours and hospitalisation and mortality 
outcomes is unclear. Studies in heart failure have examined self-m anagem ent
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behaviour and factors that influence performance of self-management behaviours (see 
Chapter 3) but few have prospectively examined the relationship between self­
managem ent behaviours and outcomes. The behaviours recommended in heart failure 
guidelines are included based on clinical consensus rather than controlled trials and 
have been inferred from retrospective examination of precipitants of hospitalisation 
(see Chapter 2).
It must therefore be borne in mind that changes in behaviour will not necessarily 
translate into health benefits. Reports of keeping to a low salt diet and within fluid 
guidelines were not related to hospitalisation and mortality outcomes in this study. A 
recent study (Travers, O ’Loughlin, Murphy et al 2007) questioned the routine 
application of fluid restriction in heart failure. They found that fluid restriction in patients 
admitted to hospital with heart failure did not reduce the time to achieving clinical 
stability. This would appear to support the findings of the current study in which 
adhering to fluid guidelines was not associated with outcomes.
The systematic review reported in Chapter 3 found that few interventions assessed  
self-management behaviour or its relation to outcomes. One study that had (Jaarsma 
et al, 1999) reported better performance of self-management behaviours in the 
intervention group than the control group at 1 month and 3 months post intervention but 
this was not maintained at the 9 month assessment. The study did not find a significant 
difference between the groups in hospital admissions at 1, 3 or 9 months. Since the 
commencement of the current study, a further 15 published studies have been 
identified that directly targeted behaviour change in heart failure as an important focus 
of their intervention (Krumholz, Amatruda, Smith et al 2002; Kuehneman, Saulsbury, 
Splett & Chapman, 2002; Laramee, Levinsky, Sargent et al, 2003; Miche, Herrmann, 
W irtz et al, 2003; Wright, Walsh, Ingley et al, 2003; DeWalt, Pignone, Malone et al 
2004, DeW alt, Malone, Bryant et al, 2006; Sethares & Elliott, 2004; Arcand et al 2005;
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Caldwell, Peters & Dracup 2005; Dunbar, Clark, Deaton et al 2005; Gwadry-Sridhar, 
Arnold, Zhang et al 2005; Koelling, Johnson, Cody & Aaronson, 2005; Shively, Kodiath, 
Smith et al 2005; Kutzleb & Reiner, 2006; Rucker-Whitaker, Flynn, Kravitz et al 2006). 
However, the criticisms outlined in the systematic review in Chapter 3 still apply, in that 
most did not assess behaviour. Others that did assess behaviour did not necessarily 
assess the impact of the intervention on hospitalisation and mortality. It is therefore not 
always possible to identify the mechanisms of action or to make a comparison between 
their findings and those of the current study. Two exceptions were studies by Laramee, 
Levinsky, Sargent et al (2003) and Wright, Walsh, Ingley et al (2003).
Laram ee et al (2003) evaluated a case m anagem ent intervention that incorporated 
discharge planning and coordination of input from multidisciplinary services, followed 
by an education programme after discharge from hospital. The intervention group 
reported better performance of self-m anagem ent behaviours than the control group at 
4 weeks and 12 weeks following hospital discharge, with the exception of medication 
adherence at 4 weeks, which was very high in both groups. Better performance in the 
intervention group at both timepoints was reported in daily weight monitoring, 
monitoring for signs of oedem a, and following guidelines for fluid and salt intake. 
However, this did not translate into fewer hospital admissions over 90 days, which did 
not differ between the intervention and control groups.
Wright et al (2003) exam ined the outcomes of participants in an intervention by 
comparing those who adopted the recommended self-management strategies with 
those who did not. The study did not find any significant difference between the 
intervention and control groups in the combined outcome of death or hospital 
readmission (reported in Doughty, Wright, Pearl et al 2002). Patients in the intervention 
group received a diary to aid self-management and Wright et al (2003) compared 
patients who used the diary with those who did not. Those who used the diary had
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lower mortality and a longer event-free survival time. Wright et al also compared  
intervention patients who self-monitored their weight with those who did not. Patients 
who did not weigh themselves had more hospital admissions and a shorter event-free 
survival time.
McMurray & Pfeffer (2005) have commented that self-monitoring by daily weighing 
seems crude, however the current study also found a relationship between daily 
weighing and mortality, but only in univariate analysis; it was not significant in 
multivariate analysis when age was included. Unlike the current study, Wright et al
(2003) did not find any relationship between weight monitoring and age. However this 
relationship was found by van der W al et al (2006). Possible explanations for this 
relationship could include greater physical disability making it difficult to weigh (as 
suggested by Jaarsma et al (2000) or older patients holding different beliefs about 
weight monitoring that make them less likely to perform this behaviour. The current 
study has not established the most likely reason for the relationship but it suggests that 
further exploration may be helpful.
Duration of weekly exercise at the 6 -8  week assessent was associated with the risk of 
all cause hospitalisation and mortality in univariate analysis. The benefits of exercise 
for heart failure patients has been shown in other studies (McKelvie et al, 1995) so if a 
greater improvement in exercise duration had been achieved, it may have translated 
into a benefit on other outcomes.
Performance of self-management behaviours may have failed to translate into an 
impact on outcomes because they were not maintained for long enough. Significant 
group differences existed at 6-8 weeks but the groups no longer differed significantly at 
12 months, except on checking their weight (Table 9.2). It is not known how quickly 
performance of the behaviours diminished after the 6-8 week assessment and a further
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assessment at, say 6 months, could have been illuminating. Further assessments were 
not requested, however, in order to avoid placing too heavy a burden on mostly elderly 
patients.
Failure to maintain effects over time is a recognised shortcoming of self-management 
interventions (Newm an et al, 2004). Consideration of ways in which this intervention 
could have resulted in longer-term maintenance of behaviour change is therefore 
important. It may be unreasonable to assume that a brief intervention which was 
delivered over a period of approximately two weeks could achieve changes that would 
last for at least a year. The addition of one or more booster sessions may have helped 
to overcome this problem and could have been easily incorporated into this intervention 
with additional telephone follow-up. This does nevertheless raise the issue of the 
intervention becoming more intensive.
The relationship between self-m anagem ent behaviours and hospitalisation in this study 
is difficult to tease out because while poorer self-management may lead to an event, 
the occurrence of an event may impact on the practice of self-management behaviours. 
This process could not be exam ined because information about practice of self­
m anagement behaviours was collected at only two follow-up assessments 
approximately 10 months apart. It would be interesting to examine how patients 
responded to intervening hospital admissions and how their self-m anagem ent 
behaviour was influenced.
There may have been some limitations to the measurement of behaviour which 
concealed some important effects. For example, patients in both intervention and 
control groups in this study reported high adherence to medication. However, 
adherence was assessed using a questionnaire, which may have been unable to 
detect some barriers to adherence. A questionnaire may detect instances of intentional
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non-adherence where patients choose to report them or patients may acknowledge 
that they sometimes to forget to take medication. However, a questionnaire may be 
less likely to identify unintentional non-adherence i.e. instances of which patients are 
genuinely unaware. For example, a difficulty that patients with heart failure are likely to 
have in taking medication as prescribed is confusion arising from a complex medication 
regime (Cline, Bjorck-Linne, Israelsson et al 1999). Cognitive decline, which has been 
found to be common in heart failure, may contribute to this problem (Almeida & Flicker 
2001). Accordingly patients may believe themselves to be taking medication as 
prescribed when this is not necessarily the case. For example, Cline et al (1999) found 
patients who were taking medication that should have been discontinued.
Other heart failure intervention studies have also reported very high rates of self- 
reported medication adherence in both the intervention and control groups (e.g. 
Laramee et al 2003, Jaarsma et al 1999). A study by Bohachick, Burke, Sereika et al 
(2002) measured adherence using M E M S  and found lower rates of adherence than 
had been reported in these studies. This suggests that alternative methods of 
assessing medication adherence in heart failure may be necessary, although all 
approaches have their limitations (DiMatteo, 2004). One method would be to ask 
patients to bring their medication to the assessment session and to explain to the 
researcher exactly how much of each medication they take and when. The researcher 
could then compare this with the prescription.
Factors which were hypothesised to be important influences on behaviour in this 
intervention were self-efficacy and medication and illness beliefs. It may be that a 
greater impact on behaviour and overall outcomes could have been achieved through a 
greater impact on these variables. This will be discussed in the following sections.
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11.4.2 The role of self-efficacy
It had been hypothesised that following the intervention, patients in the intervention 
group would report greater self-efficacy in their ability to manage their heart failure than 
patients in the control group. This was supported to some extent in that self-efficacy to 
follow a low salt diet and to keep within fluid guidelines improved between baseline and 
6-8 weeks however these were not maintained over time. Significant differences 
between the intervention and control groups were also found on these behaviours. The 
significant relationships found between baseline self-efficacy and the practise of some 
of the specific self-management behaviours at the 6-8 week follow-up (Table 10.7) 
suggest that greater success in changing self-efficacy may have led to greater effects 
on behaviour. A study by Joekes, van Elderen & Schreurs (2007) assessed the 
relationship between self-efficacy in relationship to self-management in cardiac patients, 
which included 41 patients with a diagnosis of heart failure. They found that self- 
efficacy was related to self-m anagem ent behaviour in cross-sectional analysis, 
however, baseline self-efficacy did not predict self-management behaviour 3 months 
later. The study did not report the changes over time in self-efficacy and self­
management, which may have helped to clarify this relationship.
It may be the case that the behaviours were adopted for a short time but if patients did 
not experience benefits, self-efficacy remained unchanged and performance of the 
behaviours began to tail off. Lenker, Lorig & Gallagher (1984) found that improvements 
in health status were associated more with increased self-efficacy than adoption of 
health behaviours and it may be the case that this study failed to achieve overall 
benefits because it did not sufficiently enhance self-efficacy. The relationship between  
these variables is thought to operate as one of ongoing feedback and change. 
Examination of this process was not possible given the limited number of follow-up 
assessments in the study, however examination of this process is probably very limited
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in any study. There remains a need for more studies that use statistical modelling to 
gain a better understanding of this relationship.
It may be the case that if greater change in self-efficacy had been achieved, this would 
have been reflected in a greater impact on behaviour and perhaps longer term 
maintenance of the behaviours. An important factor in increasing self-efficacy is 
mastery over the behaviours concerned (Bandura, 2000). To help enhance mastery, 
self-management interventions often include formal goal-setting by patients in which 
the patients choose the goals (although limited to the behaviours addressed by the 
intervention) and write contracts for the completion of the goals. In this intervention, the 
aim was to encourage patients to adopt all the intervention behaviours, rather than 
patients choosing which goals to follow, however patients were actively involved in 
deciding how to implement these behaviours. Formal goal-setting by patients was not 
included because of the timing of the intervention and the small number of sessions 
involved. Many of the patients were newly diagnosed with heart failure during the index 
hospital admission and therefore had no prior experience of trying to manage the 
illness at home other than the recent episode which had led to their hospitalisation. 
Even patients with a longer standing diagnosis could not be expected to know how they 
would feel in the early stages of recovery from the current episode. For example, it 
would have been difficult to set realistic goals around physical activity at such an early 
stage. Formal goal-setting was therefore considered inappropriate at that stage before 
patients had adequate experience of living with the illness and identifying where they 
experienced difficulties in their self-management. If the intervention had included more 
sessions over a longer time period, formal goal-setting and contracting could have 
been included.
Vicarious learning is another important factor in improving self-efficacy, for example by 
modelling the successful behaviour of a person with whom one identifies. While the
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nurse could introduce examples of techniques that other patients have found helpful, 
vicarious learning is likely to occur more successfully in a group format. This method of 
delivering the intervention was not available in the in-patient setting where only one or 
two eligible patients may have been in hospital at the same time.
Although self-efficacy did not predict admission to hospital, an interesting finding was 
the relationship between baseline self-efficacy and mortality. In multivariate analysis, 
higher baseline self-efficacy to ‘do all the things necessary to manage heart failure on a 
regular basis’ was associated with a lower risk of mortality in the full sample studied, 
although it is recognised that the overall predictive power of the model was quite small. 
The only other significant predictor in the multivariate analysis was age. Other research 
that has examined predictors of mortality in heart failure has focused on demographic 
and clinical factors and, not surprisingly, has found older age to be among the 
strongest predictors (e.g. Cowie, Fox, W ood et al 2002; Pocock, W ang, Pfeffer et al
2006). A study by Bouvy, Heerdink, Leufkens et al (2003) reported predictors of 
mortality in 10 studies, which showed considerable variation in the predictor variables 
assessed and also inconsistency in the significance of different variables. Other 
significant predictors of mortality reported by Cowie et al (2002) were NYHA class and 
serum creatinine level but neither of these were significant univariate predictors in the 
current study (Table 10.1). Pocock et al (2006) found that in addition to age, a 
diagnosis of diabetes and lower left ventricular ejection fraction (LVEF) were the most 
powerful predictors of mortality. The current study used the echocardiographic 
assessment of global function, rather than LVEF, as a measure of systolic function and 
found that contrary to Pocock et al’s findings, both this variable and diabetes did not 
predict mortality.
Heart failure is a major cause of death and understanding what factors relate to 
mortality is an important area for research, both to identify patients who may benefit
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from additional input and to inform the development of interventions. The finding that 
self-efficacy may predict mortality could be an important addition to this research. This 
relationship has also been found in another study. Rohrbaugh, Shoham, Coyne.et al
(2004) found that patients’ self-efficacy to perform self-management behaviours was 
associated with survival over the following 4 years. Kempen, Sanderman, Miedem a et 
al (2000) found that self-efficacy predicted functional decline in the 8 weeks after 
diagnosis of heart failure but they did not examine the relationship with hospitalisation 
and mortality. The mechanism(s) by which self-efficacy may influence mortality are as
yet unknown and the intervention reported in the current study did not succeed in
improving the aspect of self-efficacy that was related to mortality, but these findings 
suggest that this is an important area to pursue in future research.
11.4.3 The role of illness and medication beliefs
Other variables that were expected to have an influence on outcomes were the beliefs 
patients held about their illness and medication. The intervention had little impact on 
patients’ beliefs about their illness or medication. Both groups reported less belief in 
cure/control at the 12-month follow-up however there was not a significant difference 
between the groups. The perceived duration of the illness (IPQ Timeline) increased in 
the intervention group but again there was no significant difference between the groups.
According to self-regulatory theory, patients’ beliefs about their illness should influence 
how they respond to it, which will also affect outcomes (Leventhal et al, 1984). There  
were some significant relationships between baseline beliefs and self-m anagem ent 
behaviours at 6-8 weeks but only perceived timeline was a significant predictor of one 
of the self-m anagem ent behaviours (self-monitoring for signs of oedem a) in 
multivariate analysis. Self-reported adherence to medication was very high in both the 
intervention and control groups so it was not possible to evaluate the importance of
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medication beliefs. If more variability in adherence was found in another study, 
addressing medication beliefs may be an important factor in improving adherence 
(Horne & W einman, 1999).
The self-regulatory model (Leventhal et al, 1984) proposes that illness beliefs indirectly 
affect health outcomes through their impact on coping strategies (which would include 
self-management behaviours) but others have also examined the direct relationship 
between illness beliefs and health outcomes (Hagger & Orbell 2003). The current study 
found that Illness Identity was a significant predictor of admission to hospital (Table 
10.1), but only in univariate analysis. A stronger belief in cure/control at baseline was 
related to a longer event-free survival, but again this was only significant in univariate 
analysis (Table 10.1). The current study was not designed as an evaluation of the self- 
regulatory model and may not have sufficient power to identify these inter-relationships 
therefore the low predictive value of these variables can not be taken as evidence that 
the model is inadequate. The significant relationships that were found indicate that this 
may be an interesting area for further study. Although many studies have examined the 
relationship between illness beliefs and health outcomes, the outcomes chosen are 
usually quality of life, psychological well-being and self-reported physical function. Of 
the 45 studies reviewed by Hagger & Orbell (2003), none examined the relationship 
between illness beliefs and hospitalisation or mortality. Further examination of these 
relationships would possibly add to the value of the theory.
An important issue to exam ine is whether this study assessed and targeted the most 
salient beliefs in heart failure. Very few studies have examined patients’ beliefs about 
heart failure and a better understanding of this area may help in the future development 
of self-management interventions.
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11.4.4 The role of mood
It is perhaps surprising that depression at baseline did not predict outcome as this 
variable has been found to predict outcome in other studies (Jiang et al; 2001, Junger 
et al, 2005). A possible explanation for the relationship between mood and outcomes 
being weaker than expected is that patients with severe psychiatric disorders were 
excluded from the study thereby reducing the variance in scores on measures of mood. 
However, the percentage of patients with a depression score in the clinical range 
(HADS score >8) was very similar to that reported by Junger et al (2005), who found 
that 30 .1%  of patients had a depression score within the clinical range on the HADS, 
compared with 31.1%  in the current study (Table 6.5). Depression was however a 
significant predictor of shorter exercise duration in univariate analysis, concurring with 
the findings of van der Wal et al (2006). This suggests that addressing mood is still an 
important issue to consider in order to optimise the benefits of self-management 
interventions in heart failure.
The question nonetheless remains as to whether directly addressing mood would have 
improved the outcomes of this intervention. There is some related evidence in coronary 
heart disease that suggests that this approach may not lead to improvement in other 
outcomes. The Enhancing Recovery in Coronary Heart Disease Patients (EN R IC H D ) 
Randomized Trial (Berkman et al, 2003) examined whether mortality and recurrent Ml 
were reduced by treatment of depression and low perceived social support. Although 
improvements in depression and perceived social support were found, these did not 
translate into improvements in event-free survival.
11.4.5 The importance of comorbidity
Analysis of predictors of outcome found that one of the most consistent baseline 
predictors of outcome were the number of comorbid illnesses. It is important that
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comorbidity increased the risk not only of all cause events but also heart failure events. 
Approximately 70%  of the study sample had at least one non-cardiac co-morbidity and 
these could have contributed to many readmissions. McMurray & Stewart (2002) found 
a similar level, with 65%  of patients hospitalised with heart failure having at least one 
major co-morbidity. The risk of hospitalisation among people with heart failure has 
been found to increase with the number of non-cardiac comorbidities (Braunstein, 
Anderson, Gerstenblith et al 2003). The intervention in the current study was brief and 
focussed on self-management of heart failure. Perhaps in an elderly population with 
such a high prevalence of co-morbid illness, it is unrealistic to target a single disease. 
The Expert Patient Programme (Department of Health, 2001), based on the Chronic 
Disease Self-M anagem ent Programme (Lorig et al, 1999) takes this approach and 
instead welcomes people with any chronic illness to attend a generic group self­
m anagement programme. A recent randomised controlled trial of this programme 
(Kennedy, Reeves, Bower et al, 2007) included 629 patients with a wide range of long­
term conditions, although it is not known if any had heart failure. The study found that 
at the 6-month follow-up, the intervention group reported greater self-efficacy, more 
energy, better psychological well-being, less health distress and less limitation in social 
roles than the control group. However there were no differences between the groups in 
the number of health care visits, self-reported general health or pain. A drawback of 
this programme is that participants receive no disease-specific information -  the 
programme concentrates on teaching generic self-management skills such as problem­
solving which they can then apply to all aspects of their lives. Patients with heart failure, 
like patients with other chronic illnesses, need to know how to m anage the specific 
demands of their illness as well as learning generic skills, so would need additional 
input over and above the Expert Patient Programme. The issue of how best to develop 
self-management interventions that deal with the demands of both a specific disease 
and one or more co-morbid illnesses remains unresolved and is an important area for 
further research.
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11.5 Intervention efficacy -  quality of life and mood
The sections above discuss the efficacy of the intervention on hospitalisation and 
mortality and possible explanations for the findings. Other study outcomes included the 
secondary outcomes of quality of life and mood. These are important outcomes since it 
is crucial not only to reduce hospitalisation and mortality but to do so without having a 
detrimental impact on patients’ quality of life and psychological well-being. On the 
contrary, it would be expected that a self-m anagem ent intervention which helped to 
enhance patients’ ability to manage their illness would improve their quality of life.
It had been hypothesised that patients in the intervention group would report better 
quality of life and mood than the standard care control group at 6-8 weeks and 12 
months following discharge from the index admission. Patients in the intervention group 
reported significant improvement in mental quality of life over the study period whereas 
those in the control group did not (Tables 8.3 and 8.4), however the differences 
between the groups at 6-8 weeks and 12 months were not statistically significant. It is 
nevertheless encouraging that an intervention which required patients to pay closer 
attention to their illness did not have a detrimental effect on their mental quality of life 
but, on the contrary, may have conferred some benefit. In contrast, physical quality life, 
assessed by the SF-36, was not influenced by the intervention and neither did it 
change over time for the whole sample.
Few other heart failure intervention studies have evaluated generic health-related 
quality of life as an outcome. Seven randomised controlled trials were identified that 
assessed quality of life using the SF-36 (Stewart et al, 1999; Harrison et al, 2002; 
Dunagan et al, 2005; Martensson, Stromberg, Dahlstrom et al, 2005; Shively et al, 
2005; Smith, Forkner, Zaslow et al, 2005; Thompson, Roebuck & Stewart, 2005). Of 
these, 4 studies found no effect of the intervention on either physical or mental quality
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of life (Harrison et al, 2002; Shively et al, 2005; Smith et al, 2005; Thompson, Roebuck 
& Stewart, 2005). The remaining 3 studies found a significant impact on physical, but 
not mental quality of life (Stewart et al, 1999; Dunagan et al, 2005; Martensson et al, 
2005), however, only in the study by Martensson et al (2005) were the effects 
maintained up to 12 months. It is possible that studies that found benefits on physical 
quality of life are ones which, in contrast to the current study, had also found an impact 
on hospital admissions. However, examination of these studies indicated that this was 
not necessarily the case. Only 4 of these studies had also evaluated admission to 
hospital so it is not possible to draw any conclusions about the relationship between 
reductions in hospital admission and improvements in physical quality of life. Stewart et 
al (1999), Dunagan et al (2005) and Thompson, Roebuck & Stewart (2005) all reported 
reductions in hospital admissions but the latter study did not find an effect on quality of 
life. Harrison et al (2002) did not find an effect on either outcome.
It would appear to be the case that physical quality of life as assessed by the SF-36 is 
difficult to change in heart failure. Although better delivery of care through disease 
m anagem ent programmes may improve health outcomes in some studies, changes in 
care do not necessarily impact on physical quality of life, other than in the short term. 
Heart failure is a serious and chronic illness therefore its impact on aspects of physical 
quality of life, such as patients’ perceptions of their general health and performance of 
life roles, may remain unchanged even when symptoms improve. This may help to 
explain why physical quality of life did not change in the current study even though 
disease-specific quality of life improved in the sample as a whole.
Disease specific quality of life, as measured with the MLHF, did not differ between 
groups but there was a significant improvement over time in the whole sample. 
Baseline reports will inevitably have been affected by patients being in hospital at that 
time however the improvement over the following 12 months was highly significant
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(p<.001) and it is encouraging that one year further on in their illness, patients were still 
experiencing better heart failure specific quality of life. This may be a reflection of the 
early optimisation of treatment and ongoing care.
The intervention did not have an impact on patients’ mood, neither did mood change 
over time in the sample as a whole (Tables 8.7 -  8.12). Few other heart failure 
interventions have assessed mood as an outcome. No randomised controlled trial was 
identified that used the HADS or PANAS. Dunagan et al (2005) used the Beck 
Depression Inventory (Beck, W ard, Mendelson et al, 1961) in an evaluation of a 
disease-m anagem ent programme but did not find a significant effect. The intervention 
in the current study did not directly target mood and, therefore it may not be surprising 
that mood scores did not change significantly over time. Although mood was not a 
significant predictor of primary outcomes in the study, it is an important outcome in its 
own right. Incorporation of techniques that directly address anxiety and depression, 
which have been evaluated in post-myocardial-infarction rehabilitation (Lewin, 
Robertson, Cay, Irving & Campbell, 1992), may be a useful addition to heart failure 
self-management.
11.6 Efficacy of the intervention in newly diagnosed patients
An important finding of this study was that the intervention resulted in better outcomes 
in the subgroup of patients who had been newly diagnosed with heart failure. 
Differences between newly diagnosed intervention and control group patients were 
already apparent at 90 days following discharge from the index admission, during 
which time the intervention group patients had fewer readmissions for heart failure and 
spent fewer days in hospital for heart failure. Over the 12-month follow-up period, fewer 
patients in the intervention group were admitted to hospital for heart failure and the 
number of heart failure admissions and the days spent in hospital for worsening heart
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failure were lower in the intervention group. The percentage of patients experiencing a 
heart failure event i.e. the combined outcome of death or readmission for heart failure, 
was also lower in the intervention group. No differences were observed between the 
groups in all-cause events or hospital admissions. The groups did not differ significantly 
in 12 month mortality however the low mortality rate (4.7% ) in newly diagnosed 
intervention group patients is noteworthy.
As this was a subgroup analysis, the findings must be treated with caution, 
nevertheless they highlight an important area for further study. In addition, a new 
diagnosis of heart failure was in itself a predictor of outcome, indicating that the period 
immediately following diagnosis is an important time for further intervention. Stromberg
(2005) maintained that newly diagnosed patients would not be receptive to education 
because receipt of the diagnosis could trigger a crisis but the findings of this study 
suggest that such concerns are unfounded. A study by Riegel et al (2000) reported that 
their intervention was not effective overall but did have a beneficial effect in patients 
who were moderately symptomatic. Riegel et al proposed that there may be a ‘window  
of opportunity’ in which interventions to enhance self-management are most likely to 
have an effect. Recruitment to the current study took place when patients were in 
hospital and it may be the case that newly diagnosed patients and those with a longer- 
standing illness respond differently to a hospitalisation.
In order to identify why the intervention was effective for newly diagnosed patients but 
not those with established disease, analysis was performed to examine whether there 
were any differences between new and existing patients in changes in process 
variables. For example, it would seem reasonable to expect that patients who have had 
heart failure for some time would have developed ways of managing it and even where 
these are ineffective they may remain difficult to change. In contrast, newly diagnosed 
patients may find it easier to adopt the self-management behaviours introduced by the
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nurse. However, the findings did not support this hypothesis in that self-management 
behaviours did not differ between the intervention and control groups by subgroup.
Another possible explanation of the findings was that the cognitions and/or mood of 
newly diagnosed patients were more amenable to change than those of patients with a 
longer standing diagnosis and that such changes influenced outcomes. This hypothesis 
was also unsupported by the findings in that cognitions and mood did not change 
differentially by study group within these subgroups.
The process(es) by which the intervention was effective in newly diagnosed patients 
but not those with longer-standing illness remains unexplained. It may be the case that 
the number of patients in this subgroup (n = 90) provided insufficient power to detect 
any effects. Another possibility is that the findings may be explained by variables that 
were not assessed in the study. It is also possible that differences in self-reported 
adherence were not identified by the measurement tool used in this study. It may be 
the case that adherence was better in newly diagnosed patients. Those with longer- 
standing illness may have had several changes of medication during their illness 
possibly leading to greater scope for confusion whereas newly diagnosed patients were 
starting afresh so the intervention may have been easier to put into practice. This 
remains an important and interesting area for further study.
This study is probably unusual in including both newly diagnosed patients and those 
with longer-standing illness in a single self-managment intervention. Other studies have 
tended to include either one or the other of these subgroups of patients, but not both. 
When Farmer, W ade, Goyder et al (2007) examined the effects of a self-monitoring 
intervention in diabetes within subgroups, they did not find any effect within a subgroup 
defined by duration of diabetes. However, they had defined the subgroups by median 
duration (<36 months and >36 months) rather than identifying those who were recently
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diagnosed. In contrast, when Parchman, Arambula-Solomon, Noel et al (2003) 
examined progress through stages of change for self-management behaviours 
following a diabetes education programme, they found that those with diabetes for less 
than 2 years were significantly more likely to progress at least 1 stage of change for 
diet and exercise than those with diabetes for more than 2 years. This progress was 
significantly associated with a decline in blood glucose levels assessed by HbA1c. 
Neither of these studies examined effects in newly diagnosed patients however. The 
applicability of self-management interventions across the duration of an illness and how 
they may need to change to meet the needs of patients at different stages of their 
illness is an interesting area for further study.
11.7 Other considerations in interpretation of the study 
findings
It is important to ask whether there are alternative explanations for the study findings. 
For example, the study found a positive effect of the intervention on some self­
m anagement behaviours, at least in the short term, so it is important to consider 
whether these findings did in fact result from the intervention or whether they can be 
explained by other factors. One possibility is that the difference found between the 
groups in self-reported performance of self-management behaviour does not reflect a 
real difference between the groups but is a result of a social desirability response bias 
(Marlowe & Crowne (1961) in the intervention group, as a consequence of having 
participated in a self-management intervention that they know aimed to encourage 
performance of these behaviours. This explanation would appear unlikely in view of the 
variability of response across behaviours. If patients were responding according to 
what they perceived were the expectations of the study, it would seem likely that they 
would report high performance across all behaviours that were included in the 
intervention. In fact, high performance of these behaviours (performance on >6 days in
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the preceding week) varied from virtually all patients reporting taking medication as 
prescribed to less than half reporting eating a low salt diet.
It is also important to consider whether the differences found in self-management 
behaviour resulted from the problem-solving approach used or whether they were 
achieved simply by better provision of information about self-management to the 
intervention group than to the control group (Table 4.1). The findings from interventions 
in other chronic illnesses suggests that this is unlikely, as provision of information is not 
usually sufficient to achieve behaviour change. However, it would have been possible 
to examine this more effectively by providing the control group with the intervention 
booklet (Appendix B) while the intervention group received both the booklet and the 
nurse intervention.
Lack of a significant effect on some questionnaire measures could also come about as 
a result of ‘response shift’. Follow-up responses to questions about constructs such as 
self-efficacy and quality of life may not simply reflect real changes in those constructs 
over time but may reflect changes in the way respondents conceptualise those 
constructs, in the importance they give to them and in their internal standards of 
m easurem ent (Schwartz & Sprangers, 1999). So, for example, following an intervention, 
participants may be able to do more physically but this may not be reflected in an 
improvement in reported quality of life if patients’ expectations of what they should be 
able to do have also increased. Or patients’ standard of measurement of a construct 
such as self-efficacy may change, for example by becoming more realistic following the 
intervention than it had been previously. This ‘down-regulation’ of the internal standard 
of measurem ent may mask actual improvements. Such phenomena could also occur in 
the opposite direction leading to an exaggerated positive effect. It is not known if 
response shift contributed to any of the findings in the current study. Some studies 
have tested for response shift by asking people to retrospectively evaluate their
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baseline status on a particular construct and to compare it with their actual baseline 
reports. A difference between these two measures is judged to result from response 
shift (Rapkin & Schwartz, 2004). Such evaluations are not routinely reported in studies 
in health psychology, for example a search of the journal Health Psychology found 
response shift discussed in only one article (Schwarz, 1999) while Psychology and 
Health identified two articles (Schwartz, Sprangers, Carey et al, 2004; Yardley & Dibb,
2007). W hen Yardley & Dibb (2007) examined scores on the SF-36 in a sample of 
patients with M eniere’s disease, they found evidence for response shift on all scales 
except physical function. Such findings suggest that response shift could be an 
important factor to exam ine in evaluations of self-management interventions.
The intervention was found to have benefits in a sub-group of newly diagnosed patients. 
Caution has already been expressed above regarding the interpretation of sub-group 
findings but other possibilities for the findings must also be considered. One is that the 
doctors providing follow-up care did not remain blind to study group allocation as 
specified in the study design and differences in outcomes between the groups resulted 
from differences in follow-up care. This explanation is not supported by the study 
findings. The newly diagnosed intervention and control group patients did not differ in 
the number of follow-up appointments or in the prescription of heart failure medication. 
Furthermore, if unblinding of the doctors had led to the intervention effect, it is likely 
that it would have led to an effect in the whole study sample, not just those who were 
newly diagnosed.
W hen people choose to participate in a randomised controlled trial, it is possible, or 
even likely, that they will have a preference for one arm of the trial over the other 
(Brewin & Bradley, 1989) and therefore may be disappointed if they are randomised to 
the alternative arm. This could affect study outcomes. It would be expected that 
patients would only have chosen to take part in the study if they were interested in
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participating in the intervention. Randomisation to the control group could have resulted 
in disappointment which adversely affected patients’ mood or quality of life. This 
possibility would appear unlikely given the lack of significant group differences on these 
outcomes. Alternatively, disappointment at randomisation to the control group could 
have prompted patients to seek out more information about how they could self- 
manage their heart failure and make changes they would otherwise not have made, 
thus reducing the differences in behaviour between the groups. It is not possible to tell 
if this occurred in this study but the low levels of performance of some of the 
behaviours in the control group suggest it is unlikely. Preference trial designs (Brewin & 
Bradley, 1989) can be used to try to overcome the problems that randomisation to the 
non-preferred arm can raise but it must be borne in mind that this type of design 
requires a much larger study sample.
It is necessary to consider whether the failure to find significant effects on some of the 
secondary outcomes could have been the result of insufficient power to detect effects 
on these outcomes. The outcomes of quality of life and mood were analysed using 
ANCOVAs and repeated m easure ANOVAs. To detect a moderate effect on these tests, 
with p<.05 and power of .80, would have required sample sizes of 130 and 86 
respectively. Accordingly the sample sizes of 143 at 6-8 weeks and 110 at 12 months 
were sufficient for the repeated measures ANOVAs over the three time-points and for 
the ANCOVAs at 6-8 weeks, but not 12 months. It is therefore acknowledged that the 
sample sizes did not m eet the required numbers for some analyses at the final 
assessment. However, given the consistant pattern of findings, it is considered unlikely 
that increased numbers would have resulted in different findings.
Differential dropout between the groups is another potential confounding factor. 
However, completion rates of the questionnaire measures over time were similar in
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both the intervention and control groups so this cannot be seen as contributing to the 
non-significant findings in the study.
11.8 Suggestions to improve the efficacy of the self­
management intervention
One question in all studies that develop and apply self-management interventions is 
whether the findings and the experience of the study lead to any suggestions of how 
the intervention may be improved in an attempt to increase efficacy.
The intervention evaluated in this study produced significant improvements in some 
aspects of self-m anagem ent behaviour and self-efficacy and also showed benefit in a 
subgroup of newly diagnosed patients. It is important to consider ways in which these 
effects could have been strengthened so that they may have translated into an overall 
impact on the primary outcomes.
A key factor to consider is the brevity of this intervention. The non-significant outcomes 
of such an intensive intervention as the COACH study (Jaarsma et al, 2004) serve to 
highlight the scale of the challenge for this brief self-management intervention to 
produce a reduction in hospital admissions. The current study had aimed to design a 
brief intervention that would be low in cost and could be delivered within the staffing 
resources available to most hospitals. The self-management intervention was briefer 
than most other interventions that have been evaluated in heart failure which may 
explain the non-significant findings. Although the study by Stewart et al (1999) had 
consisted of only a single home visit, the intervention also allowed for referral to other 
services of patients who were showing signs of deterioration at the home visit. Stewart 
& Horowitz (2002) reported that 26%  of patients received additional home support 
services but the intensity of this additional care was not reported. Such additional care 
may have made a significant contribution to overall outcomes. The study by Koelling et
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al (2005) evaluated a single intervention session, however it has been highlighted 
above that the benefits achieved may have been possible only because of the poor 
outcomes in the control group. Varma et al (1999) also reported significant benefit 
following a single education session (although reporting was unclear) however, this 
was also in comparison to very poor outcomes in the control group with 66%  
readmitted for heart failure over the 12 month follow-up period.
An important point to consider therefore is whether a more intensive self-management 
intervention would result in improved outcomes. One or more extra sessions could 
have been used to include additional strategies to enhance self-efficacy for self­
m anagement behaviours (see section 11.4.1). Maintenance of performance of self­
m anagement behaviours could have been addressed by the inclusion of additional 
booster sessions. Exercise em erged as a potentially important variable and the 
inclusion of extra sessions could have allowed a greater emphasis on overcoming 
barriers to increasing physical activity. W hen Lorig, Gonzalez, Laurent et al (1998) 
compared a 3 week programme for arthritis with their standard 6 week programme, 
they found that the more intensive programme achieved better results. A recent review  
of diabetes self-management interventions (Glazier, Bajcar, Kennie & Willson, 2006) 
also suggested that more intensive programmes may achieve better outcomes, 
although not all the studies included in the review evaluated self-management 
interventions. Nevertheless, research in other chronic illnesses has not identified an 
optimal intervention intensity (Newm an et al 2004).
One option to consider is additional sessions to be delivered on an out-patient basis or 
in the community. These sessions could be delivered on a group basis which would 
have the advantage of containing costs and would also confer the benefits of meeting 
as a group, for example, a greater opportunity to enhance self-efficacy (see section 
11.4.2). A group programme could also be made available on a wider basis to patients
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who have been diagnosed with heart failure but have not necessarily been admitted to 
hospital. There is some indication that rehabilitation programmes are being introduced 
into heart failure management (e.g. Austin, Williams, Ross et al 2005) and this type of 
programme could readily be adapted to incorporate self-management principles. The 
optimal intensity for such an intervention remains a question for future research.
Another important issue to consider is treatment fidelity (Bellg, Borrelli, Resnick et al 
2004), that is, the extent to which the intervention was delivered as intended. It is a 
possibility that the lack of an overall effect of the intervention resulted from it not being 
delivered as intended. Delivering a self-management intervention was new to the nurse 
involved in this study therefore the study involved a learning period. Evaluation of the 
nurse’s development was made through role play in training sessions, one of which 
was video-recorded. Further evaluation could have been made by observing or tape- 
recording the nurse in practice, delivering the intervention to one or more patients. This 
would have brought attention to any areas which could have been improved, for 
example if the nurse was inclined to revert to a didactic approach. This type of 
evaluation was not incorporated due to practical constraints but would now be 
considered an important aspect of training and would be included as an ongoing 
feature of any future nurse training. Ensuring that treatment fidelity is satisfactory 
provides greater confidence that lack of an effect can be attributed to the content of the 
intervention, rather than the way it is implemented.
This study also raises an important question about what are the minimum criteria for a 
self-management intervention. An examination of the literature on self-management in 
other chronic diseases identifies considerable variation in their content. Some, 
particularly in diabetes and arthritis, are intensive interventions that target a range of 
areas, including behaviours, cognitions and mood (Newman et al 2004). Many teach 
skills such as problem-solving and goal-setting which Lorig & Holman (2003) contend
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are key self-management skills. Definitions of self-management such as that given by 
Barlow et al (2002) imply that interventions should address self-m anagem ent of the 
medical and emotional aspects of the illness and the changes in life roles that are 
required. The intervention which has formed the subject of this thesis focussed on 
improving self-management of medical aspects of heart failure.
It might be argued that an intervention that does not address all of these aspects of 
self-management does not conform to a biopsychosocial approach (Engel, 1977). 
However, minimising unplanned hospital admissions, a primary aim of the current 
intervention, is not a purely biological outcome but clearly has psychological and social 
significance as well as behavioural antecedents. The intervention was delivered on an 
individual basis and accordingly those issues which a patient identified as most 
important for managing his/her heart failure, including psychological and social issues, 
could be addressed using the problem-solving approach. Nevertheless, the inclusion of 
a period of preliminary qualitative research in the development phase of the 
intervention, which had not been undertaken due to time constraints, may have 
uncovered other outcomes which patients considered important to address. While 
steps to help prevent rapid deterioration in patients’ health (and thus avoid unplanned 
hospital admissions) are an essential element of heart failure self-management, 
extension of the intervention to address additional aspects of heart failure self­
management may have led to greater benefits.
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11.9 Strengths of the study
A number of factors contributed to the strength of this study.
11.9.1 Quality of standard care
The design of this study improved upon many other interventions that have been 
developed in heart failure in that it compared the intervention to a control group who 
received optimised medical care. In contrast, many other heart failure interventions 
have compared an intervention group who received optimised care with a control group 
who did not. The design of the current study means that any effects found are over and 
above those achieved through optimised medical care.
11.9.2 Blinding
Another strength of this study was that the cardiologists who delivered patient care 
were blind to study group allocation. This is another important way in which the study 
has improved on the design of most other studies of heart failure interventions. In 
studies where the cardiologists were not blind, it is possible that the cardiology care 
received by the intervention and control groups could have differed. W here this type of 
intervention is delivered by a heart failure nurse, consultation with the cardiology team  
is likely to remain an essential part of the nurse’s practice therefore blinding can be 
difficult. Nevertheless, if the benefit of this type of intervention is to be evaluated  
properly it is essential that the only differences in care between the intervention and 
control groups are as stated in the intervention description.
11.9.3 Intention to treat analysis
The study used intention-to-treat analysis, which includes the outcomes of all patients 
recruited even if they dropped out before the end of the study. This type of analysis
273
helps to give a more realistic indication of the likely effectiveness of the intervention 
once integrated into routine care.
11.9.4 Study outcomes assessed
Another strength of this study is that it assessed a wide range of variables including 
clinical outcomes. The primary outcomes that are typically assessed in other heart 
failure studies i.e. hospital admission and mortality were also assessed in this study 
which is important if the intervention is to be compared with other work in the field. 
Assessment of other variables such as cognition and behaviour is also important in 
order to gain a better understanding of how the intervention achieves any observed 
effects. Measurement of these variables is rare in other heart failure studies so while 
they may aim to improve outcomes by advising patients to adopt a number of self­
management behaviours, it is not possible to tell if this aspect of the intervention has 
had any impact. The wider range of variables assessed in this study has helped to 
identify some factors that are important for this type of intervention to address.
The current study is somewhat unusual in health psychology research in having clinical 
events as its primary outcome. Michie & Abraham (2004) argue that where an 
intervention is targeted at changing behaviour then behavioural outcomes are likely to 
prove the most informative when considering whether such an intervention works. In 
the current study, the intervention did have a significant effect on behaviour, providing 
evidence of its efficacy on the areas targeted. Michie & Abraham (2004) make the 
important point that as health status is influenced by many factors other than health 
behaviours, a focus on health status as an outcome could obscure effective targeting of 
behaviour. This point is very pertinent to the current study as the positive effect of the 
intervention on behaviour did not translate into an overall benefit on health outcomes 
and the limitations of using hospitalisation as an outcome are acknowledged.
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Nevertheless, if the reason for targeting health behaviours is to improve health status, 
then assessment of any clinical benefit is also important. Evidence of benefit for such 
outcomes is likely to be necessary if self-management interventions are to be widely 
adopted in the health service.
11.9.5 Intervention manual
The intervention evaluated in this study was described in a manual for use by the nurse 
delivering the intervention (Appendix A). The development of manuals for self­
m anagement interventions is important. Journal articles do not allow for a detailed 
description of an intervention so a full understanding of what actually occurred can be 
difficult. This raises problems for making comparisons between studies that describe 
their interventions in similar ways but may in practice have differed in their delivery. For 
example, the intervention by Stewart et al (1999) referred to ‘remedial counseling’ 
which was not described in further detail. W hen asked about the nature of the 
counselling and whether any particular counselling model had been used, Stewart 
responded that they were ‘pragmatic and eclectic’ (personal communication). The  
intervention also referred to ‘strategies designed to improve treatment adherence and 
response’ but it is not clear what these were. The level of detail in the reporting of 
Stewart et al’s study is by no means atypical and it can be seen that without greater 
precision about the content of the intervention it would be difficult to know if two 
interventions describing their intervention in these terms were actually similar in 
practice. Replication of interventions also becomes difficult if the content and process 
of delivery are not laid out in detail. This is not to say that a manual should act as a 
rigid protocol. An important aspect of delivering a self-management intervention is 
being able to adapt it to the needs of the participants therefore the person delivering 
the intervention needs to adopt a flexible approach. The manual nevertheless serves
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the purpose of clarifying the techniques used and the self-management behaviours that 
are to be addressed.
11.10 Limitations of the study
Recruitment to the study took longer than anticipated and was curtailed before the 
required sample size was reached. This will have reduced the power of the study to 
find any effect.
The duration of follow-up in this study was only 12 months therefore it is not known if 
any beneficial effects were maintained after this time. Failure to maintain benefits is a 
common short-coming of self-management interventions (Newman et al, 2004) 
therefore knowledge of the longer-term outcomes of this intervention would be helpful. 
Nevertheless, the period of follow-up is longer than for many studies in heart failure. 
For example the study by Blue et al (2001) reported 12 month outcomes but the 
intervention itself ran for the whole 12 month period, whereas in the current study the 
12 month assessment time was approximately 50 weeks after the end of the 
intervention. When Ojeda Anguita, Delgado et al (2005) ran an intervention for an 
average of 16 ±8 months, they reported a lower rate of heart failure admissions and 
lower mortality in the intervention group during the treatment period. One year after 
stopping the programme, however, there was no longer any difference between the 
groups in these outcomes. It is therefore important when comparing the duration of 
effects with other studies to take this into consideration.
The intervention was delivered by one heart failure nurse. While this has the benefit of 
reducing inconsistencies in delivery, it is possible that there would be differences in the 
efficacy between health care professionals. The description of the intervention in a 
manual was designed to minimise such differences but it remains possible that some
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health care professionals may be better than others at learning the skills needed to 
facilitate a self-management intervention.
Ideally, the design of the study would have involved keeping the self-management 
intervention completely independent of medical and nursing care. However, some 
confounding of self-management and nursing care were inevitable in that the nurse 
also performed a clinical assessment at the home visit and the clinic visits that 
occurred as a result of patients’ contacts. Complete separation of the self-m anagem ent 
intervention from clinical care would have required the intervention to be delivered by a 
person who did not have any other contact with the patients but this was not possible 
as additional personnel were not available. Nevertheless, it must be borne in mind that 
the model of delivery used in this study would facilitate the integration of self­
m anagem ent into standard care.
In designing the study, the timing of the second assessment was a pragmatic decision 
to arrange assessments to coincide with out-patient visits. W e wished to carry out an 
early assessment to evaluate any immediate effects of the intervention but the first out­
patient visits were organised for 6-8 weeks after discharge from hospital. A 
disadvantage of this duration was that it allowed quite a lot of time in which 
readmissions to hospital could occur and these admissions would be likely to impact on 
the variables that were being assessed.
This study was not able to monitor the impact of an admission to hospital during the 
follow-up period on self-m anagem ent behaviours and cognitions. Rothman (2000) 
asserted that people have clear expectations about the outcome of a new behaviour 
and if these expectations are not met they will be less likely to maintain the behaviour. 
The study had been designed so that if deterioration triggered further contact with the 
nurse, this would allow for further input and reinforcement of the intervention as
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necessary. Nevertheless, an admission to hospital may have led people to discontinue 
behaviours they had been performing previously. Examination of this self-regulatory 
process in greater detail would require more frequent assessments than were 
performed in this study. In any event, a detailed understanding of this ongoing adaptive 
process would probably entail more assessments than is feasible for any research 
study.
W hen the study questionnaires were being chosen, it was decided not to include a 
measure of self-management behaviour at baseline because it was anticipated that 
many patients would be newly diagnosed and would not have experience of self- 
managing heart failure. In retrospect perhaps these behaviours should have been 
examined anyway, allowing for the fact that they would not have applied to some 
patients. A proportion of newly diagnosed patients may have been engaging in some of 
the behaviours to manage other cardiac conditions. A baseline measure would have 
the advantage of enabling assessment of change over time and examination of any 
correlation between change in process variables and change in behaviours. More 
detailed assessment of salt and fluid intake could also have been made which would 
have enabled examination of any relationship between intake levels and clinical 
outcomes. The measurement of behaviour could also have been improved by taking 
additional steps to establish the psychometric properties of the measure in line with 
recommended good practice (DeVellis, 2003). Internal consistency had been assessed 
but was not high, which was expected as self-management behaviours are not 
necessarily highly correlated with each other (Glasgow et al, 1989). Additional tests 
could have been performed, for example, test - re-test reliability could have been 
established by preliminary piloting of the measure on two or more occasions within a 
brief timeframe. Construct validity could have been assessed by comparing the 
reported findings for physical activity with another measure such as a 6-minute walk 
test, a widely used measure of physical function in healthcare settings or responses for
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individual behaviours on this scale could have been compared with other scales that 
assess behaviours such as exercise, diet and medication adherence. These tests were 
not undertaken because of time constraints in the development phase but this is 
recognised as a study limitation.
Understanding of the relationship between psychological factors, behaviours and 
health outcomes is not well developed in heart failure and requires further exploration. 
For this reason, a period of exploratory research prior to the development of the 
intervention would have been helpful however this was not feasible within the financial 
and time constraints of the study. Without the benefit of such research at the inception 
of this study, pragmatic decisions had to be made about how best to proceed on some 
matters, making use of what was considered to be the most relevant research from 
other chronic illnesses. This follows the path by which many self-management 
interventions have been developed, drawing on existing theory and clinical opinion and 
working within the constraints of the clinical environment in which they are to be 
delivered. A more detailed knowledge of the behaviours, cognitions and emotions that 
are related to outcomes in heart failure should greatly enhance the development of 
future interventions.
11.11 Conclusions and recommendations for further research
The aims of this study were to design a self-management intervention for people 
admitted to hospital with heart failure, to describe the intervention in detail in a manual 
and to evaluate the intervention in a randomised controlled trial. These aims were 
achieved and, to my knowledge, this is the first study of a self-management 
intervention for heart failure to be conducted in the UK.
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The intervention had a significant impact on some aspects of self-management 
behaviour and although the intevention did not have a significant overall effect on the 
primary outcome of hospital admissions, subgroup analysis suggested that the 
intervention was successful in reducing hospital admissions for heart failure in newly 
diagnosed patients.
This study has identified several areas which could benefit from further research. A 
greater understanding of the relationship between psychological factors, behaviours 
and health outcomes would be of benefit in the design of future interventions. This area 
is not well developed in heart failure and requires further examination.
This study found that exercise duration and weight monitoring were related to 
outcomes but the relationships, although significant in univariate analysis, were no 
longer significant in multivariate analyses. Possible explanations include inadequate 
m easurem ent of behaviour in this study, lack of power to detect effects or absence of a 
strong relationship between these behaviours and the outcomes of hospital admissions 
and mortality. A better understanding of the nature of this relationship has important 
implications for the development of clinical guidelines for heart failure and the content 
of future self-management interventions.
Self-efficacy proved to be a potentially important predictor of mortality in heart failure. 
Further exploration of this relationship and ways to enhance patients’ self-efficacy to 
manage their illness may provide a valuable contribution to improving outcomes in 
heart failure.
The study findings suggest that the period shortly after diagnosis is an important time 
for intervention in heart failure. Contrary to the views of Stromberg (2005), this study 
has shown that newly diagnosed patients may be particularly receptive to a self­
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management intervention. Although further research is needed to confirm the findings, 
this has clear implications for the incorporation of self-management interventions into 
clinical practice. W hen heart failure is first diagnosed on admission to hospital, the 
period shortly before and after discharge would appear to offer a key time for 
introducing a self-management intervention. It is important to explore how self­
m anagement interventions could be adapted and their benefits evaluated for people 
who are first diagnosed with heart failure as out-patients or in primary care.
Further research is needed to examine ways in which the benefits seen in newly 
diagnosed patients can be enhanced. Two issues appear of particular importance. It is 
necessary to explore ways to extend the benefits seen for newly diagnosed patients to 
those already diagnosed with heart failure and it is also important to try to reduce all­
cause admissions to hospital, not only admissions for heart failure.
It may be the case that patients would benefit from a more intensive intervention.The 
current intervention was very brief and it may have been overly ambitious to expect to 
achieve a significant overall benefit with an intervention of such low intensity. One 
option to consider is additional sessions to be delivered on an out-patient basis or in 
the community. These sessions could be delivered on a group basis which would have 
the advantage of containing costs and would also confer the benefits of meeting as a 
group, for example, a greater opportunity to enhance self-efficacy (see section 11.4.2.). 
There is some indication that rehabilitation programmes are being introduced into heart 
failure m anagement (e.g. Austin et al, 2005) and this type of programme could readily 
be adapted to incorporate self-management principles. Exploring the possible benefits 
of extending the intervention in these ways is an important area for future study.
In newly diagnosed patients, the intervention was successful in reducing hospital 
admissions for heart failure but not all-cause admissions. Coupled with the finding that
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comorbidity was a significant predictor of both all cause and heart failure outcomes, 
this suggests that further examination of how a self-management intervention for heart 
failure should address comorbidity is essential. The intervention in the current study 
was brief and focussed on self-management issues specific to heart failure. Perhaps in 
an elderly population with such a high prevalence of co-morbid illness, it is unrealistic 
to target a single disease. The issue of how best to develop self-management 
interventions that deal with the demands of both a specific disease and one or more 
co-morbid illnesses remains unresolved and is an important area for further research.
The current study has made a number of important contributions to the field of self­
m anagem ent in heart failure. The need to develop interventions that can help to 
enhance upon optimised medical care has been highlighted. A number of areas that 
would benefit from further research and suggestions for ways to enhance self­
m anagem ent interventions have been discussed. The findings of subgroup analysis 
have provided a fascinating hypothesis for future work in the field of heart failure self­
management.
282
REFERENCES
Ajzen, I. (1991). The theory of planned behavior. Organizational Behavior and 
Human Decision Processes., 50, 179-211.
Almeida, 0 .  P. & Flicker, L. (2001). The mind of a failing heart: a systematic 
review of the association between congestive heart failure and cognitive functioning. 
Internal Medicine Journal, 31, 290-295.
Arcand, J. A., Brazel, S., Joliffe, C., Choleva, M., Berkoff, F., Allard, J. P. et al. 
(2005). Education by a dietitian in patients with heart failure results in improved 
adherence with a sodium-restricted diet: a randomized trial. American Heart Journal, 
150, 716.
Armitage, C. J. & Conner, M. (2001). Efficacy of the Theory of Planned 
Behaviour: a meta-analytic review. British Journal o f Social Psychology, 40, 471-499.
Artinian, N. T., Magnan, M., Sloan, M., & Lange, M. P. (2002). Self-care 
behaviors among patients with heart failure. Heart and Lung, 31, 161-172.
Ashton, C. M., Kuykendall, D. H., Johnson, M. L., Wray, N. P., & W u, L. (1995). 
The Association between the Quality of Inpatient Care and Early Readmission. Annals 
of Internal Medicine, 122, 415-421.
Attkisson, C. C. & Zwick, R. (1982). The client satisfaction questionnaire. 
Psychometric properties and correlations with service utilization and psychotherapy 
outcome. Evaluation and Program Planning, 5, 233-237.
Austin, J., Williams, R., Ross, L., Moseley, L., & Hutchison, S. (2005). 
Randomised controlled trial of cardiac rehabilitation in elderly patients with heart failure. 
European Journal of Heart Failure, 7, 411-417.
283
Bandura, A. (1977). Self-efficacy: toward a unifying theory of behavior change. 
Psychological Review, 84, 191-215.
Bandura, A. (1986). Social foundations of thought and action: a social-cognitive 
theory. Englewood Cliffs, NJ: Prentice-Hall.
Bandura, A. (1997). Self-Efficacy: The exercise of control. New York: Freeman
& Co.
Bandura, A. (2000). Health promotion from the perspective of social cognitive 
theory. In P.Norman, C. Abraham, & M. Connor (Eds.), Understanding and changing 
health behaviour: From health beliefs to self regulation. Amsterdam: Harwood 
Academic Publishers.
Bardy, G. H., Lee, K. L., Mark, D. B., Poole, J. E., Packer, D. L., Boineau, R. et 
al. (2005). Amiodarone or an Implantable Cardioverter-Defibrillator for Congestive 
Heart Failure. The New England Journal of Medicine, 352, 225-237.
Barlow, J., Wright, C., Sheasby, J., Turner, A., & Hainsworth, J. (2002). Self­
management approaches for people with chronic conditions: a review. Patient 
Education and Counseling, 48, 177-187.
Barlow, J. H., Turner, A. P., & Wright, C. C. (2000). A randomized controlled 
study of the Arthritis Self-M anagem ent Programme in the UK. Health Education 
Research, 15, 665-680.
Baron, R.M. & Kenny, D.A. (1986) The moderator-mediator variable distinction 
in social psychological research: Conceptual, strategic, and statistical considerations. 
Journal o f Personality and Social Psychology, 51, 1173-1182
Beck, A. (1976). Cognitive therapy and the emotional disorders. New York: 
Penguin.
284
Beck, A. T., W ard, C. H., Mendelson, M., Mock, J., & Erbaugh, J. (1961). An 
inventory for measuring depression. Archives of General Psychiatry, 4, 561-571.
Becker, M. H. (1974). The health belief model and personal health behavior. 
Health Education Monographs, 2, 324-473.
Belardinelli, R., Georgiou, D., Cianci, G., & Purcaro, A. (1999). Randomized, 
controlled trial of long-term moderate exercise training in chronic heart failure: effects 
on functional capacity, quality of life, and clinical outcome. Circulation, 99, 1173-1182.
Bellg, A. J., Borrelli, B., Resnick, B., Hecht, J., Minicucci, D. S., Ory, M. et al. 
(2004). Enhancing treatment fidelity in health behavior change studies: best practices 
and recommendations from the NIH Behavior Change Consortium. Health Psychology, 
23, 443-451.
Bennett, S. J., Milgrom, L. B., Champion, V., & Huster, G. A. (1997). Beliefs 
about medication and dietary compliance in people with heart failure: An instrument 
development study. Heart and Lung, 26, 273-279.
Berkman, L. F., Blumenthal, J., Burg, M., Carney, R. M., Catellier, D., Cowan, M. 
J., Czajkowski, S. M., DeBusk, R., Hosking, J., Jaffe, A., Kaufmann, P. G., Mitchell, P., 
Norman, J., Powell, L. H., Raczynski, J. M., & Schneiderman, N. (2003) Effects of 
treating depression and low perceived social support on clinical events after myocardial 
infarction: the Enhancing Recovery in Coronary Heart Disease Patients (EN R IC H D ) 
Randomized Trial. JAMA, 289, 3106-3116.
Berry, C. & McMurray, J. (1999). A review of quality-of-life evaluations in 
patients with congestive heart failure. Pharmacoeconomics., 16, 247-271.
285
Beta-Blocker Evaluation of Survival Trial Investigators (2001). A Trial of the 
Beta-Blocker Bucindolol in Patients with Advanced Chronic Heart Failure. The New 
England Journal of Medicine, 344, 1659-1667.
Blue, L., Lang, E., McMurray, J., Davie, A., McDonagh, T., Murdoch, D. et al.
(2001). Randomised controlled trial of specialist nurse intervention in heart failure. 
British Medical Journal, 323, 715-718 .
Bohachick, P., Burke, L. E., Sereika, S., Murali, S., & Dunbar-Jacob, J. (2002). 
Adherence to angiotensin-converting enzyme inhibitor therapy for heart failure. 
Progress in Cardiovascular Nursing, 17, 160-166.
Bonneux, L., Barendregt, J. J., Meeter, K., Bonsel, G. J., & van der Maas, P. J. 
(1994). Estimating clinical morbidity due to ischemic heart disease and congestive 
heart failure: the future rise of heart failure. American Journal of Public Health, 84, 20- 
28.
Bouvy, M. L., Heerdink, E. R., Leufkens, H. G. M., & Hoes, A. W . (2003). 
Predicting mortality in patients with heart failure: a pragmatic approach. Heart, 89, 605- 
609.
Braunstein, J. B., Anderson, G. F., Gerstenblith, G., Weller, W ., Niefeld, M., 
Herbert, R. et al. (2003). Noncardiac comorbidity increases preventable 
hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. 
Journal of the American College of Cardiology, 42, 1226-1233.
Brewin, C.R. & Bradley, C. (1989). Patient preferences and randomised clinical 
trials. BMJ, 299, 313-315
286
Brophy, J. M., Joseph, L., & Rouleau, J. L. (2001). (beta}-Blockers in 
Congestive Heart Failure: A Bayesian Meta-Analysis. Annals of Internal Medicine, 134, 
550-560.
Bruggink-Andre-de-la-Porte, P. W . F., Lok, D. J., van Wijngaarden, J., Cornel, J. 
H., Pruijsers-Lamers, D., van Veldhuisen, D. J. et al. (2005). Heart failure programmes 
in countries with a primary care-based health care system. Are additional trials 
necessary? Design of the DEAL-HF study. European Journal of Heart Failure, 7, 910- 
920.
Bushnell, F. K. (1992). Self-care teaching for congestive heart failure patients. 
Journal of Gerontological Nursing., 18, 27-32.
Butler, J., Arbogast, P. G., Daugherty, J., Jain, M. K., Ray, W . A., & Griffin, M. R.
(2004). Outpatient utilization of angiotensin-converting enzyme inhibitors among heart 
failure patients after hospital discharge. Journal of the American College of Cardiology, 
43, 2036-2043.
Caldwell, M. A., Peters, K. J., & Dracup, K. A. (2005). A simplified education 
program improves knowledge, self-care behavior, and disease severity in heart failure 
patients in rural settings. American Heart Journal, 150, 983.
Cameron, L. D. & Leventhal, H. D. (2003). Self-regulation, health and illness: an 
overview. In L.D.Cameron & H. Leventhal (Eds.), The self-regulation of health and 
illness behaviour, (pp. 1-13). New York: Routledge.
Carlson, B., Riegel, B., & Moser, D. K. (2001). Self-care abilities of patients with 
heart failure. Heart and Lung, 30, 351-359.
Carr, J. G., Stevenson, L. W ., Walden, J. A., & Heber, D. (1989). Prevalence 
and hemodynamic correlates of malnutrition in severe congestive heart failure
287
secondary to ischemic or idiopathic dilated cardiomyopathy. The American Journal of 
Cardiology, 63, 709-713.
Chaturvedi, N. (2003). Ethnic differences in cardiovascular disease. Heart, 89, 
681-686.
Chriss, P. M., Sheposh, J., Carlson, B., & Riegel, B. (2004). Predictors of 
successful heart failure self-care maintenance in the first three months after 
hospitalization. Heart and Lung, 33, 345-353.
Chui, M. A., Deer, M., Bennett, S. J., Tu, W ., Oury, S., Brater, D. C. et al. (2003). 
Association between adherence to diuretic therapy and health care utilization in 
patients with heart failure. Pharmacotherapy, 23, 326-332.
Cleland, J. G., Swedberg, K., Cohen, S. A., Cosin, A. J., Dietz, R., Follath, F. et 
al. (2000). The Euro Heart Failure Survey of the EU RO HEA RT survey programme. A 
survey on the quality of care among patients with heart failure in Europe. The Study 
Group on Diagnosis of the Working Group on Heart Failure of the European Society of 
Cardiology. The Medicines Evaluation Group Centre for Health Economics University 
of York. European Journal of Heart Failure, 2, 123-132.
Cleland, J. G. F., Swedberg, K., Follath, F., Komajda, M., Cohen-Solal, A., 
Aguilar, J. C. et al. (2003). The EuroHeart Failure survey programme--a survey on the 
quality of care among patients with heart failure in Europe: Part 1: patient 
characteristics and diagnosis. European Heart Journal, 24, 442-463.
Cleland, J. G. F., Daubert, J. C., Erdmann, E., Freemantle, N., Gras, D., 
Kappenberger, L. et al. (2005). The Effect of Cardiac Resynchronization on Morbidity 
and Mortality in Heart Failure. The New England Journal of Medicine, 352, 1539-1549.
288
Cleland, J. G. F., Coletta, A. P., & Clark, A. L. (2007). Clinical trials update from 
the American College of Cardiology 2007: ALPHA, EVEREST, FUSIO N II, VALIDD, 
PARR-2, REMODEL, SPICE, CO U R A G E, COACH, REMADHE, pro-BNP for the 
evaluation of dyspnoea and THIS-diet. European Journal of Heart Failure, 9, 740-745.
Cline, C. M., Israelsson, B. Y., W illenheimer, R. B., Broms, K., & Erhardt, L. R. 
(1998). Cost effective management programme for heart failure reduces hospitalisation. 
Heart, 80, 442-446.
Cline, C. M. J., Bjorck-Linne, A. B., Israelsson, B. Y. A., Willenheimer, R. B., & 
Erhardt, L. R. (1999). Non-compliance and knowledge of prescribed medication in 
elderly patients in heart failure. European Journal of Heart Failure, 1, 145-149.
Coates, V. E. & Boore, J. R. (1996). Knowledge and diabetes self-management. 
Patient Education and Counseling, 29, 99-108.
CO N SEN SU S Trial Study Group (1987). Effects of enalapril on mortality in 
severe congestive heart failure. Results of the Cooperative North Scandinavian 
Enalapril Survival Study (C O N S E N S U S ). The New England Journal of Medicine, 316, 
1429-1435.
Corvera-Tindel, T., Doering, L. V., Woo, M. A., Khan, S., & Dracup, K. (2004). 
Effects of a home walking exercise program on functional status and symptoms in 
heart failure. American Heart Journal, 147, 339-346.
Cowie, M. R., W ood, D. A., Coats, A. J., Thompson, S. G., Suresh, V., Poole- 
Wilson, P. A. et al. (2000). Survival of patients with a new diagnosis of heart failure: a 
population based study. Heart, 83, 505-510.
289
Cowie, M. R., Fox, K. F., Wood, D. A., Metcalfe, C., Thompson, S. G., Coats,
A.-J. S. et al. (2002). Hospitalization of patients with heart failure: a population-based 
study. European Heart Journal, 23, 877-885.
Crawford, J. R., Henry, J. D., Crombie, C., & Taylor, E. P. (2001). Normative 
data for the HADS from a large non-clinical sample. British Journal of Clinical 
Psychology, 40, 429-434.
Crawford, J. R. & Henry, J. D. (2004). The Positive and Negative Affect 
Schedule (PANAS): Construct validity, measurement properties and normative data in 
a large non-clinical sample. British Journal of Clinical Psychology, 43, 245-265.
Creer, T. L. & Holroyd, K. A. (1997). Self-management. In A.Baum, S. Newman, 
J. W einm an, R. West, & C. McManus (Eds.), Cambridge handbook of psychology, 
health and medicine, (pp. 255-258). Cambridge: Cambridge University Press.
Creer, T. L. (2000). Self-management of chronic illness. In Boekaerts M,
Pintrich PR, & Zeidner M (Eds.), Handbook of self-regulation (pp. 601-629). Academic 
Press.
D'Zurilla, T. J. & Goldfried, M. R. (1971). Problem solving and behavior 
modification. Journal of Abnormal Psychology, 78, 107-126.
D'Zurilla, T. J. & Nezu, A. M. (2001). Problem-solving therapies. In Dobson KD 
(Ed.), Handbook of cognitive-behavioral therapies. (Second ed., pp. 211-245).
De Geest, S., Scheurweghs, L., Reynders, I., Pelemans, W ., Droogne, W ., Van 
Cleemput, J. et al. (2003). Differences in psychosocial and behavioral profiles between 
heart failure patients admitted to cardiology and geriatric wards. European Journal of 
Heart Failure, 5, 557-567.
290
Department of Health (2000). Heart failure. In Coronary Heart Disease. National 
Service Frameworks {pp. 1-21). Crown Copyright.
Department of Health (2001). The expert patient: a new approach to chronic 
disease management for the 21st century. London: Department of Health.
DeVellis, R. F. (2003). Scale development: Theory and applications. (Second 
ed.) Thousand Oaks, California: Sage.
DeW alt, D. A., Pignone, M., Malone, R., Rawls, C., Kosnar, M. C., George, G. 
et al. (2004). Development and pilot testing of a disease management program for low 
literacy patients with heart failure. Patient Education and Counseling, 55, 78-86.
DeW alt, D. A., Malone, R. M., Bryant, M. E., Kosnar, M. C., Corr, K. E., 
Rothman, R. L. et al. (2006). A heart failure self-management program for patients of 
all literacy levels: a randomized, controlled trial. BMC Health Services Research, 30.
DiMatteo, M. R., Lepper, H. S., & Croghan, T. W . (2000). Depression Is a Risk 
Factor for Noncompliance With Medical Treatment: Meta-analysis of the Effects of 
Anxiety and Depression on Patient Adherence. Archives of Internal Medicine, 160, 
2101-2107.
DiMatteo, M. R. (2004). Social support and patient adherence to medical 
treatment: a meta-analysis. Health Psychology, 23, 207-218.
DiMatteo, M. R. (2004). Variations in patients' adherence to medical 
recommendations: a quantitative review of 50 years of research. Medical Care, 42, 
200-209.
Dolgin, M. (1994). Nomenclature and Criteria for Diagnosis of Diseases of the 
Heart and Great Vessels. (Ninth ed.) Boston, Mass.: Little Brown & Co.
291
Doughty, R. N., Wright, S. P., Pearl, A., Walsh, H. J., Muncaster, S., Whalley, G.
A. et al. (2002). Randomized, controlled trial of integrated heart failure management. 
The Auckland Heart Failure Management Study. European Heart Journal, 23 ,139-146.
Dunagan, W . C., Littenberg, B., Ewald, G. A., Jones, C. A., Emery, V. B., 
Waterman, B. M. et al. (2005). Randomized trial of a nurse-administered, telephone- 
based disease management program for patients with heart failure. Journal of Cardiac 
Failure, 11, 358-365.
Dunbar, S. B., Clark, P. C., Deaton, C., Smith, A. L., De, A. K., & O'Brien, M. C.
(2005). Family education and support interventions in heart failure: a pilot study.
Nursing Research, 54, 158-166.
Ekman, I., Andersson, B., Ehnfors, M., Matejka, G., Persson, B., & Fagerberg,
B. (1998). Feasibility of a nurse-monitored, outpatient-care programme for elderly 
patients with moderate-to-severe, chronic heart failure. European Heart Journal, 19, 
1254-1260.
Ellis, C., Gnani, S., & Majeed, A. (2001). Prevalence and management of heart 
failure in general practicie in England and W ales, 1994-98. Health Statistics Quarterly, 
11, 17-24.
Engel, G. (1977). The need for a new medical model: A challenge 
for biomedicine. Science, 196, 129-136 .
Evangelista, L., Doering, L. V., Dracup, K., Westlake, C., Hamilton, M., & 
Fonarow, G. C. (2003). Compliance behaviors of elderly patients with advanced heart 
failure. Journal of Cardiovascular Nursing, 18,197-206.
292
Evangelista, L. S., Kagawa-Singer, M., & Dracup, K. (2001). Gender differences 
in health perceptions and meaning in persons living with heart failure. Heart and Lung, 
30, 167-176.
Evangelista, L. S., Berg, J., & Dracup, K. (2001). Relationship between  
psychosocial variables and compliance in patients with heart failure. Heart and Lung, 
30, 294-301.
Evangelista, L., Dracup, K., & Doering, L. (2000). Treatment-seeking delays in 
heart failure patients. Journal of Heart and Lung Transplant, 19, 932-938.
Faris, R., Purcell, H., Henein, M. Y., & Coats, A. J. (2002). Clinical depression is 
common and significantly associated with reduced survival in patients with non- 
ischaemic heart failure. European Journal of Heart Failure, 4, 541-551.
Faris, R., Flather, M., Purcell, H., Henein, M., Poole-Wilson, P., & Coats, A.
(2002). Current evidence supporting the role of diuretics in heart failure: a meta 
analysis of randomised controlled trials. International Journal of Cardiology, 82 ,149- 
158.
Farmer, A., W ade, A., Goyder, E., Yudkin, P., French, D., Craven, A. et al. 
(2007). Impact of self monitoring of blood glucose in the management of patients with 
non-insulin treated diabetes: open parallel group randomised trial. British Medical 
Journal, 335, 132.
Feenstra, J., Grobbee, D. E., Jonkman, F. A. M., Hoes, A. W ., & Strieker, B. H.
C. (1998). Prevention of relapse in patients with congestive heart failure: the role of 
precipitating factors. Heart, 80, 432-436.
Fonarow, G. C., Stevenson, L. W ., W alden, J. A., Livingston, N. A., Steimle, A. 
E., Hamilton, M. A. et al. (1997). Impact of a comprehensive heart failure management
293
program on hospital readmission and functional status of patients with advanced heart 
failure. Journal of the American College of Cardiology, 30, 725-732.
Freedland, K. E. & Carney, R. M. (2000). Psychosocial considerations in elderly 
patients with heart failure. Clinics in Geriatric Medicine, 16, 649-661.
Freedland, K. E., Rich, M. W ., Skala, J. A., Carney, R. M., Davila-Roman, V. G., 
& Jaffe, A. S. (2003). Prevalence of depression in hospitalized patients with congestive 
heart failure. Psychosomatic Medicine, 65, 119-128.
Friedman, M. M. (1997). Older adults' symptoms and their duration before 
hospitalization for heart failure. Heart & Lung: The Journal of Acute and Critical Care, 
26, 169-176.
Friedmann, E., Thomas, S. A., Liu, F., Morton, P. G., Chapa, D., & Gottlieb, S. 
S. (2006). Relationship of depression, anxiety, and social isolation to chronic heart 
failure outpatient mortality. American Heart Journal, 152, 940.
Gallant, M. P. (2003). The influence of social support on chronic illness self­
management: A review and directions for research. Health Education & Behavior, 30, 
170-195.
Garg, R. & Yusuf, S. (1995). Overview of randomized trials of angiotensin- 
converting enzyme inhibitors on mortality and morbidity in patients with heart failure. 
Collaborative Group on A CE Inhibitor Trials. JAMA: The Journal of the American 
Medical Association, 273, 1450-1456.
Gattis, W . A., Hasselblad, V., Whellan, D. J., & O'Connor, C. M. (1999). 
Reduction in heart failure events by the addition of a clinical pharmacist to the heart 
failure management team: results of the Pharmacist in Heart Failure Assessment
294
Recommendation and Monitoring (PHARM ) Study. Archives of Internal Medicine, 159, 
1939-1945.
Ghali, J. K., Kadakia, S., Cooper, R., & Ferlinz, J. (1988). Precipitating factors 
leading to decompensation of heart failure. Traits among urban blacks. Archives of 
Internal Medicine, 148, 2013-2016.
Gibson, P. G., Coughlan, J., Wilson, A. J., Hensley, M. J., Abramson, M., 
Bauman, A. et al. (2000). Limited (information only) patient education programs for 
adults with asthma. Cochrane.Database.Syst.Rev., CD001005.
Glasgow, R. E., Eakin, E. G., & Toobert, D. J. (1996). How generalizable are 
the results of diabetes self-management research? The impact of participation and 
attrition. Diabetes Educator, The, 22, 573-574.
Glasgow, R. E., Hampson, S. E., Strycker, L. A., & Ruggiero, L. (1997). 
Personal-model beliefs and social-environmental barriers related to diabetes self­
management. Diabetes Care, 20, 556-561.
Gnani, S. & Ellis, C. (2001). Trends in hospital admissions and case fatality due 
to heart failure in England, 1990/1 to 1999/2000. Health Statistics Quarterly, 13, 16-21.
Goldman, L., Hashimoto, B., Cook, E. F., & Loscalzo, A. (1981). Comparative 
reproducibility and validity of systems for assessing cardiovascular functional class: 
advantages of a new specific activity scale. Circulation, 64 ,1227-1234.
Gollwitzer, P. M. (1993). Goal achievement: The role of intentions. European 
Review of Social Psychology., 4, 141 -185.
Gollwitzer, P. M. (1999). Implementation intentions: Strong effects of simple 
plans. American Psychologist, -503.
295
Gonseth, J., Guallar-Castillon, P., Banegas, J. R., & Rodriguez-Artalejo, F. 
(2004). The effectiveness of disease management programmes in reducing hospital re­
admission in older patients with heart failure: a systematic review and meta-analysis of 
published reports. European Heart Journal, 25, 1570-1595.
Gottlieb, S. S., Khatta, M., Friedmann, E., Einbinder, L., Katzen, S., Baker, B. et 
al. (2004). The influence of age, gender and race on the prevalence of depression in 
heart failure patients. Journal of the American College of Cardiology, 43, 1542-1549.
Grady, K. L., Dracup, K., Kennedy, G., Moser, D. K., Piano, M., Stevenson, L. 
W . et al. (2000). Team management of patients with heart failure: A statement for 
healthcare professionals from The Cardiovascular Nursing Council of the American 
Heart Association. Circulation, 102, 2443-2456.
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000). 
Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: A new  
health status measure for heart failure. Journal of the American College of Cardiology, 
35, 1245-1255.
Griffin, S., Kinmouth, A. L., Skinner, C., & Kelly, J. (1998). Educational and 
psychosocial interventions for adults with diabetes. London: British Diabetic 
Association.
Gustafsson, F. & Arnold, J. M. (2004). Heart failure clinics and outpatient 
management: review of the evidence and call for quality assurance. European Heart 
Journal, 25, 1596-1604.
Guyatt, G. H., Nogradi, S., Halcrow, S., Singer, J., Sullivan M.J., & Fallen, E. L. 
(1989). Development and testing of a new measure of health status for clinical trials in 
heart failure. Journal of General Internal Medicine, 4, 101-107.
296
Gwadry-Sridhar, F. H., Flintoft, V., Lee, D. S., Lee, H., & Guyatt, G. H. (2004). A 
systematic review and meta-analysis of studies comparing readmission rates and 
mortality rates in patients with heart failure. Archives of Internal Medicine, 164, 2315- 
2320.
Gwadry-Sridhar, F. H., Arnold, J. M., Zhang, Y., Brown, J. E., Marchiori, G., & 
Guyatt, G. (2005). Pilot study to determine the impact of a multidisciplinary educational 
intervention in patients hospitalized with heart failure. American Heart Journal, 150,
982.
Hagger, M. S. & Orbell, S. (2003). A meta-analytic review of the common-sense 
model of illness representations. Psychology and Health, 18,141-184.
Happ, M. B., Naylor, M. D., & Roe-Prior, P. (1997). Factors contributing to 
rehospitalization of elderly patients with heart failure. Journal of Cardiovascular Nursing, 
11, 75-84.
Harrell, F.-E. J., Lee, K. L., Califf, R. M., Pryor, D. B., & Rosati, R. A. (1984). 
Regression modelling strategies for improved prognostic prediction. Statistics in 
Medicine, 3, 143-152.
Harrison, M. B., Browne, G. B., Roberts, J., Tugwell, P., Gafni, A., & Graham, I.
D. (2002). Quality of life of individuals with heart failure: a randomized trial of the 
effectiveness of two models of hospital-to-home transition. Medical Care, 40, 271-282.
Haworth, J. E., Moniz-Cook, E., Clark, A. L., Wang, M., Waddington, R., & 
Cleland, J. G. F. (2005). Prevalence and predictors of anxiety and depression in a 
sample of chronic heart failure patients with left ventricular systolic dysfunction. 
European Journal of Heart Failure, 7, 803-808.
297
Hershberger, R. E., Ni, H., Nauman, D. J., Burgess, D., Toy, W., Wise, K. et al.
(2001). Prospective evaluation of an outpatient heart failure management program. 
Journal of Cardiac Failure, 7, 64-74.
Hobbs, F. D., Kenkre, J. E., Roalfe, A. K., Davis, R. C., Hare, R., & Davies, M.
K. (2002). Impact of heart failure and left ventricular systolic dysfunction on quality of 
life: a cross-sectional study comparing common chronic cardiac and medical disorders 
and a representative adult population. European Heart Journal, 23 ,1867-1876.
Hodkinson HM. (1972) Evaluation of a mental test score for assessment of 
mental impairment in the elderly. Age and Ageing, 1(4), 233-8.
Holland, R., Battersby, J., Harvey, I., Lenaghan, E., Smith, J., & Hay, L. (2005). 
Systematic review of multidisciplinary interventions in heart failure. Heart, 91, 899-906.
Horne, R. (1998). Adherence to medication: a review of existing research. In 
L.B.Myers & K.Midence (Eds.), Adherence to treatment in medical conditions, (pp. 285- 
310). Amsterdam: Harwood Academic Publishers.
Horne, R., Weinman, J., & Hankins, M. (1998). The Beliefs about Medicines 
Questionnaire (BMQ): the development and evaluation of a new method for assessing 
the cognitive representation of medication. Psychology and Health, 14, 1-24.
Horne, R. & Weinman, J. (1999). Patients' beliefs about prescribed medicines 
and their role in adherence to treatment in chronic physical illness. Journal of 
Psychosomatic Research, 47(6), 555-567.
Horowitz, C. R., Rein, S. B., & Leventhal, H. (2004). A story of maladies, 
misconceptions and mishaps: effective management of heart failure. Social Science 
and Medicine 1982, 58, 631-643.
298
Hunt, S. A., Baker, D. W., Chin, M. H., Cinquegrani, M. P., Feldman, A. M., 
Francis, G. S. et al. (2002). ACC/AHA guidelines for the evaluation and management of 
chronic heart failure in the adult: executive summary: A report of the American College 
of Cardiology/American Heart Association Task Force on Practice Guidelines 
(Committee to Revise the 1995 Guidelines for the Evaluation and Management of 
Heart Failure) Developed in Collaboration with the International Society for Heart and 
Lung Transplantation Endorsed by the Heart Failure Society of America. The Journal of 
Heart and Lung Transplantation, 21, 189-203.
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., 
Ganiats, T. G. et al. (2005). ACC/AHA 2005 Guideline Update for the Diagnosis and 
Management of Chronic Heart Failure in the Adult: A Report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines (Writing 
Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart 
Failure): Developed in Collaboration With the American College of Chest Physicians 
and the International Society for Heart and Lung Transplantation: Endorsed by the 
Heart Rhythm Society. Circulation, 112, e154-e235.
Jaarsma, T., Halfens, R., Abu-Saad, H. H., Dracup, K., Gorgels, T., van Ree, J. 
et al. (1999). Effects of education and support on self-care and resource utilization in 
patients with heart failure. European Heart Journal, 20, 673-682.
Jaarsma, T., Abu Saad, H. H., Dracup, K., & Halfens, R. (2000). Self-care 
behaviour of patients with heart failure. Scandinavian Journal of Caring Sciences, 14, 
112-119.
Jaarsma, T., van der Wal, M. H. L., Hogenhuis, J., Lesman, I., Luttik, M. L., 
Veeger, N. J. G. M. et al. (2004). Design and methodology of the COACH study: a 
multicenter randomised Coordinating study evaluating Outcomes of Advising and 
Counselling in Heart failure. European Journal of Heart Failure, 6, 227-233.
299
Janz, N. K. & Becker, M. H. (1984). The health belief model: a decade later. 
Health Education Quarterly, 11, 1 -47.
Jenkinson, C., Layte, R., Wright, L., & Coulter, A. (1996). The U.K. SF-36: An 
analysis and interpretation manual. Oxford: Health Services Research Unit.
Jerant, A. F., Azari, R., & Nesbitt, T. S. (2001). Reducing the cost of frequent 
hospital admissions for congestive heart failure: a randomized trial of a home telecare 
intervention. Medical Care, 39, 1234-1245.
Jiang, W., Alexander, J., Christopher, E., Kuchibhatla, M., Gaulden, L. H., Cuffe, 
M. S. et al. (2001). Relationship of depression to increased risk of mortality and 
rehospitalization in patients with congestive heart failure. Archives of Internal Medicine, 
161, 1849-1856.
Joekes, K., van Elderen, T., & Schreurs, K. (2007). Self-efficacy and 
overprotection are related to quality of life, psychological well-being and self­
management in cardiac patients. Journal of Health Psychology, 12, 4-16.
Junger, J., Schellberg, D., Muller-Tasch, T., Raupp, G., Zugck, C., Haunstetter, 
A. et al. (2005). Depression increasingly predicts mortality in the course of congestive 
heart failure. European Journal of Heart Failure, 7, 261-267.
Kamalesh, M. & Nair, G. (2005). Disproportionate increase in prevalence of 
diabetes among patients with congestive heart failure due to systolic dysfunction. 
International Journal of Cardiology, 99, 125-127.
Karoly, P. (1993). Mechanisms of Self-Regulation: A Systems View. Annual 
Review of Psychology, 44, 23-52.
Kelly, D. T. (1997). 1996 Paul Dudley White International Lecture : Our Future 
Society: A Global Challenge. Circulation, 95, 2459-2464.
300
Kempen, G. I., Sanderman, R., Miedema, I., Meyboom-de-Jong, B., & Ormel, J.
(2000). Functional decline after congestive heart failure and acute myocardial infarction 
and the impact of psychological attributes. A prospective study. Quality of Life 
Research, 9, 439-450.
Kenchaiah, S., Evans, J. C., Levy, D., Wilson, P. W. F., Benjamin, E. J., Larson, 
M. G. et al. (2002). Obesity and the Risk of Heart Failure. The New England Journal of 
Medicine, 347, 305-313.
Kennedy, A., Reeves, D., Bower, P., Lee, V., Middleton, E., Richardson, G. et al. 
(2007). The effectiveness and cost effectiveness of a national lay-led self care support 
programme for patients with long-term conditions: a pragmatic randomised controlled 
trial. Journal of Epidemiology and Community Health, 61, 254-261.
Koelling, T. M., Johnson, M. L., Cody, R. J., & Aaronson, K. D. (2005).
Discharge education improves clinical outcomes in patients with chronic heart failure. 
Circulation, 111, 179-185.
Komajda, M., Follath, F., Swedberg, K., Cleland, J., Aguilar, J. C., Cohen Solal, 
A. et al. (2003). The EuroHeart Failure Survey programme-a survey on the quality of 
care among patients with heart failure in Europe. Part 2: treatment. European Heart 
Journal, 24, 464-474.
Komajda, M., Lapuerta, P., Hermans, N., Gonzalez-Juanatey, J. R., van 
Veldhuisen, D. J., Erdmann, E. et al. (2005). Adherence to guidelines is a predictor of 
outcome in chronic heart failure: the MAHLER survey. European Heart Journal, 26, 
1653-1659.
Konstam, V., Salem, D., Pouleur, H., Kostis, J., Gorkin, L., Shumaker, S. et al. 
(1996). Baseline quality of life as a predictor of mortality and hospitalization in 5,025
301
patients with congestive heart failure. SOLVD Investigations. Studies of Left Ventricular 
Dysfunction Investigators. American Journal of Cardiology, 78, 890-895.
Kostis, J. B., Rosen, R. C., Cosgrove, N. M., Shindler, D. M., & Wilson, A. C. 
(1994). Nonpharmacologic therapy improves functional and emotional status in 
congestive heart failure. Chest, 106, 996-1001.
Krasuski, R. A. (2006). Heart failure, www.med.uc.edu/kranias/heart_failure.htm 
[On-line]. Available: www.med.uc.edu/kranias/heart failure.htm
Krum, H. & Gilbert, R. (2003). Demographics and concomitant disorders in 
heart failure. The Lancet, 362, 147-158.
Krumholz, H. M., Amatruda, J., Smith, G. L., Mattera, J. A., Roumanis, S. A., 
Radford, M. J. et al. (2002). Randomized trial of an education and support intervention 
to prevent readmission of patients with heart failure. Journal of the American College of 
Cardiology, 39, 83-89.
Kuehneman, T., Saulsbury, D., Splett, P., & Chapman, D. B. (2002). 
Demonstrating the impact of nutrition intervention in a heart failure program. Journal of 
the American Dietetic Association, 102,1790-1794.
Kutzleb, J. & Reiner, D. (2006). The impact of nurse-directed patient education 
on quality of life and functional capacity in people with heart failure. Journal of the 
American Academy of Nurse Practitioners, 18,116-123.
Lagakos, S. W. (2006). The Challenge of Subgroup Analyses -- Reporting 
without Distorting. The New England Journal of Medicine, 354, 1667-1669.
Laramee, A. S., Levinsky, S. K., Sargent, J., Ross, R., & Callas, P. (2003).
Case management in a heterogeneous congestive heart failure population: a 
randomized controlled trial. Archives of Internal Medicine, 163, 809-817.
302
Lazarus, R. S. & Folkman, S. (1984). Stress, appraisal and coping. New York: 
Springer.
Lenker, S. L., Lorig, K., & Gallagher, D. (1984). Reasons for the lack of 
association between changes in health behavior and improved health status: an 
exploratory study. Patient Education and Counseling, 6, 69-72.
Leventhal, H., Nerenz, D. R., & Steele, D. J. (1984). Illness representations and 
coping with health threats. In A.Baum, S E Taylor, & J E Singer (Eds.), Social 
Psychological Aspects of Health (pp. 219-252). New Jersey: Erlbaum.
Levy, D., Kenchaiah, S., Larson, M. G., Benjamin, E. J., Kupka, Mi. J., Ho, K. K. 
L. et al. (2002). Long-Term Trends in the Incidence of and Survival with Heart Failure. 
The New England Journal of Medicine, 347,1397-1402.
Lewin, B., Robertson, I. H., Cay, E. L., Irving, J. B., & Campbell, M. (1992). 
Effects of self-help post-myocardial-infarction rehabilitation on psychological 
adjustment and use of health services. Lancet, 339,1036-1040.
Lindesay, J., Briggs, K., & Murphy, E. (1989). The Guy's/Age Concern survey. 
Prevalence rates of cognitive impairment, depression and anxiety in an urban elderly 
community. The British Journal Of Psychiatry: The Journal Of Mental Science, 155, 
317-329.
Linne, A. B., Liedholm, H., & Israellson, B. (1999). Effects of systematic 
education on heart failure patients' knowledge after 6 months. A randomised, controlled 
trial. European Journal of Heart Failure, 1, 219-227.
Lip, G., Zarifis, J., & Beevers, D. (1997). Acute admissions with heart failure to 
a district general hospital serving a multiracial population. International Journal of 
Clinical Practice, 51, 223-227.
303
Lorig, K., Seleznick, M., Lubeck, D., Ung, E., Chastain, R. L., & Holman, H. R. 
(1989). The beneficial outcomes of the arthritis self-management course are not 
adequately explained by behavior change. Arthritis and Rheumatism, 32, 91-95.
Lorig, K., Stewart, A., Ritter, P., Gonzalez, V., Laurent, D., & Lynch, J. (1996). 
Outcome Measures for Health Education and Other Health Care Interventions. 
California: Sage Publications Inc.
Lorig, K., Gonzalez, V. M., Laurent, D. D., Morgan, L., & Laris, B. A. (1998). 
Arthritis self-management program variations: three studies. Arthritis Care and 
Research, 11, 448-454.
Lorig, K. R., Sobel, D. S., Stewart, A. L., Brown, B.-W. J., Bandura, A., Ritter, P. 
et al. (1999). Evidence suggesting that a chronic disease self-management program 
can improve health status while reducing hospitalization: a randomized trial. Medical 
Care, 37, 5-14.
Lorig, K. R. & Holman, H. (2003). Self-management education: history, 
definition, outcomes, and mechanisms. Annals of Behavioral Medicine, 26, 1-7.
Luskin, F., Newell, K., & Haskel, W. (1999). Stress management training of 
elderly patients with congestive heart failure: Pilot study. Preventive Cardiology, 2 ,101- 
104.
MacIntyre, K., Capewell, S., Stewart, S., Chalmers, J. W. T., Boyd, J., Finlayson, 
A. et al. (2000). Evidence of Improving Prognosis in Heart Failure : Trends in Case 
Fatality in 66 547 Patients Hospitalized Between 1986 and 1995. Circulation, 102, 
1126-1131.
Marlowe D, & Crowne D.P. (1961) Social desirability and response to perceived 
situational demands. Journal of Consulting and Clinical Psychology,25,109-15.
304
Martensson, J., Stromberg, A., Dahlstrom, U., Karlsson, J. E., & Fridlund, B.
(2005). Patients with heart failure in primary health care: effects of a nurse-led 
intervention on health-related quality of life and depression. European Journal of Heart 
Failure, 7, 393-403.
McAlister, F. A., Lawson, F. M., Teo, K. K., & Armstrong, P. W. (2001). A 
systematic review of randomized trials of disease management programs in heart 
failure. American Journal of Medicine, 110, 378-384.
McAlister, F. A., Stewart, S., Ferrua, S., & McMurray, J. J. V. (2004). 
Multidisciplinary strategies for the management of heart failure patients at high risk for 
admission. A systematic review of randomized trials. Journal of the American College 
of Cardiology, 44, 810-819.
McDonald, K., Ledwidge, M., Cahill, J., Kelly, J., Quigley, P., Maurer, B. et al.
(2001). Elimination of early rehospitalization in a randomized, controlled trial of 
multidisciplinary care in a high-risk, elderly heart failure population: the potential 
contributions of specialist care, clinical stability and optimal angiotensin-converting 
enzyme inhibitor dose at discharge. European Journal of Heart Failure, 3, 209-215.
McDonald, K., Ledwidge, M., Cahill, J., Quigley, P., Maurer, B., Travers, B. et al.
(2002). Heart failure management: Multidisciplinary care has intrinsic benefit above the 
optimization of medical care. Journal of Cardiac Failure, 8 ,142-148.
McDonald, K. (2005). Current guidelines in the management of chronic heart 
failure: Practical issues in their application to the community population. European 
Journal of Heart Failure, 7, 317-321.
McKelvie, R. S., Teo, K. K., McCartney, N., Humen, D., Montague, T., & Yusuf, 
S. (1995). Effects of exercise training in patients with congestive heart failure: A critical 
review. Journal of the American College of Cardiology, 25, 789-796.
305
McKelvie, R. S., Teo, K. K., Roberts, R., McCartney, N., Humen, D., Montague, 
T. et al. (2002). Effects of exercise training in patients with heart failure: The Exercise 
Rehabilitation Trial (EXERT). American Heart Journal, 144, 23-30.
McMurray, J., Hart, W., & Rhodes, G. (1993). An evaluation of the cost of heart 
failure to the National Health Service in the UK. British Journal of Medical Economics, 6, 
99-110.
McMurray, J. J. & Stewart, S. (2000). Epidemiology, aetiology, and prognosis of 
heart failure. Heart, 83, 596-602.
McMurray, J. J. V. & Stewart, S. (2002). The burden of heart failure. European 
Heart Journal Supplements, 4, D50-D58.
McMurray, J. J. V. & Pfeffer, M. A. (2005). Heart failure. The Lancet, 365, 1877-
1889.
McNally, S. T. & Newman, S. (1999). Objective and subjective 
conceptualizations of social support. Journal of Psychosomatic Research, 46, 309-314.
Mehta, P., Dubrey, S., McIntyre, H., Walker, D., Sardman, S., Sutton, G. et al.
(2006). Emerging evidence for improved survival for patients with newly diagnosed 
heart failure in the UK. Heart, 92, A121.
Michalsen, A., Konig, G., & Thimme, W. (1998). Preventable causative factors 
leading to hospital admission with decompensated heart failure. Heart, 80, 437-441.
Miche, E., Herrmann, G., Wirtz, U., Laki, H., Barth, M., & Radzewitz, A. (2003). 
Effects of education, self-care instruction and physical exercise on patients with chronic 
heart failure. Z Kardiol, 92, 985-993.
306
Michie, S. & Abraham, C. (2004). Interventions to change health behaviours: 
evidence-based or evidence-inspired? Psychology and Health, 19, 29-49.
Monane, M., Bohn, R. L., Gurwitz, J. H., Glynn, R. J., & Avorn, J. (1994). 
Noncompliance with congestive heart failure therapy in the elderly. Archives of Internal 
Medicine, 154, 433-437.
Moser, D. K. & Mann, D. L. (2002). Improving outcomes in heart failure. It's not 
unusual beyond usual care. Circulation, 105, 2810-2812.
Myers, L. B. & Midence, K. (1998). Concepts and issues in adherence. In 
L.B.Myers & K. Midence (Eds.), Adherence to treatment in medical conditions (pp. 1- 
24). Amsterdam: Harwood.
National Institute for Clinical Excellence. (2003). Management of chronic heart 
failure in adults in primary and secondary care. NICE Guideline No.5.
Newell, S. A., Bowman, J. A., & Cockburn, J. D. (2000). Can compliance with 
nonpharmacologic treatments for cardiovascular disease be improved?. American 
Journal of Preventive Medicine, 18, 253-261.
Newman, S., Mulligan, K., & Steed, L. (2001). What is meant by self­
management and how can its efficacy be established? Rheumatology.(Oxford), 40 ,1-4.
Newman, S., Steed, L., & Mulligan, K. (2004). Self-management interventions 
for chronic illness. The Lancet, 364,1523-1537.
Ni, H., Nauman, D., Burgess, D., Wise, K., Crispell, K., & Herschberger, R. E. 
(1999). Factors influencing knowledge of and adherence to self-care among patients 
with heart failure. Archives of Internal Medicine, 159, 1613-1619.
307
Nunnally, J. & Bernstein, I. (1994). Psychometric Theory. (Third ed.) New York: 
McGraw Hill.
O'Loughlin, C., Ledwidge, M., & McDonald, K. (2005). Establishing the clinical 
utility of the living with heart failure quality of life measurement instrument in the 
management of heart failure patients. European Heart Journal, 26, 601.
Ojeda, S., Anguita, M., Delgado, M., Atienza, F., Rus, C., Granados, A. L. et al. 
(2005). Short- and long-term results of a programme for the prevention of readmissions 
and mortality in patients with heart failure: are effects maintained after stopping the 
programme? European Journal of Heart Failure, 7, 921-926.
Opasich, C., Febo, O., Riccardi, P. G., Traversi, E., Forni, G., Pinna, G. et al. 
(1996). Concomitant Factors of Decompensation in Chronic Heart Failure. The 
American Journal of Cardiology, 78, 354-357.
Orem, D. E. (1995). Nursing: Concepts of practice. St. Louis: Mosby.
Packer, M., Coats, A. J., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P. et al. 
(2001). Effect of carvedilol on survival in severe chronic heart failure. New England 
Journal of Medicine, The, 344, 1651-1658.
Packer, M., Fowler, M. B., Roecker, E. B., Coats, A. J. S., Katus, H. A., Krum, H. 
et al. (2002). Effect of Carvedilol on the morbidity of patients with severe chronic heart 
failure: Results of the Carvedilol Prospective Randomized Cumulative Survival 
(COPERNICUS) Study. Circulation, 106, 2194-2199.
Parchman, M. L., Arambula-Solomon, T. G., Noel, P. H., Larme, A. C., & Pugh,
J. A. (2003). Stage of change advancement for diabetes self-management behaviors 
and glucose control. Diabetes Educator, The, 29 ,128-134.
308
Park, S. J., Tector, A., Piccioni, W., Raines, E., Gelijns, A., Moskowitz, A. et al. 
(2005). Left ventricular assist devices as destination therapy: A new look at survival. 
Journal of Thoracic and Cardiovascular Surgery, 129, 9-17.
Peterson, S. & Rayner, M. (2002). Coronary heart disease statistics: heart 
failure supplement. London: British Heart Foundation.
Philbin, E. F. (1999). Comprehensive multidisciplinary programs for the 
management of patients with congestive heart failure. Journal of General Internal 
Medicine, 14,130-135.
Phillips, C. O., Wright, S. M., Kern, D. E., Singa, R. M., Shepperd, S., & Rubin,
H. R. (2004). Comprehensive discharge planning with postdischarge support for older 
patients with congestive heart failure. JAMA: The Journal of the American Medical 
Association, 291, 1358-1367.
Phillips, C. O., Singa, R. M., Rubin, H. R., & Jaarsma, T. (2005). Complexity of 
program and clinical outcomes of heart failure disease management incorporating 
specialist nurse-led heart failure clinics. A meta-regression analysis. European Journal 
of Heart Failure, 7, 333-341.
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A. et al. 
(1999). The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe 
Heart Failure. The New England Journal of Medicine, 341, 709-717.
Pocock, S. J., Wang, D., Pfeffer, M. A., Yusuf, S., McMurray, J. J. V., Swedberg, 
K. B. et al. (2006). Predictors of mortality and morbidity in patients with chronic heart 
failure. European Heart Journal, 27, 65-75.
309
Polanczyk, C., Newton, C., Dec, G., & Di Salvo, T. G. (2001). Quality of care 
and hospital readmission in congestive heart failure: An explicit review process. Journal 
of Cardiac Failure, 7, 289-298.
Prochaska, J. O. & DiClemente, C. C. (1984). The transtheoretical 
approach crossing traditional boundaries of change. Homewood, Illinois: Dow- 
Jones/lrwin.
Rapkin, B.D. & Schwartz, C.E. (2004). Toward a theoretical model of quality-of- 
life appraisal: Implications of findings from studies of response shift. Health and Quality 
of Life Outcomes, 2 ,14
Rector, T. S., Kubo, S. H., & Cohn, J. N. (1987). Patients' self-assessment of 
their congestive heart failure. Part 2: Content, reliability and validity of a new measure, 
the Minnesota Living with Heart Failure Questionnaire. Heart Failure, 198-209.
Redfield, M. M. (2002). Heart Failure -- An Epidemic of Uncertain Proportions. 
New England Journal of Medicine, 347, 1442-1444.
Remme, W. J. & Swedberg, K. (2001). Guidelines for the diagnosis and 
treatment of chronic heart failure. European Heart Journal, 22 ,1527-1560.
Remme, W. J. & Swedberg, K. (2002). Comprehensive guidelines for the 
diagnosis and treatment of chronic heart failure. European Journal of Heart Failure, 4, 
11- 22 .
Rich, M. W., Vinson, J. M., Sperry, J. C., Shah, A. S., Spinner, L. R., Chung, M. 
K. et al. (1993). Prevention of readmission in elderly patients with congestive heart 
failure. Journal of General Internal Medicine, 8, 585-590.
Rich, M. W., Beckham, V., Wittenberg, C., Leven, C. L., Freedland, K. E., & 
Carney, R. M. (1995). A multidisciplinary intervention to prevent the readmission of
310
elderly patients with congestive heart failure. The New England Journal of Medicine, 
333, 1190-1195.
Rich, M. W. (1996). Iatrogenic congestive heart failure in older adults: clinical 
course and prognosis. Journal of the American Geriatrics Society, 44, 638.
Rich, M. W. (1999). Heart failure disease management: A critical review.
Journal of Cardiac Failure, 5, 64-75.
Riegel, B., Carlson, B., Glaser, D., & Hoagland, P. (2000). Which patients with 
heart failure respond best to multidisciplinary dsease management? Journal of Cardiac 
Failure, 6, 290-299.
Riegel, B., Carlson, B., & Glaser, D. (2000). Development and testing of a 
clinical tool measuring self-management of heart failure. Heart and Lung, 29, 4-12.
Riegel, B., Carlson, B., Moser, D. K., Sebern, M., Hicks, F. D., & Roland, V.
(2004). Psychometric testing of the self-care of heart failure index. Journal of Cardiac 
Failure, 10, 350-360.
Riemsma, R. P., Kirwan, J. R., Taal, E., & Rasker, J. J. (2002). Patient 
education for adults with rheumatoid arthritis. Cochrane.Database.Syst.Rev., 
CD003688.
Roccaforte, R., Demers, C., Baldassarre, F., Teo, K. K., & Yusuf, S. (2005). 
Effectiveness of comprehensive disease management programmes in improving 
clinical outcomes in heart failure patients. A meta-analysis. European Journal of Heart 
Failure, 7, 1133-1144.
Rockwell, J. M. & Riegel, B. (2001). Predictors of self-care in persons with heart 
failure. Heart and Lung, 30, 18-25.
311
Rodriguez-Artalejo, F., Guallar-Castillon, P., Pascual, C. R., Otero, C. M., 
Montes, A. 0., Garcia, A. N. et al. (2005). Health-related quality of life as a predictor of 
hospital readmission and death among patients with heart failure. Archives of Internal 
Medicine, 165, 1274-1279.
Rogers, R. W. (1975). A protection motivation theory of fear appeals and 
attitude change. Journal of Psychology, 91, 93-114.
Rohrbaugh, M. J., Shoham, V., Coyne, J. C., Cranford, J. A., Sonnega, J. S., & 
Nicklas, J. M. (2004). Beyond the "self" in self-efficacy: Spouse confidence predicts 
patient survival following heart failure. Journal of Family Psychology, 18, 184-193.
Rothman, A. J. (2000). Toward a theory-based analysis of behavioral 
maintenance. Health Psychology, 19, 64-69.
Rucker-Whitaker, C., Flynn, K. J., Kravitz, G., Eaton, C., Calvin, J. E., & Powell, 
L. H. (2006). Understanding African-American participation in a behavioral intervention: 
results from focus groups. Contemporary Clinical Trials, 27, 274-286.
Schaufelberger, M., Swedberg, K., Koster, M., Rosen, M., & Rosengren, A.
(2004). Decreasing one-year mortality and hospitalization rates for heart failure in 
Sweden: Data from the Swedish Hospital Discharge Registry 1988 to 2000. European 
Heart Journal, 25, 300-307.
Schneider, J. K., Hornberger, S., Booker, J., Davis, A., & Kralicek, R. (1993). A 
medication discharge planning program. Clinical Nursing Research, 2, 41-53.
Schwartz, C.E. (1999) Teaching coping skills enhances quality of life more than 
peer support: Results of a randomized trial with multiple sclerosis patients. Health 
Psychology, 78,211-220.
312
Schwartz, C. E., & Sprangers, M. A. G. (Eds.). (1999). Symposium on the 
challenge of response shift in social science and medicine [special issue]. Social 
Science and Medicine, 48 {11).
Schwartz, C.E., Sprangers, M.A.G., Carey, A. & Reed, G (2004). Exploring 
response shift in longitudinal data. Psychology and Health, 19, 51-69.
Schwarzer, R. (1993). Measurement of Perceived Self-Efficacy: Psychometric 
Scales for Cross-Cultural Research. Berlin: Friei Universitat Berlin, Institut fur 
Psychologie.
Schweitzer, R. D., Head, K., & Dwyer, J. W. (2007). Psychological factors and 
treatment adherence behavior in patients with chronic heart failure. Journal of 
Cardiovascular Nursing, The, 22, 76-83.
Scottish Intercollegiate Guidelines Network (1999). Diagnosis and treatment of 
heart failure due to left ventricular systolic dysfunction. Edinburgh: SIGN Secretariat.
Serxner, S., Miyaji, M., & Jeffords, J. (1998). Congestive heart failure disease 
management study: A patient education intervention. Congestive Heart Failure, 4/3, 23- 
28.
Sethares, K. A. & Elliott, K. (2004). The effect of a tailored message intervention 
on heart failure readmission rates, quality of life, and benefit and barrier beliefs in 
persons with heart failure. Heart and Lung, 33, 249-260.
Shah, N. B., Der, E., Ruggerio, C., Heidenreich, P. A., & Masssie, B. M. (1998). 
Prevention of hospitalizations for heart failure with an interactive home monitoring 
program. American Heart Journal, 135, 373-378.
313
Shaw, W. S., Cronan, T. A., & Christie, M. D. (1994). Predictors of attrition in 
health intervention research among older subjects with osteoarthritis. Health 
Psychology, 13, 421-431.
Sheeran, P. (2002). Intention-behavior relations: A conceptual and empirical 
review. European Review of Social Psychology, 12, 1-36.
Shively, M., Kodiath, M., Smith, T. L., Kelly, A., Bone, P., Fetterly, L. et al.
(2005). Effect of behavioral management on quality of life in mild heart failure: a 
randomized controlled trial. Patient Education and Counseling, 58, 27-34.
Simpson, S. H., Farris, K. B., Johnson, J. A., & Tsuyuki, R. T. (2000). Using 
focus groups to identify barriers to drug use in patients with congestive heart failure. 
Pharmacotherapy, 20, 823-829.
Smith, B., Forkner, E., Zaslow, B., Krasuski, R. A., Stajduhar, K., Kwan, M. et al.
(2005). Disease management produces limited quality-of-life improvements in patients 
with congestive heart failure: evidence from a randomized trial in community-dwelling 
patients. American Journal of Managed Care, The, 11, 701-713.
Smith, L. E., Fabbri, S. A., Pai, R., Ferry, D., & Heywood, J. T. (1997). 
Symptomatic improvement and reduced hospitalization for patients attending a 
cardiomyopathy clinic. Clinical Cardiology, 20, 949-954.
SOLVD Investigators (1992). Effect of enalapril on mortality and the 
development of heart failure in asymptomatic patients with reduced left ventricular 
ejection fractions. The New England Journal of Medicine, 327, 685-691.
Sosin, M. D., Bhatia, G. S., Davis, R. C., & Lip, G. Y. H. (2004). Heart failure— 
the importance of ethnicity. European Journal of Heart Failure, 6, 831-843.
314
Soufer, R. (1992). Heart failure. In B.L.Zaret, M. Moser, & L. S. Cohen (Eds.), 
Yale University School of Medicine Heart Book. (pp. 177-184). New York: Hearst 
Books.
Stewart, A. L., Greenfield, S., Hays, R. D., Wells, K., Rogers, W. H., Berry, S. D. 
et al. (1989). Functional status and well-being of patients with chronic conditions.
Results from the Medical Outcomes Study. JAMA: The Journal of the American 
Medical Association, 262, 907-913.
Stewart, S., Pearson, S., Luke, C. G., & Horowitz, J. D. (1998). Effects of home- 
based intervention on unplanned readmissions and out-of-hospital deaths. Journal of 
the American Geriatric Society, 46, 174-180.
Stewart, S., Pearson, S., & Horowitz, J. D. (1998). Effects of a home-based 
intervention among patients with congestive heart failure discharged from acute 
hospital care. Archives of Internal Medicine, 158, 1067-1072.
Stewart, S., Marley, J. E., & Horowitz, J. D. (1999). Effects of a multidisciplinary, 
home-based intervention on unplanned readmissions and survival among patients with 
chronic congestive heart failure: a randomised controlled study. The Lancet, 354,1077- 
1083.
Stewart, S., MacIntyre, K., Hole, D. J., Capewell, S., & McMurray, J. J. V.
(2001). More ’malignant' than cancer? Five-year survival following a first admission for 
heart failure. European Journal of Heart Failure, 3, 315-322.
Stewart, S. & Horowitz, J. D. (2002). Detecting early clinical deterioration in 
chronic heart failure patients post-acute hospitalisation-a critical component of 
multidisciplinary, home-based intervention? European Journal of Heart Failure, 4, 345- 
351.
315
Stromberg, A., Martensson, J., Fridlund, B., Levin, L. A., Karlsson, J. E., & 
Dahlstrom, U. (2003). Nurse-led heart failure clinics improve survival and self-care 
behaviour in patients with heart failure: Results from a prospective, randomised trial. 
European Heart Journal, 24, 1014-1023.
Stromberg, A. (2005). The crucial role of patient education in heart failure. 
European Journal of Heart Failure, 7, 363-369.
Taal, E., Rasker, J. J., & Wiegman, O. (1997). Group education for rheumatoid 
arthritis patients. Seminars in Arthritis and Rheumatism, 26, 805-816.
Tabachnick, B. G. & Fidell, L. S. (1996). Using multivariate statistics. (Third ed.) 
Boston: Pearson Education.
Task Force for the Diagnosis and Treatment of Chronic Heart Failure, E. S. o. C. 
W. J. R. a. K. S. C.-C. (2001). Guidelines for the diagnosis and treatment of chronic 
heart failure. European Heart Journal, 22, 1527-1560.
Task Force for the Diagnosis and Treatment of Chronic Heart Failure, E. S. o.
C., Swedberg, K., Writing Committee:, Cleland, J., Dargie, H., Drexler, H. et al. (2005). 
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary 
(update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart 
Failure of the European Society of Cardiology. European Heart Journal, 26 ,1115-1140.
Task Force of the Working Group on Heart Failure of the European Society of 
Cardiology (1997). The treatment of heart failure. European Heart Journal, 18, 736-753.
Thompson, D. R., Roebuck, A., & Stewart, S. (2005). Effects of a nurse-led, 
clinic and home-based intervention on recurrent hospital use in chronic heart failure. 
European Journal of Heart Failure, 7, 377-384.
316
Toobert, D. J., Hampson, S. E., & Glasgow, R. E. (2000). The summary of 
diabetes self-care activities measure: results from 7 studies and a revised scale. 
Diabetes Care, 23, 943-950.
Travers, B., O'Loughlin, C., Murphy, N. F., Ryder, M., Conlon, C., Ledwidge, M. 
et al. (2007). Fluid Restriction in the Management of Decompensated Heart Failure: No 
Impact on Time to Clinical Stability. Journal of Cardiac Failure, 13,128-132.
Tsuchihashi, M., Tsutsui, H., Kodama, K., Kasagi, F., Setoguchi, S., Mohr, M. et 
al. (2001). Medical and socioenvironmental predictors of hospital readmission in 
patients with congestive heart failure. American Heart Journal, 142, E7.
Tsuyuki, R., McKelvie, R., Arnold, M., Avezum, A., Barretto, A., Carvelho, A. et 
al. (2001). Acute precipitants of congestive heart failure exacerbations. Archives of 
Internal Medicine, 161, 2337-2342.
Turvey, C. L., Schultz, K., Arndt, S., Wallace, R. B., & Herzog, R. (2002). 
Prevalence and correlates of depressive symptoms in a community sample of people 
suffering from heart failure. Journal of the American Geriatrics Society, 50, 2003-2008.
Vaccarino, V., Kasl, S. V., Abramson, J., & Krumholz, H. M. (2001). Depressive 
symptoms and risk of functional decline and death in patients with heart failure. Journal 
of the American College of Cardiology, 38 ,199-205.
van der Wal, M. H., Jaarsma, T., & van Veldhuisen, D. J. (2005). Non- 
compliance in patients with heart failure; how can we manage it? European Journal of 
Heart Failure, 7, 5-17.
van der Wal, M. H. L., Jaarsma, T., Moser, D. K., Veeger, N. J. G. M., van Gilst, 
W. H., & van Veldhuisen, D. J. (2006). Compliance in heart failure patients: the 
importance of knowledge and beliefs. European Heart Journal, 27, 434-440.
317
Varma, S., McElnay, J. C., Hughes, C. M., Passmore, A. P., & Varma, M.
(1999). Pharmaceutical care of patients with congestive heart failure: interventions and 
outcomes. Pharmacotherapy, 19, 860-869.
Vasan, R. S. & Benjamin, E. J. (2001). Diastolic heart failure - no time to relax. 
New England Journal of Medicine, 344, 56-59.
Vermeire, E., Hearnshaw, H., Van Royen, P., & Denekens, J. (2001). Patient 
adherence to treatment: three decades of research. A comprehensive review. Journal 
of Clinical Pharmacy and Therapeutics, 26, 331 -342.
Vinson, J. M., Rich, M. W., Sperry, J. C., Shah, A. S., & McNamara, T. (1990). 
Early readmission of elderly patients with congestive heart failure. Journal of the 
American Geriatric Society, 38 ,1290-1295.
Ware, J. E. J. & Sherbourne, C. D. (1992). The MOS 36-item short-form health 
survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30, 473- 
483.
Watson, D., Clark, L. A., & Tellegen, A. (1988). Development and validation of 
brief measures of positive and negative affect: The PANAS scales. Journal of 
Personality and Social Psychology, 54 ,1063-1070.
Weinberger, M., Oddone, E. Z., Henderson, W. G., & For the Veteran Affairs 
Cooperative Study Group on Primary Care and Hospital Readmission (1996). Does 
increased access to primary care reduce hospital readmissions? New England Journal 
of Medicine, 334, 1441 -1447.
Weinman, J., Petrie, K. J., Moss-Morris, R., & Horne, R. (1996). The Illness 
Perception Questionnaire: A new method for assessing the cognitive representation of 
illness. Psychology and Health, 11, 431-445.
318
Welsh, J. D., Heiser, R. M., Schooler, M. P., Brockopp, D. Y., Parshall, M. B., 
Cassidy, K. B. et al. (2002). Characteristics and Treatment of Patients With Heart 
Failure in the Emergency Department. Journal of Emergency Nursing, 28, 126-131.
West, J. A., Miller, N. H., Parker, K. M., Senneca, D., Ghandour, G., Clark, M. et 
al. (1997). A comprehensive management system for heart failure improves clinical 
outcomes and reduces medical resource utilization. American Journal of Cardiology, 79, 
58-63.
Whellan, D. J., Hasselblad, V., Peterson, E., O'Connor, C. M., & Schulman, K.
A. (2005). Metaanalysis and review of heart failure disease management randomized 
controlled clinical trials. American Heart Journal, 149, 722-729.
White, C. A. (2001). Cognitive behaviour therapy for chronic medical problems.
A guide to assessment and treatment in practice. Chichester: John Wiley & Sons.
Whitehead, D. (2001). Health education, behavioural change and social 
psychology: nursing's contribution to health promotion? Journal of Advanced Nursing, 
34, 822-832.
Whorlow, S. L. & Krum, H. (2000). Meta-analysis of effect of beta-blocker 
therapy on mortality in patients with New York Heart Association class IV chronic 
congestive heart failure. The American Journal of Cardiology, 86, 886-889.
Windham, B. G., Bennett, R. G., & Gottlieb, S. (2003). Care management 
interventions for older patients with congestive heart failure. American Journal of 
Managed Care, The, 9, 447-459.
Wright, S. P., Walsh, H., Ingley, K. M., Muncaster, S. A., Gamble, G. D., Pearl, 
A. et al. (2003). Uptake of self-management strategies in a heart failure management 
programme. European Journal of Heart Failure, 5, 371-380.
319
Yardley, L. & Dibb, B. (2007). Assessing subjective change in chronic illness: 
An examination of response shift in health-related and goal-oriented subjective status. 
Psychology and Health, 22, 813-828.
Yu, D. S. F., Thompson, D. R., & Lee, D. T. F. (2006). Disease management 
programmes for older people with heart failure: crucial characteristics which improve 
post-discharge outcomes. European Heart Journal, 27, 596-612.
Zhang, J. X., Rathouz, P. J., & Chin, M. H. (2003). Comorbidity and the 
concentration of healthcare expenditures in older patients with heart failure. Journal of 
the American Geriatrics Society, 51, 476-482.
Zigmond, A. S. & Snaith, R. P. (1983). The Hospital Anxiety and Depression 
Scale. Acta Psychiatrica Scandinavica, 67, 361-370.
320
APPENDIX A. INTERVENTION MANUAL
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A nurse-led 
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admitted to hospital with 
heart failure
This manual may be used only following an accompanying training course.
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INTRODUCTION
Patients with heart failure have to follow a complex behavioural regime, which 
can include taking different medicines, making dietary changes, monitoring for 
signs of fluid retention, and taking exercise.
The aim of this intervention is to target the behaviours that patients need to 
adopt on a daily basis in order to:
- adhere to their recommended treatment regime
- identify any signs of worsening heart failure and take appropriate action
- take control of the behaviours associated with managing their heart failure
The programme will help patients to address any difficulties they have in making 
and maintaining behavioural changes. By helping to enhance patients’ 
adherence to their recommended treatment regime, it is hoped that 
complications leading to unplanned hospitalisations will decrease, and patients’ 
quality of life will improve.
Patients with heart failure also may need to give up smoking or lose weight. 
These are very difficult to achieve and, although they are desirable and patients 
who express a wish to address them will be given support, they are not seen as 
the main targets of this intervention. This brief intervention is not considered to 
be of sufficient duration to give all of these issues the attention they require. The 
main behaviours being addressed in this intervention are monitoring of weight,
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oedema and breathlessness, adherence to medication, salt and fluid restriction 
and exercise.
A traditional educational approach to helping patients adopt treatment 
recommendations has been to provide information about what needs to be done. 
A consistent finding from work in chronic illness is that, although the correct 
information is essential to ensure that patients know what to do, it is often not 
sufficient to bring about behaviour change. Health care professionals will be 
familiar with this from their own clinical experience where patients who are very 
aware of the risks of smoking and obesity, for example, do not change their 
behaviour. A self-management approach aims to help patients identify barriers 
to optimal self-management and to help them identify the solutions that will work 
best for them.
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BEHAVIOUR CHANGE
To enable people to change their behaviours and follow the recommended 
treatment regimen, it is necessary to consider the barriers that can prevent 
them from making the required behaviour changes. Barriers to behaviour 
change can be physical or psychological and problem-solving skills can be used 
to help overcome these barriers.
Individuals’ beliefs about their illness and treatment may raise psychological 
barriers to how they deal with it. During the intervention, unhelpful beliefs will be 
challenged and beliefs that enhance self-management will be encouraged. 
Important beliefs are:
- The patient has an important role to play in managing their condition
- Performing the required behaviours will have a beneficial effect
- The patient has the ability to perform the necessary behaviour (self- 
efficacy)
By tackling unhelpful beliefs and adopting a problem-solving approach, the 
programme aims to equip patients with the ability to overcome barriers to 
following their treatment regime.
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INTERACTION WITH THE PATIENT
The aim of this programme is to help patients to follow their treatment regime 
and enhance their sense of control over their condition. Although this will 
involve providing patients with information about heart failure and its 
treatment, the approach is not intended to be one in which patients are 
simply given advice or education about what they should do. Advice alone is 
not usually enough to change behaviour, for example, all patients will have 
been told how to take their medication but many will still be non-adherent. In 
this programme, patients will be encouraged to be actively involved in making 
decisions about how best to follow their recommended treatment.
Here are a few general points to help in the consultation about behaviour 
change:
• Patients will only remember small amounts of information.
- Keep information to the minimum amount necessary for the patient to 
carry out a particular behaviour.
- It is important that the points you want the patient to remember are 
made clearly and succinctly.
- At the end of the session, summarise the main points you want the 
patient to remember.
• Make the patient a partner, indicating that you will work together to
overcome any difficulties -  the interaction with the patient is a
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collaborative one, working towards behaviour change together. This 
differs from imparting advice that the patient is expected to follow.
• Adopt an open, questioning approach, even when dealing with sections 
that may be seen as purely educational. This will:
- Help patients to see you as a partner rather than a teacher. The more 
involved they are in the process, the more likely they are to remember 
what is discussed and adopt what is agreed. This will also help to 
enhance self-efficacy (see below).
- Help to reveal patients’ illness beliefs and uncover any 
misconceptions or unhelpful beliefs they hold
• Encourage self-efficacy (confidence in ability to adopt specific behaviour).
- Provide positive feedback about successful performance.
- When using the problem-solving approach, help patients to adopt 
goals and strategies that they are confident they can follow.
- If patient adopts a passive approach and asks to be told what to do, 
you can make suggestions about possible courses of action (e.g.
‘some patients find it helpful t o  ’ but the patient must decide which
strategy to adopt
• Observe patient responses and take your cues from them. Patients will 
vary widely, from those who are compliant, to those who are 
argumentative or those who express verbal agreement but then do not 
actually carry out the behaviour. The extent to which you need to
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challenge them about their beliefs or behaviours will therefore vary.
When challenging beliefs/behaviours,
- taking a directive/persuasive approach (telling the patients what they 
should60) can lead to resistance from some patients e.g. ‘yes, but....’, 
or quiet resistance ‘mmm’ (also pay attention to person’s non-verbal 
communication).
- if a patient expresses disagreement, avoid arguing back! Instead 
open up the disagreement for discussion, suggest alternative 
formulations
- explore why patient holds the belief
- explore pros and cons of adopting/not adopting a particular behaviour
• Avoid falling back onto a lecturing approach
e.g. if you are met with silence from the patient
• Dealing with distress
- this intervention is not designed to address clinical depression or 
anxiety so if you become concerned that the patient has become 
clinically anxious or depressed you should refer them for further input 
as per normal practice
- however, in other patients, distress can still often arise from 
difficulties in coping with heart failure. Enabling patients to achieve
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greater control over their condition and treatment will help to alleviate 
distress
- acknowledge and empathise with the emotion
- explore why the patient feels this way
- how long have they felt like this?
- what do you think is causing it?
- use the problem-solving approach to break down the problem (reason
for distress) and generate possible solutions
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PROBLEM SOLVING
A problem-solving approach will be used to help patients overcome difficulties 
that act as barriers to adopting the behaviours required by their treatment 
regime. This does not mean solving the patients’ problems for them, telling 
them what to do, but involves getting patients to think through their difficulties 
and decide on a solution. The approach used here is derived from the work of 
D’Zurilla & Goldfried (1971). The main components are:
• Problem Orientation
The way a problem is perceived by the individual is crucial for successful 
problem solving:
• Problems should be seen as soluble or controllable
• Problems need to be seen as ‘difficulties to be overcome’ rather 
than ‘threats to be avoided’
• Individuals need to have confidence in their ability to overcome 
problems
• Problems attributed to personality or bad habit can be difficult to 
overcome and such beliefs need to be challenged
• Individuals need to be willing to devote the time and effort 
necessary to adopt the necessary behaviours.
Addressing problems using the following steps should help to increase 
patients’ confidence in their ability to deal with the difficulties they
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experience in following their regime. This in turn should aid the 
development of a more facilitative orientation to problem solving.
• Identify barriers (problems) to performing the behaviour as required
• This involves identifying where a behaviour is not being 
performed as required and identifying what is acting as a barrier to 
performance
• Patients may have difficulty with one or several aspects of their 
regime or may simply be overwhelmed by its complexity
• An individual may be unaware of a problem e.g. aspects of 
unintentional non-adherence such as taking the correct amount of 
medication but at the wrong time, but gentle probing may uncover 
problems
• Aspects of the regime will be new to some of the patients so it will 
be necessary to help them anticipate where difficulties or obstacles 
could arise
• Break the problem down
• Think of what smaller problems are contributing to the overall 
problem
• It will be easier to overcome a large problem if it is broken down 
into smaller components so that each barrier can be dealt with in turn
• Think of psychological and social as well as physical barriers to 
carrying out the behaviour
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• Generate alternative strategies to deal with the problem
• Take each component of a problem in turn and try to think of as 
many solutions as possible. Patients and their partners/carers should 
be encouraged to try to do this together. Encourage them to be as 
imaginative as possible as the more solutions that are suggested, the 
more good ideas are likely to be produced.
• Weigh up the pros and cons of each strategy. Do not dismiss any 
possible solution out of hand until all have been considered.
• You can introduce strategies that ‘other people in their position’ 
have found useful, but recommending that a patient tries a particular 
strategy may meet with resistance e.g. lead to the patient responding 
with reasons why it will not work
• Selecting a strategy
• While the nurse can help the patient to address problems and 
suggest possible solutions that the patient has not thought of, the 
decision about which solution will be adopted must be taken by 
the patient
• Ensure that the strategy is within the patient’s capabilities. Is 
outside help available if required? E.g. Social Services.
• Patients should feel confident in their ability to carry out the 
strategy
• Employ the strategy and evaluate the outcome
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• Patients should be encouraged to put the strategy into use from 
the time they are discharged from hospital (or before discharge, if 
appropriate)
• Problems may not be solved at the first attempt therefore it is 
necessary to review progress and amend the strategy where 
necessary
• An evaluation should be made of which aspects of the strategy 
were successful and what problems arose
Although these steps have been presented sequentially, successful problem 
solving is likely to involve movement back and forth between the different 
stages before the process is complete.
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CHALLENGING BELIEFS
The beliefs that individuals have about their illness and treatment will affect the 
likelihood of them following the recommended regime. The aim of the 
programme is to challenge unhelpful beliefs and promote more positive beliefs 
that will enhance self-management.
Unhelpful beliefs include:
• Catastrophising thoughts -  e.g. If I go out I will overdo it and end up back 
in hospital
• Overgeneralisation -  e.g. Taking diuretics means I can never go out
• All or nothing beliefs -  e.g. If I don’t exercise every day, I might as well 
not bother
• Attributing difficulties to personality -  e.g. I have no willpower, I’m not a 
person who takes medication
• Placing too much responsibility on themselves for something that is not 
their fault -  e.g. because I had to keep stopping for a rest, I ruined the 
day out for everyone else
• Jumping to conclusions based on insufficient evidence -  e.g. whatever I 
do will make no difference
• Selective abstraction -  concentrating on weaknesses and forgetting 
strengths, e.g. focussing on the aspects of their regime they have 
difficulty with and seeing this as evidence of uselessness, ignoring the 
aspects of their regime that they successfully follow.
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Here are some ways of challenging unhelpful beliefs:
• Look for evidence which contradicts belief, e.g
- Probe for counter examples which contradict the unhelpful belief
- Does this apply to every situation? Have there been times when it 
wasn’t like this? E.g. when patient did successfully take their 
medication/follow diet etc
- What was different about the times it didn’t apply?
- Highlight to patient how evidence contradicts their belief showing 
inconsistency in the belief
• Ask about possible alternative views
- Are there any other ways of looking at this?
- Do other people have different views?
• Look for advantages and disadvantages of this way of thinking
- What is helpful about looking at situation in this way?
- Is this way of thinking really helping? If not, what kinds of thoughts 
would help?
- What might happen if.....
• Look for ways to generate more helpful thoughts
- E.g. ‘I can’t do anything’. A more helpful thought might be ‘I may not 
be able to do everything I used to but there are still things I can
do ’ It is important that any failure is seen as having been specific
to a particular aspect of a behaviour and is not over generalised to ‘I
can’t do anything’.
- E.g. Til never be able to do it, it’s too difficult’ . A more helpful thought 
might be Tve never done this before but that doesn’t mean I can’t
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learn it. I could start by....’ Challenge belief e.g. by focussing on 
areas where patient has been successful.
E.g. ‘I did that badly, I might as well not bother’. A more helpful 
thought might be ‘I didn’t do that as well as I could have but I can 
learn from that and do better next time’.
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STRUCTURE OF THE PROGRAMME
The programme will be led by a cardiac nurse specialist who will see patients 
with their partner or main carer where possible/applicable. The first and second 
sessions will take place before discharge from hospital and the third session will 
take place in the home within a week of discharge. The nurse will then contact 
the patient by telephone a week later. Patients will be able to contact the nurse 
by telephone if they have any concerns. During all of these contacts, the nurse 
will encourage patients to take a problem solving approach to managing their 
own condition.
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SESSION ONE
Objectives
By the end of session 1, each participant should
- Be aware of the aims and structure of the programme
- Understand the link between heart failure and breathlessness, swelling, 
fluid intake and medication
- Understand the purpose of each of their medications
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1.1 INTRODUCTION
Aim To introduce the programme
• Explain the purpose of the programme and what it will involve 
EXAMPLE
- While you have been in hospital, we have been giving you your 
medication every day and monitoring how you are. Now that you are 
going home, we want to make sure that you can continue to do these 
things so that you remain well. It is our aim to help you to learn some 
ways to make it easier for you to manage your heart failure when you 
get home.
- I’ll see you briefly today, then I’d like to see you again, (with your 
partner) tomorrow. Also, I will come and visit you at home during the 
next week to see how you are getting on. You will also be able to 
contact me by telephone if necessary.
Question Do you have any questions about the programme?
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1.2
Aim To find out and clarify patients’ understanding of heart failure
• Use diagram of heart/lungs/body link to patient to help with 
understanding of link between heart/swelling/fluid/medication.
• Clarify any misconceptions
• Should any unhelpful beliefs arise, take he opportunity to challenge 
them
Question First of all, I’d like to ask you what you understand about what is 
happening in your heart.
[It is important to start this way to help elicit the patients’ 
understanding and beliefs about their heart failure]
Information Provide an explanation of the role of heart failure in fluid balance, 
explaining how this gives rise to the symptoms and signs they 
have experienced.
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1.3
Aim To ascertain and clarify patients’ understanding of their medication
• Explain that each of the medications has a different purpose but they 
all help to make the work of the heart easier.
• Go through each medication and what its function is, clarifying any 
misconceptions
• Record each medication and its function on diagram
Question What medication are you taking?
(How often?)
(How much?)
(What does it do?)
Information
- Water tablets
- ACE inhibitors
- Betablockers
- Other medication
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SESSION CLOSE
• Inform patient that at next session you will be looking again at their 
medication and other aspects of their treatment and ways of helping to 
make it easier for them to manage their treatment. Ask them to arrange 
for partner/spouse to be present if appropriate/possible.
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SESSION TWO
- Session takes place before discharge from hospital
- Session will be attended by patient and spouse/partner/carer where 
appropriate/possible.
- This session will set out the treatment regime and look at ways to help 
make it easier for patients to follow.
- Although addressing barriers to behaviours will be covered mainly 
during Session Three, and is outlined in that section of the manual, if 
barriers to following the regime arise during the current session, they 
should be addressed when they arise.
Objectives
By the end of session 2, participants should:
- Understand how to use the medication chart
- Understand how and when to weigh themselves and complete the weight
chart
- Understand how and when to check for signs of swelling
- Understand the triggers for contacting you
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- Understand the need to manage their fluid intake and have identified 
ways of reducing it if necessary
- Understand the need for a low salt diet and have identified ways of 
reducing their salt intake where necessary
- Understand the importance of keeping active and have identified ways of 
incorporating regular physical activity into their daily lives
- Have identified possible ways of dealing with any foreseen problems in 
following their treatment regime
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2.1
Aims To introduce treatment regime.
• Give an overview of the programme
EXAMPLE
- In managing your heart condition there are several things that you 
need to do, like take medication, make some dietary changes, monitor 
yourself for signs of fluid retention and incorporate some exercise into 
your daily routine.
- We know that it can be difficult to follow some parts of this routine and 
our aim is to help you to learn some ways to make it easier for you
- We will cover some of these things today and then I will visit you at 
home in the week after you are discharged to see how you are getting 
on
- You will also be able to telephone me (during office hours) if you have 
any problems
Question Any questions?
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2.2
Aim To introduce medication chart and find most suitable ways of 
incorporating medication into daily regime
Question The last time we met, we spoke a little about the medications you 
are taking. Do you have any questions about what we talked 
about at the last session?
• Explain that you want to look at ways that could help to make it easier 
for them to remember to take all their medication as prescribed. One 
way is to use a medication chart which they complete every day.
• Introduce and explain monthly tick chart and again go through which 
medications they take, when and how much.
• Suggest that the chart will make it easier for them to always remember 
their medication.
• Explain that it will be easier for them to remember their medication if it 
becomes part of their daily routine, like brushing their teeth.
• Ask participants to think through the most suitable time to take their
tablets by thinking through a typical day Let’s start with your water
tablet, which probably causes most disruption to people’s routines
• Use problem-solving approach to ask patient and partner to generate 
possible solutions to the most suitable time(s) to take diuretics.
• Use same approach for any other medications that have to be taken at 
different times.
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Probes
Where would be the most useful place to keep the medication chart so 
that it acts as a reminder? (In same place as medications)
What other triggers can they use to help them remember?
Can they foresee any problems in taking their mediations every day as 
prescribed?
Can they think of particular times/situations that may prove more difficult?
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2.3
Aim To ensure patient understands and can follow weight monitoring regime
• Ensure that patient will have weighing scales by time of discharge
• Explain the purpose of weight monitoring
• Explain how and when to weigh and complete the chart
• Explain what to do in the event of weight change
• Identify barriers to weight monitoring and problem solve with patient
Information
• If the heart is not working as well as it should, you may start to retain fluid. 
It is possible to detect this quickly by monitoring your weight on a daily 
basis to watch out for any unexplained weight gain.
• Weigh yourself at the same time every morning, after going to the toilet 
but before breakfast and before getting dressed
• Use the same scales every day
• Fill in your daily weight chart
• If you gain (or lose) 1 -2 lbs (1 kilo) one day and the same again the next
day, OR if you notice a more gradual change in your weight of 3-4 lbs (2
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kilos) over 1 -  2 weeks, contact me - it may be necessary to alter your 
water tablet prescription and look at what other factors might be causing 
the weight change
Probes
Can you foresee any problems in monitoring your weight?
What would be the best place to keep the scales and chart to help you 
remember?
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2.4
Aim To ensure patient understands and can follow monitoring for oedema
• Explain the purpose of checking for swelling
• Explain how and when to check ankles and ask patient to practice
• Explain what to do in the event of increased swelling
• Identify barriers to checking for swelling and problem solve with patient
Information
• Another early sign of fluid retention is swelling around the ankles or stomach
• To check for this, look to see if the skin around your ankles/feet appears 
stretched and shiny
• When you press on the skin around your ankles, does the indentation 
remain?
• Have you noticed that your clothing/belt is getting tight or your shoes do not 
fit?
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• Check every evening for any of these signs of swelling. If you notice signs 
of increased swelling over 3 consecutive days, contact me as we may need 
to adjust your water tablet prescription and look at what might be causing 
the fluid retention
Probes
Can you foresee any problems in checking your ankles?
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2.5
Aim To ensure patient understands and can follow fluid monitoring regime
• Explain the purpose of monitoring fluid intake
• Find out how much the patient drinks in a typical day
• Identify ways of reducing fluid intake where necessary
Information
• It is important to take in enough fluid for the body’s needs but too much 
can cause fluid retention
• Remember that all fluids are included e.g. water, tea, alcohol, soup
• You are advised to take in about 1.5 -  2 litres (2.5 -  3 pints) a day.
This amounts to about 10 average sized teacups.
• It will help if you pace the amount you drink throughout the day. Discuss 
times when they like to drink and assess whether it is within the limit.
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Probe
• Take me through a typical day, telling me about what you drink during 
the day. Ask specifically about water, tea, coffee, milk with cereal, juices, 
alcohol, night time drink.
• Can you think of ways to reduce the amount of fluid. These need to be 
specific, e.g
- Change from mug to cup
- Cut out cup at specific selected time(s) of day 
not just a more general ‘try to cut down a bit on tea’.
• Can you think of ways of quenching thirst without drinking too much. E.g. 
suck ice cube, drink cold fluids rather than hot, rinse mouth out regularly 
with cold water, avoid salty/sugary foods.
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2.6
Aim To ensure patient understands and can follow low salt diet
• Explain the purpose of reducing salt intake
• Find out if patient is taking too much salt
• Identify ways of reducing salt intake where necessary
Information
Salt can make you
• retain more fluid
• more thirsty, making it more difficult to stick to the recommended daily 
fluid intake
• it is therefore important to eat a diet which is low in salt 
Probe
• Can you think of ways that you can reduce the salt in your diet?
- Do not add salt to your food while cooking
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- Do not add salt to your food on the plate
- Use herbs and spices as an alternative to salt
- Avoid ready meals, tinned foods, smoked meat and fish, cheese,
bacon and ham, salted snacks such as crisps and nuts and sausages 
or other made up meat dishes such as beef burgers and pies.
• Can you think of times or situations when it may be more difficult to stick 
to a low salt diet?
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2.7
Aim To ensure patient is aware of importance of keeping active and to 
discuss what activities they can do.
• Explain that we know that many people with heart failure will have 
concerns about taking exercise but it is important for them to keep as 
active as possible.
• Check patient’s understanding of what is meant by exercise -  that it does 
not just mean sports but that many activities such as walking, stair 
climbing, gardening, dancing can be included.
• It may be helpful to ask patient to think of benefits of keeping active
- Strengthen heart muscle
- Improve circulation
- Make you feel better
- Help to lose any excess weight
- Can help with other health conditions
• Explore type of exercise that would be most suitable for patient (usually
walking).
• Explore ways patient will incorporate activity into daily routine.
• Include ways of ensuring they won’t ‘overdo it’:
- Exercise with a friend, partner
- Build up slowly
- Exercise as much as you can without getting tired, out of 
breath or making your heart beat too fast
- Stop if feeling dizzy and rest for a few minutes
- If walking, find a route which is reasonably flat
Use problem-solving approach to address any barriers to exercise
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SESSION CLOSE
• Give patient a copy of the heart failure booklet and supply of charts
• Explain that the booklet will act as a reminder of the things that they 
can do to keep feeling well. The charts will help with their medication 
and monitoring of weight and swelling.
• Tell patients that you will see them and their partner/main carer at their 
home within the next week. Arrange suitable time.
• Remind them that they can contact you if they have any problems in 
the meantime
Questions
Do you want to ask me anything about what we have covered today?
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SESSION 3 -  HOME VISIT
Objectives
By the end of session 3, patients should have
- Reviewed how they are getting on in each of the areas covered in the
intervention
- Identified aspects which they found more difficult
- Identified possible solutions to these problems, revising and adapting 
where necessary
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3.1
Aim To assess how successful patients have been in following their regime, 
and to address any barriers to following the regime using the problem­
solving approach.
General points for dealing with setbacks:
• Patients with heart failure have to follow a complex regime and will not 
always be successful in following all aspects of their regime.
• Challenge any beliefs patients have about setbacks resulting from 
personal inadequacy
• Positive efforts to overcome barriers should be reinforced regardless of 
outcome
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General points to review if patients have been able to perform required 
behaviours and to address any barriers (problems):
• Take each behaviour in turn -  adherence to medication, self-monitoring 
etc. Each of these is covered in more detail below.
• Ask patients to feedback on how they are getting on with each 
behaviour
• Emphasise that you would like them to tell you any difficulties they 
have had in adopting the behaviour as well as positive experiences.
• Give positive reinforcement for effort in tackling behaviour even if not 
completely successful
• Address each problem in turn using the problem-solving approach as 
described in Session 1.
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3.2
Aim To address any barriers to taking medication
• Ask patients for feedback on how they managed with their medications 
and the tick chart
• Patients may be very reluctant to admit to non-adherence, wanting to 
appear to be ‘good’ patients. Acknowledge that it can be very difficult to 
follow recommendations all the time and you want to look at ways that 
you can work together to overcome any difficulties the patient has.
Probe
- When people have to take several tablets, it can be difficult to always 
remember to take them every day, exactly as prescribed. Do you find 
that this has sometimes been a problem?
Use the problem-solving approach to break down how the problem arises,
- Are they more likely to forget in certain situations?
- Do they remember to take their tablets every day but have 
problems taking them at the right times e.g. before/after meals?
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- What do they do if they forget and what should they do e.g. double 
up next dose/ reduce time between next doses until they ‘catch 
up’/ skip forgotten dose
Probe
- One of the reasons that people stop taking their medications is that
they feel they are getting some unwanted effects of the medicines.
Have you experienced any side effects from your medications?
- Advise any ways there are to avoid these side effects
- When people experience side effects they can sometimes be 
tempted not to take their tablets as prescribed. If you do 
experience any side effects, always discuss them with your doctor 
(or you can telephone me) rather than not taking them. It may be 
possible to change to another similar medication which will suit 
you better
Probe
- Are there any other difficulties with following medication regime? E.g. 
Patients may express a general reluctance to take several 
medications
e.g. not wanting to see themselves as a ‘tablet person’ 
e.g. believing that they should give their body ‘a rest’ from 
medication
Explore these beliefs further and challenge unhelpful beliefs using the 
techniques described above.
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3.3
Aim To address any barriers to daily weighing
• Check weight chart
• Ask patients for feedback on how they managed with daily weighing
• Address barriers to daily weighing using problem solving techniques
Probe
Is there anything that has made it difficult for you to weigh yourself every day? 
E.g....
Forgetting to monitor
- In what situations do they forget?
- What would make it easier to remember?
- Where could they put chart to remind them (if current 
place not working)?
e.g. put up chart in place where it will be seen first
thing in the morning
e.g. put up sign in prominent place
- What else might help them to remember?
e.g. partner can help by reminding
Would rather not know
- If patients feel that there is little they can do to change
their heart condition they may feel that daily weighing is
pointless. Unhelpful beliefs need to be challenged.
Other barriers?
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3.4
Aim To address any barriers to checking oedema
• Ask patients for feedback on how they managed with checking oedema
• Address barriers to daily monitoring for oedema using problem solving
techniques
Probe
Is there anything that has made it difficult for you to check your ankles 
every day? E.g.
Forgetting
Would rather not know 
Other barriers?
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3.5
Aim To address any barriers to maintaining appropriate fluid intake
• Ask patients for feedback on how they managed with fluid intake
• Address barriers to keeping within recommended daily fluid intake
• Revisit the approach used in Session Two:
- Take me through a typical day, telling me about what you have 
been drinking during the day. Ask specifically about water, tea, 
coffee, milk with cereal, juices, alcohol, night-time drink.
- Work out ways to pace fluid intake during the day (bearing in 
mind what didn’t work first time around).
- Ask patients if they can remember ways of quenching thirst 
without drinking too much. E.g. suck ice cube, drink cold fluids 
rather than hot, rinse mouth out regularly with cold water, avoid 
salty/sugary foods -  what will patient find most useful?
Probe
Have there been any times/situations when it has been harder for you to 
keep to the recommended daily fluid intake?
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3.6
Aim To address barriers to following a low salt diet
• Ask patients for feedback on how they managed with reducing salt in 
diet
• Address barriers to reducing salt intake
Probes
What difficulties have you had in following a low salt diet? Examples:
- Food doesn’t taste as good
- It’s more convenient to use ready meals
- It’s difficult to eat different foods from the rest of the family
- I snack on crisps when I’m bored or fed up
- I just haven’t got any willpower
Use problem-solving approach to generate solutions to address these 
problems.
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- Try allowing yourself a set period to try to get used to the taste of food 
with less salt
- Reduce salt intake gradually over a set period
- What healthier alternatives could be eaten as snacks?
- What alternatives are there to eating when bored?
- Negotiate with family ways of incorporating a low salt diet 
Can you remember ways that you can reduce the salt in your diet?
- Do not add salt to your food while cooking
- Do not add salt to your food on the plate
- Use herbs and spices as an alternative to salt
- Avoid ready meals, tinned foods, smoked meat and fish, cheese, 
bacon and ham, salted snacks such as crisps and nuts and sausages 
or other made up meat dishes such as beef burgers and pies.
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3.7
Aim To address barriers to exercise
• Ask patients for feedback on how they managed with exercise
• Explore patient’s concerns about physical activity and help to problem 
solve ways of overcoming concerns about incorporating activity into their 
daily routine.
E.g. Patients may be particularly concerned about health risks. Reiterate 
the benefits of exercise for heart failure and ways of ensuring they won’t 
‘overdo it’ i.e.
- Exercise with a friend
- Build up slowly
- Exercise as much as you can without getting tired, out of
breath or making your heart beat too fast
- Stop if feeling dizzy and rest for a few minutes
- If walking, find a route which is reasonably flat
• Explore other barriers to exercise which might include
- I’m too old to exercise, what difference can it make now?
- Exercise is boring
- I don’t have time
- I can’t afford it (e.g. to join a health club)
• Use problem solving approach to generate possible solutions to overcome 
these barriers e.g.
- Challenge beliefs about exercise not being useful
- Ask patient to think of other activities which they might find
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more enjoyable
- Ask patient to think about ways of incorporating activity into 
their normal day so that it is not an additional ‘chore’.
- Increasing normal daily activities such as walking and stair 
climbing is free
• Help patient to think of how they will plan to incorporate activity into their 
day e.g
- What they will do
- For how long
- At what time
- Ensure that plan seems realistic
SESSION CLOSE
• Advise patient and partner that you will contact them by telephone in 
about a week to see how they are getting on.
• Remind them that they can contact you if they have any problems in 
the meantime
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TELEPHONE FOLLOW UP
Problems are not always resolved at the first attempt and the problem-solving 
process involves continual review.
Objectives
- To provide an on-going link between nurse and patient
- To evaluate the ongoing effectiveness of patients’ problem-solving 
strategies and amend them where necessary
- To identify any new problems
- To provide encouragement and reinforcement
- To remind patients that they should telephone in response to any triggers.
- The aim of the telephone follow-up is to assess how successful patients 
have been in following their regime, to evaluate the effectiveness of their 
problem-solving strategies and to amend them where necessary.
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READMISSIONS TO HOSPITAL
• Visit patient before they are discharged from hospital
• Explore factors that led to current admission
• If these were related to difficulties with self-management, problem-solve 
ways that this could be avoided in future
• Reinforce what has been covered in the intervention
• Remind patients to contact you if they show signs of deterioration
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DEALING WITH POSSIBLE SCENARIOS ARISING WITH 
PATIENTS DURING THIS INTERVENTION
• Patient attentive only to one doctor
- Ask doctor to accompany you and tell patient that what you are going
to tell them is very important.....
• Patient maintains that some people take tablets, some don’t and he is
one who doesn’t
- Ask why he defines himself this way
- Ask if he has taken any tablets, which ones, ask how they are
different, what would make him feel the same about the tablets he 
doesn’t take as the ones he does?
- Challenge his belief about his sense of himself as a person, it is 
untenable if he is taking some tablets
- Resist reverting to stressing the importance of taking tablets
• Patient anxious about other aspects of care and keeps deviating from
subjects in programme
- Acknowledge patient’s concern, promise to sort it out, show patient 
that you are writing it down and will come back to it. Bring patient 
back to intervention by saying you need their full attention
• Disruptive, unhelpful carer
- Put responsibility back on them e.g. How will you help patient to....
• Patient who had put on weight but not contacted nurse
- Make it clear that you want them to call you, it’s no bother....
• Patient reluctant to seek help, I’m not the kind of person who looks for
help
- Challenge patient on this -  they came for help by coming to hospital
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So you’re the kind of patient who delays looking for help
Do you delay everything e.g. taking car to garage if petrol tank was
leaking? Show patient how bizarre this belief is
• Patient who agrees with everything but it is not clear if they are taking it 
in
- Adopt questioning approach -  see general guidelines for intervention
• Patient very enthusiastic but perhaps unrealistic
- Look at targets they have set, break it down, set lower goal, review 
success at home visit
• Patient reluctant to weigh
- Think of it like brushing your teeth -  it only takes 30 seconds
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APPENDIX B. INTERVENTION BOOKLET AND CHARTS
375
Managing Heart Failure
376
v iw
This booklet has been written to explain the many 
things you can do to help you manage your heart 
failure and so keep you feeling as well as possible.
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Your Cardiac Nurse
Name:
You can contact your cardiac nurse 
Monday - Friday 
09.00 - 16.30
D i re c t L i n e Vo i c e mail 
Or
 Bleep 
I f  you are unable to contact your cardiac nurse directly 
please leave a message on voicemail and your call w ill 
be returned as soon as possible. I f  you do not have a 
phone in your home, establish before leaving hospital 
the best times to contact vour nurse.
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H K A R T  F A IL U R E
The term heart fa ilure may sound alarming but simply 
means that the m uscular pump o f the heart is not 
w o rk in g  as w e ll as it  should. Th is  m ay cause 
breathlessness and tiredness. It can also cause a build  
up o f flu id  in the body, especially in the ankles or lungs.
Heart failure is a very common condition and in recent 
years there have been enormous advances in our 
understanding o f  heart fa ilure and its treatment.
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HOW W ) l  ( AN fil l P YOURSELF
There are several things that you can do to help you 
remain well. These are covered in more detail in the 
fo llow ing pages and include:
• Taking your medication as prescribed
• M onitoring your symptoms for signs o f change
• Being careful about the amount you drink
• M aking a few simple lifestyle changes
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MKDIC A I ION
There are a n um be r o f  m edic ines ava ilab le  fo r heart 
fa ilu re . Y o u r d o c to r w i l l  decide on the m ost suitable 
treatm ent fo r you  and m ay g ive  you one o r m ore o f  
these d iffe re n t types o f  m edicines.
Some m ed ic ines are designed to help yo u r sym ptom s 
and w i l l  m ake you  feel better. W ith  others you may 
not notice  any d iffe re nce  but they have been shown to 
im prove  the strength  o f  the heart muscle over a period 
o f  tim e.
Y our d oc to r m ay g ra du a lly  in troduce new m edicines 
o r change v o u r m ed ic ines a fter carefu l assessment.
%
m .
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fo  get {he m o s t  f r o m  y o u r  m e d ic a t io n :
• Take your medication every day as prescribed "  
by your doctor. Complete the medication chart 
to help you remember
• Do not stop taking any medicines without 
talking to vour doctor/nurse
• Make sure you keep an adequate supply o f your 
medicines
• Keep an up to date list o f all your medicines and 
carry it w ith you
• Bring your medication list with you every time 
you see your doctor/nurse/pharmacist
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M O N IT O R IN G  SYM PTOM S
As a patient w ith heart failure you can have long 
periods o f feeling well and other times when your 
symptoms may return. By learning to recognise signs 
o f change you can get help at an earlier stage. Small 
changes in your treatment at this stage usually prevent 
more serious problems developing and w ill keep you 
feeling well.
One o f the symptoms o f heart failure is the tendency 
to retain fluid. You can check for early signs o f fluid 
retention by :
- weighing yourself every day
- checking for signs o f swelling in your ankles
- noticing i f  you become more breathless
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Daily Weighing
One o f the ways o f checking for early signs o f fluid 
retention is to weigh yourself every day. I f  you gain 
weight over a number o f days, this might be a sign 
that you are building up too much fluid.
To check i f  this is happening:
• Weigh yourself every morning, after going to the 
toilet but before breakfast and before dressing
• Use the same scales and weigh yourself in the 
same wav every dav ....
y S s  '
• Complete your weight chart
• I f  you find you are consistently gaining or losing 
weight, you should contact your cardiac nurse. 
Everyone's weight varies a little from day to day 
but i f  you gain or lose 21 bs (1 k ilo )  on 2 
consecutive days, or 3-4 lbs. or more over a period 
of 1-2 weeks, contact your cardiac nurse
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Swelling
Another sign that you may be retaining too much fluid 
is i f  your ankles are more swollen than usual.
You may notice that:
• the skin around your ankles/feet looks more
stretched and shinv than usual •/
• when you press on the skin around your ankles, 
the indentation remains
• your shoes feel tight
Check for signs o f swelling at the same time every 
morning, and make a note on your chart.
I f  you notice signs o f increased swelling for 
3 consecutive days, contact your cardiac nurse.
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H r e ■’ * * ^ K\s s n ess
Increased breathlessness mav be a sign that fluid is•» c?
starting to build up in your lungs. I f  you become 
more short o f breath when doing your usual 
activities or i f  you find you are waking at night due 
to breathlessness, contact your cardiac nurse.
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F L U I D  I N T A K E
Patients w ith heart failure need to take a little  extra 
care w ith the amount o f flu id  they drink. You need to 
drink enough to allow your kidneys to work properly 
but not so much that you retain excess fluid.
To help you do this:
• Drink 1 Vi-2 litres (or 2 !/2-3 Vi pints) 
o f flu id  a day only. (This is about 
10 average size teacups.) Include all types o f flu id  
in this total e.g. water, tea, coffee, juices, alcohol, 
soup etc.
• Plan how you w ill pace your flu id intake over the 
course o f the day
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• On hot days, or i f  you are physically active and 
perspiring a lot, then you can drink 1-2 extra cups 
o f fluid. You may find it useful to rinse your mouth 
out w ith cold water or suck ice occasionally i f  you 
have reached your flu id  lim it
• Avoid ing salty and sugary foods w ill help to 
prevent you getting too thirsty
Diuretics (water tablets) are designed to prevent you 
retaining too much flu id  by making you pass more 
water. You w ill soon learn how often you usually pass 
water.
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LIFESTY LE  ISSUES
Some other changes can also help you to control 
your symptoms and improve your quality o f life.
Keeping active
• Keeping active w ill improve your circulation, 
strengthen your heart muscle and make you feel 
and sleep better
• Try to make sure that you do some physical 
activity every day. Your nurse w ill discuss 
activities that most suit you
Activities can include walking regularly, gardening, 
bowling, swimming, golfing or any other physical 
activity you enjoy.
4
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• Build up your activity gradually, doing a little more 
each day. Try to avoid sudden strenuous exertion
• Rest is also beneficial so remember to include a 
quiet period every day - some people find a short 
nap helpful. I f  you have been very active on one 
day, it is natural for you to feel more tired and 
need a little more rest the next day
• I f  you are physically restricted for other reasons, 
you can keep active by doing some exercises in 
your chair or bed. Your cardiac nurse w ill discuss 
these with you
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Salt Reduction
Salt can make you retain more flu id and feel more 
thirsty, making it harder to fo llow  recommendations 
about daily flu id  intake.
Reducing the amount o f salt in your diet can help to 
ensure that you do not retain too much fluid.
To reduce your salt intake:
• Avoid foods w ith  a high salt content. These 
include: salted crisps and nuts, smoked meats and 
fish, bacon, ham and sausages. Remember that 
all processed foods have some added salt
• Do not add salt to your food when cooking or at 
the table
• Add herbs and spices as an alternative to salt
Avoid salt that is termed flow salt’ as it contains 
other minerals that can be harmful in large doses to 
people w ith heart failure
•a
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Smoking
• I f  you smoke, stopping now is very important for 
your health
• I f  you continue to smoke you may make your 
condition worse
• For help in giving up smoking contact the NHS 
Quitline 
Weight reduction
I f  you are overweight, your heart has 
to work harder. It is important to lose 
weight slow ly and steadily. Aim for 
a weight loss o f no more than 21bs. 
(1 k ilo ) per week.
Any sudden unexpected weight loss 
should be discussed with your cardiac 
nurse (see section about daily weighing)
,vf*
r *
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Alcohol
• You are advised to drink no more than 1 - 2 units 
o f alcohol a day. This should not be saved up for 
one or two evenings! One unit is equal to xh  pint 
o f normal strength lager or one pub measure o f 
spirits or one small glass o f w ine
• REMEMBER that alcohol forms part o f your daily 
flu id intake
I f  you have been told that alcohol has caused your 
heart fa ilu re , then you should avoid a lcohol 
completely.
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Immunisation
People w ith heart failure are more prone to chest 
infections. Ask your GP to arrange the follow ing 
vaccinations:
• Yearly flu  jab to help prevent you developing 
extreme bouts o f colds and flu
• Pneumonia vaccination ( i f  you have not had one 
in the last 10 years)
Try to avoid unnecessary contact w ith people who 
are unwell w ith  chest infections.
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S U M M A R Y
There are many things you can do to keep you 
feeling as well as possible. The purpose o f this 
booklet is to act as a reminder o f what you can do 
and when you may need to contact your nurse.
Every day, remember to:
• Take your medication
• Weigh yourself
• Check for signs o f swelling
• Complete the charts that are included with your 
folder
I f  this booklet has raised any further questions for 
you, your cardiac nurse w ill be happy to discuss 
them with you.
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Weight Chart MONTH,
Date Weight Swelling
Yes No
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Date Weight Swelling
Yes No
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
• Weigh yourself every morning, after going to the toilet but before breakfast and 
before dressing
• Use the same scales every day
• If you gain or lose 1 -2lbs (or 1 kilo) on 2 consecutive days, or 3-4lbs or more 
over a period of 1-2 weeks, contact your cardiac nurse on 
• Check your ankles every morning. If you notice signs of increased swelling for 
3 consecutive days, contact your cardiac nurse
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APPENDIX C. HOSPITAL GUIDELINES FOR MANAGEMENT OF
HEART FAILURE
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Guidelines for the Management of Heart Failure
The aims of these guidelines are to:
1. Establish or refute the diagnosis of heart failure.
2. Optimise the therapy for patients with heart failure.
3. Stabilise patients prior to discharge from hospital
Definition of heart failure 
Essential features
• Symptoms of heart failure (breathlessness, fatigue, ankle oedema)
• Objective evidence of left ventricular systolic dysfunction (usually 
echocardiogramme)
Non-essential features
• Response to treatment directed towards heart failure_______________________
Patients with suspected heart failure will be admitted by the take team. These patients 
should then be referred to the cardiology team via the cardiology SpRs (bleep 
3038/3096) or Patsy Hargrave (Specialist heart failure nurse) during normal working 
hours. Thereafter the patients will receive shared care (according to this guideline) with 
regular advice by a cardiology SpR and/or consultant. Patients will remain primarily 
under the care of the admitting team with advice from cardiologists.
On admission obtain a full history and record symptoms of heart failure. Record clinical 
signs of heart failure.
Arrange the following investigations if not already done U&Es, ABGs, TFT, FBC, ECG, 
CXR, echocardiogram.
When a diagnosis of heart failure has been confirmed, then potential causes should be 
investigated.
Causes of heart failure to consider include; ischaemic heart disease, hypertension, 
valvular heart disease, thyrotoxicosis, toxins e.g. alcohol, viral myocarditis, 
haemochromatosis and infiltrative disease, persistant tachycardias, atrial fibrillation or 
one of the cardiomyopathies.
Additional investigations to consider include ferritin, viral screen (coxsackie, 
enterovirus), auto-anti-bodies.
NYHA association classification of heart failure
• Class I Asymptomatic. No limitation of ordinary physical activity
• Class II Mild. Slight limitation of physical activity
• Class III Moderate. Limitation of normal physical activity such as walking on the
flat causes symptoms
• Class IV Severe. Symptoms of heart failure present at rest and increase with
any physical activity________________________________________________
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Treatment 1 Acute Severe Pulmonary Oedema
1. high flow oxygen by mask
2. intravenous loop diuretic e.g. frusemide 40-80 mg
3. intravenous opiate e.g. diamorphine 2.5-1 Omg with anti-emetic
4. identify and treat any precipitating or exacerbating factor e.g. atrial fibrillation, 
chest infection, unstable angina
Additional measures that may be of use:
1. intravenous aminophylline infusion
2 . venesection
3. intravenous nitrate infusion
4. consider non-invasive ventilation
5. inotropes
Treatment 2 More stable patients
Review current medication and omit any potential aggravating agents (NSAID ’s,
steroids, Ca antagonists).
Diuretics are indicated in patients with symptomatic systolic dysfunction and usually
provide rapid relief of symptoms.
•  In patients who are not receiving any diuretic it is reasonable to start at a low dose
e.g. 40mg of frusemide orally and assess clinical response.
•  In patients who are already receiving oral frusemide at doses of 40-80 mg 
conversion to intravenous frusemide may improve diuresis.
•  Patients with mainly right-sided failure will need IV diuretics for several days. Gl 
tract oedem a can often reduce absorption of oral medication. During this period aim 
for 1kg weight loss daily, with close monitoring of U&Es and creatinine.
•  Avoid over-diuresing the patient prior to initiation of ACE inhibitor therapy as 
dehydration increases the potential for renal side effects.
•  Treatment with diuretics should be directed towards control of symptoms and aim 
for optimal dry weight.
•  Potassium levels should be kept towards the high side (aim for 4.0 to 5.5 mmol/l)
In patients who do not respond to initial diuretic treatment, the following changes in
medication may be of use:
•  Increasing I.V. frusemide dose or increasing to twice daily dosing
•  Combination of loop and bendrofluazide 2.5 mg od. Monitor renal biochemistry and 
electrolytes on alternate days.
•  Combination of loop and metolazone 2.5 mg od or alt days. Monitor renal 
biochemistry and electrolytes daily.
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Drugs of prognostic benefit in heart failure
ACE Inhibitors
ACE inhibitors improve the prognosis in heart failure at all stages of the disease. Once 
LV dysfunction has been confirmed introduce ACE inhibitor unless contraindicated. 
Therapy should be initiated at low dose and increased to therapeutic doses if tolerated.
N.B. ACE inhibitors and potassium retaining diuretics can be give together, but the 
plasma potassium levels will need checking.
Recommended doses of ACE inhibitors which have been approved by C&l HA for use 
in heart failure in the community (on the basis of evidence and cost)_______________
Drua Starting Dose (mg) Target Dose (mg)
Captopril 6 .25 tds 25-50 tds
Enalapril 2 .5  bd 20 bd
Lisinopril 2 .5  od 20 od
Ramipril 1.25 od 5 bd
Spironolactone
If symptoms persist or class lll/IV  heart failure and on optimal dose of ACE-inhibitor 
consider initiation of spironolactone 25 mg od.
In patients with hypokalaemia, spironolactone may be especially useful to maintain 
serum potassium levels, but 25m g bd or more may be needed.
Beta-Blockers
Beta blockers are of prognostic benefit in patients with heart failure. They should not be 
introduced in patients until a stable (see below) period of three months has elapsed.
In patients where ischaemia or uncontrolled atrial fibrillation contributes to worsening 
heart failure beta-blockers may be considered, and the cardiology team will direct their 
use.
N.B patients who are admitted with worsening heart failure who are established on 
beta-blockers as part of their heart failure treatment, should not have their beta- 
blockers stopped. It is better to reduce the dose of beta-blocker and increase diuretic 
dose. THIS DOES NOT APPLY TO PATIENTS ADMITTED IN SEVERE 
PULMONARY OEDEMA, IN WHOM BETA-BLOCKERS SHOULD BE WITHELD
Additional Medication
Digoxin
Digoxin seems to provide symptomatic benefit in patients with chronic heart failure -  
even in sinus rhythm. You may want to consider adding digoxin to patients in whom 
symptom control is difficult.
N.B. do not add digoxin unless potassium is > 4.0mmol/l
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Stabilisation of patient
A stable patient will have
•  Well controlled symptoms
• Stable body weight
•  Stable electrolytes and creatinine
At this stage patient will be randomised to nurse led care or not. Please do not 
discharge during this period or later medication.
Patients should be given an information sheet (available on wards), with advice tailored 
to their needs included.
Follow-up after discharge should be arranged for 6 -  8 weeks with a consultant 
cardiologist, please liase with one of the cardiology SpR prior to making the 
appointment. Other medical follow-up can be arranged as appropriate.
These guidelines are complimentary to the district wide heart failure guidelines which 
will be available through casualty and which you may wish to read. It is our intention to 
ensure a consistent approach to heart failure irrespective of which health care system 
or professional a patient encounters.
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APPENDIX D. HOSPITAL HEART FAILURE LEAFLET
(This appendix reproduces the text contained in the leaflet, rather than being a copy of
the leaflet itself)
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Heart Failure
This information leaflet is for patients who have heart failure. It explains what it 
is, what symptoms to expect and the treatment available.
What is heart failure?
This sounds alarming but just means that your heart’s pumping power is weaker than 
normal, so that it is failing to pump enough blood around your body to supply all its 
needs.
For most patients heart failure is a chronic condition,
which means that it is a long-term problem and can be 
treated but not cured.
What are the usual causes of heart failure?
•  A previous heart attack
• High blood pressure
• Heart valve disease
•  Long term excess alcohol
What ever the cause may be, the treatment will mostly be the same.
What are the signs and symptoms?
The most common symptoms are:
•  Tiredness and weakness; you may find that walking, going upstairs or carrying 
groceries can be difficult.
•  Shortness of breath when doing exercise or when lying down at night;
•  Swelling of ankles and legs.
Please note - some other medical problems can cause the same sort of symptoms. 
What is the treatment?
Treatment is usually very effective and is aimed at:
•  getting you back to as normal a life as possible;
•  reducing your symptoms;
•  preventing your heart failure from getting worse.
Your treatment may include:
•  Medicines - prescribed by your doctor
•  Changing your life style by exercise, diet, and not 
smoking - you can take an active part in this
•  Surgery -  very occasionally the cause of heart failure can be put right by surgery, 
such as by having a heart valve replaced
Medicines
The medicines usually prescribed by the doctor to treat heart failure include diuretics 
and ACE inhibitors - which may be started first, with beta blockers being added later. 
Sometimes digoxin is also given, depending on your symptoms. Your specialist 
doctor will select a combination of these, and sometimes, other drugs to suit your 
needs. For the side effects of these medicines please check the information 
included with your prescription. If you want to discuss the side effects further, do 
ask your doctor or pharmacist.
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1) Diuretics
Diuretics (water pills) help to remove excess fluid and salt from the body, (making you 
pass more urine). By helping you get rid of excess amounts of fluid, diuretics help to 
reduce ankle swelling and improve breathing.
2) ACE inhibitors
These medicines relax the arteries (blood vessels) making it easier for the heart to 
pump the blood around the body. They make you feel better and improve your life 
quality.
You will start on a low dose and then gradually increase the amount, depending on 
your blood pressure and kidney function.
3) Spironalactone
This drug has been shown to give added protection to some patients with heart failure. 
You may not feel any different but it can still have long-term benefits.
4)Beta-blockers
Beta-blockers slow the pulse rate and reduce the workload of the heart
with useful long-term benefits. If you have asthma you must tell the doctor prescribing
these tablets; it often means you will not be able to take these drugs.
5) Digoxin
Digoxin has been used to treat heart failure for many years and continues to be used
for some patients. It is used to strengthen the heart beat and if the beat is irregular it
can help steady this.
Changing your lifestyle
You can help to prevent the heart failure getting worse by:
•  Reducing your weight (if you are overweight) - by planned exercise and diet.
•  Changing your diet -  a low salt diet is usually advised advised; avoid adding salt to 
food, and buying food with high salt content.
• Changing your fluid intake -  it is important to get the balance right, not too much 
and not too little. You should only drink 11/2 — 2 litres (21/2- 3 1/2 pints) a day, about 10 
average size teacups. Fluids including water, tea, coffee, juices, alcohol and soup.
•  Not smoking -  advice is readily available via the “NHS Quitline” on 0800 002200
• Keeping active and exercising regularly -  walking and swimming are good forms 
of exercise. Do as much exercise as you feel comfortable with every day and 
gradually increase the amount.
• Moderating your weekly intake of alcohol to a maximum of 1-2 units per day for 
women, and 2-3  units per day for men; (one unit = a small glass of wine/pub 
measure of spirits/1/2 pint of standard strength beer). You should have at least 2 
alcohol free days per week.
• If you have been told your heart failure was caused by alcohol you should stop 
drinking alcohol completely.
Surgical treatment
Most heart failure can be treated medically, as above, but a small number of patients
may benefit from surgery.
Your doctor will discuss this option with you if it is necessary.
You may want to discuss the following issues further with your doctor:
•  Infection -  people with heart failure are more at risk from chest infections. Ask your 
GP to arrange the following immunisations for you:
o Yearly flu jab to help prevent extreme bouts of cold or flu.
405
o Pneumonia vaccination (if you have not had one in the last 10 years).
• Work - you may have some restrictions depending on your job
• Exercise - you may wish to discuss your individual needs.
• Sex - people with heart failure are often concerned about sexual activity, but you
can resume a sexual relationship with your partner once you feel erady to do so. As
with other forms of activity you may become tired or breathless. If this happens stop 
and rest for a short time. This may also prompt you to explore different approaches 
which can still be very enjoyable.
• Driving - it is usually all right to drive but you should discuss it with your doctor, as it 
will depend on the type of licence you hold. You should also tell your insurance 
company.
• At night -  some people find sleeping with an extra pillow helpful.
Any further questions?
If you have any more questions please discuss them with your doctor.
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APPENDIX E. STUDY QUESTIONNAIRES
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1. In general, would you say your health is:
(Circle One Number)
Excellent................................................................ 1
Very good.............................................................. 2
Good...................................................................... 3
Fair......................................................................... 4
Poor........................................................................ 5
2. Compared to one year ago, how would you rate your health in general 
now?
(Circle One Number)
Much better now than one year ago.......................  1
Somewhat better now than one year ago................. 2
About the same as one year ago............................  3
Somewhat worse now than one year ago................  4
Much worse now than one year ago.......................  5
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3. The following items are about activities you might do during a typical 
day. Does your health now limit you in these activities? I f  so, how much?
(Circle One Number on 
Each Line)
Yes, Yes, No, Not
Limited Limited Limited
a Lot a Little at All
a. Vigorous activities, such as running, lifting 
heavy objects, participating in strenuous 
sports
b. Moderate activities, such as moving a 
table, pushing a vacuum cleaner, bowling, 
or playing golf
c. Lifting or carrying shopping bags.
d. Climbing several flights of stairs.
e. Climbing one flight of stairs
f. Bending, kneeling, or stooping
g. Walking more than a mile
h. Walking half a mile
i. Walking 100 yards
j. Bathing or dressing yourself
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
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4. During the past 4 weeks, have you had any of the following problems 
with your work or other regular daily activities as a result of your 
physical health?
(Circle One Number on Each Line)
Yes No
Cut down the amount of time you spent on work or 
other activities?
1 2
Accomplished less than you would have liked? 1 2
Were limited in the kind of work or other activities? 1 2
Had difficulty performing the work or other activities 
(for example, it took extra effort)?
1 2
5. During the past 4 weeks, have you had any of the following problems 
with your work or other regular daily activities as a result of any 
emotional problems (such as feeling depressed or anxious)?
(Circle One Number on Each Line)
Yes No
a. Cut down the amount of time you spent on work 1 2
or other activities?
b. Accomplished less than you would have liked? 1 2
c. Didn’t do work or other activities as carefully as 1 2
usual?
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6. During the past 4 weeks, to what extent have your physical health or
emotional problems interfered with your normal social activities with 
family, friends, neighbours, or clubs?
(Circle One Number)
Not at a ll...................................................................  1
Slightly...................................................................... 2
Moderately................................................................  3
Quite a b it .................................................................  4
Extremely..................................................................  5
7. How much bodily pain have you had during the past 4 weeks?
(Circle One Number)
None.......................................................................... 1
Very m ild.................................................................. 2
M ild........................................................................... 3
Moderate..................................................................  4
Severe......................................................................  5
Very severe..............................................................  6
8. During the past 4 weeks, how much did pain interfere with your 
normal work (including both work outside the home and housework)?
(Circle One Number)
Not at a ll................................................................ 1
A little b it............................................................... 2
Moderately............................................................. 3
Quite a b it .............................................................. 4
Extremely............................................................... 5
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9. These questions are about how you feel and how things have been with 
you during the past 4 weeks. For each question, please give the one 
answer that comes closest to the way you have been feeling.
How much of the time during the past 4 weeks...
(Circle One Number on Each Line)
a. Did you feel full of life?
All Most A Good Some A None
of the of the Bit of of the Little of the
Time Time the Time Time of the Time
Time
1
b. Have you been a very 1 2
nervous person?
c. Have you felt so down in 1 2
the dumps that nothing
could cheer you up?
d. Have you felt calm and 1 2
peaceful?
e. Did you have a lot of 1 2
energy?
f. Have you felt downhearted 1 2
and unhappy?
g. Did you feel worn out? 1 2
h. Have you been a happy 1 2
person?
i. Did you feel tired? 1 2
j. How much of your time has 
your health or emotional 
problems limited your 
social activities
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10. Please choose the answer that best describes how TRUE or FALSE 
each of the following statements is for you.
a. I seem to get ill 
more easily than 
other people
b. I am as healthy as 
anybody I know
c. I expect my health 
to get worse
d. My health is 
excellent
(Circle One Number on Each Line)
Definitely Mostly Don’t Mostly Definitely
True True Know False False
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The following scale consists of a number of words that describe 
different feelings and emotions. Read each item and then circle the 
appropriate number to indicate to what extent you have felt this way 
during the past week.
Very slightly 
or not at all
A little Moderately Quite a bit Extremely
1 Interested 1 2 3 4 5
2 Distressed 1 2 3 4 5
3 Excited 1 2 3 4 5
4 Upset 1 2 3 4 5
5 Strong 1 2 3 4 5
6 Guilty 1 2 3 4 5
7 Scared 1 2 3 4 5
8 Hostile 1 2 3 4 5
9 Enthusiastic 1 2 3 4 5
10 Proud 1 2 3 4 5
11 Irritable 1 2 3 4 5
12 Alert 1 2 3 4 5
13 Ashamed 1 2 3 4 5
14 Inspired 1 2 3 4 5
15 Nervous 1 2 3 4 5
16 Determined 1 2 3 4 5
17 Attentive 1 2 3 4 5
18 Jittery 1 2 3 4 5
19 Active 1 2 3 4 5
20 Afraid 1 2 3 4 5
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The following questions are designed to help us know 
how you have been feeling in the past week. Please 
answer each question by circling the appropriate 
number.
1 .1 feel tense or 'wound up’:
Most of the time 1
A lot of the time 2
From time to time, occasionally 3
Not at all 4
2 .1 still enjoy the things I used to enjoy:
Definitely as much 1
Not quite so much 2
Only a little 3
Hardly at all 4
3 .1 get a sort of frightened feeling as if something awful is 
about to happen:
Very definitely and quite badly 1
Yes, but not too badly 2
A little, but it doesn’t worry me 3
Not at all 4
4 .1 can laugh and see the funny side of things:
As much as I always could 1
Not quite so much now 2
Definitely not so much now 3
Not at all 4
5. Worrying thoughts go through my mind:
A great deal of the time 1
A lot of the time 2
From time to time but not too often 3
Only occasionally 4
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6 .1 feel cheerful:
Not at all 1
Not often 2
Sometimes 3
Most of the time 4
7 .1 can sit at ease and feel relaxed:
Definitely 1
Usually 2
Not often 3
Not at all 4
8 .1 feel as if I am slowed down:
Nearly all the time 1
Very often 2
Sometimes 3
Not at all 4
9 .1 get a sort of frightened feeling like 'butterflies’ in the 
stomach:
Not at all 1
Occasionally 2
Quite often 3
Very often 4
10.1 have lost interest in my appearance:
Definitely 1
I don’t take as much care as I should 2
I may not take quite as much care 3
I take just as much care as ever 4
11.1 feel restless as if I have to be on the move:
Very much indeed 1
Quite a lot 2
Not very much 3
Not at all 4
416
12.1 look forward with enjoyment to things:
As much as ever I did 1
Rather less than I used to 2
Definitely less than I used to 3
Hardly at all 4
13.1 get sudden feelings of panic:
Very often indeed 1
Quite often 2
Not very often 3
Not at all 4
14.1 can enjoy a good book or radio or TV programme:
Often 1
Sometimes 2
Not often 3
Very seldom 4
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We would like to know your views about the medicines prescribed
for you:
St
ro
ng
ly
aa
re
e
Ag
re
e
Un
ce
rta
in
Di
sa
gr
ee
St
ro
ng
ly
di
sa
ar
ee
BS1 My health, at present, depends on my 
medicines
1 2 3 4 5
BS2 Having to take medicines worries me 1 2 3 4 5
BS3 My life would be impossible without my 
medicines
1 2 3 4 5
BS4 Without my medicines I would be very il 1 2 3 4 5
BS5 I sometimes worry about long-term 
effects of my 
medicines
1 2 3 4 5
BS6 My medicines are a mystery for me 1 2 3 4 5
BS7 My health in the future will depend on 
my
medicines
1 2 3 4 5
BS8 My medicines disrupt my life 1 2 3 4 5
BS9 I sometimes worry about becoming too 
dependent 
on my medicines
1 2 3 4 5
BS10 My medicines protect me from 
becoming worse
1 2 3 4 5
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Please indicate how frequently you now experience the following 
symptoms as part of your heart failure by ticking the appropriate box.
All of the 
time
Frequently Occasionally Never
1. Fatigue/lack of energy
2. Nausea
3. Breathlessness
4. Chest pain
5. Tightness in the 
chest/ 
arm/neck
6. Upset stomach
7. Sore eyes
8. Sleep difficulties
9. Dizziness
10. Difficulty 
concentrating
11. Irritability
12. Stiff or sore joints
13. Headaches
14. Loss of strength
15. Dry mouth
16. Dry cough
17. Swollen ankles
18. Weight gain
19. Weight loss
20. Other
21. Other
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We are interested in your own personal views of how you now see your heart condition. Please indicate how much you agree 
or disagree with the following statements about your illness by ticking the appropriate box.
Strongly
Agree
Agree Neither
agree
nor
disagree
Disagre
e
Strongly
Disagree
1. My heart failure will last a short time
2. My heart failure is likely to be permanent rather than 
temporary
3. My heart failure will last for a long time
4. My heart failure is a serious condition
5. My heart failure has had major consequences on my life
6. My heart failure has become easier to live with
7. My heart failure has not had much effect on my life
8. My heart failure has strongly affected the way others see me
9. My heart failure has serious economic and financial 
consequences
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Strongly
Agree
Agree Neither
agree
nor
disagree
Disagre
e
Strongly
Disagree
10. My heart failure has strongly affected the way I see myself 
as a person
11. My heart failure will improve in time
12. There is a lot which I can do to control my symptoms
13. There is very little that can be done to improve my heart 
failure
14. My treatment will be effective in curing my heart failure
15. Recovery from my heart failure is largely dependent on 
chance or fate
16. What I do can determine whether my heart failure gets 
better or worse
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The following items are about family and friends. Please indicate the extent to which you agree or disagree with each 
statement by circling the appropriate number.
Very
Strongly
Disagree
Strongly
Disagree
Disagree Neither
agree
nor
disagree
Agree Strongly
Agree
Very
Strongly
Agree
1 There is a special person who is around when I am in need 1 2 3 4 5 6 7
2 There is a special person with whom I can share my joys 
and sorrows
1 2 3 4 5 6 7
3 My family really tries to help me 1 2 3 4 5 6 7
4 I get the emotional help and support I need from my family 1 2 3 4 5 6 7
5 I have a special person who is a real source of comfort to 
me
1 2 3 4 5 6 7
6 My friends really try to help me 1 2 3 4 5 6 7
7 I can count on my friends when things go wrong 1 2 3 4 5 6 7
8 I can talk about my problems with my family 1 2 3 4 5 6 7
9 I have friends with whom I can share my joys and sorrows 1 2 3 4 5 6 7
10 There is a special person in my life who cares 
about my feelings
1 2 3 4 5 6 7
11 My family is willing to help me make decisions 1 2 3 4 5 6 7
12 I can talk about my problems with my friends 1 2 3 4 5 6 7
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Having an illness often means doing different tasks and activities to manage your condition. How confident are 
you that you can:
Not at all 
Confident
Somewhat
Confident
Moderatel
y
Confident
Very
Confident
Totally
Confident
1 Do all the things necessary to 
manage your condition on a regular 
basis?
1 2 3 4 5
2 Monitor yourself for signs of change 
in your illness?
1 2 3 4 5
3 Judge when the changes in your 
illness mean you should contact 
your doctor/ nurse?
1 2 3 4 5
4 Take all your medications as 
prescribed?
1 2 3 4 5
5 Exercise regularly? 1 2 3 4 5
6 Follow a low salt diet? 1 2 3 4 5
7 Stick to the recommended daily 
fluid intake?
1 2 3 4 5
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These questions concern how your heart failure has prevented you from living as you wanted during the last month. The items below describe different 
ways some people are affected. I f  you are sure an item does not apply to you or is not related to your heart failure then circle 0 (No) and go on to the 
next item. I f  an item does apply to you, then circle the number rating how much it prevented you from liv ing as you wanted. Remember to think about 
O N LY THE LAST MONTH.
Did your heart failure prevent you from living as you wanted 
during the last month by:
No Very Very 
little much
1 Causing swelling in your ankles, legs etc? 0 1 2 3 4 5
2 Making you sit or lie down to rest during the day? 0 1 2 3 4 5
3 Making your walking about or climbing stairs difficult? 0 1 2 3 4 5
4 Making your working around the house or garden difficult? 0 1 2 3 4 5
5 Making your going places away from home difficult? 0 1 2 3 4 5
6 Making your sleeping well at night difficult? 0 1 2 3 4 5
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Did your heart failure prevent you from living as you wanted 
during the last month by:
No Very Very 
little much
7 Making your relating to or doing things with your friends or 
family difficult?
0 1 2 3 4 5
8 Making your working to earn a living difficult? 0 1 2 3 4 5
9 Making your recreational pastimes, sports or hobbies 
difficult?
0 1 2 3 4 5
10 Making your sexual activities difficult? 0 1 2 3 4 5
11 Making you eat less of the foods you like? 0 1 2 3 4 5
12 Making you short of breath? 0 1 2 3 4 5
13 Making you tired, fatigued, or low on energy? 0 1 2 3 4 5
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Did your heart failure prevent you from living as you wanted 
during the last month by:
No Very Very 
little much
14 Making you stay in hospital? 0 1 2 3 4 5
15 Costing you money for medical care? 0 1 2 3 4 5
16 Giving you side effects from medications? 0 1 2 3 4 5
17 Making you feel you are a burden to your family or friends? 0 1 2 3 4 5
18 Making you feel a loss of self-control in your life? 0 1 2 3 4 5
19 Making you worry? 0 1 2 3 4 5
20 Making it difficult for you to concentrate or remember 
things?
0 1 2 3 4 5
21 Making you feel depressed? 0 1 2 3 4 5
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We are interested in how much each of the following statements applies to you. Please respond by circling the 
appropriate number.
Not at all 
true
Barely
true
Moderatel 
y true
Exactly
true
1 I can always manage to solve difficult problems if I 
try hard enough
1 2 3 4
2 If someone opposes me, I can find means and 
ways to get what I want
1 2 3 4
3 It is easy for me to stick to my aims and 
accomplish my goals
1 2 3 4
4 I am confident that I could deal efficiently with 
unexpected events
1 2 3 4
5 Thanks to my resourcefulness, I know how to 
handle unforeseen situations
1 2 3 4
6 I can solve most problems if I invest the necessary 
effort
1 2 3 4
7 I can remain calm when facing difficulties because 
I can rely on my coping abilities
1 2 3 4
8 When I am confronted with a problem, I can 
usually find several solutions
1 2 r 3 4
9 If I am in a bind, I can usually think of something to 
do
1 2 3 4
10 No matter what comes my way, I’m usually able to 
handle it
1 2 3 4
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During the past week (even if it was not a typical week), how much total time (for the entire week) did you spend 
on each of the following? (Please circle one number for each question).
None Less 
than 30 
minutes 
per week
30 -60  
minutes 
per week
1 -3
hours per 
week
More 
than 3 
hours per 
week
1 Stretching or strengthening exercises 
(range of motion, using weights, etc.)
0 1 2 3 4
2 Walk for exercise 0 1 2 3 4
3 Swimming or aquatic exercise 0 1 2 3 4
4 Bicycling (including stationary exercise 
bike)
0 1 2 r 3 4
5 Other aerobic exercise equipment 
(treadmill, rowing machine)
0 1 2 3 4
6 Other aerobic exercise -  specify 0 1 2 3 4
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The questions below ask about your self-care activities during the last 7 days. 
Please answer each question by circling the number that applies to you.
1 . On how many of the last SEVEN DAYS did you eat a low salt diet?
0 1 2 3 4 5 6 7
2. On how many of the last SEVEN DAYS did you add salt to your food at the 
table?
0 1 2 3 4 5 6 7
3. On how many of the last SEVEN DAYS did you eat food to which salt had 
been
added during cooking?
0 1 2 3 4 5 6 7
4. On how many of the last 7 days did you take your medicines as prescribed?
0 1 2 3 4 5 6 7
5. On how many of the last 7 days did you stick to the recommended daily fluid 
intake?
0 1 2 3 4 5 6 7
6 . On how many of the last 7 days did you weigh yourself?
0 1 2 3 4 5 6 7
7. On how many of the last 7 days did you check your ankles for signs of 
swelling?
0 1 2 3 4 5 6 7
8 . On how many of the last 7 days did you follow exercise recommendations?
0 1 2 3 4 5 6 7
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Please help us improve our programme by answering some questions about the services you have received. We 
are interested in you honest opinions, whether they are positive or negative. Please answer all o f the questions. 
We also welcome your comments and suggestions. Thank you very much, we really appreciate your help.
1. How would you rate the quality of the service you have received?
4 3 2
Excellent Good Fair
2. Did you get the kind of service you wanted?
1 2 3
No, definitely not No, not really Yes, generally
3. To what extent has our treatment met your needs?
4 3 2
Almost all of my Most of my Only a few of
needs have been needs have been my needs have
met met been met
1
Poor
4
Yes, definitely
1
None of my 
needs have 
been met
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1
No, definitely not
2
No, I don’t think so
3
Yes, I think so
4
Yes, definitely
5. How satisfied are you with the amount of help you have received?
1 2 3 4
Quite dissatisfied Indifferent or Mostly satisfied Very satisfied
mildly dissatisfied
6. Have the services you received helped you to deal more effectively with your problems?
4 3 2 1
Yes, they helped Yes, they helped No, they really No, they seemed to
a great deal somewhat didn’t help make things worse
7. In an overall, general sense, how satisfied are you with the service you have received?
4 3 2 1
Very satisfied Mostly satisfied Indifferent or Quite dissatisfied
Mildly dissatisfied
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8. If you were to seek help again, would you come back to our program?
1 2 3 No, definitely not No, I don’t think so Yes, I think so
4
Yes, definitely
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Not at Very 
all much
How helpful did you find the nurse intervention? 1 2 3 4 5
To what extent do you think you were able to put into 
practice the information and advice provided?
1 2 3 4 5
How helpful did you find the medication charts? 1 2 3 4 5
How helpful did you find the weight charts? 1 2 3 4 5
How helpful did you find the information booklet? 1 2 3 4 5
Are you still using the medication charts? Y / N If no, for how long did you use them?
Are you still using the weight charts? Y / N If no, for how long did you use them?
Have you referred to the information booklet since leaving hospital? Y / N
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APPENDIX F. PATIENT INFORMATION AND CONSENT FORMS
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PA T IE N T  IN F O R M  A T IO N  S H E E T
Title of study: The evaluation of a self-management programme for patients 
admitted to hospital with heart failure
Investigators: Dr. Suzanna Hardman, Professor Stanton Newman, Dr. Alex 
Zaphiriou, Kathleen Mulligan, Patsy Hargrave, Dr. Deblina Dasgupta,
Dr Sandeep Gandhi
We would like to invite you to take part in a research study. This information 
sheet will explain why and how the study is being carried out.
Purpose of the Study
At the Whittington Hospital we are striving to improve the treatment we give to 
all our heart failure patients. As part of this improved service you will have 
already been seen by a cardiologist and you will have a further appointment with 
a cardiologist about 6 - 8  weeks after you have been discharged from hospital 
and again at 12 months.
The purpose of this study is to assess whether added input from a cardiac nurse 
specialist can provide additional benefits. In order to see whether the nurse 
specialist does provide additional benefit it is necessary to compare two groups 
of patients one of which is seen by the nurse and the other group who is not.
If this nurse-led intervention is shown to be beneficial, it should be made 
available to all patients. We also want to gain a better understanding of how 
patients and their partners understand their illness. This information will also 
assist us in providing better care.
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What will happen?
If you decide to take part in the study, you will be randomly allocated to one of 
two groups. One of the groups will have two meetings with a nurse during their 
hospital stay plus a home visit following discharge.
You will also be asked to complete some questionnaires before you go home and 
again when attending your out-patient appointments. The questionnaires will ask 
about how you are feeling and how you manage your illness. These assessments 
will take approximately 45 minutes to complete.
We need your permission to access the parts of your hospital records that relate 
to the study. We would also like your permission to access information held by 
the NHS and records maintained by the General Register Office so that we can 
follow up your health status and contact your new GP if you move out of the area.
During your stay in hospital and when you come back to outpatients, we 
normally monitor your kidney function as part of your care using blood tests. If 
you agree to help us with this research study we would like to take a small 
additional sample of blood on these occasions to give us an additional measure of 
how well your heart is pumping.
Confidentiality of records
All information you give will be confidential; only the researcher will know that 
the information is related to you. The results of the study may be published in the 
medical literature, however your name and details will not be revealed.
Please note. You do not have to take part in this study if you do not want to. 
If you decide to take part you may withdraw at any time without having to 
give a reason. Your decision whether to take part or not will not affect your 
care and management in any way.
All proposals for research using human subjects are reviewed by an ethics 
committee before they can proceed. This proposal was reviewed by the 
Whittington Hospital Ethics Committee.
If you have any questions or would like any further information, please contact: 
Kathleen Mulligan Tel: 
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St Mary's Wing. Highgate Hill 
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AGREEMENT TO PARTICIPATE IN RESEARCH PROJECT
The evaluation of a Self-Management Programme for Patients admitted to Hospital with Heart
Failure.
Investigators: Dr. Suzanna Hardman , Professor Stanton Newman, Dr. Alex Zaphiriou, 
Kathleen Mulligan, Patsy Hargrave, Dr. Deblina Dasgupta, Dr. Sandeep Ghandi.
1. Have you read the information sheet about this study? YES/NO
2. Have you had the opportunity to ask questions and discuss the study? YES/NO
3. Have you received satisfactory answers to all your questions? YES/NO
4. Have you received enough information about this study? YES/NO
5. Which doctor have you spoken to about this study? .................................
6. Do you understand that you are free to withdraw from this study
* at any time
* without giving a reason for withdrawing YES/NO
7. Do you agree to take part in this study? YES/NO
8. Are you happy for us to approach your spouse/partner/carer
to take part in the study? YES/NO
9. Do you give permission for information held by the NHS and records 
maintained by the General Register Office to be used to keep in touch
with you and follow up your health status? YES/NO
Signed.................................................................................Date....................................
Name in Block Letters...................................................................................................
Doctor.............................................................................................................................
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